Some sample records from the "NPLCITE_15.TXT" file: --------------------------------------------------- SAMPLE_NPLCITE_15.TXT 7/7/2016 5:26PM 8999999 1 Hagemeister (Drugs, Feb. 2010, 70, (3), 261-272). 8999999 2 Davis et al. (Nature, 463, Jan. 2010, p. 88-94). 8999999 3 U.S. Appl. No. 13/654,173, filed Oct. 17, 2012, Honigberg et al. 8999999 4 U.S. Appl. No. 13/736,812, filed Jan. 8, 2013, Buggy et al. 8999999 5 U.S. Appl. No. 13/747,322, filed Jan. 22, 2013, Buggy et al. 8999999 6 U.S. Appl. No. 13/747,319, filed Jan. 22, 2013, Buggy et al. 8999999 7 Advani et al. "The BTK inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study", Ann. Oncol., 22(suppl 4): abstract 153 (2011). 8999999 8 Apsel et al. "Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases." Nature Chem. Bio., 4(11):691-699 (2008). 8999999 9 Arnold et al. "Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck 1," Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000). 8999999 10 Banker et al. "Modern Pharmaceutics," p. 596 (1996). 8999999 11 Brown et al. "Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL)", J Clin. Oncol. 30(suppl):abstract 8032 (2012); [online][retrieved on Oct. 4, 2012] Retrieved from the Internet: --detail--view& confID=114& abstractID=98841>. 8999999 12 Browning, J.L., "B cells move to centre stage: novel opportunities for autoimmune disease treatment", Nature Reviews/Drug Discovery, 5:564-576 (Jul. 2006). 8999999 13 Burchat et al., "Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck--a Selectivity Insight," Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002). 8999999 14 Burger, J.A., "Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape", Curr. Opin. Oncol. (Epub Sep. 6, 2012), 24(6):643-649 (Nov. 2012). 8999999 15 Carmi et al. "Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer," Biochem. Pharmacol. (Epub Aug. 4, 2012), 84(11):1388-1399 (Dec. 2012). 8999999 16 Chang et al. "The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells." Arthritis Research & Therapy, 13:R115 (2011). 8999999 17 Cohen et al. "Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors," Science, 308:1318-1321 (May 27, 2005). 8999999 18 Czuczman et al. "Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma", J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005). 8999999 19 Davids et al. "Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia", Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012). 8999999 20 Desiderio, S., "Role of Btk in B cell development and signaling," Curr. Opin. Imm. 9:534-540 (1997). 8999999 21 Dorwald, F.Z., Side Reactions in Organic Synthesis, Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & Co. KGaA (2005). 8999999 22 EA200901313 Notification of Office Action mailed Oct. 31, 2011. 8999999 23 EA201000599 Search Report dated Nov. 15, 2010. 8999999 24 Edwards, C.M., "BTK inhibition in myeloma: targeting the seed and the soil", Blood 120(9):1757-1759 (Aug. 2012). 8999999 25 EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010. 8999999 26 EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010. 8999999 27 EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010. 8999999 28 EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011. 8999999 29 EP 10155834.4 Search Report and Written Opinion dated May 27, 2010. 8999999 30 EP 10823966.6 Search Report dated Oct. 17, 2011. 8999999 31 EP 10823966.6 Written Opinion dated Dec. 6, 2011. 8999999 32 EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012. 8999999 33 EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012. 8999999 34 EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012. 8999999 35 EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012. 8999999 36 EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012. 8999999 37 EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012. 8999999 38 EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012. 8999999 39 EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012. 8999999 40 EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012. 8999999 41 EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012. 8999999 42 EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013. 8999999 43 Fabian et al. "A small molecule-kinase interaction map for clinical kinase inhibitors." Nature Biotechnology, 2005, 23(3): 329-336. 8999999 44 Fisher et al. "Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse", Ann. Intern. Med., 90(5):761-763 (1979). 8999999 45 Fowler et al. "The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma", 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, Abstract 156 (Dec. 8-11, 2012). 8999999 46 Fruman, D.A., "Xid-like Phenotypes: A B Cell Signalosome Takes Shape", Immunity, 13:1-3 (Jul. 2000). 8999999 47 Giuliani, N., "Multiple myeloma bone disease: pathophysiology of osteoblast inhibition," Blood (Epub Aug. 17, 2006), 108(13):3992-3996 (2006). 8999999 48 Gold, M.R., "To make antibodies or not:signaling by the B-cell antigen receptor," Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002). 8999999 49 Hantschel et al. "The Btk Tyrosine Kinase is a Major Target of the Bcr-Abl Inhibitor Dasatinib", PNAS 104(33):13283-13288 (2007). 8999999 50 Hata et al. "Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells," J. Biol. Chem. 273(18): 10979-10987 (1998). 8999999 51 Herman et al. "Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765", Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011). 8999999 52 Hiddeman et al. "Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group", Blood (Epub Aug. 25, 2005), 106(12):3725-3732 (Dec. 2005). 8999999 53 Horwood et al. "Bruton's Tyrosin Kinase Is Required for Lipopolysaccharide--induced Tumor Necrosis Factor .alpha. Production," J. Exp. Med., 197(12):1603-1611 (Jun. 2003). 8999999 54 http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011. 8999999 55 Iwaki et al. "Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit," J. Biol. Chem., 280(48):40261-40270 (Dec. 2, 2005). 8999999 56 Jefferies et al. "Bruton's Tyrosine Kinase Is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor {acute over (k)}B Activation by Toll-like Receptor 4," J. Biol. Chem., 278:26258-26264 (2003). 8999999 57 Kawakami et al. "Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase," PNAS USA, 96:2227-2232 (1999). 8999999 58 Korade-Mirnics et al. "Src kinase-mediated signaling in leukocytes," J. Leukoc. Bio., 68(5):603-613 (Nov. 2000). 8999999 59 Kozaki et al. "Development of a Bruton's tyrosine kinase (Btk) inhibitor--ONO-WG-307, a potential treatment for B-cell malignancies", 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011). 8999999 60 Kuppers, R., "Mechanisms of B-cell lymphoma pathogenesis," Nature Reviews/Cancer, 5:251-262 (Apr. 2005). 8999999 61 Kurosaki, T. "Functional dissection of BCR signaling pathways," Curr. Op. Imm. 12:276-281 (2000). 8999999 62 Liu et al. "Structural Basis for selective inhibition of Src family kinases by PPI." Chemistry and Biology, 1999, No. 6, pp. 671-678, in particular table 1, p. 671. 8999999 63 Luskova, P. and Draber, P., "Modulation of the Fce Receptor I Signaling by Tyrosin Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases," Curr. Pharmaceutical Design 10:1727-1737 (2004). 8999999 64 Mahajan et al. "Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [.alpha.-Cyano-.beta.-Methyl-N-(2,5-Dibromophenyl)Propenamide]," J. Biol. Chem., 274(14):9587-9599 (Apr. 2, 1999). 8999999 65 Mallis et al. "Structural characterization of a proline-driven conformational switch within the Itk SH2 domain," Nat. Struct. Biol., 9(12):900-905 (2002). 8999999 66 Mangla et al. "Pleiotropic consequences of Bruton tyrosin kinase deficiency in myeloid lineages lead to poor inflammatory responses," Blood, 104(4):1191-1197 (2004). 8999999 67 Merged Markush Service Search, Jun. 27, 2005. 8999999 68 Middendorp et al. "Tumor Suppressor Function of Bruton Tyrosine Kinase is Independent of its catalytic activity", Blood 105(1):259-261 (2005). 8999999 69 Mukoyama et al., "Preparation of imidazol [1,5-a]pyrazine derivatives, pharmaceutical compositions containing them, and their uses for prevention or treatment of protein tyrosine kinase-related diseases," retrieved from STN Database Accession No. 2005:299462, Patent No. JP2005089352, Apr. 7, 2005, *abstract*. 8999999 70 Niiro, H. and Clark, E.A., "Regulation of B-Cell Fate by Antigen-Receptor Signals," Nature Reviews, 2:945-956 (2002). 8999999 71 Nisitani et al. "In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies," PNAS USA, 96:2221-2226 (1999). 8999999 72 Oligino, T.J. and Dalrymple, S.A., "Targeting B cells for the treatment of rheumatoid arthritis," Arthirits Res. Ther., 5(Supp1.4):S7-S11 (2002). 8999999 73 Pagel et al. "Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas", Clin. Cancer Res. (Epub Jul. 6, 2005), 11(13):4857-4866 (2005). 8999999 74 Pan et al. "Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase," ChemMedChem, 2:58-61 (2007). 8999999 75 PCT/US06/49626 Search Report dated Apr. 9, 2008. 8999999 76 PCT/US09/50897 IPER and Written Opinion dated Jan. 27, 2011. 8999999 77 PCT/US09/50897 Search Report dated Mar. 15, 2010. 8999999 78 PCT/US08/058528 Search Report and Written Opinion dated Sep. 30, 2008. 8999999 79 PCT/US10/52377 Search Report and Written Opinion mailed Jun. 29, 2011. 8999999 80 Peterson et al. "Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group", Br. J. Clin. Oncol., 21(1):5-15 (Jan. 1, 2003). 8999999 81 Ponader et al. "The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo", Blood (Epub Dec. 16, 2011), 119(5):1182-1189 (Feb. 2012). 8999999 82 Powers et al. "Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases," Chem. Rev., 102(12):4639-4750 (2002). 8999999 83 Prakash et al. "Chicken sarcoma to human cancers: a lesson in molecular therapeutics," The Ochsner Journal, 7(2):61-64 (Jan. 1, 2007). 8999999 84 Quek et al. "A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen," Curr. Biol., 8(20):1137-1140 (1998). 8999999 85 Robak et al. "A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia", Curr. Med. Chem. (Epub Jul. 24, 2012), 19(31):5294-5318 (2012). 8999999 86 Robak et al. "Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders", Expert Opin. Investig. Drugs (Epub May 22, 2012), 21(7):921-947 (Jul. 2012). 8999999 87 Rushworth et al. "BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-.kappa.B", Cell Signal (Epub Sep. 11, 2012), 25(1):106-112 (Jan. 2013). 8999999 88 Sada, K. and Yamamura, H., "Protein-Tyrosine Kinases and Adaptor Proteins in FceRI-Mediated Signaling in Mast Cells," Curr. Mol. Med., 3(1):85-94 (2003). 8999999 89 Schaeffer, E.M. and Schwartzberg, P.L., "Tec family kinases in lymphocyte signaling and function," Curr. Opin. Imm., 12:282-288 (2000). 8999999 90 Schwamb et al. "B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides", Blood (Epub Aug. 27, 2012), 120(19):3978-3985 (Nov. 2012). 8999999 91 Science IP CAS Search, Mar. 16, 2006. 8999999 92 Science IP CAS Search, Sep. 5, 2006. 8999999 93 Shaffer et al."Lymphoid malignancies: the dark side of B-cell differentiation," Nature Rev. Immun., 2.920-932 (Dec. 2002). 8999999 94 Smaill et al. "Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)prido[d]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor," J. Med. Chem., 42(10):1803-1815 (1999). 8999999 95 Smith et al. "The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species," BioEssays, 23:436-446 (2001). 8999999 96 Smolen, J.S. and Steiner, G., "Therapeutic Strategies for Rheumatoid Arthritis," Nature Reviews, 2:473-488 (2003). 8999999 97 Tinmouth et al. "Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma", Leuk. Lymphoma, 41(1-2):137-145 (2001). 8999999 98 Traxler et al., "Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenlyamino)pyrazolo[3,4-d]pyrimidines," J. Med. Chem., 40(22):3601-3616 (1997). 8999999 99 U.S. Appl. No. 11/617,645 Final Office Action mailed Oct. 16, 2008. 8999999 100 U.S. Appl. No. 11/617,645 Notice of Allowance mailed Feb. 9, 2009. 8999999 101 U.S. Appl. No. 11/617,645 Office Action mailed Jan. 24, 2008. 8999999 102 U.S. Appl. No. 11/617,645 Office Action mailed May 13, 2008. 8999999 103 U.S. Appl. No. 11/692,870 Final Office Action mailed Aug. 19, 2009. 8999999 104 U.S. Appl. No. 11/692,870 Office Action mailed Jan. 26, 2009. 8999999 105 U.S. Appl. No. 12/356,498 Final Office Action mailed Jul. 8, 2011. 8999999 106 U.S. Appl. No. 12/356,498 Office Action mailed Apr. 14, 2011. 8999999 107 U.S. Appl. No. 12/499,002 Final Office Action mailed Dec. 14, 2012. 8999999 108 U.S. Appl. No. 12/499,002 Final Office Action mailed Oct. 25, 2011. 8999999 109 U.S. Appl. No. 12/499,002 Office Action mailed Jun. 5, 2012. 8999999 110 U.S. Appl. No. 12/499,002 Office Action mailed Mar. 3, 2011. 8999999 111 U.S. Appl. No. 12/499,005 Office Action mailed Feb. 17, 2011. 8999999 112 U.S. Appl. No. 12/499,008 Office Action mailed Jul. 19, 2011. 8999999 113 U.S. Appl. No. 12/499,008 Office Action mailed Mar. 9, 2011. 8999999 114 U.S. Appl. No. 12/594,805 Office Action mailed Oct. 15, 2012. 8999999 115 U.S. Appl. No. 12/727,703 Final Office Action mailed Jul. 19, 2011. 8999999 116 U.S. Appl. No. 12/727,703 Office Action mailed Mar. 3, 2011. 8999999 117 U.S. Appl. No. 12/887,428 Office Action mailed Apr. 20, 2011. 8999999 118 U.S. Appl. No. 13/011,258 Office Action mailed Nov. 22, 2011. 8999999 119 U.S. Appl. No. 13/162,449 Office Action mailed Feb. 9, 2012. 8999999 120 U.S. Appl. No. 13/249,066 Office Action mailed Nov. 27, 2012. 8999999 121 U.S. Appl. No. 13/312,606 Office Action mailed Sep. 19, 2012. 8999999 122 U.S. Appl. No. 13/328,718 Final Office Action mailed Dec. 27, 2012. 8999999 123 U.S. Appl. No. 13/328,718 Office Action mailed Jul. 3, 2012. 8999999 124 U.S. Appl. No. 13/340,276 Office Action mailed Sep. 26, 2012. 8999999 125 U.S. Appl. No. 13/361,733 Notice of Allowance mailed Nov. 14, 2012. 8999999 126 U.S. Appl. No. 13/361,733 Office Action mailed Jul. 6, 2012. 8999999 127 U.S. Appl. No. 13/404,422 Office Action mailed Sep. 28, 2012. 8999999 128 U.S. Appl. No. 13/410,110 Office Action mailed Sep. 28, 2012. 8999999 129 U.S. Appl. No. 13/439,775 Office Action mailed Dec. 10, 2012. 8999999 130 U.S. Appl. No. 13/526,161 Office Action mailed Nov. 27, 2012. 8999999 131 U.S. Appl. No. 13/526,163 Office Action mailed Nov. 28, 2012. 8999999 132 U.S. Appl. No. 13/607,036 Office Action mailed Nov. 14, 2012. 8999999 133 Uckun et al. "Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity." Expert Opinion Ther. Patents 2010, 20(11):1-14. 8999999 134 Uckun, F.M., "Bruton's Tyrosine Kinase (BTK) as a Dual-Function Regulator of Apoptosis," Biochem. Pharmacology, 56:683-691 (1998). 8999999 135 Uckun et al. "Btk as a Mediator of Radiation-Induced Apoptosis in DT-40 Lymphoma B Cells," Science, 273(5278):1096-1100 (1996). 8999999 136 Uckun et al. "In Vivo Pharmacokinetic Features, Toxicity Profile, and Chemosensitizing Activity of .alpha.-Cyano-.beta.-hydroxy-.beta.-methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a Novel Antileukemic Agent Targeting Bruton's Tyrosine Kinase," Clin. Cancer Res., 8:1224-1233 (2002). 8999999 137 Uckun et al. "The Anti-leukemic Bruton's Tyrosine Kinase Inhibitor .alpha.-cyano-.beta.-hydroxy-.beta.-mehyl-N-(2,5-dibromophenyl)Propenamide (LFM-A13) Prevents Fatal Thromboembolism," Leuk. Lymphoma, 44(9):1569-1577 (2003). 8999999 138 Vassilev, A.O. and Uckun, F.M., "Therapeutic Potential of Inhibiting Bruton's Tyrosine Kinase, (BTK)," Current Pharmaceutical Design, 10:1757-1766 (2004). 8999999 139 Vassilev et al. "Bruton's Tyrosine Kinase as an Inhibitor of the Fas/CD95 Death-inducing Signaling Complex," J. Biol. Chem. 274(3):1646-1656 (1999). 8999999 140 Vippagunta et al., "Crystalline Solids," Advanced Drug Delivery Reviews, 48:3-26 (2001). 8999999 141 Vose, J.M., "Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management", Am. J. Hematol. 87(6):604-609 (Jun. 2012). 8999999 142 Wilkinson et al. "Selective tyrosine kinase inhibitors," Expert Opin. Emerging Drugs 5(3):287-297 (2000). 8999999 143 Witzens-Harig et al. "Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting", Ann Hematol. (Epub Aug. 29, 2012), 91(11):1765-1772 (Nov. 2012). 8999999 144 Witzig et al. "Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma", J. Clin. Oncol. (Epub Oct. 5, 2009), 27:5404-5409 (2009). 8999999 145 Wolff, M.E., "Burger's Medicinal Chemistry and Drug Discovery," 5th Ed. Part 1, pp. 975-977 (1995). 8999999 146 Yamamoto et al. "The Orally Available Spleen Tyrosine Kinase Inhibitor 2-[7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicotinamide Dihydrochloride (BAY61-3606) Blocks Antigen-Induced Airway Inflammation in Rodents," J. Pharma. And Exp. Therapeutics, 306(3):1174-1181 (2003). 8999999 147 Yasuhiro et al. "ONA-WG-307, a Novel, Potent and Selective Inhibitor of Bruton's Tyrosine Kinase, in sustained inhibition of the Erk, Akt and PKD signaling pathways", 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #2021 (Dec. 10-13, 2011). 8999999 148 Zhu et al. "Calpain Inhibitor II Induces Caspase-dependent Apoptosis in Human Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma Cells as well as Some Solid Tumor Cells", Clin. Cancer Res. 6:2456-2463 (2000). 8999999 149 EP 08744513.6 Examination Report dated Jan. 16, 2013. 8999999 150 EP 12151943.3 Examination Report dated Feb. 5, 2013. 8999999 151 EP 12172842.2 Partial Search Report dated Jan. 24, 2013. 8999999 152 EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013. 8999999 153 U.S. Appl. No. 13/341,695 Office Action mailed Feb. 1, 2013. 8999999 154 U.S. Appl. No. 13/890,498, filed May 9, 2013, Honigberg et al. 8999999 155 U.S. Appl. No. 13/869,700, filed Apr. 24, 2013, Buggy et al. 8999999 156 U.S. Appl. No. 13/849,399, filed Mar. 22, 2013, Honigberg et al. 8999999 157 U.S. Appl. No. 13/003,811 Office Action mailed Feb. 25, 2013. 8999999 158 Carrie et al. "Current Strategies of Chemotherapy in Osteosarcoma", International Orthopaedics 30:445-451 (2006). 8999999 159 Marina et al. "Biology and Therapeutic Advances for Pediatric Osteosarcoma", The Oncologist 9:422-441 (2004). 8999999 160 Picci, P. "Osteosarcoma (Osteogenic Sarcoma)", Orphanet J. Rare Diseases 2(6):1-4 (2007). 8999999 161 Ritter et al. "Osteosarcoma", Ann. Oncol. 21(Supplement 7):320-325 (2010). 8999999 162 U.S. Appl. No. 13/472,292 Office Action mailed Mar. 13, 2013. 8999999 163 U.S. Appl. No. 13/340,522 Office Action mailed Mar. 13, 2013. 8999999 164 U.S. Appl. No. 13/340,533 Final Office Action mailed Feb. 25, 2013. 8999999 165 PRNewswire, "Pharmacyclics, Inc. Announces Presentation of Interim Results from Phase I Trial of its First-in-Human Btk Inhibitor PCI-32765", Dec. 7, 2009. 8999999 166 Pollyea et al., "A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay", Poster Abstract #3713, 51st ASH Annual Meeting and Exposition (Dec. 3, 2009). 8999999 167 Hiddeman et al., "Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas", Seminars in Oncology 30(1)Supp1.2:16-20 (Feb. 2003). 8999999 168 U.S. Appl. No. 13/340,276 Final Office Action mailed Apr. 4, 2013. 8999999 169 Ahn et al. "Michael acceptors as a tool for anticancer drug design", Current Pharmaceutical Design 2(3):247-262 (1996). 8999999 170 U.S. Appl. No. 13/312,606 Final Office Action mailed Apr. 5, 2013. 8999999 171 U.S. Appl. No. 13/404,422 Final Office Action mailed Apr. 16, 2013. 8999999 172 U.S. Appl. No. 13/410,110 Final Office Action mailed Apr. 16, 2013. 8999999 173 U.S. Appl. No. 13/965,135, filed Aug. 12, 2013, Buggy et al. 8999999 174 U.S. Appl. No. 14/033,344, filed Sep. 20, 2013, Honigberg et al. 8999999 175 U.S. Appl. No. 14/073,543, filed Nov. 6, 2013, Honigberg et al. 8999999 176 U.S. Appl. No. 14/073,594, filed Nov. 6, 2013, Honigberg et al. 8999999 177 U.S. Appl. No. 14/079,508, filed Nov. 14, 2013, Honigberg et al. 8999999 178 U.S. Appl. No. 14/080,640, filed Nov. 14, 2013, Honigberg et al. 8999999 179 U.S. Appl. No. 14/080,649, filed Nov. 14, 2013, Honigberg et al. 8999999 180 U.S. Appl. No. 14/152,886, filed Nov. 1, 2014, Honigberg et al. 8999999 181 U.S. Appl. No. 14/156,247, filed Jan. 15, 2014, Honigberg et al. 8999999 182 U.S. Appl. No. 14/188,390, filed Feb. 24, 2014, Buggy et al. 8999999 183 U.S. Appl. No. 13/526,161 Final Office Action mailed May 15, 2013. 8999999 184 U.S. Appl. No. 13/526,163 Final Office Action mailed May 15, 2013. 8999999 185 U.S. Appl. No. 13/249,066 Final Office Action mailed May 15, 2013. 8999999 186 EP 12172842.2 Extended Search Report dated May 14, 2013. 8999999 187 U.S. Appl. No. 13/341,695 Final Office Action mailed Jun. 7, 2013. 8999999 188 U.S. Appl. No. 13/439,775 Final Office Action mailed Jun. 17, 2013. 8999999 189 U.S. Appl. No. 13/607,036 Final Office Action mailed Jun. 24, 2013. 8999999 190 U.S. Appl. No. 12/594,805 Final Office Action mailed Jun. 27, 2013. 8999999 191 U.S. Appl. No. 13/153,291 Office Action mailed Jul. 5, 2013. 8999999 192 Gordon et al. "Somatic hypermutation of the B cell receptor genes B29 (Ig.beta., CD79b) and mb1 (Ig.alpha., CD79a)," PNAS 100(7):4126-4131 (2003). 8999999 193 Lossos, I.S. "Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma," J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005). 8999999 194 Friedberg et al "Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia," Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009]. 8999999 195 Chen et al. "SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma," Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007]. 8999999 196 Kuglstatter et al. "Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures," Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010]. 8999999 197 Davis et al. "Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma," Nature 463(7277):88-92 (2010). 8999999 198 Yang et al. "Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib," Leukemia 22(9):1755-1766 (2008) [E-pub Jul. 3, 2008]. 8999999 199 U.S. Appl. No. 13/361,726 Office Action mailed Jul. 18, 2013. 8999999 200 U.S. Appl. No. 13/340,409 Office Action mailed Jul. 19, 2013. 8999999 201 U.S. Appl. No. 13/153,317 Office Action mailed Jul. 29, 2013. 8999999 202 Advani et al. "Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study." J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010). 8999999 203 Chang et al. "PCI-45292, a Novel Btk Inhibitor with Optimized Pharmaceutical Properties, Demonstrates Potent Activities in Rodent Models of Arthritis." ACR/ARHP Scientific Meeting, Nov. 6-11, 2010, Poster #286. 8999999 204 Huhn et al. "Rituximab therapy of patients with B-cell chronic lymphocytic leukemia." Blood 98(5):1326-1331 (Sep. 1, 2001). 8999999 205 Lou, et al. "Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies." J. Med. Chem. 55:4539-4550 (2012). 8999999 206 Science Daily "Counting tumor cells in blood predicts treatment benefit in prostate cancer." (Jul. 7, 2008), http://www.sciencedaily.com/releases/2008/07/080706083142.htm , last accessed Jul. 23, 2013. 8999999 207 Schnute et al. "Bruton's tyrosine kinase (Btk)." Anti-Inflammatory Drug Discovery.Ed. J.I. Levin and S. Laufer. (2012), pp. 297-326. 8999999 208 U.S. Appl. No. 13/335,719 Office Action mailed Jul. 31, 2013. 8999999 209 U.S. Appl. No. 13/340,556 Office Action mailed Jul. 31, 2013. 8999999 210 U.S. Appl. No. 13/526,161 Office Action mailed Aug. 1, 2013. 8999999 211 U.S. Appl. No. 13/526,163 Office Action mailed Aug. 2, 2013. 8999999 212 U.S. Appl. No. 12/907,759 Office Action mailed Aug. 13, 2013. 8999999 213 U.S. Appl. No. 13/479,053 Office Action mailed Sep. 6, 2013. 8999999 214 U.S. Appl. No. 13/340,276 Office Action mailed Sep. 10, 2013. 8999999 215 U.S. Appl. No. 13/003,811 Final Office Action mailed Oct. 11, 2013. 8999999 216 U.S. Appl. No. 13/542,440 Non-Final Office Action mailed Oct. 31, 2013. 8999999 217 U.S. Appl. No. 13/450,158 Non-Final Office Action mailed Oct. 31, 2013. 8999999 218 U.S. Appl. No. 13/606,949 Non-Final Office Action mailed Oct. 29, 2013. 8999999 219 U.S. Appl. No. 13/340,522 Final Office Action mailed Nov. 1, 2013. 8999999 220 U.S. Appl. No. 12/907,759 Final Office Action mailed Nov. 8, 2013. 8999999 221 U.S. Appl. No. 13/335,719 Final Office Action mailed Nov. 8, 2013. 8999999 222 U.S. Appl. No. 13/340,409 Final Office Action mailed Nov. 12, 2013. 8999999 223 U.S. Appl. No. 13/249,066 Office Action mailed Dec. 11, 2013. 8999999 224 EP 12166305.8 Examination Report dated Dec. 3, 2013. 8999999 225 U.S. Appl. No. 12/907,759 Office Action mailed Dec. 31, 2013. 8999999 226 U.S. Appl. No. 13/153,291 Final Office Action mailed Jan. 3, 2014. 8999999 227 U.S. Appl. No. 13/542,440 Office Action mailed Jan. 7, 2014. 8999999 228 U.S. Appl. No. 13/341,708 Office Action mailed Jan. 22, 2014. 8999999 229 PRNewswire, "Update on Preclinical Finding and Development Timeline for PCI-45292", Mar. 2, 2011. 8999999 230 Witzig et al. "Detection of myeloma cells in the peripheral blood by flow cytometry." Cytometry (Communications in Clinical Cytometry), 26:113-120 (1996). 8999999 231 Lichtman "Battling the hematological malignancies: The 200 years' war." The Oncologist, 13:126-138 (2008). 8999999 232 U.S. Appl. No. 13/153,317 Final Office Action mailed Jan. 23, 2014. 8999999 233 Science Daily "Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma." (Jun. 19, 2013), http://www.sciencedaily.com/releases/2013/06/130619195217.htm, last accessed Jan. 30, 2014. 8999999 234 Wang et al. "Targeting BTK with ibrutinib in relapsed or refractory mantel-cell lymphoma." N Engl J Med 369(6):507-516 (Aug. 8, 2013). 8999999 235 U.S. Appl. No. 13/606,949 Final Office Action mailed Feb. 14, 2014. 8999999 236 U.S. Appl. No. 13/404,422 Office Action mailed Feb. 21, 2014. 8999999 237 U.S. Appl. No. 13/410,110 Office Action mailed Feb. 24, 2014. 8999999 238 U.S. Appl. No. 13/430,173 Office Action mailed Feb. 25, 2014. 8999999 239 U.S. Appl. No. 13/607,036 Office Action mailed Mar. 6, 2014. 8999999 240 U.S. Appl. No. 13/439,775 Office Action mailed Mar. 6, 2014. 8999999 241 U.S. Appl. No. 13/340,621 Office Action mailed Mar. 6, 2014. 8999999 242 U.S. Appl. No. 13/232,784 Office Action mailed Mar. 6, 2014. 8999999 243 Martin et al., "Novel therapeutic targets in mantle cell lymphoma," Expert Opin. In Therapeutic Targets, 11:929-940 (2007). 8999999 244 Chang et al. "Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients", Blood, 122:2412-2424 (2013). 8999999 245 Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013-[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033. 8999999 246 Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). Aug. 9, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322. 8999999 247 Ohio State University Comprehensive Cancer Center. PCI-32765 (Ibrutinib) in treating patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, or B-cell prolymphocytic leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 23, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01589302 NLM Identifier: NCT01589302. 8999999 248 Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791. 8999999 249 National Cancer Institute (NCI). Rituximab and bendamustine hydrochloride, rituximab and ibrutinib, or ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 24, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01886872 NLM Identifier: NCT01886872. 8999999 250 Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686. 8999999 251 Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651. 8999999 252 Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750. 8999999 253 Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266. 8999999 254 National Center Institute (NCI). Lenalidomide and Ibrutinib in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 24, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01886859 NLM Identifier: NCT01886859. 8999999 255 Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936. 8999999 256 Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750. 8999999 257 National Cancer Institute (NCI). Rituximab, lenalidomide, and ibrutinib in treating patients with previously untreated stage II-IV follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 9, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01829568 NLM Identifier: NCT01829568. 8999999 258 Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 28, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440. 8999999 259 Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387. 8999999 260 Pharmacyclics, Inc. Study of the Bruton's tyrosine kinase inhibitor in combination with carfilzomib (Kyprolis), in subjects with relapsed or relapsed and refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 27, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01962792 NLM Identifier: NCT01962792. 8999999 261 Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821. 8999999 262 National Cancer Institute (NCI). Ibrutinib in treating patients with relapsed or refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 6, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01849263 NLM Identifier: NCT01849263. 8999999 263 National Cancer Institute (NCI). Lenalidomide and ibrutinib in treating patients with relapsed or refractory B-Cell non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 27, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01955499 NLM Identifier: NCT01955499. 8999999 264 M.D. Anderson Cancer Center. Pilot study to determine effects of the Btk inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using heavy water labeling in subjects with CLL and SLL. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 13, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01752426 NLM Identifier: NCT01752426. 8999999 265 Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949. 8999999 266 Pharmacyclics, Inc. Study of the Bruton's tyrosine kinase inhibitor in combination with rituximab in previously untreated subjects with follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 24, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01980654 NLM Identifier: NCT01980654. 8999999 267 Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090. 8999999 268 M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 14, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 NLM Identifier: NCT01880567. 8999999 269 Pharmacyclics, Inc. A phase 3 study of ibrutinib (PCI-32765) versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (RESONATE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 11, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01578707 NLM Identifier: NCT01578707. 8999999 270 Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021. 8999999 271 Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01833039 NLM Identifier: NCT01833039. 8999999 272 Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840. 8999999 273 National Cancer Institute (NCI). Ibrutinib in treating patients with relapsed hairy cell leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 24, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01841723 NLM Identifier: NCT01841723. 8999999 274 Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021. 8999999 275 Pharmacyclics, Inc. A multicenter phase 2 study of PCI-32765 (Ibrutinib) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with 17p deletion. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 3, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01744691 NLM Identifier: NCT01744691. 8999999 276 Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948. 8999999 277 Ohio State University Comprehensive Cancer Center. Rituxan/Bendamustine/PCI-32765 in relapsed DLBCL, MCL, or indolent non-Hodgkin's lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Nov. 1, 2011--[cited Feb. 6, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT01479842 NLM Identifier: NCT01479842. 8999999 278 Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963. 8999999 279 Pharmacyclics, Inc. Study of the Bruton's tyrosine kinase inhibitor in subjects with relapsed/refractory marginal zone lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 29, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01980628 NLM Identifier: NCT01980628. 8999999 280 Pharmacyclics, Inc. Safety of PCI-32765 in chronic lymphocytic leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 13, 2010--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01105247 NLM Identifier: NCT01105247. 8999999 281 National Heart, Lung, and Blood Institute (NHLBI). PCI-32765 for special cases of chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 22, 2011--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01500733 NLM Identifier: NCT01500733. 8999999 282 National Cancer Institute (Nci). A multicenter phase 2 study of the Bruton's tyrosine kinase inhibitor PCI-32765 for treatment of relapsed hairy cell leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Nov. 2, 2013--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01981512 NLM Identifier: NCT01981512. 8999999 283 Pharmacyclics, Inc. Safety and efficacy of PCI-32765 in subjects with relapsed/refractory mantel cell lymphoma (MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 18, 2010--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01236391 NLM Identifier: NCT01236391. 8999999 284 M.D. Anderson Cancer Center. Phase 2 study of the combination of Bruton's tyrosine kinase inhibitor PCI-32765 and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01520519 NLM Identifier: NCT01520519. 8999999 285 Pharmacyclics, Inc. An open-label extension study in patients 65 years or older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who participated in study PCYC-115-CA (PCI-32765 versus chlorambucil). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Nov. 2, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01724346 NLM Identifier: NCT01724346. 8999999 286 Pharmacyclics, Inc. Study of the Bruton's tyrosine kinase inhibitor in subjects with relapsed or relapsed and refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Nov. 18, 2011--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01478581 NLM Identifier: NCT01478581. 8999999 287 Pharmacyclics, Inc. A multicenter, open-label, phase 3 study of the Bruton's tyrosine kinase inhibitor PCI-32765 versus chlorambucil in patients 65 years or older with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (RESONATE-2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 29, 2012--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01722487 NLM Identifier: NCT01722487. 8999999 288 Pharmacyclics, Inc. Study of the safety and tolerability of PCI-32765 in patients with recurrent B cell lymphoma (PCYC-04753). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Feb. 20, 2009--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT00849654 NLM Identifier: NCT00849654. 8999999 289 Pharmacyclics, Inc. Efficacy and safety study of PCI-32765 combined with ofatumumab in CLL (PCYC-1109-CA). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 7, 2010--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01217749 NLM Identifier: NCT01217749. 8999999 290 Pharmacyclics, Inc. Safety and tolerability study of PCI-32765 in B Cell lymphoma and chronic lymphocytic leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 19, 2010--[cited Nov. 25, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01109069 NLM Identifier: NCT01109069. 8999999 291 Pharmacyclics, Inc. Safety and tolerability study of PCI-32765 combined with fludarabine/cyclophosphamide/rituximab (FCR) and bendamustine/rituximab (BR) in chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Feb. 2, 2011--[Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01292135 NLM Identifier: NCT01292135. 8999999 292 Pharmacyclics, Inc. Safety and efficacy study of Bruton's tyrosine kinase inhibitor in subjects with relapsed or refractory diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Feb. 2, 2011--[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01325701 NLM Identifier: NCT01325701. 8999999 293 U.S. Appl. No. 14/340,483, filed Jul. 24, 2014, Honigberg et al. 8999999 294 U.S. Appl. No. 13/340,559 Office Action mailed Mar. 17, 2014. 8999999 295 U.S. Appl. No. 13/736,812 Office Action mailed Mar. 18, 2014. 8999999 296 Hagemeister, F. "Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia," Drugs, 70(3):261-272 (2010). 8999999 297 U.S. Appl. No. 13/747,319 Office Action mailed Mar. 20, 2014. 8999999 298 U.S. Appl. No. 13/543,065 Office Action mailed Mar. 25, 2014. 8999999 299 U.S. Appl. No. 13/543,394 Office Action mailed Mar. 25, 2014. 8999999 300 U.S. Appl. No. 13/543,399 Office Action mailed Mar. 26, 2014. 8999999 301 U.S. Appl. No. 13/654,173 Office Action mailed Apr. 7, 2014. 8999999 302 Burger, J.A. and Peled, A., "CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers," Leukemia 23:43-52 (2009). 8999999 303 Gazitt et al., "Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors," J of Hematotherapy & Stem Cell Research 10:167-176 (2001). 8999999 304 U.S. Appl. No. 13/869,700 Office Action mailed May 16, 2014. 8999999 305 Byrd et al., "Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia," NEJM 369(1): 32-42 (Jul. 4, 2013). 8999999 306 U.S. Appl. No. 13/612,143 Office Action mailed Jun. 23, 2014. 8999999 307 U.S. Appl. No. 12/907,759 Office Action mailed Jul. 10, 2014. 8999999 308 U.S. Appl. No. 13/153,291 Office Action mailed Jul. 18, 2014. 8999999 309 U.S. Appl. No. 13/849,399 Office Action mailed Jul. 23, 2014. 8999999 310 U.S. Appl. No. 14/179,457 Office Action mailed Aug. 4, 2014. 8999999 311 U.S. Appl. No. 13/849,399 Office Action mailed Aug. 4, 2014. 8999999 312 U.S. Appl. No. 13/890,498 Office Action mailed Aug. 19, 2014. 8999999 313 U.S. Appl. No. 13/543,399 Office Action mailed Sep. 10, 2014. 8999999 314 U.S. Appl. No. 13/430,173 Office Action mailed Sep. 9, 2014. 8999999 315 U.S. Appl. No. 13/232,784 Office Action mailed Sep. 15, 2014. 8999999 316 National Cancer Institute (NCI). Ibrutinib and rituximab compared with fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 27, 2014--[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02048813 NLM Identifier: NCT02048813. 8999999 317 M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 5, 2013--[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02007044 NLM Identifier: NCT02007044. 8999999 318 The Lymphoma Academic Research Organisation. Bruton's tyrosine kinase (BTK) inhibition in B-cell lymphomas (BIBLOS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 31, 2014--[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02055924 NLM Identifier: NCT02055924. 8999999 319 Pharmacyclics, Inc. Ibrutinib in combination with lenalidomide, with and without rituximab in participants with relapsed or refractory diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Feb. 10, 2014--[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02077166 NLM Identifier: NCT02077166. 8999999 320 TG Therapeutics, Inc. Ublituximab + ibrutinib in select B-cell malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 11, 2013--[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02013128 NLM Identifier: NCT02013128. 8999999 321 U.S. Appl. No. 13/543,399 Office Action mailed Sep. 24, 2014. 8999999 322 U.S. Appl. No. 13/607,036 Office Action mailed Sep. 26, 2014. 8999999 323 U.S. Appl. No. 13/439,775 Office Action mailed Sep. 26, 2014. 8999999 324 U.S. Appl. No. 13/340,621 Office Action mailed Sep. 26, 2014. 8999999 325 U.S. Appl. No. 13/340,559 Office Action mailed Sep. 26, 2014. 8999999 326 U.S. Appl. No. 13/410,110 Office Action mailed Sep. 29, 2014. 8999999 327 Shah et al. "Ibrutinib for the treatment of mantle cell lymphoma," Expert Rev. Hematol. 7(5):521-531 (2014) (Epub Aug. 27, 2014). 8999999 328 Ghia, P. "Ibrutinib: better combined with other drugs?" Lancet 15:1043-1044 (2014). 8999999 329 Byrd et al. "Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician," J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262). 8999999 330 U.S. Appl. No. 13/543,065 Office Action mailed Oct. 8, 2014. 8999999 331 U.S. Appl. No. 14/069,222 Office Action mailed Oct. 9, 2014. 8999999 332 U.S. Appl. No. 13/543,394 Office Action mailed Oct. 9, 2014. 8999999 333 U.S. Appl. No. 13/747,319 Office Action mailed Oct. 10, 2014. 8999999 334 U.S. Appl. No. 13/736,812 Office Action mailed Oct. 10, 2014. 8999999 335 Maddocks, et al. "Ibrutinib in B-cell lymphomas," Current Treatment Options in Oncology 15:226-237 (2014) (Epub: Feb. 1, 2014). 8999999 336 U.S. Appl. No. 13/341,695 Office Action mailed Oct. 31, 2014. 8999999 337 U.S. Appl. No. 14/448,963 Office Action mailed Nov. 12, 2014. 8999999 338 Rastetter, et al. "Rituximab: expanding role in therapy for lymphomas and autoimmune diseases," Annu. Rev. Med. 55:477-503 (2004) (Epub: Sep. 15, 2003). 8999999 339 U.S. Appl. No. 13/869,700 Office Action mailed Nov. 28, 2014. 8999999 340 Honigberg, et al. "Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo," ASH Annual Meeting Abstracts. 110 (11): 475A (Nov. 16, 2007). 8999999 341 Pharmacyclics: "Pharmacyclics initiates phase 1 clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma," The American Association of Cancer Research (AACR) 100th Annual Meeting in Denver, CO (Apr. 13, 2009). 8999999 342 Wang et al. "Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a Phase II clinical trial," Oral Abstract Session 624, 56th ASH Annual Meeting and Exposition (Dec. 6-9, 2014). 9000001 1 Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, 975. 9000001 2 Banker, Gilbert S. et al., Modem Pharmaceutics, Marcel Dekker, New York, 1996. 9000001 3 Xia, et al., Synthesis and Evaluation of Polycyclic Pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP Phosphodiesterase Inhibitors, J. Med. Chem., 40, 4372-77 (1997). 9000001 4 U.S. Appl. No. 12/746,236, Final Rejection Mar. 27, 2012. 9000001 5 U.S. Appl. No. 12/746,236, Non-Final Office Action Nov. 29, 2011. 9000001 6 Ahn, H., et al. "Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity", J. Med. Chern. (1997) 40(14):2196-2210. 9000001 7 Bastia et al., Effect of A1 and A2A Adenosine Receptor Ligands in Mouse Acute Models of Pain, Neuroscience letters (2002) 328:241-244. 9000001 8 Bender et al., "Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use" PharmcoL Rev., 2006, 58, pp. 488-520. 9000001 9 Burnouf et al., "Synthesis, Structure-Activity Relationships, and Pharmacological Profile of 9-Amino-4-Oxo-1-Phenyl-3,4,5,6, 7-Tetrahydrol[1,4]Diazepino[6, 7, 1-hi]Indoles: Discovery of Potent, Selective Phosphodiesterase Type 4 Inhibitors," (2000), J. Med. Chem., 43:4850-4867. 9000001 10 Chebib et al., 1-Phenylpyrazolo[3,4-d]pyrimidines; Structure-Activity Relationships for C6 Substituents at A1 and A2A Adenosine Receptors Bioorganic & Medicinal Chemistry (2000) 8:2581-2590. 9000001 11 Chermat et al. Journal Pharmacology (1986) 17: 348-350. 9000001 12 Dewald et al., Synthesis and Potential Antipsychotic Activity of 1 H-Imidazo[1.2-c]pyrazolo[3,4-e]pyrimidines, J. Med. Chem. 1988, 31, pp. 454-461. 9000001 13 Fienberg et al., "DARPP-32: Regulator of the Efficacy of Dopaminergic Neurotransmission", Science, (1998) 281, pp. 838-842. 9000001 14 Greengard et al., "Beyond the Dopamine Receptor: the DARPP-321Protein Phosphatase-1 Cascade", Neuron, 1999,23, pp. 435,447. 9000001 15 Han et al., "The Calcium/Calmodulin-dependent Phosphodiesterase PDE1C Downregulates Glucose-induced Insulin Secretion", J. Bio, Chem., 1999,274(32), pp. 22337-22344. 9000001 16 Jiang, et al., Chemoenzymatic Asymmetric Total Synthesis of Phosphodiesterase Inhibitors: Preparation of a Polycyclic Pyrazolo[3,4-d]pyrimidine from an Acylnitroso Oiels-Alder Cycloadduct-Derived Aminocyclopentenol, J. Org. Chem., 70, 2824-2827 (2004). 9000001 17 Lundqvist et al., Exploitation of Structural and Regulatory Diversity in Glutamate Racemases, Nature (2007) 447:817-822. 9000001 18 Mani et al., Science (2000) 287: 1053. 9000001 19 Murray et al., "Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1", Am. J. Physiol. Lunr:I Cell Mol. Physiol. 2007, 292, pp. L294-L303. 9000001 20 Murray et al., LY503430, a Novel ---Amino-3-hydroxy-5-methylisoxazole-4-proplonic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson's Disease JPEJ (2003) 306:752-762. 9000001 21 Nishi, A., et al., "Advanced Research on Dopamine Signaling to Develop Drugs for the Treatment of Mental Disorders: Biochemical and Behavioral Profiles of Phosphodiesterase Inhibition in Dopaminergic Neurotransmission", J. Pharmacol. Sci. vol. 114, pp. 6-16, (2010). 9000001 22 Polli et al., "Expression of a Calmodulin-Dependent Phosphodiesterase Isoform (PDE1 B1) Correlates With Brain Regions Having Extensive Dopaminergic Innervation," (1994), The Journal of Neuroscience, 14:1251-1261. 9000001 23 Porsolt et al. Nature (1977) 266:730-732. 9000001 24 Poulsen et al.HIgh-Pressure Synthesis of Enantiomerlcally Pure C-6 Substituted Pyrazolo[3,4-d]pyrimidines Biorganic & Medicinal Chemistry letter (2001) 11:191-193. 9000001 25 Reed et al., "Phosphodiesterase 1 B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning", The Journal of Neuroscience, 2002, 22(12), pp. 5188-5197. 9000001 26 Rybalkin et al., "Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function", Circ. Res. 2003,93, pp. 280-291. 9000001 27 Shimizu et al., "Calmodulin-Dependent Cyclic Nucleotide Phosphodiesterase (PDE1) Is a Pharmacological Target of Differentiation-Inducing Factor-1, an Antitumor Agent Isolated from Dictyostelium", Cancer Research, 2004, 64, pp. 2568-2571. 9000001 28 Turko et al., Inhibition of Cyclic GMP-Binding Cyclic GMP-Specific Phosphodiesterase (Type 5) by Sildenafil and Related Compounds Molecular Pharmacology (1990) 56:124-130. 9000001 29 Ungerstedt Acta Physiology Second Suppl. (1971) 367:1-48. 9000001 30 Ungerstedt et al. Brain Research (1970) 24: 485-493. 9000001 31 Vatter, et al., Differential Phosphodiesterase Expression and Cytosolic Ca2+ in Human CNS Tumour Cells and in Non-Malignant and Malignant Cells of Rat Origin, J. of Neurochemistry, 93, 321-329 (2005). 9000001 32 U.S. Appl. No. 14/125,017, filed Mar. 2014, Li, et al. 9000001 33 U.S. Appl. No. 14/252,511, filed Apr. 2014, Li, et al. 9000001 34 U.S. Appl. No. 14/169,352, filed Jan. 2014, Li, et al. 9000001 35 "Anxiety," [retrieved on May 14, 2008]. Retrieved online via Internet, URL: http://www.nim.nih.gov/medlineplus/anxiety.html. 9000001 36 "Autism," [retrieved on May 14, 2008]. Retrieved online via Internet, URL: http://www.nim.nih.gov/medlineplus/autism.html. 9000001 37 Al-Afaleq, E., et al., "Heterocyclic o-Aminonitriles: Preparation of Pyrazolo[3,4-d]-pyrimidines with Modification of the substituents at the 1-position", Molecules, 6, pp. 621-638, (2001). 9000001 38 Gelbin, et al., "Ketene-S, N-acetals as synthons for heterocycles new synthesis of pyrimidinones", Journal Fuer Praktische Chemie, vol. 329, No. 5, pp. 753-766, (1987). 9000001 39 Goodman & Gilman, The Pharmacological Basis of Therapeutics, McGraw-Hill Interamericana. 2007, p. 892. 9000001 40 Park, et al., "Traumatic Brain Injury: Can the consequences be stopped?" CMAJ, 178(9), 1163-1170, (2008). 9000001 41 Shook, et al. "Design and Characterization of Optimized Adenoside A2A/A1 Receptor Antagonists for the Treatment of Parkinson's Disease", J. Med. Chem., pp. 1-47 (2012). 9000001 42 Aswar, "Anti-Cataleptic Activity of Various Extracts of Ocimum sanctum", International Journal of Pharma. Research and Development, vol. 2, Issue 6, pp. 1-7 (2010). 9000001 43 Boyd et al., "Dopamine receptor signaling and current and future antipsychotic drugs", Handb Exp Pharmacol. 2012; (212):53-86. doi: 10.1007/978-3-642-25761-2--3. 9000001 44 Deshmukh et al., "Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine--a PDE1 inhibitor" European Journal of Pharmacology (2009), 620(1-3), 49-56. 9000001 45 Filgueiras et al., "Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation" Neuroscience Letters (2010), 473(3), 202-207. 9000001 46 Schmidt, "Phosphodiesterase inhibitors as potential cognition enhancing agents" Current Topics in Medicinal Chemistry (2010), 10(2), 222-230. 9000001 47 Ehrman et al., "Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice", Genes Brain Behav. Oct. 2006;5(7):540-51. 9000001 48 Klaissle, "Physical activity and environmental enrichment regulate the generation of neural precursors in the adult mouse substantia nigra in a dopamine-dependent manner" BMC Neurosci. 2012)31;13:132. doi: 10.1186/1471-2202-13-132. 9000001 49 Kleppisch, "Phosphodiesterases in the central nervous system" Handb Exp Pharmacol. 2009;(191):71-92. doi: 10.1007/978-3-540-68964-5--5. 9000001 50 Chalimoniuk "Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice" Biochem Biophys Res Commun. Nov. 5, 2004;324(1):118-26. 9000001 51 Kakkar, et al. "Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1)" Cell Mol Life Sci. Jul. 1999;55(8-9):1164-86. 9000001 52 Kakkar, et al. "Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme", Brain Res. Feb. 28, 1997;749(2):290-4. 9000001 53 Hulley et al., "Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+" J Neural Transm Suppl. (1995); 46:217-28. 9000001 54 Laddha et al., "A new therapeutic approach in Parkinson's disease: Some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents" Bioorganic & Medicinal Chemistry (2009), 17(19), 6796-6802. 9000001 55 Medina. "Therapeutic Utility of Phosphodiesterase Type 1 Inhibitors in Neurological Conditions", Front. Neurosci. 5: 21, 6 pages, (2011). 9000001 56 Kakkar, et al., "Inhibition of Bovine Brain Calmodulin-Dependent Cyclic Nucleotide Phosphodiesterase Isozymes by Deprenyl", Life Sciences, vol. 59, No. 21, pp. 337-341 (1996). 9000001 57 Sharma, et al., "Regulation of Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase (PDE1): Review", International Journal of Molecular Medicine, 18: 95-105 (2006). 9000001 58 Blokland, "PDE Inhibition and Cognition Enhancement", vol. 22 No. 4, pp. 349-354 (2012) (Abstract Only). 9000001 59 Chen et al., Effects of Bimatoprost 0.03% on Ocular Hemodynamics in Normal Tension Glaucoma; Journal of Ocular Pharmacology and Therapeutics, vol. 22, No. 3, (2006). 9000001 60 Noguchi et al; "A Facile Preparation of 7-(substituted amino-)-6H-pyrrolo[3,4-d]-pyrimidine Derivatives"; Bulletin Chem. Soc. of Japan, 62(9), 3043-5; (1989). 9000001 61 Notice of Allowance and Interview Summary for U.S. Appl. No. 12/746,236 mailed Apr. 26, 2012. 9000001 62 Office Actions for U.S. Appl. No. 13/486,264, Apr. 30, 2014 & Oct. 24, 2013. 9000001 63 Pardo, et al., "Synthesis of 1-(p-Nitrobenzyl)azoles and 1-(p-Nitrobenzyl)benzazoles", OPPI Briefs vol. 32, No. 4, pp. 385-390 (2000). 9000002 1 International Search Report and Written Opinion for PCT/US2012/050930, Oct. 15, 2012. 9000002 2 International Search Report for PCT/US2010/044579, Sep. 21, 2010. 9000002 3 Chiacchio U, et al. Enantioselective Syntheses and Cytotoxicity of N,O-Nucleosides. Journal of Medicinal Chemistry, Jan. 1, 2003, vol. 46, pp. 3696-3702. 9000002 4 Morris J Robins, et al. A direct synthesis of 5-fluorocytosine and its nucleosides using trifluoromethyl hypofluorite. Journal of the Chemical Society, Chemical Communications, No. 1, Jan. 1, 1972, p. 18. 9000002 5 Arthur F. Lewis et al. Synthesis and in vitro anti-human cytomegalovirus (hcmv) activity of certain alkenyl substituted cytosines and 5-halocytosines. Journal of Heterocyclic Chemistry, Sep. 1, 1995, vol. 32, Nr:5, pp. 1513-1515. 9000002 6 Kulikowski et al. Methylation and tautomerism of 5-fluorocytosine nucleosides and their analogues. Journal Nucleic Acids Research, Jan. 1, 1978, vol. 4, pp. S7-S10. 9000002 7 Supplemental European Search Report for EP10807172 (PCT/US2010/044579), Dec. 7, 2012. 9000002 8 International Search Report for PCT/US2010/044592, Sep. 21, 2010. 9000002 9 International Search Report for PCT/US/2009/031683, Jan. 22, 2009. 9000002 10 Jaworski et al. Infrared spectra and tautomerism of 5-fluorocytosine, 5-bromocytosine and 5-iodocytosine. Matrix isolation and theoretical ab initio studies. Journal of Molecular Structure, Jan. 1, 1990, vol. 223, pp. 63-92. 9000002 11 Gabriella et al. Some 5-fluorosulfanilamidopyrimidines, Gazzetta Chimica Italiana, Jan. 1, 1963, vol. 93, Nr:10, pp. 1268-1278. 9000002 12 Zhang et al., Improved method for synthesis of 5-fluorocytosine (5-FC). CAPLUS Abstract 111:134074 (1989). 9000002 13 International Search Report for PCT/US2011/020351, Mar. 14, 2011. 9000002 14 Liang et al., A facile synthesis and herbicidal activities of novel fluorine-containing thiazolo[4,5-d] pyrimidin-7(6H)-ones. Journal of Fluorine Chemistry [online], Jul. 2007, vol. 128, Iss. 7, pp. 879-884. 9000002 15 Bera et al., Nucleosides with furanyl scaffolds. Tetrahedron, Jun. 10, 2002, vol. 58, Nr:24, pp. 4865-4871. 9000002 16 Duschinsky et al., Cytosine derivatives. CAPLUS Abstract 61:18527, 1964. 9000002 17 International Search Report for PCT/US2010/044588, Oct. 1, 2010. 9000002 18 International Search Report for PCT/US2012/050931, Oct. 9, 2012. 9000002 19 Waring, M J, Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability, Bioorganic & Medical Chemistry Letters, May 15, 2009, vol. 19, Nr: 10, pp. 2844-2851. 9000002 20 International Search Report for PCT/US2010/060792, Apr. 22, 2011. 9000002 21 International Search Report for PCT/US2010/044576, Sep. 23, 2010. 9000002 22 Duschinsky et al., Nucleosides. XXXIII. N4-Acylated 5-Flurocytosines and a Direct Synthesis of 5-Fluoro-2'-deoxycytidine. Journal of Medicinal Chemistry, Jul. 1, 1966, vol. 9, Nr:4, pp. 566-572. 9000002 23 European Search Opinion and Supplemental European Search Report for EP App. No. 10 807 175.4, Jan. 7, 2013, pp. 1-5, Berlin. 9000004 1 Merck Index 1895, p. 36. 9000004 2 Balsamo et al. (Eur Respir Rev 2010; 19(116):127-133). 9000005 1 Loewenthal; "A Guide for the Perplexed Organic Experimentalist" Second Edition, 1990, Wiley & Sons. 9000005 2 Beviglia et al. "Expression of the c-Met/HGF Receptor in Human Breast Carcinoma: Correlation with Tumor Progression." Int. J. Cancer. 74.3(1997):301-309. 9000005 3 Danilkovitch-Miagkova et al. "Dysregulation of Met Receptor Tyrosine Kinase Activity in Invasive Tumors." J. Clin. Invest. 109(2002):863-867. 9000005 4 Faul et al. "A New, Efficient Method of the Synthesis of Bisindolylmaleim ides." J. Org. Chem. 63.17(1998):6053-6058. 9000005 5 Ma et al. "c-Met: Structure, Functions and Potential for Therapeutic Inhibition." Cancer Metastasis Rev. 22.4(2003):309-325. 9000005 6 Qian et al., "Met Protein Expression Level Correlates with Survival in Patients with Late-stage Nasopharyngeal Carcinoma", Cancer Res., 62:589-596 (2002). 9000005 7 Qiao et al. "Constitutive Activation of Met Kinase in Non-Small-Cell Lung Carcinomas Correlates with Anchorage-Independent Cell Survival." J. Cell. Biochem. 86.4(2002):665-677. 9000005 8 Takeuchi et al. "c-Met Expression Level in Primary Colon Cancer: A Predictor of Tumor Invasion and Lymph Node Metastases." Clin. Cancer Res. 9.4(2003):1480-1488. 9000005 9 Zhang et al. "Met Decoys: Will Cancer Take the Bait?" Cancer Cell. 6.1(2004):5-6. 9000006 1 Balant, et al., "Metabolic Considerations, etc.," in Manfred ed. Burger's Medicinal Chemistry and Drug Discovery, 5th ed. vol. 1: Principles and Practice, John Wiley & Sons, Inc., (1995). 9000006 2 Ettmayer, et al., "Lessons Learned from Marketed and Investigational Prodrugs," J. Med. Chem., 47(10): 2393-2404 (2004). 9000006 3 Stella, "Prodrugs as Therapeutics," Expert Opin. Ther. Patents, 14(3): 277-280 (2004). 9000006 4 Testa, "Prodrug Research, etc.," Biochemical Pharmacology, 68: 2097-2106 (2004). 9000007 1 International Search Report and Written Opinion dated Feb. 25, 2013, for corresponding International Patent Application No. PCT/IB2012/002435. 9000007 2 Gordon et al., "High-Density Lipoprotein Cholesterol and Cardiovascular Disease--Four Prospective American Studies", Circulation, Jan. 1989, pp. 8-15, vol. 79--issue No. 1, American Heart Association. 9000007 3 Despres et al., "HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study", Atherosclerosis, 2000, pp. 263-272, vol. 153, Elsevier Science Ireland Ltd. 9000007 4 International Search Report and Written Opinion dated May 8, 2013, for corresponding International Patent Application No. PCT/IB2012/002056. 9000007 5 International Search Report and Written Opinion dated Mar. 27, 2014, for corresponding International Patent Application No. PCT/IB2013/002909. 9000007 6 Tae-Wan Kim et al., "Modified Release of Coated Sugar Spheres Using Drug-Containing Polymeric Dispersions", Arch Pharm Res, 2007, pp. 124-130, vol. 30--issue No. 1. 9000007 7 Tae-Wan Kim et al., "Characterization of Dual Layered Pellets for Sustained Release of Poorly Water-Soluble Drug", Chem. Pharm. Bull., Jul. 2007, pp. 975-979, vol. 55--issue No. 7, Pharmaceutical Society of Japan. 9000007 8 Toshiya Kai et al., "Oral Absorption Improvement of Poorly Soluble Drug Using Solid Dispersion Technique", Chem. Pharm. Bull., Mar. 1996, pp. 568-571, vol. 43--issue No. 3, Pharmaceutical Society of Japan. 9000007 9 Tomaz Einfalt et al., "Methods of amorphization and investigation of the amorphous state", Acta Pharm., 2013, pp. 305-334, vol. 63. 9000007 10 Al-Dabbagh and Smith, "Species Differences in Oxidative Drug Metabolism: Some Basic Considerations", Archives of Toxicology, 1984, pp. 219-231, Suppl. 7, Springer-Verlag. 9000007 11 Hans Bundgaard, "Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities", Design of Prodrugs, 1985, p. 1, Elsevier Science Publishers B.V. (Biomedical Division). 9000007 12 Richard B. Silverman, "Prodrugs and Drug Delivery Systems", The Organic Chemistry of Drug Design and Drug Action, 1992, pp. 352-400, Academic Press, Inc. 9000007 13 Vippagunta et al., "Crystalline Solids", Advanced Drug Delivery Reviews, 2001, pp. 3-26, vol. 48, Elsevier Science B.V. 9000007 14 Extended European Search Report dated Jun. 22, 2010, for corresponding European Patent Application No. 06 77 4300. 9000007 15 Kerns and Di, "Permeability Structure Modification Strategies", Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization, 2008, pp. 92-93, Elsevier Inc. 9000007 16 Goosen et al., "Physiochemical Characterization and Solubility Analysis of Thalidomide and Its N-Alkyl Analogs", Pharmaceutical Research, Jan. 1, 2002, pp. 13-19, vol. 19--issue No. 1, Plenum Publishing Corporation. 9000007 17 Fourie et al., "Percutaneous delivery of carbamazepine and selected N-Alkyl and N-hydroxyalkyl analogues", International Journal of Pharmaceutics, 2004, pp. 59-66, vol. 279, Elsevier B.V. 9000007 18 Edwards et al., "Nonpeptidic Inhibitors of Human Neutrophil Elastase. 7. Design, Synthesis, and in Vitro Activity of a Series of Pyridopyrimidine Trifluromethyl Ketones", Journal of Medicinal Chemistry, 1996, pp. 1112-1124, vol. 39--issue No. 5, American chemical Society. 9000007 19 Rautio et al., "Piperazinyalkyl prodrugs of naproxen improve in vitro skin permeation", European Journal of Pharmaceutical Sciences, 2000, pp. 157-163, vol. 11, Elsevier Science B.V. 9000007 20 Anzini et al., "Mapping and Fitting the peripheral Benzodiazepine Receptor Binding Site by Carboxamide Derivatives. Comparison of Different Approaches to Quantitative Ligand-Receptor Interaction Modeling", J. Med. Chem., 2001, pp. 1134-1150, vol. 44--issue No. 8, American Chemical Society. 9000007 21 Sculley and Hamilton, "Some Amide Derivatives of Certain Aminomethylpyridines", J. American Chem. Soc., Jul. 20, 1953, pp. 3400-3403, vol. 75. 9000007 22 Berge et al., "Pharmaceutical Salts", Review Article, Journal of Pharmaceutical Studies, Jan. 1977, p. 1-19, vol. 66--issue No. 1. 9000007 23 Derry E. V. Wilman, "Prodrugs in cancer chemotheraphy", Action Cancer Guest Lecture, Biochemical Society Transactions, 615th Meeting, Belfast, 1986, pp. 375-385, vol. 14. 9000007 24 Stella and Himmelstein, "Prodrugs: A Chemical Approach to Targeted Drug Delivery", Directed Drug Delivery--A Multidisciplinary Problem, 1985, pp. 247-267, Humana Press, Clifton, New Jersey. 9000007 25 Ali et al., "An Efficient and Facile Synthesis of 2-Chloro-3-formyl Quinolines from Acetanilides in Micellar Media by Vilsmeier-Haack Cyclisation", Letter, Synlett, 2001, pp. 251-253, issue No. 2, Thieme Stuttgart, New York. 9000007 26 John B. Paine III, "A Convenient Synthesis of Nicotinate Esters from 3-Cyanopyridones", J. Heterocyclic Chem., 1987, pp. 351-355, vol. 24. 9000007 27 Boatman et al., "Alkylations at the Methyl or .alpha.-Methylene Group of 6- or 4-Alkyl-3-cyano-2(1)-pyridones through Dianions", J. Organic Chemistry, Nov. 1965, pp. 3593-3597, vol. 30. 9000007 28 Cappelli et al., "Design, Synthesis, Structural Studies, Biological Evaluation, and Computational Simulations of Novel Potent AT1 Angiotensin II Receptor Antagonists Based on the 4-Phenylquinolines Structure", J. Med. Chem., 2004, pp. 2574-2586, vol. 47--issue No. 10, American Chemical Society. 9000007 29 Izumi et al., "1H-Imidazo[4,5-c]quinoline Derivatives as Novel potent TNF-.alpha. Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines", Bioorganic & Medicinal Chemistry, 2003, pp. 2541-2550, vol. 11, Elsevier Science Ltd. 9000007 30 Yin and Buchwald, "Palladium-Catalyzed Intermolecular Coupling of Aryl Halides and Amides", Organic Letters, 2000, pp. 1101-1104, vol. 2--issue No. 8, American Chemical Society. 9000007 31 Robert Franzen, "The Suzuki, the Heck, and the Stille reaction--three versatile methods for the introduction of new C--C bonds on solid support", Can. J. Chem., 2000, pp. 957-962, vol. 78, NRC Canada. 9000007 32 Negishi et al., "Cyclic Carbopalladation. A Versatile Synthetic Methodology for the Construction of Cyclic Organic Compounds", Chemical Reviews, 1996, pp. 365-393, vol. 96--issue No. 1, American Chemical Society. 9000007 33 McGee, Jr. et al., "Fusicoccin Synthesis by Intramolecular [4+4] Photocycloaddition of 2-Pyridones: Stereocontrol of the Cycloaddition and Elaboration of the Pentacyclic Product", Paper, Synthesis, Jun. 18, 2001, pp. 1185-1196, issue No. 8, Georg Thieme Verlag Stuttgart, New York. 9000007 34 Bisgaier et al., "Use of flourescent cholesteryl ester microemulsions in cholesteryl ester transfer protein assays", Paper on Methodology, Journal of Lipid Research, 1993, pp. 1625-1634, vol. 34. 9000007 35 Epps et al., "Method for measuring the activities of cholesteryl ester transfer protein (lipid transfer protein)", Chemistry and Physics of LIPIDS, 1995, pp. 51-63, vol. 77, Elsevier Science Ireland Ltd. 9000007 36 Derwent World Patent Index Search Results, obtained from Delphion website (www.delphion.com), 5 pages. 9000007 37 INPADOC/Family and Legal Status Search Results, obtained from Dialog Database #345, Jun. 14, 2006, 19 pages. 9000007 38 International Search Report and Written Opinion dated Oct. 23, 2006, for corresponding International Patent Application No. PCT/US06/25427. 9000008 1 J-L. Galzi et al.: "Neuronal Nicotinic Receptors: Molecular Organization and Regulations," Neuropharmacology, vol. 34, No. 6, 1995, pp. 563-582. 9000008 2 D. S. McGehee et al.: "Physiological Diversity of Nicotinic Acetylcholine Receptors Expressed by Vertebrate Neurons," Annu. Rev. Physiol., vol. 57, 1995, pp. 521-546. 9000008 3 A. H. Rezvani et al.: "Cognitive Effects of Nicotine," Biological Psychiatry, vol. 49, 2001, pp. 258-267. 9000008 4 P. Seguela et al.: "Molecular Cloning, Functional Properties, and Distribution of Rat Brain .varies.7: A Nicotinic Cation Channel Highly Permeable to Calcium," The Journal of Neuroscience, vol. 13, No. 2, Feb. 1993, pp. 596-604. 9000008 5 R. S. Broide et al.: "The .varies.7 Nicotinic Acetylcholine Receptor in Neuronal Plasticity," Molecular Neurobiology, vol. 20, 1999, pp. 1-16. 9000008 6 E. Oppenheimer et al.: "EO-1999, A Specific Antagonist of Antiarrhythmic Drugs: Assessment by Binding Experiments and In Vivo Studies," Life Sciences, vol. 48, 1991, pp. 977-985. 9000008 7 A. R. West et al.: "Solid State Chem. and its Appl.," Wiley, New York, 1988, pp. 358 & 365--[best available copy]. 9000008 8 A. Ennaceur et al.: "Effects of Physostigmine and Scopolamine on Rats' Performances in Object Recognition and Radial-Maze Tests," Psychopharmacology, vol. 109, 1992, pp. 321-330. 9000008 9 E. Ennaceur et al.: "A New One-Trial Test for Neurobiological Studies of Memory in Rats. 1: Behavorial Data," Behavioural Brain Research, vol. 31, 1988, pp. 47-59. 9000008 10 A. Blokland et al.: "State-Dependent Impairment in Object Recognition after Hippocampal NOS Inhibition," NeuroReport, vol. 9, 1998, pp. 4205-42058. 9000008 11 M. Kato et al.: "New 5--HT3-(Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetaide Derivatives," Chem. Phar. Bull, vol. 43, No. 8, 1995, pp. 1351-1357. 9000008 12 A. R. L. Davies et al.: "Charaterisation of the Binding of [3H]methyllycaconitine: a New Radioligand for Labelling .varies.7-type Neuronal Nicotinic Acetylcholine Receptors," Neuropharmacology, vol. 38, 1999, pp. 679-690. 9000008 13 J. Prickaerts et al.: "Possible Role of Nitric Oxide-Cyclic GMP Pathway in Object Recognition Memory: Effects of 7-Nitroindazole and Zaprinast," European Journal of Pharmacology, vol. 337, 1997-, pp. 125-136. 9000008 14 A. Blodland et al.: "State-Dependent Impairment in Object Recognition after Hippocampal NOS Inhibition," NeuroReport, vol. 9, 1998, pp. 4205-42058. 9000009 1 Pandolfo, Massimo, Frataxin Deficiency and Mitochondrial Dysfunction, 2 Mitochondrion 87-93 (2002). 9000009 2 Rai et al. HDAC Inhibitors Correct Frataxin Deficiency in Friedreich's Ataxia Mouse Model in Journal PLOS One, vol. 3, Apr. 9, 2008 pp. 1-8, p. 1, abstract; p. 2, col. 1, para 3. 9000009 3 Calmels et al., "The first cellular models based on frataxin missense mutations that reproduce spontaneously the defects associated with Friedreich ataxia", PLoS One. Jul. 24, 2009;4(7):e6379. 9000009 4 Goodson. "In Medical Applications of Controlled Release", supra, vol. 2, pp. 115-138, (1984). 9000009 5 Langer et al. "New methods of drug delivery" Science vol. 249 No. 4976 pp. 1527-1533 Sep. 28, 1990. 9000009 6 Saudek et al. "A preliminary trial of the programmable implantable medication system for insulin delivery." N. Engl. J. Med. 321:574 (1989). 9000009 7 Sefton, 1987, "Implantable pumps." CRC Crit. Ref. Biomed. Eng. 14:201. 9000009 8 Buchwald et al. "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis." Surgery 88:507 (1980). 9000010 1 ChemBank, RN 913493-23-9 (2006). 9000010 2 Ahn et al. "Fatty acid amide hydrolase . . . " Exp. Opin. Drug Discov. vol. 4(7) 763-784 (2009). 9000010 3 Chemcats 0094165461 (2014). 9000010 4 Chemcats 0097895413 (2014). 9000010 5 Improper Markush Fed. Reg. vp; 76(27) 7162-7175, slides 1, 64-67 (2011). 9000010 6 Johnson et al. "Benzothiophene piperazine . . . " Bioorg. Med. Chem. Lett. vo. 19 1865-1869 (2009). 9000010 7 Lima et al. "Bioisosterism: a useful . . . " Curr. Med. Chem. v.12 p. 23-39 (2005). 9000010 8 Patani et al. "Bioisosterim: a rational . . . " Chem Rev v.96 p. 3147-3176(1996). 9000010 9 Schlosburg, Joel E. et al., "Targeting Fatty Acid Amide Hydrolase (FAAH) to Treat Pain and Inflammation," The AAPS Journal (2009), vol. 11, No. 1, pp. 39-44. 9000010 10 Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; Nov. 17, 2006, XP002633069, retrieved from STN, Database accession No. 913493-23-9, abstract; compounds 913493-23-9. 9000010 11 International Search Report dated May 25, 2011 issued in PCT/IB2011/050229. 9000010 12 French Search Report dated Jun. 11, 2010 issued in FR1050583. 9000010 13 Japanese Office Action in corresponding JP2012-549449, dated Nov. 11, 2014. 9000011 1 Fan et al., 1999, "Accelerated Transport and Maturation of Lysosomal Alpha-Galactosidase in Fabry Lymphoblasts by an Enzyme Inhibitor", Nat Med., vol. 5, No. 1: p. 112-115. 9000011 2 Desnick et al., In Scriver, et al. (eds.), 2001, Metabolic and Molecular Bases of Inherited Disease, 8th ed. McGraw-Hill, New York: p. 3733-3774. 9000011 3 Fan et al., 2003, "A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity", TRENDS in Pharm. Sci., vol. 24, No. 7: p. 355-360. 9000011 4 Frustaci, Andrea et al., "Improvement in Cardiac Function in the Cardiac Variant of Fabry's Disease with Galactose-Infusion Therapy", New England Journal of Medicine, vol. 345, No. 1: pp. 25-32 (Jul. 5, 2001). 9000011 5 Sawkar, Anu R., et al., "Gaucher Disease-Associated Glucocerebrosidases Show Mutation-Dependent Chemical Chaperoning Profiles", Chemistry & Biology, vol. 12, pp. 125-1244 (Nov. 2005). 9000011 6 Shin, Sang H., et al., "Prediction of Response of Mutated .alpha.-Galactosidase A to a Pharmacological Chaperone", Pharmacogenet Genomics, vol. 18, No. 9, pp. 773-780 (Sep. 2008). 9000011 7 Yam, Gary Hin-Fai, et al., "Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants", Am J. Physiol. Cell Physiol., vol. 290, pp. C1076-C1082 (Apr. 2006). 9000011 8 Yam, Gary Hin-Fai, et al., "A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder", The FASB Journal, (2004) pp. 12-18. 9000011 9 Supplementary European Search Report for European Application No. 08 747 020.9 dated Aug. 10, 2010. 9000011 10 Supplementary European Search Report for European Application No. 07 797 506.8 dated Feb. 15, 2010. 9000011 11 Bishop, et al., 1985, "Molecular Genetics", Am. J. Hum. Genet., vol. 37: p. A144. 9000011 12 Bishop, et al., 1986, "Human Alpha-Galactosidase A: Nucleotide Sequence of a cDNA Clone Encoding the Mature Enzyme", Proc. Natl. Acad. Sci. USA, vol. 83: p. 4859-4863. 9000011 13 Brady, et al., 1967, "Enzymatic Defect in Fabry's Disease. Ceramidetrihexosidase Deficiency", N. Engl. J. Med., vol. 276: p. 1163-1167. 9000011 14 Branum, et al., 1988, "Effect of Two Anticoagulants on Leukocyte Yield and Function and on Lysosomal Enzyme Activity", Clin Chem, vol. 34, No. 1: p. 110-113. 9000011 15 Brown, et al., 1997, "Strategies for Correcting the Delta F508 CFTR Protein-Folding Defect", Journal of Bioenergetics and Biomembranes, vol. 29, No. 5: p. 491-502. 9000011 16 Brooks, "Getting into the fold", Nature Chemical Biology, Feb. 2007, 3(2), pp. 84-85. 9000011 17 Calhoun, et al., 1985, "Fabry Disease: Isolation of a cDNA Clone Encoding Human Alpha-Galactosidase A", Proc. Natl. Acad. Sci. USA, vol. 82: p. 7364-7368. 9000011 18 Davies, et al., 1996, "Fabry Disease: Fourteen Alpha-Galactosidase A Mutations in Unrelated Families From the United Kingdom and Other European Countries", Eur. J. Hum. Genet., vol. 4: p. 219-224. 9000011 19 Eng, et al., 1993, "Nature and Frequency of Mutations in the Alpha-Galactosidase A Gene That Cause Fabry Disease", Am. J. Hum. Genet., vol. 53: p. 1186-1197. 9000011 20 Eng, et al., 1997, "Fabry Disease: Thirty-Five Mutations in the Alpha-Galactosidase A Gene in Patients with Classic and Variant Phenotypes", Mol. Med., vol. 3: p. 174-182. 9000011 21 Fuller, et al., 2005, "Urinary Lipid Profiling for the Identification of Fabry Hemizygotes and Heterozygotes", Clinical Chemistry, vol. 51: p. 688-694. 9000011 22 Ishii, et al., 1996, "Aggregation of the Inactive Form of Human .alpha.-Galactosidase in the Endoplasmic Reticulum", Biochem. Biophys. Res. Comm., vol. 220: p. 813-815. 9000011 23 Ishii, et al, 2004, "Transgenic mouse expressing human mutant .alpha.-Galactosidase A in an endogenous enzyme deficient background; a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease", Biochem et Biophysica Acta 1690 (2004) pp. 250-257. 9000011 24 Kornreich, et al., 1989, "Nucleotide Sequence of the Human Alpha-Galactosidase A Gene", Nucleic Acids Res., vol. 17: p. 3301-3302. 9000011 25 Kusiak, et al., 1978, "Purification and Properties of the Two Major Isozymes of Alpha-Galactosidase from Human Placenta", J. Biol. Chem., vol. 253, No. 1: p. 184-190. 9000011 26 Mayes, et al., 1981, "Differential Assay for Lysosomal Alpha-Galactosidases in Human Tissues and its Application to Fabry's Disease", Clin. Chim. Acta., vol. 112, No. 2: p. 247-251. 9000011 27 Nakao, et al., 1995, "An Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy", N. Engl. J. Med., vol. 333: p. 288-293. 9000011 28 Park, et al, 2003, "Long-Term Correction of Globotriaosylceramide Storage in Fabry Mice by Recombinant Adeno-Associated Virus-Mediated Gene Transfer", Proc. Natl. Acad. Sci, USA, vol. 100: p. 3450-3454. 9000011 29 Shin, S., 2007, "Screening for Pharmacological Chaperones in Fabry Disease", Materials and Methods, vol. 359: p. 168-173. 9000011 30 Steet, et al., "The iminosugar isofagomine increases the activity of N370S mutant acid beta-gluosidase in Gaucher fibroblasis by several mechanisms", PNAS 2006, 103(37), pp. 13813-13818. 9000011 31 Tsuji et al., 1987, "Signal Sequence and DNA-Mediated Expression of Human Lysosomal Alpha-Galactosidase A", Eur. J. Biochem., vol. 165: p. 275-280. 9000011 32 Weinberg, et al., 1998, "Effect of Shipment, Storage, Anticoagulant, and Cell Separation on Lymphocyte Proliferation Assays for Human Immunodeficiency Virus-Infected Patients", Clin Diag Lab Immunol, vol. 5, No. 6: p. 804-807. 9000011 33 Welch, et al., 1996, "Influence of Molecular and Chemical Chaperones on Protein Folding", Cell Stress and Chaperones, vol. 1, No. 2: p. 109-115. 9000012 1 U.S. Appl. No. 13/518,753, corresponding to PCT/EP2010/070772, having an International filed of Dec. 28, 2010, published as WO 2011/080255 by Christian Beier et al., entitled Fungicidal Hydroxiivioyl-Tetrazole Derivatives. 9000012 2 U.S. Appl. No. 13/519,293 corresponding to PCT/EP2010/070773, having an International filed of Dec. 28, 2010, published as WO 2011/080256 by Christian Beier et al., entitled Fungicide Hydroximoyl-Tetrazole Derivatives. 9000012 3 International Search Report issued Aug. 18, 2011 in corresponding International Application No. PCT/EP2010/070771, published as WO 2011/080254 A3. 9000014 1 Degliesposti et al., "Design and Discovery of Plasmepsin II Inhibitors," ChemMedChem, (2009), 4(7), pp. 1164-1173, Abstract. 9000014 2 AC1L8WR3--Compound Summary (CID 409375), Mar. 27, 2005, http://pubchem.ncbi.nlm.nih.gov/search/search.cgi. 9000014 3 Atwal et al., "N-[1-Ary1-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase," Bioorganic & Medicinal Chemistry Letters, vol. 14, (2004), pp. 1027-1030. 9000014 4 Bisaha et al., "A switch in enantiomer preference between mitochondrial F1F0-ATPase chemotypes," Bioorganic & Medicinal Chemistry Lette, vol. 15, (2005), pp. 2749-2751. 9000014 5 Brown et al., "ATP Synthase is Responsible for Maintaining Mitochondrial Membrane Potential in Bloodstream Form Trypanosoma brucei," Eukaryotic Cell, vol. 5, No. 1, (2006), pp. 45-53. 9000014 6 Comelli et al., "Downmodulation of mitochondrial F0F1 ATP synthase by diazoxide in cardiac myoblasts: a dual effect of the drug," Am J Physiol Heart Circ Physiol, vol. 292, (2007), pp. H820-H829. 9000014 7 Cunha et al., "Bismuth nitrate pentahydrate: a new and environmentally benign reagent for guanidylation of N-benzoylthioureas," Tetrahedron Letters, vol. 43 (2002), pp. 49-52. 9000014 8 Cunha et al., "The first bismuth(III)-catalyzed guanylation of thioureas," Tetrahedron Letters, vol. 47, (2006), pp. 6955-6956. 9000014 9 Cunha et al., "The first synthesis of pyridinium N-benzoylguanidines by bismuth- and mercury-promoted guanylation of N-iminopyridinium ylide with thioureas," Tetrahedron, vol. 61, (2005) pp. 10536-10540. 9000014 10 Database Registry on STN, RN 669724-32-7, RN 351226-10-3, and RN 330829-66-8, 3 pages, (2010). 9000014 11 Extended European Search Report for European Application No. EP11846398.3, dated Feb. 28, 2014, 5 pages. 9000014 12 Extended European Search Report for European Application No. EP11846595.4, dated Jun. 12, 2014, 6 pages. 9000014 13 Grover et al., "Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity," Am J Physiol Heart Circ Physiol, vol. 287, (2004), pp. H1747-H1755. 9000014 14 Hamann et al., "Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase," Bioorg Med Chem Lett, (2004), vol. 14, pp. 1031-1034, Abstract. 9000014 15 International Preliminary Report on Patentability of the International Bureau of WIPO, for International Application No. PCT/US2011/063943, dated Feb. 25, 2014, 5 pages. 9000014 16 International Search Report and Written Opinion of the International Searching Authority, the Korean Intellectual Property Office, for International Application No. PCT/US2008/076021, dated Mar. 27, 2009, 8 pages. 9000014 17 International Search Report and Written Opinion of the International Searching Authority, the Korean Intellectual Property Office, for International Application No. PCT/US2009/056675, dated Apr. 14, 2010, 9 pages. 9000014 18 International Search Report and Written Opinion of the International Searching Authority, the U.S. Patent & Trademark Office, for International Application No. PCT/US2011/063943, dated Apr. 9, 2012, 7 pages. 9000014 19 International Search Report and Written Opinion of the International Searching Authority, the U.S. Patent & Trademark Office, for International Application No. PCT/US2011/063945, dated Apr. 18, 2012, 8 pages. 9000014 20 International Search Report and Written Opinion of the International Searching Authority, the U.S. Patent & Trademark Office, for International Application No. PCT/US2011/063950, dated Apr. 26, 2012, 8 pages. 9000014 21 International Search Report and Written Opinion of the International Searching Authority, the U.S. Patent & Trademark Office, for International Application No. PCT/US2013/044734, dated Nov. 20, 2013, 14 pages. 9000014 22 International Search Report and Written Opinion of the International Searching Authority, the U.S. Patent & Trademark Office, for International Application No. PCT/US2013/044736, dated Nov. 8, 2013, 13 pages. 9000014 23 International Search Report and Written Opinion of the International Searching Authority, the U.S. Patent & Trademark Office, for International Application No. PCT/US2013/044738, dated Nov. 20, 2013, 17 pages. 9000014 24 Ito et al., "A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals," Cancer Sci, (2003), vol. 94, No. 1, pp. 3-8. 9000014 25 Kryl'skii, et al., "Arylbiguanides in Heterocyclization Reactions," Russian Journal of General Chemistry, vol. 75, No. 2, (2005), pp. 303-310. 9000014 26 Lubbers et al., "Design, Synthesis, and Structure-Activity Relationship Studies of ATP Analogues as DNA Gyrase Inhibitors," Bioorganic & Medicinal Chemistry Letters, vol. 10, (2000), pp. 821-826. 9000014 27 Schnaufer et al., "The F1-ATP synthase complex in bloodstream stage trypanosomes has an unusual and essential function," The European Molecular Biology Organization Journal, vol. 24, (2005), pp. 4029-4040. 9000014 28 STN Search Transcript Registry/Caplus Databases, 108 pages, (2010). 9000014 29 STN Search Transcript Registry/Caplus Databases, 30 pages, (2010). 9000014 30 STN Search Transcript Registry/Caplus Databases, 85 pages, (2010). 9000014 31 Williams et al., "Identification of Compounds that Bind Mitochondrial F1F0 ATPase by Screening a Triazine Library for Correction of Albinism," Chemistry & Biology, vol. 11, (2004), pp. 1251-1259. 9000015 1 Dick and Agrawal "The Genetics of Alcohol and other Drug Dependence" Alcohol Research and Health 2008, vol. 31, No. 2, 111-118. 9000015 2 Luo et al Am. J. Hum. Genet. 2006, 78, 973-987. 9000015 3 Chen, C. et al., (2008) "Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart" www.sciencemag.org 321:1493-1495. 9000015 4 Gao, G. et al. (2001) "Synthesis of Potential Antidipsotropic Isoflavones: Inhibitors of the Mitochondrial Monoamine Oxidase-Aldehyde Dehydrogenase Pathway" Journal of Medicinal Chemistry 44(20):3320-3328. 9000015 5 Gao, G. et al. (2003) "Synthesis of Daidzin Analogues as Potential Agents for Alcohol Abuse" Bioorganic & Medicinal Chemitry 11:4069-4081. 9000015 6 Keung et al. (1993) "A Potent, Selective Inhibitor of Human Mitochondrial Aldehyde Dehydrogenase" Proceedings of the National Academy of Sciences of the USA 90:1247-1251. 9000015 7 Keung et al. (1998) "Kudzu Root: An Ancient Chinese Source of Modern Antidipsotropic Agents" Phytochemistry 47(4):499-506. 9000015 8 Keung (2003) "Anti-Dispotropic Isoflavones: The Potential Therapeutic Agents for Alcohol Dependence" Medicinal Research Reviews 23(4):669-696. 9000015 9 Keung et al. (1993) "Daidzin and Daidzein Suppress Free-choice Ethanol Intake by Syrian Golden Hamsters" Proceedings of the National Academy of Sciences of the USA 90:1000810012. 9000015 10 Lowe et al. (2008) "Structure of Daidzin, a Naturally Occurring Anti-Alcohol-Addiction Agent, in Complex with Human Mitochondrial Aldehyde Dehydrogenase" Journal of Medicinal Chemistry 51:4482-4487. 9000015 11 Perez-Miller et al. (2010) "Alda-1 is an Agonist and Chemical Chaperone for the Common Human Aldehyde Dehydrogenase 2 Variant" Nature Structural & Molecular Biology 17(2):159165. 9000015 12 Rooke et al. (2000) "The Mitochondrial Monoamine Oxidase-Aldehyde Dehydrogenase Pathway: A Potential Site of Action of Daidzin" Journal of Medicinal Chemistry 43(22):41694179. 9000015 13 International Search Report for PCT/US2012/044809, International Filing Date Jun. 29, 2012, mailed Aug. 13, 2012. 9000015 14 Office Action dated Mar. 14, 2013 Pakistan Patent Application No. 427/2012. 9000016 1 Brinkmann, V. Pharmacology & Therapeutics 2007, 115, 87-105. 9000016 2 Wang et al. Microvascular Research 2009, 77, 39-45. 9000016 3 Alewijnse et al. European Journal of Pharmacology 2008, 585, 292-302. 9000016 4 Sumida et al. Am J Physiol Cell Physiol 2011, 300, C1164-C1171. 9000016 5 Roberts et al. Expert Opin. Ther. Patents 2013, 23, 817-818. 9000016 6 Luo et al. Cell, 2009, 136, pp. 823-837. 9000016 7 International Search Report for PCT/US2013/068400, Dec. 10, 2013. 9000016 8 Cross, L.C. et al, Rules for the Nomenclature of Organic Chemistry, Section E: Stereochemistry, Pure & Appl. Chem., 1976, 11-30, 45. 9000016 9 Stahl, Heinrich et al, Handbook of Pharmaceutical Salts, Verlag Helvetica Chimica Acta--Zurich, 2002, 329-345. 9000017 1 European Search Report of Application No. EP06110745, 5 pages, dated Jun. 13, 2006. 9000017 2 International Preliminary Report on Patentability and Written Opinion, 7 pages, dated Sep. 9, 2008. 9000017 3 Database, WPI, Section CH, Week 199517, Derwent Publications Ltd., London, GB; AN 1995-131302, XP002383453 & WO 95/07913 A1 (Meiji Milk Prod Co Ltd) Mar. 23, 1995. 9000017 4 International Search Report, PCT/EP2007/052081, dated Apr. 23, 2007, 4 pages. 9000017 5 International Written Opinion, PCT/EP2007/052081, dated Apr. 23, 2007, 6 pages. 9000017 6 International Search Report and Written Opinion, PCT/EP2008/061765, dated Nov. 11, 2008, which corresponds to U.S. Appl. No. 12/677,012, 9 pages. 9000017 7 International Preliminary Report and Written Opinion, PCT/EP2008/061765, Mar. 18, 2010, which corresponds to U.S. Appl. No. 12/677,012, 7 pages. 9000017 8 International Search Report and Written Opinion, PCT/EP2009/052751, dated Oct. 7, 2009, which corresponds to U.S. U.S. Appl. No. 12/921,814, Oct. 7, 2009, 9 pages. 9000017 9 International Preliminary Report and Written Opinion, PCT/EP2009/052751, dated Sep. 23, 2010, which corresponds to U.S. Appl. No. 12/921,8147, 7 pages. 9000017 10 "Pyridine Derivatives and Related Compounds (Benzopyridines = Quinolines)" Directory of Microbicides for the Protection of Materials, Jan. 1, 2005, pp. 638-649, XP009101518, ISBN: 978-1-4020-2817-5, p. 640, lines 4,5 pp. 639-646. 9000018 1 Ellis et. al., The New England Journal of Medicine, 2001, Massachusetts Medical Society, vol. 345, No. 4, pp. 248-255. 9000018 2 Anonymous, "Actelion's Orally Active Selective S1P1 Receptor Agonist to be Jointly Developed/Promoted with Roche in Autoimmune Disorders and Transplantation Deal Potentially Worth Well Over US $630 Million to Actelion", Muscoskeletal Report, [Online], Jul. 20, 2006, pp. 1, New York, NY 10016, USA, Retrieved from the Internet: URL: http://www.mscreport.com/print.cfm?articleID=827>. 9000018 3 Bailar et al.; The New England Journal of Medicine; 1997; Massachusetts Medical Society, vol. 336, Issue 22, pp. 1569-1574. 9000018 4 Baker; Journal of Applied Physiology; 2002; American Physiological Society; vol. 92; pp. 1779-1780. 9000018 5 Beger et al; World Journal of Surgery; 2003; Societe Internationale de Chirugie; vol. 27; pp. 1075-1084. 9000018 6 Berge et al; "Pharmaceutical Salts"; Journal of Pharmaceutical Sciences; vol. 66, No. 1; 1977; pp. 1-19. 9000018 7 Braun-Moscovici et al; Current Opinion in Rheumatology; 2002; Lippincott Williams and Wilkins; vol. 14; pp. 711-716. 9000018 8 Bunemann et al; "Activation of Muscarinic K+ Current in Guinea-Pig Atrial Myocytes by Sphingosine-1 phosphate", Journal of Physiology, vol. 489, pp. 701-707, (1995). 9000018 9 Carter et al; "Photochemically enhanced Binding of Samll Molecules to the Tumor Necrosis Factor Receptor-1 Inhibits the binding of TNF-alpha"; PNAS. vol. 98, No. 21, Oct. 9, 2001; pp. 11879-11884. 9000018 10 Davidov et al; "Chronic Nitric Oxide Synthase Blockade Desensitizes the Heart to the Negative Metabolic Effects of Nitric Oxide", Life Sciences, Pergamon Press, Oxford, GB, vol. 79, pp. 1674-1680, (2006). 9000018 11 Ehrlenmeyer et al; "Structural Chemical Investigations. VII. Reactive Behavior of Thiourea to Unsaturated Acids"; CA 37:10142, 1943. 9000018 12 Frolkis et al; "The Role of `Invertors` (Intracellular Activators) in Age-related Changes in Cell Response to Hormones", Experimental Gerontology, vol. 30, pp. 401-414, (1995). 9000018 13 Fujishiro et al; "Use of Sphingosine-1-Phosphate 1 Receptor Agonist, KRP-203, in Combination with a Subtherapeutic Dose of Cyclosporine A for Rat Renal Transplantation", Transplantation, vol. 82(6), pp. 804-812, (2006). 9000018 14 Gibson; "Pharmaceutical Preformulation of Formulation"; HIS Health Group, Englewood, CO, USA 2001; Table of Contents. 9000018 15 Giese et al; Journal of Cancer Research and Clinical Oncology; 2001; Springer-Verlag; vol. 127, pp. 217-225. 9000018 16 Gould et al; "Salt Selections for Basic Drugs"; Int. J. Pharm.; vol. 33; 1986; pp. 201-217. 9000018 17 Guo et al; "Effects of Sphingosine 1-phosphate on Pacemaker Activity in Rabbit Sino-atrial Node Cells", Pflugers Arch, vol. 438, pp. 642-648, (1999). 9000018 18 Hale et al; "Selecting Against S1P3 Enhances the Acute Cardiovascular Tolerability of 3-(N-benzyl)aminopropylphosphonic Acid S1P Receptor Agonists", Bioorganic & Medicinal Chemistry Letters, vol. 14(13), pp. 3501-3505, (2004). 9000018 19 Himmel et al; "Evidence for Edg-3 Receptor-Mediated Activation of IK.Ach by Sphingosine-1-Phosphate in Human Atrial Cardiomyocytes", Molecular Pharmacology, vol. 58, pp. 449-454, (2000). 9000018 20 Huwiler et al; "New Players on the Center Stage: Sphingosine 1-Phosphate and its Receptors as Drug Targets", Biochemical Pharmacology, Pergamon Press, Oxford, GB, vol. 75, pp. 1893-1900, (2008). 9000018 21 Janusz et al; "New Cyclooxygenase-2/5-Lipoxyfenase Inhibitors, 3, 7-tert-Butyl-2,3-dihydro-3, 3-dimethylbenzofuran Derivatives as Gastrointestinal Safe Antiinflammatory and Analgesic Agents: Variations at the 5 Position"; J. Medicinal Chemistry, vol. 41, 1998, pp. 3515-3529. 9000018 22 Kappos et al; "Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis", The New England Journal of Medicine, vol. 355(11), pp. 1124-1140, (2006). 9000018 23 Klika et al; "Regioselective Synthesis of 2-imino-1,3-thiazolidin-4-ones by Treatment of N-(Anthracen-9-yl)-N9-ehylthiourea [ . . . ]" Eur. J. Org. Chem. 2002, pp. 1248-1255. 9000018 24 Kovarik et al; "A Mechanistic Study to Assess Whether Isoproterenol Can Reverse the Negative Chronotropic Effect of Fingolimod", Journal of Clinical Pharmacology, vol. 48, No. 3, pp. 303-310 (2008). 9000018 25 Koyrakh et al; "The Heart Rate Decrease Caused by Acute FTY720 Administration is Mediated by the G Protein-Gated Potassium Channel IKACh", American Journal of Transplantation, vol. 5, pp. 529-536, (2005). 9000018 26 Ma; "High-Affinity Activators of Cystic Fibrosis Transmembrance Conductance Regulator (CFTR) Chloride Conductance Identified by High-Throughout Screening"; The Journal of Biological Chemistry, vol. 277, No. 40, Issue of Oct. 4, pp. 37235-37241; [2002]. 9000018 27 Martinet et al; Journal of the National Cancer Institute; 2000; National Cancer Institute; vol. 92; No. 11; pp. 931-936. 9000018 28 Non-Final Office Action dated Feb. 1. 2011, U.S. Appl. No. 12/516,055. 9000018 29 Ochi et al; "Sphingosine-1-Phosphate Effects on Guinea Pig Atrial Myocytes: Alterations in Action Potentials and K+ Currents", Cardiovascular Research, vol. 70, pp. 88-96, (2006). 9000018 30 Ottana et al; 5-Arylidene-2-imino-4-thiazolidinones: Design and Synthesis of Novel Anti-Inflammatory Agents, Biorganic and Medicinal Chemistry, 13(13) (2005) pp. 4243-4252. 9000018 31 Peters et al; "Sphingosine-1-Phosphate Signaling in the Cardiovascular System", Current Opinion in Pharmacology, vol. 7(2), pp. 156-192, (2007). 9000018 32 Remington; "The Science and Practice of Pharmacy"; 20th Edition; Philadelphia College of Pharmacy and Science; 2003; Table of Contents. 9000018 33 Sanna et al; "Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate", The Journal of Biological Chemistry, vol. 279(14), pp. 13839-13848, (2004). 9000018 34 Smith et al; Annals of Neurology; 2003; American Neurological Association; vol. 54; pp. 186-196. 9000018 35 Surh; Nature Reviews Cancer; 2003; Nature Publishing Group; vol. 3; pp. 763-780. 9000018 36 Notices of Allowance dated Jul. 21, 2011, Nov. 15, 2011 and May 3, 2012, U.S. Appl. No. 12/516,055. 9000018 37 Ottana et al; 5-Arylidene-2-imino-4-thiazolidinones: Design and Synthesis of Novel Anti-Inflammatory Agents, Bioorganic and Medicinal Chemistry, 13(13) (2005) pp. 4243-4252. (available online May 17, 2005). 9000018 38 U.S. Appl. No. 14/028,712, filed Sep. 17, 2013, Binkert et al. 9000019 1 International Preliminary Report on Patentability, dated May 6, 2014, issued in the corresponding International Application No. PCT/JP2012/079048. 9000019 2 International Search Report, mailed on Jan. 22, 2013, issued in the corresponding International Application No. PCT/JP2012/079048. 9000019 3 Kumiai Nouyaku Souran, Ja Zenno, 2008, pp. 508-509 (including an English translation). 9000019 4 The First Office Action (including an English translation), dated Nov. 15, 2014, issued in the corresponding Chinese Patent Application No. 201280052970.5. 9000021 1 PCT Notification of Transmittal of International Search Report and Written Opinion for PCT/US2013/032295. 9000021 2 PCT Written Opinion of International Search Authority for PCT/US2013/032295. 9000021 3 Search History: Limited Classification Search dated May 10, 2013, PCT/US2013/032295. 9000021 4 Biewenga, et al., "The Pharmacology of the Antioxidant Lipoic Acid," Gen. Pharmac., vol. 29, No. 3, pp. 315-331 (1997). 9000021 5 Rowe, et al., "Handbook of Pharmaceutical Excipients," 6th edition, pp. 454-455 (2009). 9000021 6 Spiegel, et al., "Use of Nonaqueous Solvents in Parenteral Products," J. Pharmac. Sciences, vol. 52, No. 10, pp. 917-927 (1963). 9000021 7 International Search Report PCT/US2011/022958 dated Apr. 12, 2011. 9000021 8 Maas B: "Stabilitaet von Bendamustinhydrochlorid in Infusionsloesungen" Die Pharmazie, Govi Verlag Pharmazeutischer Verlag GmbH, Eschborn, DE, vol. 49, No. 10, Jan. 1, 1994. 9000022 1 Bennett et al., "Liver X receptor agonist as a treatment for atheroscierosis," Expert Opinion on therapeutic Patents (2004) 14(7):967-982. 9000022 2 Giorelli et al., "Immunomodulatory properties of increased levels of liver X receptor .beta. in peripheral blood mononuclear cells from multiple sclerosis pateints," Experimental Neurology (2007): 204:759-766. 9000022 3 Goralski et al., "Chipping away at gallstones," Nature Medicine (2004) 10(12):1301-1302. 9000022 4 Joseph et al., "Synthetic LXR ligand inhibits the development of atheroscierosis in mice," PNAS (2002) 99(11):7604-7609. 9000022 5 Kalaany et al., "LXRs regulate the balance between fat storage and oxidation," Cell Metabolism (2005): 1:231-244 and Supplemental Data (4 sheets). 9000022 6 Lettau et al., "Imidazol-N-oxide 1); Eline einfache Synthese substituierter Imidazole," Zeischrift fuer Chemie (1971) 11(1):10-11. 9000022 7 Patent summary on JP4590825 corresponding to JP Application No. 2004-253298 published Sep. 9, 2004. 9000022 8 Schubert et al., "Diimidazoles. II. Synthesis of aliphatically and aromatically bridged N,N-diimidazoles," Journal fuer Praktische Chemie (Leipzig) (1963) 22(3-4):130-139. 9000022 9 Tischenko et al., "Some derivatives of 1,2,5-triphenylimidazole," Deposited Doc. (1980) SPSTL 358Khp-D80, Capius Accession No. 1982:423695, 8pp. 9000022 10 Tischenko et al., "Synthesis and luminescence of 1,2,5-triphenylimidazoles," Sisintill Org Lyuminofory (1972), 93-99. 9000022 11 Tontonoz et al., "Liver X receptor signaling pathways in cardiovascular disease," Molecular Endocrinology (2003) 17 (6):985-993. 9000022 12 Yanborisov et al., "Syntesis and pharmaceutical activity of heteroylpyruvic acids and their derivatvies," Khimiko-Farmatsevticheskii Zhurnal (Pharmaceutical chemistry Journal), 1998, 32(9), 480-482. 9000022 13 Zanlungo et al., "The molecular and metabolic basis of biliary cholesterol secretion and gallstone disease," Frontiers in Bioscience (2003) 8:1166-1174. 9000022 14 Zelcer et al., "Liver X receptors as integrators of metabolic and inflammatory signaling," The Journal of Clinical Investigation (2006): 116(3):607-614. 9000023 1 Lear, N Engl J Med 366;23, Jun. 7, 2012. 9000023 2 Yang, et al., Pathol. Oncol. Res. (2011) 17:387-391. 9000023 3 Rudin, et al., N Engl J Med 361;12, Sep. 17, 2009. 9000023 4 Hidalgo, et al., N Engl J Med 361;21, Nov. 19, 2009. 9000023 5 Wikipedia, HEK 293 cells, http://en.wikipedia.org/wiki/HEK--293--cells, last modified on Jun. 3, 2014 and downloaded on Jul. 15, 2014. 9000023 6 Pinedo, et al., "Translational Research: The Role of VEGF in Tumor Angiogenesis," The Oncologist, 5(suppl 1):1-2 (2000) [www.TheOncologist.com]. 9000023 7 Patel, Bharvin, "Identification and Characterization of a Novel Smoothened Antagonist for the Treatment of Cancer with Deregulated Hedgehog Signaling"/Powerpoint Presentation, AACR 102nd Annual Meeting. Orlando, FL, 2011. 9000023 8 Bendall, Johanna et al., "A Phase I Dose-Escalation, Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of LY2940680, an Oral Smoothened (Smo) Inhibitor"/Poster, 24th European Cancer Organization (ECCO) EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Dublin, Ireland, 2012. 9000023 9 Frank-Kamenetsky, M., et al., "Small-molecular modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists," Journal of Biolology vol. 1, Issue 2, Article 10, pp. 10.1-10.19 (2002). 9000023 10 Lee, J., et al., "A small-moleclar antagonist of the Hedgehog signaling pathway," ChemBioChem, vol. 8, pp. 1916-1919 (2007). 9000023 11 McMahon, G., VEGF Receptor Signaling in Tumor Angiogenisis. The Oncologist, 5(suppl 1):3-10 (2000). [www.TheOncologist.com]. 9000023 12 Pinedo, et al., "Translational Research . . . ," The Oncologist, 5(supp11):1-2 [www.TheOncologist.com], (2000). 9000023 13 Tremblay, M., et al., "Semisynthetic cyclopamine analogues as potent and orally bioavailable Hedgehog pathway antagonists," J. Med. Chem., vol. 51, pp. 6646-6649 (2008). 9000023 14 Tremblay, M., et al., "Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy," Expert Opin. Ther. Patents 19(8):1039-1056 (2009). 9000024 1 Baryawno et al., Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets, Neuro-Oncology 2008, 10(5): 661-674. 9000024 2 Boniface et al., Prostaglandin E2 Regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling, The Journal of Experimental Medicine 2009, 206(3), 535-548. 9000024 3 Buono et al., T-bet deficiency reduces athersclerosis and alters plaque antigen-specific immune responses, Proceedings of National Academy of Sciences of the United States of America Feb. 1, 2005, 102(5): 1596-1601. 9000024 4 Cesare et al., The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis, Journal of Investigative Dermatology 2009, 129: 1339-1350; doi:10.1038/jid.2009.59. 9000024 5 Chan et al., Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis, Rheumatology (Oxford) 2006, 45: 951-957. 9000024 6 Chell et al., Increased Ep4 Receptor Expression in Colorectal Cancer Progession Promotes Cell Growth and Anchorage Independence, Cancer Research 2006, 66: 3106-3113. 9000024 7 Chizzolini et al., Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion, Blood 2008, 112: 3696-3703. 9000024 8 Dougados et al., Efficacy of Celecoxib, a Cyclooxygenase 2--Specific Inhibitor, in the Treatment of Ankylosing Spondylitis: A Six-Week Controlled Study with Comparison Against Placebo and Against a Conventional Nonsteroidal Antiinflammatory Drug, Arthritis & Rheumatism 2001, 44(1): 180-185. 9000024 9 Elmets et al., Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of the National Cancer Institute Nov. 29, 2010, 102: 1835-1844. 9000024 10 Ghoreschi et al., A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses, Journal of Molecular Medicine 2003, 81: 471-480. 9000024 11 Gilbert et al., Pyrazolidine-3, 5-diones and 5-Hydroxy-1H-pyrazol-3(2H)-ones, Inhibitors of UDP-N-acetylenolpyruvyl Glucosamine Re-ductase, Journal of Medicinal Chemistry 2006, 49(20): 6027-6036. 9000024 12 Hotta et al., IL-23/IL-17 Immunity as a Hallmark of Crohn's Disease, Inflammatory Bowel Diseases Sep. 9, 2008, 14(9): 1175-1184. 9000024 13 Hoshikawa et al., Expression of prostaglandin E2 receptors in oral squamous cell carcinomas and growth inhibitory effects of an EP3 selective antagonist, ONO-AE3-240, International Journal of Oncology 2009, 34: 847-852. 9000024 14 International Union of Pure and Applied Chemistry (IUPAC): Rules for the Nomenclature of Organic Chemistry Section E: Stereochemistry, Pure & Applied Chemistry 1975, 45(1): 11-30. 9000024 15 Iwanami et al., Crucial Role of II-6/II-17 Axis in the Induction of Arthritis by Glucose-6-Phosphate Isomerase, Arthritis and Rheumatism Mar. 3, 2008, 58(3):754-763. 9000024 16 Jabbour et al., Prostaglandin E2 Induces Proliferation of Glandular Epithelial Cells of Human Endometrium via Extracellular Regulated Kinase 1/2-Mediated Pathway, Journal of Clinical Endocrinology & Metabolism 2003, 88(9): 4481-4487. 9000024 17 Jandus et al., Increased Numbers of Circulating Polyfunctional Th17 Memory Cells in Patients With Seronegative Spondylarthritides, Arthritis & Rheumatism 2008, 58(8): 2307-2317. 9000024 18 Juedes et al.,T-bet Controls Autoaggressive CD8 Lymphocyte Response in Type I Diabetes, Journal of Experimental Medicine Apr. 19, 2004, 199(8): 1153-1162. 9000024 19 Kundu et al., Antagonism of the prostaglandin E Receptor EP4 inhibits metastasis and enhances NK function, Breast Cancer Research and Treatment 2009, 117: 235-242. 9000024 20 Lin et al., Prostaglandin E2 Receptor EP4 Contributes to Inflammatory Pain Hypersensitivity, Journal of Pharmacology and Experimental Therapeutics 2006, 319(3): 1096-1103. 9000024 21 Liu et al., COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer, Microvascular Research Sep. 2, 2011, 82(2):131-140. 9000024 22 Ma et al., Prostaglandin E Receptor Ep4 Antagonism Inhibits Breast Cancer Metastasis, Cancer Research 2006, 66: 2923-2927. 9000024 23 Maubach et al., BGC20-1531, a novel, potent, and selective EP4 receptor antagonist: a putative new treatment for migraine headache, British Journal of Pharmacology 2009, 156: 316-327. 9000024 24 McCoy et al., The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis, Journal of Clinical Investigation 2002, 110(5): 651-658. 9000024 25 Miyata et al., Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract, Virchows Archiv 2006, 448: 822-829. 9000024 26 Napolitani et al., Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-.gamma. production by memory CD4+ T Cells, European Journal of Immunology 2009, 39: 1301-1312. 9000024 27 Narumiya, S. In The Prostanoid Receptors in Signaling Network of Chronic Inflammation--The Role of FP in Bleomycin-induced Pulmonary Fibrosis and the Role of EP4 in Experimental Autoimmune Encephalomyelitis in Mice, Eicosanoids and Chronic Inflammation, Keystone Symposia, Montana, Jan. 9, 2008 (Abstract Only). 9000024 28 Payner et al., Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E2-dependent activation of type II protein kinase A, Molecular Cancer Therapy 2006, 5: 1817-1826. 9000024 29 Peng et al,, T-bet regulates IgG class switching and pathogenic auto antibody production, Proceedings of National Academy of Sciences of the United States of America Apr. 16, 2002, 99(8): 5545-5550. 9000024 30 Potential new drug targets against hormone-dependent breast cancer identified, Expert Review of Anticancer Therapy 2008, 8(4): 507-509. 9000024 31 Rask et al., Ovarian epithelial cancer: a role for PGE2 synthesis and signaling in malignant transformation and progression, Molecular Cancer 2006, 5: 62. 9000024 32 Sasaki et al., Identification of a novel type 1 diabetes susceptibility gene, T-bet, Human Genetics 2004, 115: 177-184. 9000024 33 Sharma et al., Tumor Cyclooxygenase-2/Prostaglandin E2-Dependent Promotion of FOXP3 Expression and CD4+CD25+ T Regulatory Cell Activities in Lung Cancer, Cancer Research 2005, 65: 5211-5220. 9000024 34 Sheibanie et al., Prostaglandin E2 Exacerbates Collagen-Induced Arthritis in Mice Through the Inflammatory Interleukin-23/Interleukin-17 Axis, Arthritis and Rheumatism 2007, 56(8): 2608-2619. 9000024 35 Sheibanie et al., The Proinflammatory Effect of Prostaglandin E2 in Experimental Inflammatory Bowel Disease is Mediated through the IL-23.fwdarw.IL-17 Axis, Journal of Immunology 2007, 178: 8138-8147. 9000024 36 Terada et al., Identification of EP4 as a Potential Target for the Treatment of Castration-Resistant Prostate Cancer Using a Novel Xenograft Model, Cancer Research 2010, 70: 1606-1615. 9000024 37 Wanders et al., Nonsteroidal Antiinflammatory Drugs Reduce Radiographic Progression in Patients With Ankylosing Spondylitis: A Randomized Clinical Trial, Arthritis & Rheumatism Jun. 6, 2005, 52(6): 1756-1765. 9000024 38 Whiteside, Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression, Expert Opinion in Biological Therapy 2010, 10(7): 1019-35. 9000024 39 Williams, Collagen-Induced Arthritis as a Model for Rheumatoid Arthritis, Methods Molecular Medicine 2004, 98: 207-216. 9000024 40 Woodhams et al., Localisation and modulation of prostanoid receptors EP1 and EP4 in the rat chronic constriction injury model of neuropathic pain, European Journal of Pain 2007, 11(6): 605-613. 9000024 41 Wu et al., Prostaglandin E2 Regulates Renal Cell Carcinoma Invasion Through the EP4 Receptor-Rap Signal Transduction Pathway, Journal of Biological Chemistry Aug. 10, 2011, 286: 33954-33962. 9000024 42 Yang et al., Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis With Selective EP4 Receptor Antagonism, Cancer Research 2006, 66: 9665-9672. 9000024 43 Yao et al, Prostaglandin E2-EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion, Nature Medicine 2009, 15(6): 633-640. 9000025 1 Ferro, et al. Document No. 151:8233, retrieved from CAPLUS, 2009. 9000025 2 McKew, et al. Document No. 144:100371, retrieved from CAPLUS, 2006. 9000025 3 Acton, et al. Document No. 140:253441, retrieved from CAPLUS, 2004. 9000025 4 Mahadevan, et al. Document No. 139:230554, retrieved from CAPLUS, 2003. 9000025 5 Beckers,et al. Document No. 135:352771, retrieved from CAPLUS, 2001. 9000025 6 Sato, et al. Document No. 131:179295, retrieved from CAPLUS, 1999. 9000025 7 Tajima, et al. Document No. 130:237567, retrieved from CAPLUS, 1999. 9000025 8 Medarde, et al. Document No. 128:294632, retrieved from CAPLUS, 1998. 9000025 9 Lau, et al. Document No. 128:252531, retrieved from CAPLUS, 1998. 9000025 10 Saito, et al. Document No. 127:108841, retrieved from CAPLUS, 1997. 9000025 11 Blagg, et al. document No. 125:247521, retrieved from CAPLUS, 1996. 9000025 12 Okada, et al. (Document No. 119:95329, retrieved from CAPLUS, 1993. 9000025 13 Blagg, et al. (Document No. 120:106982, retrieved from CAPLUS, 1994. 9000025 14 Kulagowski, et al. (Document No. 117:131086, CAPLUS, 1992. 9000025 15 Kato, et al. (Document No. 107:219461, CAPLUS, 1987. 9000025 16 Powell, et al. (Document No. 153:600657, CAPLUS, 2010. 9000025 17 Cancer and Metastasis Reviews (1998), 17(1), 91-106. 9000025 18 Science (1999), vol. 286, 531-537. 9000025 19 Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL http://www.nlm.nih.gov/medlineplus/cancer.html>. 9000025 20 Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL; http://en.wikipedia.orglwikilCancer. 9000025 21 Watanabe, Naoko et al., "Both Plasma Lysophosphatidic Acid and Serum Autotaxin Levels are Increased in Chronic Hepatitis C", J Clin Gastroenterol, vol. 41, pp. 616-623. Lippincott Williams & Wilkins, Tokyo (2007). 9000025 22 Watanabe, Naoko et al, "Plasma Lysophosphatidic Acid and Serum Autotoxin Activity are Increased in Liver Injury in Rats in Relation to Its Severity", Life Sciences, vol. 81, pp. 1009-1015 Tokyo, Japan. (2007). 9000025 23 Cui,Peng et al., ".alpha.-and .beta.-Substituted phosphate analogs of LPA as autotoxin inhibitors", Bioorganic & Medicinal Chemistry, vol. 16, p. 2212-2225, (2007). 9000025 24 Evans,Jilly et al., "Seeing the Future of Bioactive Lipid Drug Targets", Nature Chemical Biology, vol. 6, pp. 476-479 (Jul. 2010). 9000025 25 Gardell, Shannon E. et al.,"Emerging Medicinal Roles for Lysophospholipid Signaling", Trends in Molecular Medicine, vol. 12, No. 2, p. 66-75 (Feb. 2006). 9000025 26 Gierse, James et al., "A Novel Autotaxin Inhibitor Reduces Lysophosphadic Acid Levels in Plasma and the Site of Inflammation", Pfizer Inflammation Research, pp. 1-40, (Apr. 14, 2010). 9000025 27 Albers, Harald et al., "Boronic acid-based inhibitor of autotoxin reveals rapid turnover of LPA in the circulation", Division of Cell Biology, pp. 1-6 (Feb. 2010). 9000025 28 Kishimoto, Tatsuya et al., "A Novel Colorimetric assay for the determination of lysophosphatidic acid in plasma using an enzymatic cycling method", Clinica Chimica Acta, pp. 59-67, (2003). 9000025 29 Mills Gordon et al, "The Emerging Role of Lysophosphatidic Acid in Cancer", Nature Reviews, vol. 3, pp. 582-591 (Aug. 2003). 9000025 30 Nakamura, Kazuhiro et al., "Measurement of lysophospholipase D/autotaxin activity in human serum samples", Clinical Biochemistry, vol. 40, pp. 274-277, (2007). 9000025 31 Prestwich, G.D et al., "New metabolically stabilized analogues of Lysphosphatidic acid: agonists, antagonists and enzyme inhibitors", Biochemical Society, pp. 1357-1361 (2005). 9000025 32 Chemical Structure Search; Science IP The CAS Search Service, Jun. 23, 2010, pp. 1-137. 9000025 33 Chemical Structure Search; Science IP The CAS Search Service, Jan. 28, 2010, pp. 1-195. 9000025 34 James, D. et al., "Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines", Bioorganic & Medicinal Chemistry Letters, Pergamon, Elsevier Science,GB, vol. 16, No. 19, pp. 5164-5168 (2006). 9000025 35 Tokumura, A., "Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids", Biochimica and Biophysica Acta. Molecular and Cell Biology of Lipids, Elsevier, Amsterdamn, NL, vol. 1582, No. 1-3, pp. 18-25 (2002). 9000026 1 Cancer and Metastasis Reviews (1998), 17(1), 91-106. 9000026 2 Science (1999), vol. 286, 531-537. 9000026 3 Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL http://www.nlm.nih.gov/medlineplus/cancer.html>. 9000026 4 Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL; http://en.wikipedia.orglwikilCancer. 9000027 1 Samuel et al. abstract (Blood (ASH Annual Meeting Abstracts) 2006 108: Abstract 1432. 9000027 2 Afshar et al., Radiation-induced caspase-8 mediates p53-independent apoptosis in glioma cells. Cancer Res. Apr. 15, 2006;66(8):4223-32. 9000027 3 Arienti et al., Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. Mar. 24, 2005;48(6):1873-85. 9000027 4 Bergeron et al., Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev. May 1, 1998;12(9):1304-14. 9000027 5 Berghmans et al., tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A. Jan. 11, 2005;102(2):407-12. Epub Jan. 3, 2005. 9000027 6 Berman et al., Zebrafish as a model for myelopoiesis during embryogenesis. Exp Hematol. Sep. 2005;33(9):997-1006. 9000027 7 Bernassola et al., The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. Oncogene. Oct. 20, 2005;24(46):6982-6. 9000027 8 Bernassola et al., Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med. Jun. 7, 2004;199(11):1545-57. 9000027 9 Bonzon et al., Caspase-2-induced apoptosis requires bid cleavage: a physiological role for bid in heat shock-induced death. Mol Biol Cell. May 2006;17(5):2150-7. Epub Feb. 22, 2006. 9000027 10 Bunz et al., Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. Nov. 20, 1998;282(5393):1497-501. 9000027 11 Castedo et al., Cell death by mitotic catastrophe: a molecular definition. Oncogene. Apr. 12, 2004;23(16):2825-37. 9000027 12 Castedo et al., The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene. May 27, 2004;23(25):4353-61. 9000027 13 Chan et al., Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev. Jul. 1, 2000;14(13):1584-8. 9000027 14 Chen et al., Chk1 in the DNA damage response: conserved roles from yeasts to mammals. DNA Repair (Amst). Aug.-Sep. 2004;3(8-9):1025-32. 9000027 15 Chen et al., Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther. Jun. 2003;2(6):543-8. 9000027 16 Chen et al., Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer. Dec. 15, 2006;119(12):2784-94. 9000027 17 Colell et al., GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell. Jun. 1, 2007;129(5):983-97. 9000027 18 Collis et al,. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. Apr. 1, 2003;63(7):1550-4. 9000027 19 Cuadrado et al., "ATR activation in response to ionizing radiation: still ATM territory". Cell Div. May 17, 2006;1(1):7. 9000027 20 Cuadrado et al., ATM regulates ATR chromatin loading in response to DNA double-strand breaks. J Exp Med. Feb. 20, 2006;203(2):297-303. Epub Feb. 6, 2006. 9000027 21 Eimon et al., Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death Differ. Oct. 2006;13(10):1619-30. Epub Aug. 4, 2006. 9000027 22 Fogarty et al., The Drosophila grapes gene is related to checkpoint gene chk1/rad27 and is required for late syncytial division fidelity. Curr Biol. Jun. 1, 1997;7(6):418-26. 9000027 23 Franken et al., Clonogenic assay of cells in vitro. Nat Protoc. 2006;1(5):2315-9. 9000027 24 Frenkel et al., Accentuated apoptosis in normally developing p53 knockout mouse embryos following genotoxic stress. Oncogene. May 6, 1999;18(18):2901-7. 9000027 25 Garber, New checkpoint blockers begin human trials. J Natl Cancer Inst. Jul. 20, 2005;97(14):1026-8. 9000027 26 Giraldez et al., MicroRNAs regulate brain morphogenesis in zebrafish. Science. May 6, 2005;308(5723):833-8. Epub Mar. 17, 2005. 9000027 27 Goldstein et al., The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol. Mar. 2000;2(3):156-62. 9000027 28 Gong et al., The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. Jun. 24, 1999;399(6738):806-9. 9000027 29 Hengartner, The biochemistry of apoptosis. Nature. Oct. 12, 2000;407(6805):770-6. 9000027 30 Hickson et al., Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. Dec. 15, 2004;64(24):9152-9. 9000027 31 Hsu et al., The pu.1 promoter drives myeloid gene expression in zebrafish. Blood. Sep. 1, 2004;104(5):1291-7. Epub Mar. 2, 2004. 9000027 32 Huang et al., CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science. Oct. 13, 2006;314(5797):294-7. 9000027 33 Imamura et al., Molecular cloning and functional characterization of zebrafish ATM. Int J Biochem Cell Biol. May 2005;37(5):1105-16. Epub Jan. 7, 2005. 9000027 34 Inohara et al., Genes with homology to mammalian apoptosis regulators identified in zebrafish. Cell Death Differ. May 2000;7(5):509-10. 9000027 35 Ishii et al., Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. Jul. 1999;9(3):469-79. 9000027 36 Kasibhatla et al., DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. Mar. 1998;1(4):543-51. 9000027 37 Kastan et al., Cell-cycle checkpoints and cancer. Nature. Nov. 18, 2004;432(7015):316-23. 9000027 38 Kawabe, G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther. Apr. 2004;3(4):513-9. 9000027 39 Kohn et al., The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. Jan. 1, 2003;63(1):31-5. 9000027 40 Kolesnick et al., Radiation and ceramide-induced apoptosis. Oncogene. Sep. 1, 2003;22(37):5897-906. 9000027 41 Kratz et al., Functional characterization of the Bcl-2 gene family in the zebrafish. Cell Death Differ. Oct. 2006;13(10):1631-40. Epub Aug. 4, 2006. 9000027 42 Lam et al., Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell. Jul. 2004;6(1):45-59. 9000027 43 Langenau et al., Myc-induced T cell leukemia in transgenic zebrafish. Science. Feb. 7, 2003;299(5608):887-90. 9000027 44 Langenau et al., Suppression of apoptosis by bcl-2 overexpression in lymphoid cells of transgenic zebrafish. Blood. Apr. 15, 2005;105(8):3278-85. Epub Dec. 23, 2004. 9000027 45 Langheinrich et al., Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. Curr Biol. Dec. 10, 2002;12(23):2023-8. 9000027 46 Lassus, Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science. Aug. 23, 2002;297(5585):1352-4. 9000027 47 Levesque et al., Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Mol Cancer Ther. Feb. 2008;7(2):252-62. 9000027 48 Li et al., Activation of caspase-2 in apoptosis. J Biol Chem. Aug. 22, 1997;272(34):21010-7. 9000027 49 Li et al., Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science. Aug. 18, 2000;289(5482):1159-64. 9000027 50 Lin et al., Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor. 9000027 51 Nur77/TR3. Cell. Feb. 20, 2004;116(4):527-40. 9000027 52 Liu et al., Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. Jun. 15, 2000;14(12):1448-59. 9000027 53 Lowe et al., Intrinsic tumour suppression. Nature. Nov. 18, 2004;432(7015):307-15. 9000027 54 Moffat et al., A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. Mar. 24, 2006;124(6):1283-98. 9000027 55 Mukhopadhyay et al., RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res. Apr. 1, 2005;65(7):2872-81. 9000027 56 Nutt et al., Metabolic regulation of oocyte cell death through the CaMKII-mediated phosphorylation of caspase-2. Cell. Oct. 7, 2005;123(1):89-103. 9000027 57 Okada et al., Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. Aug. 2004;4(8):592-603. 9000027 58 Prudhomme, Novel checkpoint 1 inhibitors. Recent Pat Anticancer Drug Discov. Jan. 2006;1(1):55-68. 9000027 59 Pyati et al., Zebrafish as a powerful vertebrate model system for in vivo studies of cell death. Semin Cancer Biol. Apr. 2007;17(2):154-65. Epub Dec. 15, 2006. 9000027 60 Reinhardt et al., p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell. Feb. 2007;11(2):175-89. 9000027 61 Rentzsch et al., Specific and conserved roles of TAp73 during zebrafish development. Gene. Dec. 24, 2003;323:19-30. 9000027 62 Rhodes et al., Interplay of pu.1 and gata1 determines myelo-erythroid progenitor cell fate in zebrafish. Dev Cell. Jan. 2005;8(1):97-108. 9000027 63 Roninson et al., If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. Oct. 2001;4(5):303-13. 9000027 64 Roos et al., DNA damage-induced cell death by apoptosis. Trends Mol Med. Sep. 2006;12(9):440-50. Epub Aug. 8, 2006. 9000027 65 Shin et al., Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J. Oct. 19, 2005;24(20):3532-42. Epub Sep. 29, 2005. 9000027 66 Sidi et al., Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell. May 30, 2008;133(5):864-77. 9000027 67 Sidi et al., Modifier genetics in zebrafish identify Chk1 and an associated survival pathway as targets for pharmacotherapy of MDS/AML with P53 mutations. Blood. Nov. 16, 2006;108(11):416A. Abstract 1432. 9000027 68 Stern et al., Small molecules that delay S phase suppress a zebrafish bmyb mutant. Nat Chem Biol. Dec. 2005;1(7):366-70. 9000027 69 Syljuasen et al., Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res. Dec. 15, 2004;64(24):9035-40. 9000027 70 Syljuasen et al., Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol. May 2005;25(9):3553-62. 9000027 71 Tao et al., Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med Chem. Jul. 2006;6(4):377-88. 9000027 72 Tinel et al., The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science. May 7, 2004;304(5672):843-6. Epub Apr. 8, 2004. 9000027 73 Troy et al., Caspase-2 redux. Cell Death Differ. Jan. 2003;10(1):101-7. 9000027 74 Tse et al., Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res. Apr. 1, 2007;13(7):1955-60. 9000027 75 Tu et al., In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis. Nat Cell Biol. Jan. 2006;8(1):72-7. Epub Dec. 18, 2005. 9000027 76 Urist et al., p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. Dec. 15, 2004;18(24):3041-54. 9000027 77 Vousden et al., Live or let die: the cell's response to p53. Nat Rev Cancer. Aug. 2002;2(8):594-604. 9000027 78 Wagner et al., Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway. J Biol Chem. Aug. 13, 2004;279(33):35047-52. Epub Jun. 1, 2004. 9000027 79 Wang et al., Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol. Apr. 2007;27(8):3098-108. Epub Feb. 12, 2007. 9000027 80 Westerfield et al., An on-line database for zebrafish development and genetics research. Semin Cell Dev Biol. Oct. 1997;8(5):477-88. 9000027 81 Wichmann et al., Ionizing radiation induces caspase-dependent but Chk2- and p53-independent cell death in Drosophila melanogaster. Proc Natl Acad Sci U S A. Jun. 27, 2006;103(26):9952-7. Epub Jun. 19, 2006. 9000027 82 Wyllie et al., Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251-306. 9000027 83 Xiao et al., A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene. Feb. 17, 2005;24(8):1403-11. 9000027 84 Yang et al., Targeted expression of human MYCN selectively causes pancreatic neuroendocrine tumors in transgenic zebrafish. Cancer Res. Oct. 15, 2004;64(20):7256-62. 9000027 85 Yount et al., Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Oncogene. May 17, 2001;20(22):2826-35. 9000027 86 Yuan et al., p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. Jun. 24, 1999;399(6738):814-7. 9000027 87 Zachos et al., Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J. Feb. 3, 2003;22(3):713-23. 9000027 88 Zhivotovsky et al., Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun. Jun. 10, 2005;331(3):859-67. 9000027 89 Zhou et al., Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer. Mar. 2004;4(3):216-25. Epub 1-10. 9000027 90 Zhou et al., The DNA damage response: putting checkpoints in perspective. Nature. Nov. 23, 2000;408(6811):433-9. 9000027 91 Gilley et al., One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus. Oncogene. 2001; 20:7447-7452. 9000027 92 Manzl, Lack of Chk1-suppressed alternative cell death pathway in murine cells. Eur. Molec. Biol. Org. Workshop Schedule. Mar. 10-14, 2011; 8 pages. 9000028 1 L. Montebugnoli et al., 104 Oral and maxillofacial surgery, 473-477 (2007). 9000028 2 A. Lipton, 38 Annual Review of Pharmacology and Toxicology, 159-177 (1998). 9000028 3 H. Girouard et al., 100 Journal of Applied Physiology, 328-335, 332 (2006). 9000028 4 R. S. Shah et al., 52 Biomedicine & Pharmacotherapy, 199-207 (2008). 9000028 5 J.T. O'Brien et al., 2 The Lancet Neurology, 89-98, 96 (2003). 9000028 6 V.J. Desmet et al., 19 Hepatology, 1513-1520 (1994). 9000028 7 S. Terai et al., 24 Stem Cells, 2292-2298 (2006). 9000028 8 I. Collins, Current Signal Transduction Therapy, 1, 13-23, 13 (2006). 9000028 9 F.F. Piccioitto et al., 46 Journal of Hepatology, 459-465 (2007). 9000028 10 M. Buti et al., 47 Journal of Hepatology, 366-371 (2007). 9000028 11 K. Weigand et al., 13 World Journal of Gastroenterology, 1897-1905 (2007). 9000028 12 C-L Lai et al., 357 The New England Journal of Medicine, 2576-2588 (2007). 9000028 13 J. Lehmann et al., 50 European Urology, 141-147, 143 (2006). 9000028 14 Y. Nakayama et al., 161 Cancer Letters, 63-71 (2000). 9000028 15 S. Ellenberg et al., 8 Statistics in Medicine, 405-413 (1989). 9000028 16 D. Schuppan et al., 371 The Lancet, 838-851 (2008). 9000028 17 R. Bataller et al., 115 The Journal of Clinical Investigation, 209-218 (2005). 9000028 18 S. Erickson, 50 Journal of Lipid Research, s412-s416 (2009). 9000028 19 J.R. Lewis et al., 55 Digestive Diseases and Sciences, 560-578 (2010). 9000028 20 J.H. Poupaert, Drug Design: Basic Principles and Applications, in 2 Encyclopedia of Pharmaceutical Technology 1362-1369, 1367 (James Swarbrick ed., 3rd ed., 2007). 9000028 21 L.I. Zon et al., Nature Reviews Drug Discovery 4, 35 (2005). 9000028 22 B.A. Chabner et al., Chemotherapy of Neoplastic Diseases, Neoplastic Agents in, Goodman & Gilman's: The Pharmacological Basis of Therapeutics 1315-1403, 1315 (L.L. Brunton et al., eds., 11th ed., 2006). 9000028 23 Dai, W. et al, "Chemistry of aminophenols. Part 2: A general and efficient synthesis of indoles possessing a nitrogen substituent at the C4, C5, C6 and C7 positions," Tetrahedron Letters, 2002, vol. 43, pp. 7699-7702. 9000028 24 Huang et al., "4-Bromo-N-(2-phenyl-1H-indol-7-yl)-benzenesulfonamide", Acta Cryst., vol. E60, 2004 (Published online Mar. 6, 2004), pp. o488-o489. 9000028 25 Huang et al., "Crystal structures of p-methyl-N-(2-phenyl-1H-indol-7-yl)-benzene-sulfonamide, C21H18N2O2S, and p-methoxy-N-(2-phenyl-1H-indol-7-yl)-benzene-sulfonamide, C21H18N2O3S", Z. Kristallogr. NCS, vol. 220, 2005, pp. 258-260. 9000029 1 Adam, T. et al., "Stress, Eating and the Reward System," Physiology and Behavior, 2007, 91 (4), 449-458. 9000029 2 Aston-Jones, G. et al., "Lateral Hypothalamic Orexin/Hypocretin Neurons: A Role in Reward-Seeking and Addiction," Brain Research, 2009, doi:10.1016/j.brainres.2009.09.106 (uncorrected proof), 18 pages. 9000029 3 Berridge, C. et al., "Hypocretin/Orexin in Arousal and Stress," Brain Research, NIH Public Access, Author Manuscript, available in PMC Feb. 16, 2011, 21 pages, published in final edited form as Brain Research, 2010, 1314, 91-102. 9000029 4 Borgland, S. et al., "Orexin A in the VTA Is Critical for the Induction of Synaptic Plasticity and Behavioral Sensitization to Cocaine," Neuron, 2006, 49 (4), 589-601. 9000029 5 Boss, C. et al., "Biomedical Application of Orexin/Hypocretin Receptor Ligands in Neuroscience," Journal of Medicinal Chemistry, 2009, 52 (4), 891-903. 9000029 6 Boutrel, B. et al., "Role for Hypocretin in Mediating Stress-Induced Reinstatement of Cocaine-Seeking Behavior," Proceedings of the National Academy of Sciences, 2005, 102 (52), 19168-19173. 9000029 7 Brisbare-Roch, C. et al., "Promotion of Sleep by Targeting the Orexin System in Rats, Dogs and Humans," Nature Medicine, published online Jan. 28, 2007, doi:10.1038/nm1544, 6 pages. 9000029 8 Cai, J. et al., "Antagonists of the Orexin Receptors," Expert Opinion on Therapeutic Patents, 2006, 16(5), 631-646. 9000029 9 Carter, M. et al, "The Brain Hypocretins and Their Receptors: Mediators of Allostatic Arousal," Current Opinion in Pharmacology, 2009, doi:10.1016/j.coph.2008.12.018, 7 pages. 9000029 10 Chang, L. et al., "Highly Constrained Bicyclic VLA-4 Antagonists," Bioorganic and Medicinal Chemistry Letters, 2007, 17 (3), 597-601. 9000029 11 Chemelli, R. et al., "Narcolepsy in orexin Knockout Mice: Molecular Genetics of Sleep Regulation," Cell, 1999, 98, 437-451. 9000029 12 Chrousos, G. et al., "The Concepts of Stress and Stress System Disorders," JAMA, 1992, 267 (9), 1244-1252. 9000029 13 Desarnaud, F. et al., "The Diurnal Rhythm of Hypocretin in Young and Old F344 Rats," Sleep, 2004, 27 (5), 851-856. 9000029 14 Dietrich, H. et al., "Intact Learning and Memory in Rats Following Treatment with Dual Orexin Receptor Antagonist Almorexant," Psychopharmacology, 2010, 212, 145-154. 9000029 15 English-language abstract from the European Patent Office website for JP 55-81857, http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC& II=0& ND=4& adjacent=true& locale=en--EP& FT=D& date=19800620& CC=JP& NR=S5581857A& KC=A, website accessed Feb. 21, 2014, 2 pages. 9000029 16 Fendt, M. et al., "The Neuroanatomical and Neurochemical Basis of Conditioned Fear," Neuroscience and Biobehavioral Reviews, 1999, 23, 743-760. 9000029 17 Feng, P. et al., "Changes in Brain Orexin Levels in a Rat Model of Depression Induced by Neonatal Administration of Clomipramine," Journal of Psychopharmacology, 2008, 22 (7), 784-791. 9000029 18 Furlong, T. et al., "Hypocretin/Orexin Contributes to the Expression of Some But Not All Forms of Stress and Arousal," European Journal of Neuroscience, 2009, doi:10.1111/j.1460-9568.2009.06952.x, 12 pages. 9000029 19 Gennaro, A., Ed., Remington: The Science and Practice of Pharmacy, 20th Edition, Philadelphia College of Pharmacy and Science, 2001. 9000029 20 Georgescu, D. et al., "Involvement of the Lateral Hypothalamic Peptide Orexin in Morphine Dependence and Withdrawal," The Journal of Neuroscience, 2003, 23 (8), 3106-3111. 9000029 21 Gibson, M., Ed., Pharmaceutical Preformulation and Formulation, A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, IHS Health Group, A CRC Press Book, Englewood, CO, USA, 2001, ISBN: 1574911201. 9000029 22 Gould, P., "Salt Selection for Basic Drugs," International Journal of Pharmaceutics, 1986, 33, 201-217. 9000029 23 Gozzi, A. et al., "Functional Magnetic Resonance Imaging Reveals Different Neural Substrates for the Effects of Orexin-1 and Orexin-2 Receptor Antagonists," PLoS One, 2011, 6(1), e16406, doi:10.1371/journal.pone.0016406, 12 pages. 9000029 24 Harris, G. et al., "A Role for Lateral Hypothalamic Orexin Neurons in Reward Seeking," Nature, 2005, 437 (7058), 556-559. 9000029 25 Hollander, J. et al., "Insular Hypocretin Transmission Regulates Nicotine Reward," Proceedings of the National Academy of Sciences, 2008, 105 (49), 19479-19484. 9000029 26 Hutcheson, D. et al., "Orexin-1 Receptor Antagonist SB-334867 Reduces the Acquisition and Expression of Cocaine-Conditioned Reinforcement and the Expression of Amphetamine-Conditioned Reward," Behavioural Pharmacology, 2011, doi:10.1097/FBP.0b013e328343d761, 9 pages. 9000029 27 International Preliminary Report on Patentability for International Application No. PCT/IB2011/053693, date of issuance Feb. 26, 2013, 9 pages. 9000029 28 International Search Report for International Application No. PCT/IB2011/053693 mailed Dec. 2, 2011, 4 pages. 9000029 29 Kane, J. et al., "Nicotine Up-Regulates Expression of Orexin and its Receptors in Rat Brain," Endocrinology, 2000, 141 (10), 3623-3629. 9000029 30 Kang, J. et al., "Amyloid-.beta. Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle," Sciencexpress, 2009, doi:10.1126/science.1180962, 8 pages. 9000029 31 Kayaba, Y. et al., "Attenuated Defense Response and Low Basal Blood Pressure in Orexin Knockout Mice," American Journal of Physiology--Regulatory, Integrative, and Comparative Physiology, 2003, 285, R581-R593. 9000029 32 Kiwaki, K. et al., "Orexin A (Hypocretin 1) Injected into Hypothalamic Paraventricular Nucleus and Spontaneous Physical Activity in Rats," American Journal of Physiology--Endocrinology and Metabolism, 2004, 286 (4), E551-E559. 9000029 33 Kiyashchenko, L. et al., "Release of Hypocretin (Orexin) During Waking and Sleep States," The Journal of Neuroscience, 2002, 22 (13), 5282-5286. 9000029 34 Koob, G. et al., "Neurobiological Mechanisms of Addiction: Focus on Corticotropin-Releasing Factor," Current Opinion in Investigational Drugs, 2010, 11 (1), 63-71. 9000029 35 Lawrence, A. et al., "The Orexin System Regulates Alcohol-Seeking in Rats," British Journal of Pharmacology, 2006, 148 (6), 752-759. 9000029 36 Lee, M. et al., "Discharge of Identified Orexin/Hypocretin Neurons Across the Sleep-Waking Cycle," The Journal of Neuroscience, 2005, 25 (28), 6716-6720. 9000029 37 Lesage, M. et al., "Nicotine Self-Administration in the Rat: Effects of Hypocretin Antagonists and Changes in the Hypocretin mRNA," Psychopharmacology, 2010, 209 (2), 203-212. 9000029 38 Liu, X., et al., "Insomnia and Hypersomnia Associated with Depressive Phenomenology and Comorbidity in Childhood Depression," Sleep, 2007, 30 (1), 83-90. 9000029 39 Majzoub, J., "Corticotropin-Releasing Hormone Physiology," European Journal of Endocrinology, 2006, 155 (suppl 1), S71-S76. 9000029 40 Mathes, W. et al., "The Biology of Binge Eating," Appetite, 2009, 52, 545-553. 9000029 41 Mileykovskiy, B. et al., "Behavioral Correlates of Activity in Identified Hypocretin/Orexin Neurons," Neuron, 2005, 46 (5), 787-798. 9000029 42 Narita, M. et al., "Direct Involvement of Orexinergic Systems in the Activation of the Mesolimbic Dopamine Pathway and Related Behaviors Induced by Morphine," The Journal of Neuroscience, 2006, 26 (2), 398-405. 9000029 43 Nollet, M. et al., "Activation of Orexin Neurons in Dorsomedial/Perifornical Hypothalamus and Antidepressant Reversal in a Rodent Model of Depression," Neuropharmacology, 2011, doi:10.1016/j.neuropharm.2011.04.022, 11 pages. 9000029 44 Piper, D. et al., "The Novel Brain Neuropeptide, Orexin-A, Modulates the Sleep-Wake Cycle of Rats," European Journal of Neuroscience, 2000, 12 (2), 726-730. 9000029 45 Prud'Homme, M. et al., "Nutritional Status Modulates Behavioural and Olfactory Bulb Fos Responses to Isoamyl Acetate or Food Odour in Rats: Roles of Orexins and Leptin," Neuroscience, 2009, 162 (4), 1287-1298. 9000029 46 PubChem Compound Summary for: CID 16828035, AGN-PC-016WCG, Create Date: Nov. 13, 2007, 4 pages, retrieved on Apr. 23, 2014. 9000029 47 PubChem ZINC09068446--Compound Summary (CID 40924317), Create Date: May 30, 2009, 2 pages, retrieved on Sep. 1, 2011. 9000029 48 PubChem Compound Summary for: CID 40924321, ZINC09068450, Create Date: May 30, 2009, 4 pages, retrieved on Apr. 23, 2014. 9000029 49 PubChem BioAssay: AID 434989, Deposit Date: Jun. 15, 2010, 7 pages, retrieved on Apr. 23, 2014. 9000029 50 PubChem BioAssay: AID 504701, Deposit Date: Apr. 22, 2011, 8 pages retrieved on Apr. 23, 2014. 9000029 51 PubChem MLS002247905--Substance Summary, Chemical Structure (CID 2315573), Deposited Record (SID 85268585), Deposit Date: Nov. 5, 2009, Modify Date: Nov. 5, 2009, 2 pages, retrieved on Sep. 14, 2011. 9000029 52 PubChem MLS001076936--Substance Summary, Chemical Structure (CID 20880646), Deposited Record (SID 49718691), Deposit Date: May 21, 2008, Modify Date: May 21, 2008, 2 pages, retrieved on Sep. 14, 2011. 9000029 53 PubChem MLS001223988--Substance Summary, Chemical Structure (CID 3228462), Deposited Record (SID 49727331), Deposit Date: May 21, 2008, Modify Date: May 21, 2008, 2 pages, retrieved on Sep. 14, 2011. 9000029 54 PubChem MLS002166024--Substance Summary, Chemical Structure (CID 4879906), Deposited Record (SID 57262856), Deposit Date: Feb. 23, 2009, Modify Date: Feb. 23, 2009, 2 pages, retrieved on Sep. 14, 2011. 9000029 55 PubChem MLS000937074--Substance Summary, Chemical Structure (CID 22429402), Deposited Record (SID 49715682), Deposit Date: May 21, 2008, Modify Date: May 21, 2008, 2 pages, retrieved on Sep. 14, 2011. 9000029 56 PubChem MLS00531786--Substance Summary, Chemical Structure (CID 2961359), Deposited Record (SID 14736873), Deposit Date: Oct. 20, 2006, Modify Date: Feb. 10, 2007, 2 pages, retrieved on Sep. 14, 2011. 9000029 57 PubChem Compound Summary for: CID 651337, 1-(4-Methoxy-benzenesulfony1)-pyrrolidine-2-carboxylic acid p-tolyamide, Create Date: Jun. 4, 2005, 3 pages, retrieved on Mar. 13, 2014. 9000029 58 PubChem Compound Summary for: CID 2937052, F1475-0198, Create Date: Jul. 29, 2005, 3 pages, retrieved on Mar. 13, 2014. 9000029 59 PubChem Compound Summary for: CID 2948105, ST50102148, Create Date: Jul. 29, 2005, 3 pages, retrieved on Mar. 13, 2014. 9000029 60 Quarta, D. et al., "The Orexin-1 Receptor Antagonist SB-334867 Reduces Amphetamine-Evoked Dopamine Outflow in the Shell of the Nucleus Accumbens and Decreases the Expression of Amphetamine Sensitization," Neurochemistry International, 2009, doi:10.1016/j.neuint.2009.08.012 (uncorrected proof), 5 pages. 9000029 61 Sakurai, T. et al., "Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior," Cell, 1998, 92, 573-585. 9000029 62 Salomon, R. et al., "Diurnal Variation of Cerebrospinal Fluid Hypocretin-1 (Orexin-A) Levels in Control and Depressed Subjects," Biological Psychiatry, 2003, 54 (2), 96-104. 9000029 63 Samson, W. et al., "Orexin Receptor Subtype Activation and Locomotor Behavior in the Rat," Acta Physiologica, NIH Public Access, Author Manuscript, available in PMC Mar. 1, 2011, 33 pages, published in final edited form as Acta Physiologica, 2010, 198 (3), 313-324. 9000029 64 Sharf, R. et al., "Role of Orexin/Hypocretin in Dependence and Addiction," Brain Research, 2010, 1314, 130-138. 9000029 65 Shippenberg, T. et al., Chapter 97, "Recent Advances in Animal Models of Drug Addiction," 2002, pp. 1381-1397 in Neuropsychopharmacology: The Fifth Generation of Progress, Davis, K. et al., Eds., 2002. 9000029 66 Smith, R. et al., "Orexin/Hypocretin Signaling at the OX1 Receptor Regulates Cue-Elicited Cocaine-Seeking," European Journal of Neuroscience, NIH Public Access, Author Manuscript, available in PMC Aug. 1, 2010, 21 pages, published in final edited form as European Journal of Neuroscience, 2009, 30 (3), 493-503. 9000029 67 Smith, R. et al., "Orexin/Hypocretin is Necessary for Context-Driven Cocaine-Seeking," Neuropharmacology, NIH Public Access, Author Manuscript, available in PMC Jan. 1, 2011, 14 pages, published in final edited form as Neuropharmacology, 2010, 58 (1), 179-184. 9000029 68 Spealman, R. et al., "Pharmacological and Environmental Determinants of Relapse to Cocaine-Seeking Behavior," Pharmacology Biochemistry and Behavior, 1999, 64 (2), 327-336. 9000029 69 Stickgold, R., "Sleep-Dependent Memory Consolidation," Nature, 2005, 437 (7063), 1272-1278. 9000029 70 Sutcliffe, J. et al., "The Hypocretins: Setting the Arousal Threshold," Nature Reviews, Neuroscience, 2002, 3 (5), 339-349. 9000029 71 Tsujino, N. et al., "Orexin/Hypocretin: A Neuropeptide at the Interface of Sleep, Energy Homeostasis and Reward System," Pharmacological Reviews, 2009, 61 (2), 162-176. 9000029 72 Vanderschuren, L. et al., "Sensitization Processes in Drug Addiction," Current Topics in Behavioral Neurosciences, Behavioral Neuroscience of Drug Addiction, 2009, 3, 179-195. 9000029 73 Vinkers, C. et al., "Translational Aspects of Pharmacological Research into Anxiety Disorders: The Stress-Induced Hyperthermia (SIH) Paradigm," European Journal of Pharmacology, 2008, 585, 407-425. 9000029 74 Winrow, C. et al., "Orexin Receptor Antagonism Prevents Transcriptional and Behavioral Plasticity Resulting from Stimulant Exposure," Neuropharmacology, 2009, doi:10.1016/j.neuropharm.2009.07.008 (uncorrected proof), 10 pages. 9000029 75 Zeitzer, J. et al., "Circadian and Homeostatic Regulation of Hypocretin in a Primate Model: Implications for the Consolidation of Wakefulness," The Journal of Neuroscience, 2003, 23 (8), 3555-3560. 9000029 76 Zhang, G. et al., "Long-Lasting Up-Regulation of Orexin Receptor Type 2 Protein Levels in the Rat Nucleus Accumbens After Chronic Cocaine Administration," Journal of Neurochemistry, 2007, 103 (1), 400-407. 9000029 77 Zhang, W. et al., "Multiple Components of the Defense Response Depend on Orexin: Evidence from Orexin Knockout Mice and Orexin Neuron-Ablated Mice," Autonomic Neuroscience: Basic and Clinical, 2006, 126-127, 139-145. 9000030 1 Aracava et al. Memantine blocks a-7 nicotinic acetylcholine receptors more potently than N-methyl-D-asparate receptors in rat hippocampal neurons. The Journal of Pharmcology and Experimental Therapeutics, vol. 312. No. 3 pp. 1195-1205, 2005. 9000030 2 Giorgetti et a. Local GABAergic modulation of acetylcholine release from the cortex of free moving rats, Europena Journal of Neuroscience, vol. 12, pp. 1941-1948, 2000. 9000030 3 Materi et al. Inhibition of synaptically evoked cortical acetylcholine release by intracortical glutamate: involvement of GABAergic neruons. Eur J. Neurosci, vol. 14, pp. 38-46, 2001. 9000031 1 Amaravadi et al., Principles and current strategies for targeting autophagy for cancer treatment. Clinical Cancer Research, 17: 654-666 (2011). 9000031 2 Brech et al., Autophagy in tumour suppression and promotion. Molecular Oncology, 3: 366-375 (2009). 9000031 3 Carew et al., Lucanthone is a novel inhibitor of autophagy that induces cathepsin d-mediated apoptosis. The Journal of Biological chemistry, vol. 286, No. 8, pp. 6602-6613 (2011). 9000031 4 Chabner et al., Combination therapy. Merck Manual: Home Edition. Electronic Resource: [http://merck.com/mmhe/sec15/ch182/ch182h.html]. Retreived online by Examiner on Sep. 11, 2010 (2007). 9000031 5 Emert-Sedlak et al., Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death. Molecular Cancer Therapeutics, 4: 733-742 (2005). 9000031 6 Faivre et al., Molecular basis for sunitinib efficacy and future clinical development. Nature Reviews. Drug Discovery, vol. 6, No. 9, pp. 734-735 (2007). 9000031 7 Fossella, Pemetrexed for treatment of advanced non-small cell lung cancer. Seminars in Oncology, vol. 31, No. 1, Suppl. 1, pp. 100-105 (2004). 9000031 8 Geisler et al., Mechanisms of action of the cytotoxic drugs in gynecologic oncology. CME Journal of Gynaecological Oncology, 12: 12-15 (2007). 9000031 9 Hanauske et al., Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist, vol. 6, No. 4, pp. 363-373 (2001). 9000031 10 Ijiri et al., Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br. J. Cancer 55. pp. 113-123 (1987). 9000031 11 International Search Report and Written Opinion mailed Jul. 11, 2011 for International Application No. PCT/US2011/027606 filed on Mar. 8, 2011. 9000031 12 International Search Report and Written Opinion mailed on May 13, 2009 for International Application No. PCT/US2009/034629 filed on Feb. 20, 2009. 9000031 13 Kaye, SB, New antimetabolites in cancer chemotherapy and their clinical impact. British Journal of Cancer, 78 (Supplement 3) 1-7 (1998). 9000031 14 Kinsella et al., Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. British Journal of Cancer 75(7): 935-945 (1997). 9000031 15 Kirkegaard et al., Lysosomal involvement in cell death and cancer. Biochimica et Biophysica Act 1793, pp. 746-754 (2009). 9000031 16 Koons et al., Potentiation of mitomycin C by lucanthone HCI (Miracil D) in transplanted C3H mammary tumors. Mitomycin C: Current Status and New Developments, Academic Press, New York, Chapter 7, pp. 69-75 (1979). 9000031 17 Lee et al., Histone deacetylase inhibitors in cancer therapy. Current Opinion in Oncology, 20: 639-649 (2008). 9000031 18 Leyton et al., In vivo Biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F] fluorothymidine positron emission tomography. Cancer Research 66 (15): 7621-7629 (2006). 9000031 19 Luo et al., Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Research, vol. 24, No. 4, pp. 2127-2134 (2004). 9000031 20 Ma et al., Histone deacetylase inhibitors: current status and overview of clinical trials. Drugs, vol. 69, No. 14, pp. 1911-1934 (2009). 9000031 21 Mendez, F., et al., Abasic Sites in DNA HeLa Cells Induced by Lucanthone, Cancer Inves. 20(7& 8): 983-991 (2002). 9000031 22 Miller, Jr., Molecular targets of arsenic trioxide in malignant cells. The Oncologist, vol. 7, Suppl. 1, pp. 14-19 (2002). 9000031 23 Murgo, Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National cancer Institute cooperative resarch and development studies. The Oncologist, vol. 6,. Suppl. 2, pp. 22-28 (2001). 9000031 24 Prescott, Some new salts of lucanthone as potential anticancer agents. J. Med. Chem., 11(1): 156-158 (1968). 9000031 25 Reddy et al., Lucanthone potentiates the anti-tumor activity of pemetrexed in a lung cancer model. Proceedings of the American Association for Cancer Research, vol. 49, p. 1349, abstract (2008). 9000031 26 Remiszewski et al., Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. Journal of Medicinial Chemistry. vol. 45, No. 4, pp. 753-757 (2002). 9000031 27 Rochetti et al., Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach. Eur. J. Cancer, 45(18): 3336-3346 (2009). 9000031 28 Rosell et al., Pemetrexed combination therapy in the treatment of non-small cell lung cancer. Seminars in Oncology, vol. 29, No. 2, Suppl. 5, pp. 2329 (2002). 9000031 29 Sarraf et al., Bromodeoxyuridine-labelled apoptosis after treatment with antimetabolites in two murine tumours and in small intestinal crypts. Br. J. Cancer, 68: 678-680 (1993). 9000031 30 Savickiene et al., The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. European Journal of Pharmacology, vol. 549, No. 1-3, pp. 9-18 (2006). 9000031 31 Spectrum Pharmaceutical presents data on lucanthone, a novel anticancer drug, at the meeting of the American association of cancer research (2008). 9000031 32 White, E. & Dipaola, R.S., The Double-Edged Sword of Autophagy Modulation in Cancer, Clin. Cancer Res. 15(17): 5308-5316 (2009). 9000031 33 Yang et al., The role of autophagy in cancer: therapeutic implications. Molecular Cancer Therapeutics, 10: 1533-1541 (2011). 9000032 1 Yoshitaka, Uji, Drug Treatment of Glaucoma, Frontiers in Glaucoma, 2006, p. 26(144)-33(151). (Complete Translation), vol. 7, No. 3. 9000032 2 Carey, Francis A., Organic Chemistry, New York: McGraw-Hill Book Company, 1987, p. 63. 9000032 3 Silverman, Richard B., Organic Chemistry of Drug Design and Drug Action, 2nd Edition, Elsevier Academic Press: Amsterdam, 2004, p. 497-557. 9000032 4 Remingtons Pharmaceutical Sciences, Mack Publishing Company, Easton, PA., 16th Edition, 1980. 9000033 1 Tahara, et al. (1995) "Prenylated Isoflavonoids--An Update", Phytochemistry, 38(5): 1073-94. 9000033 2 Gygi (1999) "Correlation between Protein and mRNA Abundance in Yeast", Molecular and Cellular Biology, 19(3): 1720-30. 9000033 3 Fulton, et al. (2008) "Crystal structure of a UDP-glycose-specific Glycosyltransferase from a Mycobacterium species" Journal of Biological Chemistry, 283(41): 27881-90. 9000033 4 Tian, et al. (2006) "Phenylpropanoid glycosyltransferases from osage orange (Maculara pomifera) fruit", FEBS Letters, 6915-20. 9000033 5 Svasti J et al., Proteomic profiling of cholangiocarcinoma cell line treated with pomiferin from Derris malaccensis. Proteomics 5 (2005) 4504-4509. 9000033 6 Li H, Yang M, Ma X. Zhongguo Zhong, Yao Za Zhi Mar. 2009;34(6):724-6 Flavonoids from roots of Flemingia philippinensis. (abstract only). 9000033 7 Shiao YJ, Wang CN, Wang Wy, Lin YL. Planta Med. Sep. 2005;71(9):835-40. Neuroprotective flavonoids from Flemingia macrophylla. 9000033 8 Galicka et al. "Stimulation of collagen biosynthesis by flavonoid glycosides in skin fibroblasts of osteogeneis imperfecta type I and the potential mechanism of their action", International Journal of Molecular Medicine 20: pp. 889-895, 2007. 9000033 9 Tsao et al. "Antioxidant Isoflavones in Osage Orange, Maclura pomifera (Raf) Schneid", J. Agric. Food Chem. 2003, 51, pp. 6445-6451. 9000033 10 Hamed et al. "Effect of Maclura pomifera total acetonic extract, pomiferin and osajin on the autooxidation of purified sunflower triacylglycerols", Grasas y Aceites, vol. 56. Fasc 1 (2005), pp. 21-24. 9000033 11 Marek et al. "Pomiferin", Acta Cryst. (2003) C59, pp. o127-o128. 9000033 12 Vesela et al. "Antioxidative and EROD activities of osajin and pomiferin", Fitoterapia 75 (2004) pp. 209-211. 9000033 13 Liskova et al. "Osajin", Acta Cryst (2005) E61, pp. o1848-o1850. 9000033 14 Mahmoud, Zeinab F., "Antimicrobial Components from Maclura pomifera Fruit" Journal of Medicinal Plant Research. vol. 42: 299-301, 1981. 9000033 15 Choi, Eun-Mi, "The licorice root derived isoflavan glabridin increases the function of osteoblastic MC3t3-E1 cells" Biochemical Pharmacology. vol. 70: 363-368, 2005. 9000033 16 Extended European Search Report dated Nov. 19, 2014, issued in counterpart European Application No. 09 80 3624. 9000034 1 Park et al., LAMI-085 Erythorbyl Laurate: A Promising Candidate for Novel Antimicrobial Agent with Antioxidative Activity, 10th Euro Fed Lipid Congress, Cracow, Sep. 23-26, 2012 (Abstract). 9000034 2 Park et al., Lipase-catalyzed synthesis of erythorbyl laurate in acetonitrile, Food Chemistry (2011), 129(1), 59-63. 9000034 3 STN document No. 155:180402. 9000035 1 Kim et al. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin. International Journal of Pharmaceutics, 272, 2004: 79-89. 9000035 2 Anderson, Hamilton H., "The Use of Fumagillin in Amoebiasis," Annals New York Academy of Sciences, 1118-1124. 9000035 3 Benny, Ofra, et al., (2008) "An Orally Delivered Small-Molecule Formulation with Antiangiogenic and Anticancer Activity," Nature Biotechnology, 26, 7:799-807. 9000035 4 Bernier et al. (2005) "Fumagillin class inhibitors of methionine aminopeptidase-2," Drugs of the Future 30(5): 497-500. 9000035 5 Brakenhielm, E., et al., (2004) "Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice," Circulation Research, http://circres.ahajournals.org (accessed on Feb. 8, 2007). 9000035 6 Braunwald, et al.. "Obesity" in Harrison's Principles of Internal Medicine, 15th Ed., 479-86 (2001). 9000035 7 Didier, Peter J., et al. (2006) "Antimicrosporidial Activities of Fumagillin, TNP-470, Ovalicin, and Ovalicin Derivatives in Vitro and in Vivo," Antimicrobial Agents and Chemotherapy, p. 2146-2155. 9000035 8 DiPaolo, J.A., et al. (1958-1959) "Studies on the Carcinolytic Activity of Fumagillin and Some of its Derivatives," Antibiotics Annual, 541-546. 9000035 9 Drevs, Joachim, et al. (2003) "Antiangiogenic Potency of FK866/K22.175, a New Inhibitor of Intracellular NAD Biosynthesis, in Murine Renal Cell Carcinoma," Anticancer Research 23: 4853-4858. 9000035 10 Dumas, J., et al., "Synthesis and Structure Activity Relationships of Novel Small Molecule Cathepsin D Inhibitors," Bioorganic & Medicinal Chemistry Letters 9 (1999) 2531-2536. 9000035 11 Eder, JP, et al., (2006) "Phase 1 Dose Escalation Safety & Tolerance Study of PPI-2458 in Subjects with Non-Hodgkin's Lymphoma or Solid Tumors," (Presented on Nov. 7-10, 2006 at EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics."). 9000035 12 Everhart (1993) "Contributions of Obesity and Weight Loss to Gallstone Disease," Ann Intern Med. 119:1029-1035. 9000035 13 Ingber et al. (1990) "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," Nature 348: 555-557. 9000035 14 Jeong, et al., "Total Synthesis and Antiangiogenic Activity of Cyclopentane Analogues of Fumagillol," Bioorg. Med. Chem. Lett. 15 3580-83 (2005). 9000035 15 Kim, YM, et al. (2007) "Assessment of the Anti-Obesity Effects of the TNP-470 Analog, CKD-732," Journal of Molecular Endocrinology 38, 455-465. 9000035 16 Kruger, Erwin, A., (2000) "TNP-470: An Angiogenesis Inhibitor in Clinical Development for Cancer," Exp. Opin. Invest. Drugs 9(6), pp. 1383-1396. 9000035 17 Masiero, Laura, et al. (1997) "New Anti-angiogenesis Agents: Review of the Clinical Experience with Carboxyamido-Triazole (CAI), Thalidomide, TNP-470 and Interleukin-12," Angiogenesis, 1: 23-35. 9000035 18 McCowan, Max C., et al., (1951) Fumagillin (H-3), a New Antibiotic with Amebicidal Properties, Science, vol. 113, p. 202-203. 9000035 19 Milkowski, Deborah M., et al., Antiangiogenic Agents in Cancer Therapy, Chapter 22 "TNP-470," pp. 385-398. 9000035 20 Molina et al. (1997) "Potential Efficacy of Fumagillin in Intestinal Microsporidiosis Due to Enterocytozoon Bieneusi in Patients with HIV Infection: Results of a Drug Screening Study," AIDS, 11:1603-1610. 9000035 21 Molina et al. (2002) "Fumagillin Treatment of Intestinal Microsporidiosis," N. Engl. J. Med. 346(25): 1963-1969. 9000035 22 Molina, et al.(2000) "Trial of Oral Fumagillin for the Treatment of Intestinal Microsporidiosis in Patients with HIV Infection," AIDS, 14:1341-1348. 9000035 23 Naganuma, Yasuko, et al. (2011) "Metronomic Doxifluridine Chemotherapy Combined with the Anti-Angiogenic Agent TNP=470 Inhibits the Growth of Human Uterine Carcinosarcoma Xenografts," Cancer Sci 102(8): pp. 1545-1552. 9000035 24 National Task Force on the Prevention and Treatment of Obesity (1993) "Very Low-Calorie Diets," JAMA 270(8):967-974. 9000035 25 Noel et al. (2009) "Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients with Type 2 Diabetes," Diabetes Care 32(5):834-838. 9000035 26 Pagliarulo et al. (2003) "Gallstone disease and related risk factors in a large cohort of diabetic patients," Digestive and Liver Disease 36:130-134. 9000035 27 Picoul et al. (2003) "Progress in fumagillin synthesis," Pure Appl. Chem. 75(2-3): 235-249. 9000035 28 Rupnick, MA (2002) "Adipose Tissue Mass Can be Regulated Through the Vasculature," PNA 99, 10730-10735. 9000035 29 Seneca et al. (1956) "Amebiasis: a review. II. Laboratory diagnosis, differential diagnosis and therapy," Am J. Digestive Dis. 1: 310-322. 9000035 30 International Search Report and Written Opinion for PCT/US2011/062413, mailed Feb. 17, 2012 (8 pages). 9000035 31 Shin, SJ (2010) "A Phase I Pharmacokinetic and Pharmacodynamic Stdy of CKD-732, an Antiangiogenic Agent, in Patients with Refractory Solid Cancer," Invest New Drugs 28:650-658. 9000035 32 Weinsier et al. (1993) "Gallstone Formation and Weight Loss," Obesity Research 1(1):51-56. 9000035 33 Weinsier, et al. (1995) "Medically Safe Rate of Weight Loss for the Treatment of Obesity: A Guideline Based on Risk of Gallstone Formation " The American Journal of Medicine 98:115-117. 9000035 34 Winter et al. (2006) "Endothelial .alpha..nu..beta.3 Integrin-Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis," Arterioscler Thromb Vasc Biol.: 2103-2109. 9000035 35 Yanai, Shigeo, et al. (1995) "Antitumor Effect of Arterial Administration of a Medium-Chain Triglyceride Solutionof an Angiogenesis Inhibitor, TNP-470, in Rabbits Bearing VX-2 Carcinoma," Pharmaceutical Research 12(5): pp. 653-657. 9000035 36 Yanai, Shigeo, et al., (1994) "Antitumor Activity of a Medium-Chain Triglyceride Solution of the Angiogenesis Inhibitor TNP-470 (AGM-1470) when Administered Via the Hepatic Artery to Rats Bearing Walker 256 Carcinosarcoma in the Liver," The Journal of Pharmacology and Experimental Therapeutics 271(3): pp. 1267-1273. 9000035 37 Lijnen, H.R., et al. (2010) "Fumagillin Reduces Adipose Tissue Formation in Murine Models of Nutritionally Induced Obesity," Obesity 18: 2241-2246. 9000035 38 Teicher, et al (1999) "Antiangiogenic Agents in Cancer Therapy" pp. 385-398. 9000035 39 Garrabrant et al. (2004) "Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2) fail to inhibit endothelial cell proliferation or formation of microvessels from rat aortic rings in vitro," Angiogenesis 7:91-96. 9000035 40 Chun et al. (2005) "Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model," Int J Cancer 114(1):124-30. 9000035 41 Han et al. (2000) "Design and Synthesis of Highly Potent Fumagillin Analogues from Homology Modeling for a Human MetAP-2," Bioorganic & Medicinal Chemistry Letters 10:39-43. 9000035 42 Kim et al. (2004) "Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin," Int J Pharm. 272(1-2):79-89. 9000035 43 Kim et al. (2005) "General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system," Biol Pharm Bull. 28(2):217-23. 9000035 44 Lee et al. (2004) "Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs," Arch Pharm Res. 27(2):265-72. 9000035 45 Lee et al. (2006) "Selective N-demethylation of tertiary aminofumagillols with selenium dioxide via a non-classical Polonovski type reaction," Heterocycles 68(5):915-932. 9000035 46 Lee et al. (2007) "Design, Synthesis, and Antiangiogenic Effects of a Series of Potent Novel Fumagillin Analogues," Chem. Pharm. Bull. 55(7) 1024-1029. 9000035 47 Myung et al. (2002) "The identification of in vitro metabolites of CKD-732 by liquid chromatography/tandem mass spectrometry," Rapid Commun Mass Spectrom. 16(21):2048-53. 9000035 48 Rhee et al. (2009) Angiogenesis inhibitor attenuates parathyroid hormone-induced anabolic effect, Biomed Pharmacother. 63(1):63-8. 9000035 49 Shin et al. (2012) "A Phase lb pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy," Investigational New Drugs 30(2):672-680. (Published Online Dec. 29, 2010). 9000035 50 Srikumar et al. (2012) "Structural insights on Brugia malayi transglutaminase with cinnamoyl derivatives--a molecular docking approach " International Journal of Pharma and Bio Sciences 3(3):998-1006. 9000036 1 Auerbach, et al., "Angiogensis Inhibition: A Review" Pharmac. Ther. (1994) 63: 265-311. 9000036 2 Awwad, et al., "Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions" Cancer Immunol Immunother (1994) 38: 23-30. 9000036 3 Barbie, et al., "Nuclear tumor suppressors in space and time" TRENDS in Cell Biology (2005) 15(7): 378-385. 9000036 4 Coxon, et al., "Development of a Specific Polarisation Fluoroimmunoassay for Paraetamol in Serum" Ann Clin Biochem (1988) 25: 49-52 (Abstract Only). 9000036 5 Cripps, et al., "Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trails Group Study" Clinical Cancer Research (2002) 8: 2188-2192. 9000036 6 Dasgupta, Gargi and Jamil Momand, "Geldanamycin Prevents Nuclear Translocation of Mutant p53" Experimental Cell Research (1997) 237: 29-37. 9000036 7 Dieli, et al., "TCR V.alpha. chain expression influences reactivity to the hapten TNP" International Immunology (1996) 9(1): 1-8. 9000036 8 Dima, et al., "Response of Murine Mammary Adenocarcinoma to Photodynamic Therapy and Immunotherapy" Laser Ther. (1990) 2: 153-160. 9000036 9 Edstrom, et al., "Mucosal Melanoma: Immunological Findings in a Rare Case Treated With BCG Vaccine, Autologous Tumor Cells, and Cytarabine" Arch Otolaryngol (1979) 105(1): 48-50. 9000036 10 Ferguson, et al., "Cell death and immune privilege" Int. Re. Immunol. (2002) 21(2-3): 153-172 (Abstract Only). 9000036 11 Gong, et al., "Differential Regulation of Sentrinized Proteins by a Novel Sentrin-specific Protease" J. of Biological Chem. (2000) 275(5): 3355-3359. 9000036 12 Hawkins, et al., "Clinical trails of antiangiogenic agents" Current Opinion in Oncology (1995) 7: 90-93. 9000036 13 Hino, et al., "Disappearance of pulmonary metastases by OK-432 treatment in a Case of Hepatocellular Carcinoma" Acta Med Okayama (1993) 47(4): 289-292. 9000036 14 Jenks, Susan, "Blocking Angiogenesis May Help Keep Tumors Dormant" J. Natl. Cancer Institute (1996) 88(12): 787. 9000036 15 Jones, et al., "Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression" Advanced Drug Delivery Reviews (1998) 31: 153-170. 9000036 16 Karzulli, et al., "N-ethylmaleimide as oxidizing agent in biological and non-biological systems " Boll. Soc. It. Biol. Sper. (1985) 1(LXI): 121-127. 9000036 17 Krosl, et al., "Potentiation of Photodynamic Therapy-elicited Antitumor Response by Localized Treatment with Granulocyte-Macrophase Colony-stimulating Factor" Cancer Research (1996) 56: 3281-3286. 9000036 18 Lin, et al., "Non-surgical treatment of hepatocellular carcinoma" J. Gastroenterology and Hepatology (1997) 12(Suppl.): 5319-5328. 9000036 19 Mansouri, Ali, "Oxidation of human hemoglobin by sodium nitrite-effect of .beta.-93 thiol groups" Biochem and Biophys Research Communications (1979) 89(2): 441-447 (Abstract Only). 9000036 20 Marshall, et al., "A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer" Clin. Colo. Cancer (2004) 4(4): 288-274. 9000036 21 Martin, et al., "Negative and Positive Assays of Superoxide Dismutase Based on Hematoxylin Autoxidation" Archives of Biochem. and Biophy. (1987) 255(2): 329-336. 9000036 22 O'Reilly, Michael S., "The preclinical evaluation of angiogensis inhibitors" Investigational New Drugs (1997) 15: 5-13. 9000036 23 Orkin, et al, "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy" NIH (1995). 9000036 24 Oza, et al., "Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)" Gyn. Oncology (2003) 89: 129-133. 9000036 25 Rudnic, E., "Oral Solid Dosage Forms" in: Remington's Pharmaceutical Sciences, 18th Ed., 1990, pp. 1633-1665. 9000036 26 Santini, et al., "The Oxidizing Agent Menadione Induces as Increase in the Intracellular Molecular Oxygen Concentration in K562 and A431 Cells: Direct Measurement Using the New Paramagnetic EPR Probe Fusinite" Free Radical Biology & Medicine (1996) 20(7): 915-924. 9000036 27 Schneider, et al., "Development of a new class of replicating viral vectors for cytolytic gene therapy" Gene Ther. (1999) 6(Suppl.): S5 (Abstract Only). 9000036 28 Skobelkin, et al., "Preoperative Activation of the Immune System by Low Reactive Level Laser Therapy (LLLT) in Oncologic Patients: A Preliminary Report" Laser Therapy (1991) 3(4): 169-176. 9000036 29 Todryk, et al., "Heat Shock Protein 70 Induced During Tumor Cell Killing Induces Th1 Cytokines and Targets Immature Dendritic Cell Precursors to Enhance Antigen Uptake" J. Immunology (1999) 163: 1398-1408. 9000036 30 Tolcher, et al., "A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer" Clin. Cancer Research (2002) 2530(2): 2530-2535. 9000036 31 Uehara, Y., "Protein kinase inhibitors--Screening of a new molecular target therapeutics" Cancer & Chemotherapy (1997) 24(2): 136-144 (Abstract Only). 9000036 32 Verma, et al., "Gene therapy--promises, problems and prospects" Nature (1997) 389: 239-242. 9000036 33 Yumita, et al., "The Increase of Generation of Superoxide Radicals and the Inhibitory Effect on Yoshida Sarcoma of Anthracycline Antitumor Agents by Ultrasound" J. Japan Society for Cancer Therapy (1989) 24(1): 63-68. (English Summary Only). 9000036 34 Zhang, et a., "Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines" Mel. Research (1998) 8: 510-515. 9000036 35 Advanced Inorganic Chemistry: A Comprehensive Text, F. Albert Cotton and Geoffrey Wilkinson 3rd Ed., 1972, p. 408. 9000036 36 Drug Facts and Comparisons, T. Burnham Ed., 2000, p. 1807. 9000036 37 Fundamental Immunology, William E. Paul, MD 3rd Ed., 1993, 1157-1170. 9000036 38 Glossary of Genetics: Classical and Molecular, Rieger, et al. 5th Ed., 1991, p. 422. 9000036 39 Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Stephen L. Eck and James M. Wilson (1996), Chapter 5, pp. 77-101. 9000036 40 Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, Mike Clark Ed., 1993, p. 4-5. 9000036 41 Remington: The Science and Practice of Pharmacy, vol. 1, Chapter 38: Stability of Pharmaceutical Products, Elizabeth B. Vodas, Ph.D., 19th ed., 1995. 9000036 42 MeSH Term Invormaiton, NLM Gateway, from http://gateway.nlm.nih.gov/gw/Cmd?linkVars=Session ID%3D080526180415458006153610 . . . , obtained on May 26, 2008. 9000036 43 International Search Report dated Dec. 6, 2007, issued in International Application No. PCT/CN2007/002671. 9000036 44 SIGMA: Biochemicals and Reagents for Life Science Research, (1999) p. 2399. 9000036 45 Okano et al., "Antitumor agents. 43. Conversion of bruceoside-A into bruceantin" J. Org. Chem. (1981) 46:1138-1141. 9000037 1 International Search Report dated Jul. 9, 2012 issued in corresponding PCT/EP2012/057884 application (pp. 1-3). 9000038 1 "Complaint", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Jan. 8, 2010, 48 pages. 9000038 2 "Answer, Defense and Counterclaims of Defendants Kremer's Urban, LLC and Kudco Ireland Ltd", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Mar. 8, 2010, 18 pages. 9000038 3 "Defendants Kremers Urban, LLC and Kudco Ireland Ltd.'s Motion for Leave to File an Amended Answer", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed May 19, 2011, 51 pages. 9000038 4 "Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Opening Brief in Support of Their Motion for Leave to File an Amended Answer", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed May 19, 2011, 24 pages. 9000038 5 "Declaration of Richard L. Horwitz, Esq. in Support of Defendants Kremers Urban, LLC and Kudco Ireland, Ltd's Motion for Leave to File an Amended Answer", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed May 19, 2011, 80 pages. 9000038 6 "Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Reply in Support of their Motion for Leave", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Nov. 19, 2010, 14 pages. 9000038 7 "Declaration of Richard L. Horwitz in Support of Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Motion for Leave", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Nov. 19, 2010, 28 pages. 9000038 8 "Plaintiffs' First Set of Interrogatories to Defendants' Kremers Urban, LLC and Kudco Ireland, Ltd.(Nos. 1-7)," In the United States District Court for the District of Delaware, Civil Action No. 10-23-LPS, Filed Dec. 1, 2010, 9 pages. 9000038 9 "Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Opposition to Plaintiffs' Motion for Leave to File Sur-Reply", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Dec. 8, 2010, 5 pages. 9000038 10 "Plaintiffs' Responses and Objections to Defendants Kremers Urban, LLC, and Kudco Ireland, Ltd.'s First Set of Interrogatories (Nos. 1-11)", In the United States District Court for the District of Delaware, Civil Action No. 10-23-LPS, filed Jan. 18, 2011, 36 pages. 9000038 11 "Declaration of Richard L. Horwitz in Support of Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Opening Claim Construction Brief", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Jan. 21, 2011, 128 pages. 9000038 12 "Plaintiffs ALZA Corporation and Ortho-McNeii-Janssen Pharmaceuticals, Inc.'s Opening Brief on Claim Construction", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Jan. 21, 2011, 57 pages. 9000038 13 "Plaintiffs ALZA Corporation and Ortho-McNeii-Janssen Pharmaceuticals, Inc.'s Responsive Claim Construction Brief", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Feb. 4, 2011, 16 pages. 9000038 14 "Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Supplemental Responses to Plaintiffs' Interrogatories (Nos. 1,2, and 6)", In the United States District Court for the District of Delaware, Civil Action No. 10-23-LPS, Filed Feb. 22, 2011, 18 pages. 9000038 15 "Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Revised Supplemental Responses to Plaintiffs' Interrogatories (Nos. 1,2, and 6)", In the United States District Court for the District of Delaware, Civil Action No. 10-23-LPS, Filed Feb. 24, 2011, 18 pages. 9000038 16 "Motion for Summary Judgment of Invalidity", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Feb. 28, 2011, 3 pages. 9000038 17 "Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Brief in Support of their Motion for Summary Judgment of Invalidity for Lack of Enablement of U.S. Patent No. 6,930,129", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Feb. 28, 2011, 19 pages. 9000038 18 "Declaration of Richard L. Horwitz in Support of Defendants Kremers Urban LLC and Kudco Ireland, Ltd.'s Motion for Summary Judgment of Invalidity due to Lack of Enablement of U.S. Patent No. 6,930,129", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Mar. 8, 2011,97 pages. 9000038 19 "Wilmington, Delaware, Thursday Feb. 24, 2011, Claim Construction Hearing", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Mar. 16, 2011,81 pages. 9000038 20 "Declaration of Peter S. Choi in Support of Plaintiffs' Answering Brief in Opposition to Defendants' Motion for Summary Judgment of Invalidity for Lack of Enablement of U.S. Patent No. 6,930,129", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Mar. 21, 2011,56 pages. 9000038 21 "Declaration of Diane J. Burgess, Ph.D. in Support of Plaintiffs' Opposition to Defendants' Motion for Summary Judgment of Invalidity for Lack of Enablement U.S. Patent No. 6,930,129", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Mar. 21, 2011, 79 pages. 9000038 22 "Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Reply in Support of their Motion for Summary Judgment of Invalidity", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Mar. 28, 2011, 15 pages. 9000038 23 "Exhibit A--U.S. Patent No. 6,919,373 B 1", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1-1, filed Sep. 1, 2005, 17 pages. 9000038 24 "Exhibit B--U.S. Patent No. 6,930,129 B 2", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1-2, filed Sep. 1, 2005, 17 pages. 9000038 25 "Acknowledgment of Receipt for AO Form 85, Notice of Availability of a United States Magistrate Judge to Exercise Jurisdiction", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1-4, filed Sep. 1, 2005, 1 page. 9000038 26 "Answer, Affirmative Defenses and Counterclaims", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 7, filed Oct. 25, 2005, 16 pages. 9000038 27 "Reply to Counterclaims", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 8, filed Nov. 4, 2005, 4 pages. 9000038 28 "Reply to Counterclaims", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 12, filed Dec. 6, 2005, 5 pages. 9000038 29 "Stipulated Order", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 75, filed Oct. 3, 2006, 1 page. 9000038 30 "Redacted Public Version First Amended Answer, Affirmative Defenses and Counterclaims", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 84, filed Nov. 10, 2006, 26 pages. 9000038 31 "Plaintiffs Alza Corporation and McNeii-PPC, Inc.'s Opening Brief on Claim Construction", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87, filed Nov. 13, 2006, 47 pages. 9000038 32 "Exhibit A--U.S. Patent No. 6,919,373 B 1", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-1, filed Nov. 13, 2006, 17 pages. 9000038 33 "Exhibit B--U.S. Patent No. 6,930,129 B 2", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-2, filed Nov. 13, 2006, 17 pages. 9000038 34 "Exhibit D--Letter from Sidley Austin LLP dated Nov. 2, 2006", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-4, filed Nov. 13, 2006, 3 pages. 9000038 35 "Exhibit E--Letter from Alan B. Clement dated Nov. 2, 2006", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-5, filed Nov. 13, 2006, 3 pages. 9000038 36 "Exhibit F--Letter from Sidley Austin LLP dated Nov. 3, 2006", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-6, filed Nov. 13, 2006, 2 pages. 9000038 37 "Exhibit G--Email from Alan B. Clement dated Nov. 8, 2006", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-7, filed Nov. 13, 2006, 2 pages. 9000038 38 "Exhibit H--Greenhill et al., "A Double-Blind, Placebo-Controlled Study of Modified-Release Methylphenidate in Children With Attention-DeficiUHyperactivity Disorder" Pediatrics, Mar. 2002, vol. 109, No. 3" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-8, filed Nov. 13, 2006, 10 pages. 9000038 39 Exhibit I--Swanson et al., "Acute Tolerance to Methylphenidate in the Treatment of Attention Deficit Hyperactivity Disorder in Children", Clinical Pharmacology & Therapeutics, 1999, 66(3), In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-9, filed Nov. 13, 2006, 12 pages. 9000038 40 "Exhibit J--U.S. Patent No. 6,124,355", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-10, filed Nov. 13, 2006,13 pages. 9000038 41 "Exhibit K--Final Judgment, Westlaw", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-11, filed Nov. 13, 2006, 10 pages. 9000038 42 Exhibit L--Hanson et al., "Handbook of Dissolution Testing, Third Edition, Revised, Chapter 1 Overall Considerations, copyright 2004", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-12, filed Nov. 13, 2006, 5 pages. 9000038 43 "Exhibit Q--Applied Biopharmaceutics & Pharmacokinetics Fourth Edition, Chapter 2 Introduction to Biopharmaceutics & Pharmacokinetics, copyright 1999", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-17, filed Nov. 13, 2006, 8 pages. 9000038 44 Redacted Public Version "Defendants' Opening Markman Brief on Claim Construction", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88, filed Nov. 20, 2006, 44 pages. 9000038 45 "Exhibit A--U.S. Patent No. 6,919,373 81", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-1, filed Nov. 20, 2006, 17 pages. 9000038 46 "Exhibit B--U.S. Patent No. 6,930,129 82", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-2, filed Nov. 20, 2006, 17 pages. 9000038 47 "Exhibit C--U.S. Patent Application Publication 2004/0156896 A1", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-3, filed Nov. 20, 2006, 16 pages. 9000038 48 "Exhibit E--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-5, filed Nov. 20, 2006, 2 pages. 9000038 49 "Exhibit G--Non-Final Office Action, In the United States Patent and Trademark Office, In re U.S. Appl. No. 09/253,317, filed Feb. 19, 1999", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-7, filed Nov. 20, 2006, 7 pages. 9000038 50 "Exhibit I--Supplemental Declaration of Suneel K. Gupta, In the United States Patent and Trademark Office, In re U.S. Appl. No. 09/253,317, filed Feb. 19, 1999", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-9, filed Nov. 20, 2006, 5 pages. 9000038 51 "Exhibit J--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-10, filed Nov. 20, 2006, 2 pages. 9000038 52 "Exhibit K--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-11, filed Nov. 20, 2006, 2 pages. 9000038 53 "Exhibit M--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-13, filed Nov. 20, 2006, 2 pages. 9000038 54 "Exhibit N--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-14, filed Nov. 20, 2006, 2 pages. 9000038 55 "Certificate of Service", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-15, filed Nov. 20, 2006, 2 pages. 9000038 56 Redacted Public Version "Declaration of Umesh V. Banakar, Ph.D. in Support of Opening Markman Brief Submitted by Andrx Pharmaceuticals, LLC and Andrx Corporation", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89, filed Nov. 20, 2006, 29 pages. 9000038 57 "Exhibit A--Curriculum Vitae, Umesh V. Banakar, Ph.D.", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-1, filed Nov. 20, 2006, 35 pages. 9000038 58 "Exhibit B--U.S. Patent No. 6,919,373 B1", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-2, filed Nov. 20, 2006, 17 pages. 9000038 59 "Exhibit C--U.S. Patent No. 6,930,129 B2", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-3, filed Nov. 20, 2006, 17 pages. 9000038 60 "Exhibit E--Final Rejection, In the United States Patent and Trademark Office, in re U.S. Appl. No. 09/253,317, filed Feb. 19, 1999", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-5, filed Nov. 20, 2006, 5 pages. 9000038 61 "Exhibit F--Non-Final Office Action, In the United States Patent and Trademark Office, In re U.S. Appl. No. 09/253,317, filed Feb. 19, 1999", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-6, filed Nov. 20, 2006, 6 pages. 9000038 62 "Exhibit G--Declaration of Suneel K. Gupta, In the United States Patent and Trademark Office, In re U.S. Appl. No. 09/253,317, filed Feb. 19, 1999", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-7, filed Nov. 20, 2006, 5 pages. 9000038 63 "Exhibit H--Supplemental Declaration of Suneel K. Gupta, In the United States Patent and Trademark Office, In re U.S. Appl. No. 09/253,317, filed Feb. 19, 1999", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-8, filed Nov. 20, 2006, 5 pages. 9000038 64 "Exhibit I--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-9, filed Nov. 20, 2006, 2 pages. 9000038 65 "Exhibit J--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-10, filed Nov. 20, 2006, 2 pages. 9000038 66 "Exhibit K--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-11, filed Nov. 20, 2006, 2 pages. 9000038 67 "Exhibit M--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-13, filed Nov. 20, 2006, 2 pages. 9000038 68 "Reply to First Amended Counterclaims", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 90, filed Nov. 22, 2006, 11 pages. 9000038 69 "Letter from Rawle & Henderson LLP dated Nov. 22, 2006", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 91, filed Nov. 22, 2006, 1 page. 9000038 70 "To Be Filed Under Seal--Defendants' Opening Markman Brief on Claim Construction", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 91-1, filed Nov. 22, 2006, 2 pages. 9000038 71 "Redacted Public Version--Defendants' Opening Markman Brief on Claim Construction", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 91-2, filed Nov. 22, 2006, 2 pages. 9000038 72 "Exhibit A--U.S. Patent No. 6,919,373 B 1", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 97-1, filed Nov. 30, 2006, 17 pages. 9000038 73 "Exhibit B--U.S. Patent No. 6,930,129 B 2", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 97-1, filed Nov. 30, 2006, 17 pages. 9000038 74 "Exhibit C--Curriculum Vitae of Professor Martyn Christopher Davies BSc PhD", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 97-2, filed Nov. 30, 2006, 52 pages. 9000038 75 "Exhibit D--U.S. Department of Commerce Patent and Trademark Office Fee Record Sheet, U.S. Appl. No. 08/910,593", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 97-3, filed Nov. 30, 2006, 55 pages. 9000038 76 "Exhibit E--U.S. Department of Commerce Patent and Trademark Office Fee Record Sheet, U.S. Appl. No. 60/030,514", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 97-4, filed Nov. 30, 2006, 56 pages. 9000038 77 "Exhibit F--Robinson et al., Controlled Drug Delivery Fundamentals and Applications, Second Edition Revised and Expanded, Chapter 9 Design and Fabrication of Oral Controlled Release Drug Delivery Systems", In the United States District Court for the District of Delaware, Case No. 1:05-cv-000642-JJF, Doc. 97-5, filed Nov. 30, 2006, 34 pages. 9000038 78 "Exhibit G--Leong et al., "Polymeric Controlled Drug Delivery", Advanced Drug Delivery Reviews, Sep. 1988, vol. 1, Issue 3", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 97-5, filed Nov. 30, 2006, 37 pages. 9000038 79 "Plaintiffs Alza Corporation and McNeii-PPC, Inc.'s Reply Brief on Claim Construction", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 99, filed Dec. 6, 2006, 47 pages. 9000038 80 "U.S. Patent No. 6,930,129 82", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 100-1, filed Dec. 6, 2006, 60 pages. 9000038 81 "Declaration of Martin S. Angst, M.D. in support of Reply Markman Brief Submitted by Plaintiffs Alza Corporation and McNeil-PPC", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 100-2, filed Dec. 6, 2006, 52 pages. 9000038 82 "Exhibit B--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 102-2, filed Dec. 7, 2006, 2 pages. 9000038 83 "Exhibit C--Supplemental Declaration of Suneel K. Gupta, In the United States Patent and Trademark Office, In re U.S. Appl. No. 09/253,317, filed Feb. 19, 1999", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 102-3, filed Dec. 7, 2006, 5 pages. 9000038 84 "Redacted Public Version Supplemental Declaration of Umesh V. Banakar, PH.D. In Support of Opposition to Plaintiffs' Opening Markman Brief", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 103, filed Dec. 7, 2006, 3 pages. 9000038 85 "Exhibit A--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 103-1, filed Dec. 7, 2006, 2 pages. 9000038 86 "Exhibit B--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 103-2, filed Dec. 7, 2006, 2 pages. 9000038 87 "Exhibit C--Supplemental Declaration of Suneel K. Gupta, In the United States Patent and Trademark Office, In re U.S. Appl. No. 09/253,317, filed Feb. 19, 1999", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 103-3, filed Dec. 7, 2006, 5 pages. 9000038 88 "Alza Corporation and McNeil, PPC, Inc. v. Andrx Pharmaceuticals, LLC and Andrx Corp., Hearing, Dec. 15, 2006", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 109, 39 pages. 9000038 89 "Plaintiffs Alza Corporation and McNeil-PPC, Inc.'s Motion and Brief in Support to Preclude Testimony of Bruce H. Stoner, Jr.", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 123, filed Aug. 20, 2007, 6 pages. 9000038 90 "Expert Report of Bruce H. Stoner, Jr.", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 123-1, filed Aug. 20, 2007, 36 pages. 9000038 91 "Exhibit B--Memorandum Opinion, Westlaw.", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 123-2, filed Aug. 20, 2007, 36 pages. 9000038 92 "The Patents in Suit", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 125-2, filed Aug. 29, 2007, 15 pages. 9000038 93 "Alza Corporation, McNeil-PPC, Inc., Andrx Pharmaceuticals, L.L.C. and Andrx Corporation's Proposed Joint Pre-Trial Order", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 128, filed Aug. 31, 2007, 75 pages. 9000038 94 "Order", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 130, filed Oct. 5, 2007, 3 pages. 9000038 95 "Letter from Ashby & Geddes dated Dec. 11, 2007", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 144, filed Dec. 11, 2007, 1 page. 9000038 96 "Order", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 144-1, filed Dec. 11, 2007, 2 pages. 9000038 97 "Alza Corporation and McNeil, PPC, Inc. v. Andrx Pharmaceuticals, LLC and Andrx Corp. Trial vol. 1, Dec. 10, 2007", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 148, 100 pages. 9000038 98 "Alza Corporation and McNeil, PPC, Inc. v. Andrx Pharmaceuticals, LLC and Andrx Corp. Trial vol. 2, Dec. 11, 2007", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 149, 70 pages. 9000038 99 "Alza Corporation and McNeil, PPC, Inc. v. Andrx Pharmaceuticals, LLC and Andrx Corp. Trial vol. 3, Dec. 12, 2007", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 150, 64 pages. 9000038 100 "Alza Corporation and McNeil, PPC, Inc. v. Andrx Pharmaceuticals, LLC and Andrx Corp. Trial vol. 4, Dec. 13, 2007", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 151, 54 pages. 9000038 101 "Alza Corporation and McNeil, PPC, Inc. v. Andrx Pharmaceuticals, LLC and Andrx Corp. Trial vol. 5, Dec. 14, 2007", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 152, 77 pages. 9000038 102 "Letter from Rawle & Henderson LLP dated Dec. 12, 2007", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 153, filed Dec. 19, 2007, 5 pages. 9000038 103 "Final Judgment of Non-Infringement", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 153-1, filed Dec. 19, 2007, 2 pages. 9000038 104 "Redacted Public Version Defendants' Opening Pretrial Brief With Proposed Findings of Fact and Conclusions of Law", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 155, filed Jan. 4, 2008, 66 pages. 9000038 105 "Comparison of claims 1 to 4 and 6 to 7 of the '373 patent with the prior art, Rawle & Henderson LLP, Dec. 3, 2007", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 155-2, filed Jan. 4, 2008, 37 pages. 9000038 106 "Redacted Public Version of Exhibits, Defendants' Opening Pretrial Brief With Proposed Findings of Fact and Conclusions of Law", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 157, filed Jan. 7, 2008, 1 page. 9000038 107 "Exhibit 1--Prosecution History of Patents-In-Suit", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 157-1, filed Jan. 7, 2008, 2 pages. 9000038 108 "Exhibit 2--Background, Westlaw", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 157-2, filed Jan. 7, 2008, 10 pages. 9000038 109 "Exhibit 3--Background, Westlaw", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 157-3, filed Jan. 7, 2008, 10 pages. 9000038 110 "Exhibit 5--Motions, Pleadings and Filings, Westlaw", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 157-5, filed Jan. 7, 2008, 6 pages. 9000038 111 "Redacted Public Version of Exhibits, Defendants' Pretrial Reply Brief", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 158, filed Jan. 7, 2008, 1 page. 9000038 112 "Exhibit 6--The Angst 23: The Exemplary 8 Hour Profiles", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 158-1, filed Jan. 7, 2008, 2 pages. 9000038 113 "Exhibit 7--Kaufman, "Petitions to FDA Sometimes Delay Generic Drugs", washingtonpost.com, Jul. 3, 2006", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 158-2, filed Jan. 7, 2008, 4 pages. 9000038 114 "Exhibit 9--Cycle 1: Gray's Andrx 54 mg Release Rate Evaluation", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 158-4, filed Jan. 7, 2008, 8 pages. 9000038 115 "Redacted Public Version, Compendium of Exhibits to Defendants' Pretrial Submissions", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 159, filed Jan. 7, 2008, 476 pages. 9000038 116 "Redacted Public Version, Compendium of Exhibits to Defendants' Pretrial Submissions", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160, filed Jan. 7, 2008, 1 page. 9000038 117 "Redacted DTX 73, DTX 106 and DTX 111 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-1, filed Jan. 7, 2008, 16 pages. 9000038 118 "McNeil Docket No. 2004P-0139: Supplement Comments on Hellerehrman Response", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-2, filed Jan. 7, 2008, 16 pages. 9000038 119 "U.S. Department of Commerce Patent and Trademark Office, U.S. Appl. No. 60/030,514, File History in File Folder", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-4, filed Jan. 7, 2008, 54 pages. 9000038 120 "Clinical Pharmacology & Therapeutics, Feb. 1991, vol. 49, No. 2", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-5, filed Jan. 7, 2008, 3 pages. 9000038 121 "U.S. Department of Commerce Patent and Trademark Office Fee Record Sheet, U.S. Appl. No. 08/937,336", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-6, filed Jan. 7, 2008, 124 pages. 9000038 122 "Notice of Abandonment, U.S. Department of Commerce Patent and Trademark Office, in Re U.S. Appl. No. 08/937,336, filed Aug. 19, 1997", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-7, filed Jan. 7, 2008, 6 pages. 9000038 123 "Redacted DTX 176, DTX 232 and DTX 234 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-9, filed Jan. 7, 2008, 1 page. 9000038 124 "Redacted DTX 176, DTX 232 and DTX 234 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-10, filed Jan. 7, 2008, 1 page. 9000038 125 "Redacted DTX 176, DTX 232 and DTX 234 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-11, filed Jan. 7, 2008, 1 page. 9000038 126 "Redacted DTX 324, DTX 361, DTX 371 and DTX 383 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-13, filed Jan. 7, 2008, 1 page. 9000038 127 "Redacted DTX 324, DTX 361, DTX 371 and DTX 383 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-14, filed Jan. 7, 2008, 1 page. 9000038 128 "Redacted DTX 324, DTX 361, DTX 371 and DTX 383 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-15, filed Jan. 7, 2008, 1 page. 9000038 129 "Redacted DTX 324, DTX 361, DTX 371 and DTX 383 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-16, filed Jan. 7, 2008, 1 page. 9000038 130 "Curriculum Vitae, Umesh V. Banakar, Ph.D.", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-17, filed Jan. 7, 2008, 34 pages. 9000038 131 "Redacted Public Version, Compendium of Exhibits to Defendants' Pretrial Submissions", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 161, filed Jan. 7, 2008, 253 pages. 9000038 132 "Redacted Public Version, Compendium of Exhibits to Defendants' Pretrial Submissions", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162, filed Jan. 7, 2008, 1 page. 9000038 133 "Curriculam Vitae, Sanford M. Bolton, Ph.D.", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-4, filed Jan. 7, 2008, 17 pages. 9000038 134 "DTX 703", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-8, filed Jan. 7, 2008, 4 pages. 9000038 135 "Klein et al., "Development of Dissolution Tests on the Basis of Gastrointestinal Physiology", Pharmaceutical Dissolution Testing, copyright 2003, DTX 716", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-169, filed Jan. 7, 2008, 6 pages. 9000038 136 "USP 23 The United States Pharmacopeia NF 18 The National Formulary, 1995, Jan. 1, 1995, DTX 720", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-10, filed Jan. 7, 2008,4 pages. 9000038 137 "Markowitz et al., "Pharmacokinetic and Pharmacodynamic Drug Interactions, Methylphenidate, Amphetamine, or Atomoxetine in ADHD", Attention Deficit Hyperactivity Disorder From Genes to Patients, DTX 930", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-11, filed Jan. 7, 2008, 13 pages. 9000038 138 "Klein et al., "Development of Dissolution Tests on the Basis of Gastrointestinal Physiology", Pharmaceutical Dissolution Testing, copyright 2003, DTX 1064", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-12, filed Jan. 7, 2008, 6 pages. 9000038 139 "Abrahamsson et al., "Biopharmaceutical Support in Formulation Development", Pharmaceutical Preformulation and Formulation, copyright 2000, DTX 1065", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-13, filed Jan. 7, 2008, 4 pages. 9000038 140 "FIP Guidelines for Dissolution Testing of Solid Oral Products, DTX 1067", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-14, filed Jan. 7, 2008, 14 pages. 9000038 141 "Redacted Public Version, Compendium of Exhibits to Defendants' Pretrial Submissions", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 163, filed Jan. 7, 2008, 1 page. 9000038 142 "U.S. Patent No. 6,919,373", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 163-1, filed Jan. 7, 2008, 17 pages. 9000038 143 "Pelham et al., "Relative Efficacy of Long-Acting Stimulants on Children With Attention Deficit-Hyperactivity Disorder: A Comparison of Standard Methylphenidate, Sustained-Release Methylphenidate, Sustained-Release Dextroamphetamine, and Pemoline", Pediatrics, Aug. 1990, vol. 86, No. 2", In the United States District Court For the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 163-3, filed Jan. 7, 2008, 12 pages. 9000038 144 "Redacted PX 207 and PX 210 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 163-4, filed Jan. 7, 2008, 1 page. 9000038 145 "Redacted PX 207 and PX 210 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 163-5, filed Jan. 7, 2008, 1 page. 9000038 146 "Office Communication--Background of the invention, In the United States Patent and Trademark Office, in re U.S. Appl. No. 10/726,024, filed Dec. 12, 2003", In the United States District Court for the District of Delaware, Case No. 1:05-cv00642-JJF, Doc. 163-7, filed Jan. 7, 2008, 3 pages. 9000038 147 "Redacted Public Version, Plaintiffs' Responsive Pretrial Submission", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 165, filed Jan. 8, 2008, 273 pages. 9000038 148 "Letter from Rawle & Henderson LLP dated Jan. 30, 2008", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 169, filed Jan. 31, 2008, 1 page. 9000038 149 "Exhibit 1--Redacted" In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 170-1, filed Feb. 6, 2008, 2 pages. 9000038 150 "Exhibit 4--Email from Todd Wagner dated Dec. 7, 2007" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 170-4, filed Feb. 6, 2008, 2 pages. 9000038 151 "Order" In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 171, filed Feb. 6, 2008, 1 page. 9000038 152 "Letter from Rawle & Henderson LLP dated Apr. 2, 2008" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 172, filed Apr. 2, 2008, 2 pages. 9000038 153 "Decision", In the United States Court of Appeals for the Federal Circuit, In re 2007-1404 Caraco Pharmaceutical Laboratories, Ltd., v Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd., and H. Lundbeck NS, In the United States District Court for The District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 172-2, filed Apr. 2, 2008, 37 pages. 9000038 154 "Letter from Ashby & Geddes dated Apr. 15, 2008" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 173, filed Apr. 15, 2008, 3 pages. 9000038 155 "Confidential: Filed Under Seal, Stipulated Order" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 176, filed May 12, 2008, 88 pages. 9000038 156 "Defendants' Proposed Findings of Fact and Conclusions of Law, pp. 123-241" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 184-1, filed Jun. 24, 2008, 121 pages. 9000038 157 "Email from Rawle & Henderson LLP dated Jul. 2, 2008" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 186, filed Jul. 8, 2008, 2 pages. 9000038 158 "Exhibit A--Transcription of Court Hearing, Friday, Dec. 14, 2007, Courtroom 48" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 188-1, filed Jul. 9, 2008, 160 pages. 9000038 159 "Notice of Contingent Motion" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 190-1, filed Aug. 4, 2008, 2 pages. 9000038 160 "Highly Confidential: Filed Under Seal, Defendants' Memorandum in Opposition to Plaintiffs' Motion to Strike Portions of Defendants' Post-Trial Findings of Fact and in Support of Their Contingent Cross-Motion to Strike Portions of Plaintiffs' Post-Trial Findings of Fact and Conclusions of Law" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 190-2, filed Aug. 4, 2008, 18 pages. 9000038 161 "Certificate of Service" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 190-3, filed Aug. 4, 2008, 2 pages. 9000038 162 "Exhibit A--Email from Ann M. Mace dated Nov. 30, 2007" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 190-4, filed Aug. 4, 2008, 2 pages. 9000038 163 "Exhibit C--Redacted" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 190-6, filed Aug. 4, 2008, 2 pages. 9000038 164 "Exhibit D--Redacted" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 190-7, filed Aug. 4, 2008, 2 pages. 9000038 165 "Defendants' Reply Memorandum in Support of Their Contingent Cross-Motion to Strike Portions of Plaintiffs Post-Trial Findings of Fact and Conclusions of Law" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 192, filed Aug. 15, 2008, 8 pages. 9000038 166 "Exhibit F--Defendants' Proposed Supplemental Findings of Fact and Conclusions of Law Regarding the '129 Patent" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 192-1, filed Aug. 15, 2008, 8 pages. 9000038 167 "Certificate of Service" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 192-2, filed Aug. 15, 2008, 2 pages. 9000038 168 "Letter from Ashby & Geddes dated Dec. 13, 2007" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 193, filed Dec. 5, 2008, 4 pages. 9000038 169 "Order" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 195, filed Mar. 30, 2009, 2 pages. 9000038 170 "Final Judgment Order" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 204, filed May 6, 2009, 3 pages. 9000038 171 "Federal Circuit Opinion", In the United States Court of Appeals for the Federal Circuit, In re 2009-1350, Alza Corporation and McNeil-PPC, Inc., v Andrx Pharmaceuticals, LLC and Andrx Corporationin the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 209-1, filed Jun. 4, 2010, 15 pages. 9000038 172 "Exhibit A--U.S. Patent No. 6,919,373 81" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1-1, filed Jan. 8, 2010, 17 pages. 9000038 173 "Exhibit B--U.S. Patent No. 6,930,129 82" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1-2, filed Jan. 8, 2010, 17 pages. 9000038 174 "Civil Cover Sheet" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1-3, filed Jan. 8, 2010, 1 page. 9000038 175 Reply to Counterclaims in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 13, filed Mar. 31, 2010,4 pages. 9000038 176 "Defendants' Kremers Urban, LLC and Kudco Ireland, Ltd.'s Motion for Leave to File Their Motion for Summary Judgment of Invalidity for Lack of Enablement of U.S. Patent Nos. 6,919,373 and 6,930,129" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 33, filed Oct. 20, 2010, 4 pages. 9000038 177 Patrick et al., "The Absorption of Sustained-Release Methylphenidate Formulations Compared to an Immediate-Release Formulation," Biopharmaceutics & Drug Disposition, 1989, 10, 165-171. 9000038 178 In the United States District Court for the stated of Delaware, Alza Corporation and McNeil-PPC, Inc. vs. Andrx Pharmaceuticals, LLC, and Andrx Corporation, Order, Filed Mar. 30, 2009, 2 pages. 9000038 179 In the United States District Court for the stated of Delaware, Alza Corporation and McNeil-PPC, Inc. vs. Andrx Pharmaceuticals, LLC, and Andrx Corporation, Opinion, Filed Mar. 30, 2009, 106 pages. 9000038 180 "[Proposed] Order" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 33-3, filed Oct. 20, 2010, 1 page. 9000038 181 "Acknowledgment of Receipt for AO Form 85, Notice, Consent, and Reference of a Civil Case to a Magistrate Judge and AO Form 85A, Notice, Consent, and Reference of a Dispositive Motion to a Magistrate Judge" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1-4, filed Jan. 8, 2010, 1 page. 9000038 182 "Answer, Defenses and Counterclaims of Defendants' Kremers Urban, LLC, and Kudco Ireland, Ltd." In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 9, filed Mar. 8, 2010, 18 pages. 9000038 183 "Breadth of Claims", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 155-1, filed Jan. 4, 2008, 56 pages. 9000038 184 "Certificate of Service" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 170-5, filed Feb. 6, 2008, 2 pages. 9000038 185 "Certificate of Service", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-14, filed Nov. 20, 2006, 2 pages. 9000038 186 "Certificate of Service", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 84-1, filed Nov. 10, 2006, 2 pages. 9000038 187 "Certificate of Service", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 102-4, filed Dec. 7, 2006, 2 pages. 9000038 188 "Certificate of Service", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 103-4, filed Dec. 7, 2006, 2 pages. 9000038 189 "Certificate of Service", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 125-3, filed Aug. 29, 2007, 2 pages. 9000038 190 "Civil Cover Sheer", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1-3, filed Sep. 1, 2005, 2 pages. 9000038 191 "Complaint" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1, filed Jan. 8, 2010, 12 pages. 9000038 192 "Complaint", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1, filed Sep. 1, 2005, 15 pages. 9000038 193 "Contingent Motion" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 190, filed Aug. 4, 2008, 1 page. 9000038 194 "Continuation of Transcription of Court Hearing, Friday, Dec. 14, 2007, Courtroom 48" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 188-2, filed Jul. 9, 2008, 163 pages. 9000038 195 "Declaration of Martyn C. Davies, Ph.D. In Support of Reply Markman Brief Submitted by Alza Corp. and McNeii-PPC, Inc.", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 97, filed Nov. 30, 2006, 2 pages. 9000038 196 "Declaration of Vivian A. Gray in Support of Reply Markman Brief Submitted by Plaintiffs Alza Corporation and McNeil-PPC", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 101, filed Dec. 6, 2006, 69 pages. 9000038 197 "Defendants' Memorandum in Opposition to Plaintiffs' Motion in Limine to Preclude the Entire Testimony of Bruce H. Stoner, Jr.", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 125, filed Aug. 29, 2007, 5 pages. 9000038 198 "Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Opening Claim Construction Brief", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Jan. 21, 2011, 19 pages. 9000038 199 "Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Response to Plaintiffs' First Set of Interrogatories (Nos. 1-7)", In the United States District Court for the District of Delaware, Civil Action No. 10-23-LPS, Filed Jan. 14, 2011, 14 pages. 9000038 200 "Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Response to Plaintiffs' Opening Claim Construction Brief", in the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Feb. 4, 2011, 11 pages. 9000038 201 "Defendants Kremes Urban, LLC and Kudco Ireland, Ltd.'s Motion for Leave to File their Motion for Summary Judgment of Invalidity for Lack of Enablement of U.S. Patent Nos. 6,919,373 and 6,930,129", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Oct. 20, 2010, 150 pages. 9000038 202 "DTX 143", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-3, filed Jan. 7, 2008, 1 page. 9000038 203 "DTX 277", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-12, filed Jan. 7, 2008, 1 page. 9000038 204 "DTX 701", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-7, filed Jan. 7, 2008, 1 page. 9000038 205 "Exhibit 0--Hubbard et al., "Enantioselective Aspects of the Disposition of dl-threo-Methylphenidate after the Administration of a Sustained-Release Formulation to Children with Attention Deficit-Hyperactivity Disorder", Journal of Pharmaceutical Sciences, Nov. 1989, vol. 78, No. 11", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-15, filed Nov. 13, 2006, 5 pages. 9000038 206 "Exhibit 2--Pages From Dr. Feifel's Deposition Transcript Cited in Defendants' Pretrial Submissions" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 170-2, filed Feb. 6, 2008, 2 pages. 9000038 207 "Exhibit 4--United States Court of Appeals for the Federal Circuit, In Re 2007-1093,-1134, Pharmaceutical Resources, Inc. and Par Pharmaceuticals, Inc. v Roxane Laboratories, Inc., Decision, dated Oct. 26, 2007", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 157-4, filed Jan. 7, 2008, 11 pages. 9000038 208 "Exhibit B--IR Overcoat Study (Tested Every 15 min)", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 158-3, filed Jan. 7, 2008, 2 pages. 9000038 209 "Exhibit A--Motion for Summary Judgment of Invalidity" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 33-1, filed Oct. 20, 2010, 64 pages. 9000038 210 "Exhibit A--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 102-1, filed Dec. 7, 2006, 2 pages. 9000038 211 "Exhibit B--Redacted" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 190-5, filed Aug. 4, 2008, 2 pages. 9000038 212 "Exhibit C--Briefs and Other Related Documents, Westlaw", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-3, filed Nov. 13, 2006, 23 pages. 9000038 213 "Exhibit C--Discussion, Westlaw", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 123-3, filed Aug. 20, 2007, 4 pages. 9000038 214 "Exhibit D--Physicians Desk Reference 591 Edition, 2005", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-4, filed Nov. 20, 2006, 6 pages. 9000038 215 "Exhibit D--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-4, filed Nov. 20, 2006, 2 pages. 9000038 216 "Exhibit E--Redacted" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 190-8, filed Aug. 4, 2008, 2 pages. 9000038 217 "Exhibit F--Final Rejection, In the United States Patent and Trademark Office, in re U.S. Appl. No. 09/253,317, filed Feb. 19, 1999", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-6, filed Nov. 20, 2006, 5 pages. 9000038 218 "Exhibit H--Declaration of Suneel K. Gupta, In the United States Patent and Trademark Office, In re U.S. Appl. No. 09/253,317, filed Feb. 19, 1999",In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-8, filed Nov. 20, 2006, 5 pages. 9000038 219 "Exhibit L--Redacted", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 89-12, filed Nov. 20, 2006, 2 pages. 9000038 220 "Exhibit L--USP 25 the United States Pharmacopeia NF 20 the National Formulary, 2002, Jan. 1, 2002", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 88-12, filed Nov. 20, 2006, 14 pages. 9000038 221 "Exhibit M--"Guidance for Industry Extended Release Oral Dosage Forms: Development, Evaluation, and Application of in Vitro/in Vivo Correlations", U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (COER), Sep. 1997, BP 2" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-13, filed Nov. 13, 2006, 28 pages. 9000038 222 "Exhibit N--Non-Final Office Action, In the United States Patent and Trademark Office, In re U.S. Appl. No. 09/802,709, filed Mar. 8, 2001", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-14, filed Nov. 13, 2006, 7 pages. 9000038 223 "Exhibit P--Reply Pursuant to 37 CFR .sctn. 1.111, In the United States Patent and Trademark Office, In re U.S. Appl. No. 09/802,709, filed Mar. 8, 2001", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 87-16, filed Nov. 13, 2006, 11 pages. 9000038 224 "Judgment", In the United States Court of Appeals for the Federal Circuit, In re 2009-1350, Alza Corporation and McNeil-PPC, Inc., v Andrx Pharmaceuticals, LLC and Andrx Corporationin the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 209, filed Jun. 4, 2010, 1 page. 9000038 225 "Laboratory Notebook BW 0392", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 160-8, filed Jan. 7, 2008, 5 pages. 9000038 226 "Impax Laboratories, Inc.'s Answer and Counterclaims", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 9, filed Nov. 16, 2005, 16 pages. 9000038 227 "Memorandum Order" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 174, filed Apr. 28, 2008, 4 pages. 9000038 228 "Opinion" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 194, filed Mar. 30, 2009, 106 pages. 9000038 229 "Plaintiffs' Answering Brief in Opposition to Defendants' Motion for Summary Judgment of Invalidity for Lack of Enablement of U.S. Patent No. 6,930,129", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Mar. 21, 2011, 25 pages. 9000038 230 "Plaintiffs' Combined Reply Memorandum in Further Support of Their Motion to Strike Portions of Defendants' Post-Trial Findings of Fact, and Answering Memorandum in Response to Defendants' Contingent Motion" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 1901, filed Aug. 7, 2008,7 pages. 9000038 231 "Plaintiffs' Motion for Leave to File Sur-Reply in Opposition to Defendants' Motion for Leave to File Motion for Summary Judgment of Invalidity for Lack of Enablement of U.S. Patent Nos. 6,919,373 and 6,390,129", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Nov. 24, 2010, 27 pages. 9000038 232 "Plaintiffs' Motion to Strike Portions of Defendants' Post-Trial Findings of Fact" In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 188, filed Jul. 9, 2008, 8 pages. 9000038 233 "Plaintiffs' Opposition to Defendants' Motion for Leave to File Motion for Summary Judgment of Invalidity for Lack of Enablement of U.S. Patent Nos. 6,919,373 and 6,930,129", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Nov. 12, 2010, 57 pages. 9000038 234 "Plaintiffs' Reply Brief in Support of Plaintiffs' Motion for Leave to File Sur-Reply in Opposition to Defendants' Motion for Leave to File Motion for Summary Judgment of Invalidity for Lack of Enablement of U.S. Patent Nos. 6,919,373 and 6,930,129", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Dec. 14, 2010, 3 pages. 9000038 235 "Plaintiffs' Supplemental and Amended Responses to Defendants' Interrogatory Nos. 7 and 8", In the United States District Court for the District of Delaware, Civil Action No. 10-23-LPS, Filed Mar. 1, 2011, 7 pages. 9000038 236 "Plaintiffs' Sur-Reply in Opposition to Defendants' Motion for Leave to File Motion for Summary Judgment of Invalidity for Lack of Enablement of U.S. Patent Nos. 6,919,373 and 6,930,129", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Jan. 5, 2011, 5 pages. 9000038 237 "Prosecution History of Patents-In-Suit", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 125-1, filed Aug. 29, 2007, 1 page. 9000038 238 "Redacted DTX 1136 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-15, filed Jan. 7, 2008, 1 page. 9000038 239 "Redacted DTX 661 and DTX 663-672 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-1, filed Jan. 7, 2008, 1 page. 9000038 240 "Redacted DTX 661 and DTX 663-672 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-2, filed Jan. 7, 2008, 1 page. 9000038 241 "Redacted DTX 661 and DTX 663-672 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-3, filed Jan. 7, 2008, 1 page. 9000038 242 "Redacted DTX 699 and DTX 700 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-5, filed Jan. 7, 2008, 1 page. 9000038 243 "Redacted DTX 699 and DTX 700 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 162-6, filed Jan. 7, 2008, 1 page. 9000038 244 "Redacted Public Version Defendants' Opposition to Plaintiffs' Markman Brief on Claim Construction", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 102, filed Dec. 7, 2006, 34 pages. 9000038 245 "Redacted Public Version Defendants' Pretrial Reply Brief", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 156, filed Jan. 4, 2008, 60 pages. 9000038 246 "Redacted Public Version, Defendants' Answering Post-Trial Brief Concerning Plaintiffs' Evidentiary Objections", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 170, filed Feb. 6, 2008, 12 pages. 9000038 247 "Redacted Public Version, Defendants' Proposed Findings of Fact and Conclusions of Law" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 184, filed Jun. 24, 2008, 134 pages. 9000038 248 "Redacted Public Version, Plaintiffs' Opening Post-Trial Brief Concerning Evidentiary Objections", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 167, filed Jan. 30, 2008, 22 pages. 9000038 249 "Redacted Public Version, Plaintiffs' Opening Pretrial Submission", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 164, filed Jan. 8, 2008, 135 pages. 9000038 250 "Redacted Public Version, Plaintiffs' Proposed Post-Trial Findings of Fact and Conclusions of Law" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 183, filed Jun. 23, 2008, 237 pages. 9000038 251 "Redacted PX 17 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 163-2, filed Jan. 7, 2008, 1 page. 9000038 252 "Redacted PX 257 Confidential", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 163-6, filed Jan. 7, 2008, 1 page. 9000038 253 "Reply to Counterclaims", In the United States District Court for the District of Delaware, Case No. 1:10-cv-00023-LPS, Filed Mar. 31, 2010, 4 pages. 9000038 254 "Response", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 156-2, filed Jan. 4, 2008, 46 pages. 9000038 255 "Response", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 156-3, filed Jan. 4, 2008, 39 pages. 9000038 256 "The Individual Plasma Concentration Data in Defendants' ANDA Does Not Demonstrate that a Substantial Population of Individuals Will Exhibit a Substantially Ascending MPH Plasma Concentration for About 8 Hours", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 156-1, filed Jan. 4, 2008, 65 pages. 9000038 257 "Letter from Ashby & Geddes dated Aug. 20, 2007", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 124, filed Aug. 20, 2007, 1 page. 9000038 258 "Exhibit 3--Email from Todd Wagner dated Dec. 5, 2007" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 170-3, filed Feb. 6, 2008, 2 pages. 9000038 259 "Letter from Rawle & Henderson LLP dated Apr. 2, 2008" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 172-1, filed Apr. 2, 2008, 2 pages. 9000038 260 "U.S. Patent No. 6,930,129 82" in the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 33-2, filed Oct. 20, 2010, 81 pages. 9000038 261 "Defendants Osmotica Kereskedelmi Es Szolgaltato Kft's and Osmotica Pharmaceutical Corp.'s Preliminary Invalidity Contentions Under Paragraph 4(d) of the District of Delaware Default Standard for Discovery", In the United States District Court for the District of Delaware, Case No. 13/1104-RGA (Consolidated), filed Jan. 14, 2014, 106 pages. 9000038 262 "Par Pharmaceutical, Inc.'s Initial Invalidity Contentions Under Paragraph 4 of the District of Delaware Default Standard for Discovery", In the United States District Court for the District of Delaware, Case No. 13/1104-RGA (Consolidated), filed Jan. 14, 2014, 32 pages. 9000038 263 Alza Corp. et al. v. Andrx Pharmaceuticals LLC et al., U.S. Court of Appeals for the Federal Circuit, Case No. 2009-1350, Apr. 26, 2010, 16 pages. 9000038 264 Chemical Engineer's Handbook, 1984, 6th Edition, 21-15. 9000038 265 Conley et al., "Clinical Spectrum of the Osmotic-Controlled Release Oral Delivery System (OROS), an Advanced Oral Delivery form", Current Medical Research and Opinion, Oct. 2006, 22(10):1879-1892. 9000038 266 Drill, Pharmacology in Medicine, Third Edition, 1965, 227, McGraw-Hill, New York, p. 798. 9000038 267 Goodman and Gilman, The Pharmacological Bases of Therapeutics, 1990, 8th Ed., 72. 9000038 268 Hubbard, J.W. et al., "Enantioselective Aspects of the Disposition of dl-threo-Methylphenidate after the Administration of a Sustained-Release Formulation to Children with Attention-Hyperactivity Disorder", Journal of Pharmaceutical Sciences, 1989, 78(11), 944-947. 9000038 269 In the United States District Court for the District of Delaware, Alza Corporation, and McNeil-PPC, Inc., Plaintiffs, v. Impax Laboratories, Inc., Andrx Pharmaceuticals, L.L.C., and, Andrx Corporation, Defendants, Civil Action No. 05-642, Answer, Affirmative Defenses and Counterclaims, Oct. 25, 2005, 16 pages. 9000038 270 In the United States District Court for the District of Delaware, Alza Corporation, and McNeil-PPC, Inc., Plaintiffs, v. Impax Laboratories, Inc., Andrx Pharmaceuticals, L.L.C., and, Andrx Corporation, Defendants, Civil Action No. 05-642-JJF, Reply to Counterclaims, Nov. 14, 2005, 4 pages. 9000038 271 In the United States District Court for the District ofDe1aware, Alza Corporation, and McNeil-PPC, Inc., Plaintiffs, v. Impax Laboratories, Inc., Andrx Pharmaceuticals, L.L.C., and, Andrx Corporation, Defendants, Civil Action No. 05-642, Complaint, Sep. 1, 2005, 15 pages. 9000038 272 Journal of the American Pharmaceutical Association., 1959, 48, 451-454. 9000038 273 Journal of the American Pharmaceutical Association., 1960, 49, 82-84. 9000038 274 Letter from Mark C. Shaw, Vice-President, Regulatory Affairs and Compliance, Impax Laboratories, Inc., t' McNeil Consumer and Specialty Pharmaceuticals & Alza Corporation, Re: Notice under 21 U.S.C. .sctn. 355 G)(2)(B)(i) and (ii), With Reference to U.S. Patent No. 6,930,129, Aug. 16, 2005, 8 pages. 9000038 275 Letter from Mark C. Shaw, Vice-President, Regulatory Affairs and Compliance, Impax Laboratories, Inc., to McNeil Consumer and Specialty Pharmaceuticals & Alza Corporation, Re: Notice under 21 U.S.C. .sctn. 355 (j){2)(B)(i) and (ii), With Reference to U.S. Patent No. 6,919,373, Jul. 20, 2005, 13 pages. 9000038 276 Letter from Ted Whitlock, Intellectual Property Counsel, Andrx Pharmaceuticals, LLC to ALZA Corporation, Re: ANDA for Concerta.RTM. Extended-release Tablets 54 mg; Patent Certification Under 21 CFR .sctn. 314.94 and Notice of Certification of Invalidity or Noninfringement of a Patent Under 21 CFR .sctn. 314.95, in reference to U.S. Pat. Nos. 6,919,373 & 6,930,129, Aug. 16, 2005, 45 pages. 9000038 277 Letter from Ted Whitlock, Intellectual Property Counsel, Andrx Pharmaceuticals, LLC. to McNeil Consumers & Specialty Pharmaceuticals, Re: ANDA for Concerta.RTM. Extended-release Tablets 54 mg; Jul. 20, 2005, 39 pages. 9000038 278 Letter from Ted Whitlock, Intellectual Property Counsel, Andrx Pharmaceuticals, LLC. To McNeil Consumers & Specialty Pharmaceuticals, Re: ANDA for Concerta.RTM. Extended-release Tablets 18, 27 and 36 mg, Jul. 20, 2005, 11 pages. 9000038 279 Longer, M.A. et al., "Sustained Release Drug Delivery Systems", 1676-1686. 9000038 280 Medicine Abstract 92226085--Fitzpatrick,1992. 9000038 281 Merck Index, 11th Edition, Item 6025, 1989, p. 960. 9000038 282 Merck Index, 12th Edition, p. 1042, Entry 6189, 1996. 9000038 283 Modem Plastics Encyclopedia, 1969, 46, 62-70. 9000038 284 Park, K. et al., "Use of a Pharmacokinetic/Pharmacodynamic Model to Design an Optimal Dose Input Profile", Journal of Pharmacokinetics and Biopharmaceutics, 1998, 26(4), 471-492. 9000038 285 Physician's Desk Reference, 451, Edition, pp. 865-866, 1991. 9000038 286 Remington, Pharm. Sci., 1970, 14th Edition, 1626-1679. 9000038 287 Remington, Pharm. Sci., 1985, 17th Edition, Chapter 68, 1305-1306. 9000038 288 Remington, Pharm. Sci., 1985, 17th Edition, 342-345. 9000038 289 Remington, Pharm. Sci., 1985, 17th Edition,1603-1632. 9000038 290 Roff, et al., Handbook of Common Polymers, 1971, published by CRC Press, 164-173. 9000038 291 Voigt, R., "Theraputische Systeme", Pharmazeutische Technologie, 1993, 556-557. 9000038 292 "Defendant Sandoz's Answer, Affirmative Defenses and Counterclaims to Plaintiffs' Complaint", In the United States District Court for the District of Delaware, Case No. 1:14-cv-00744-RGA, Doc. No. 9, filed Aug. 27, 2014, 41 pages. 9000038 293 "Exhibit 1 to Answer", In the United States District Court for the District of Delaware, Case No. 1:14-cv-00744-RGA, Doc. No. 9-1, filed Aug. 27, 2014, 18 pages. 9000038 294 "Exhibit 2 to Answer", In the United States District Court for the District of Delaware, Case No. 1:14-cv-00744-RGA, Doc. No. 9-2, filed Aug. 27, 2014, 17 pages. 9000038 295 "Exhibit 3 to Answer", In the United States District Court for the District of Delaware, Case No. 1:14-cv-00744-RGA, Doc. No. 9-3, filed Aug. 27, 2014, 55 pages. 9000038 296 "Exhibit 4 to Answer", In the United States District Court for the District of Delaware, Case No. 1:14-cv-00744-RGA, Doc. No. 9-4, filed Aug. 27, 2014, 31 pages. 9000038 297 "Exhibit 5 to Answer", In the United States District Court for the District of Delaware, Case No. 1:14-cv-00744-RGA, Doc. No. 9-5, filed Aug. 27, 2014, 21 pages. 9000038 298 "Defendant Alza Corporation's Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 105, filed Nov. 27, 2013, 30 pages. 9000038 299 "Declaration of Kennerly S. Patrick, Ph.D. In Support of ALZA Corporation's Opening Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 105-1, filed Nov. 27, 2013, 18 pages. 9000038 300 "Exhibit A of Declaration of Kennerly S. Patrick, Ph.D. in Support of ALZA Corporation's Opening Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 105-2, filed Nov. 27, 2013, 25 pages. 9000038 301 "Exhibit B of Declaration of Kennerly S. Patrick, Ph.D. In Support of ALZA Corporation's Opening Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 105-3, filed Nov. 27, 2013, 2 pages. 9000038 302 "Exhibit C of Declaration of Kennerly S. Patrick, Ph.D. in Support of ALZA Corporation's Opening Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 105-4, filed Nov. 27, 2013, 2 pages. 9000038 303 "Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106, filed Nov. 27, 2013, 5 pages. 9000038 304 "Exhibit 1 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-2, filed Nov. 27, 2013, 17 pages. 9000038 305 "Exhibit 2 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-1, filed Nov. 27, 2013, 17 pages. 9000038 306 "Exhibit 3 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-2, filed Nov. 27, 2013, 24 pages. 9000038 307 "Exhibit 4 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-3, filed Nov. 27, 2013, 9 pages. 9000038 308 "Exhibit 5 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-4, filed Nov. 27, 2013, 13 pages. 9000038 309 "Exhibit 6 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-5, filed Nov. 27, 2013, 17 pages. 9000038 310 "Exhibit 7 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-7, filed Nov. 27, 2013, 11 pages. 9000038 311 "Exhibit 8 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-8, filed Nov. 27, 2013, 9 pages. 9000038 312 "Exhibit 9 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-9, filed Nov. 27, 2013, 8 pages. 9000038 313 "Exhibit 10 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-10, filed Nov. 27, 2013, 5 pages. 9000038 314 "Exhibit 11 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-11, filed Nov. 27, 2013, 12 pages. 9000038 315 "Exhibit 12 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-12, filed Nov. 27, 2013, 9 pages. 9000038 316 "Exhibit 13 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-13, filed Nov. 27, 2013, 29 pages. 9000038 317 "Exhibit 14 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-14, filed Nov. 27, 2013, 12 pages. 9000038 318 "Exhibit 15 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-15, filed Nov. 27, 2013, 9 pages. 9000038 319 "Exhibit 16 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-16, filed Nov. 27, 2013, 18 pages. 9000038 320 "Exhibit 17 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 106-17, filed Nov. 27, 2013, 2 pages. 9000038 321 "Exhibit 18 (Part 1) of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107, filed Nov. 27, 2013, 32 pages. 9000038 322 "Exhibit 18 (Part 2) of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-1, filed Nov. 27, 2013, 25 pages. 9000038 323 "Exhibit 19 (Part 1) of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-2, filed Nov. 27, 2013, 30 pages. 9000038 324 "Exhibit 19 (Part 2) of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-3, filed Nov. 27, 2013, 36 pages. 9000038 325 "Exhibit 20 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-4, filed Nov. 27, 2013, 5 pages. 9000038 326 "Exhibit 21 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-5, filed Nov. 27, 2013, 7 pages. 9000038 327 "Exhibit 22 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-6, filed Nov. 27, 2013, 4 pages. 9000038 328 "Exhibit 23 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-7, filed Nov. 27, 2013, 31 pages. 9000038 329 "Exhibit 24 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-8, filed Nov. 27, 2013, 32 pages. 9000038 330 "Exhibit 25 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-9, filed Nov. 27, 2013, 4 pages. 9000038 331 "Exhibit 26 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-10, filed Nov. 27, 2013, 5 pages. 9000038 332 "Exhibit 27 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-11, filed Nov. 27, 2013, 6 pages. 9000038 333 "Exhibit 28 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-12, filed Nov. 27, 2013, 19 pages. 9000038 334 "Exhibit 29 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-13, filed Nov. 27, 2013, 53 pages. 9000038 335 "Exhibit 30 of Declaration of Kurt G. Calia in Support of Alza Corp.'s Opening Claim Construction Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 107-14, filed Nov. 27, 2013, 20 pages. 9000038 336 "Plaintiff Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 112, filed Dec. 13, 2013, 30 pages. 9000038 337 "Exhibit A to Declaration of Plaintiff Swanson's in Support of Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 113-1, filed Dec. 13, 2013, 31 pages. 9000038 338 "Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114, filed Dec. 13, 2013, 5 pages. 9000038 339 "Exhibit B to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-Pjh, Doc. No. 114-1, filed Dec. 13, 2013, 8 pages. 9000038 340 "Exhibit C to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-2, filed Dec. 13, 2013, 15 pages. 9000038 341 "Exhibit D to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-3, filed Dec. 13, 2013, 21 pages. 9000038 342 "Exhibit E to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-4, filed Dec. 13, 2013, 14 pages. 9000038 343 "Exhibit F to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", in the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-5, filed Dec. 13, 2013, 4 pages 9000038 344 "Exhibit G to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-6, filed Dec. 13, 2013, 2 pages. 9000038 345 "Exhibit H to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-7, filed Dec. 13, 2013, 10 pages. 9000038 346 "Exhibit J to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-8, filed Dec. 13, 2013, 38 pages. 9000038 347 "Exhibit K to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-9, filed Dec. 13, 2013, 5 pages. 9000038 348 "Exhibit L to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-10, filed Dec. 13, 2013, 2 pages. 9000038 349 "Exhibit M to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-11, filed Dec. 13, 2013, 2 pages. 9000038 350 "Exhibit N To Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-12, filed Dec. 13, 2013, 21 pages. 9000038 351 "Exhibit O to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 114-13, filed Dec. 13, 2013, 4 pages. 9000038 352 "Exhibit P To Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115, filed Dec. 13, 2013, 19 pages. 9000038 353 "Exhibit Q to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-1, filed Dec. 13, 2013, 3 pages. 9000038 354 "Exhibit R to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-2, filed Dec. 13, 2013, 11 pages. 9000038 355 "Exhibit S to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's.Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-3, filed Dec. 13, 2013, 17 pages. 9000038 356 "Exhibit T to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern.District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-4, filed Dec. 13, 2013, 24 pages. 9000038 357 "Exhibit U (Filed Under Seal) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-5, filed Dec. 13, 2013, 57 pages. 9000038 358 "Exhibit V to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-6, filed Dec. 13, 2013, 45 pages. 9000038 359 "Exhibit W to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-7, filed Dec. 13, 2013, 11 pages. 9000038 360 "Exhibit X (Part 1) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", in the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-8, filed Dec. 13, 2013, 75 pages. 9000038 361 "Exhibit X (Part 2) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-9, filed Dec. 13, 2013, 56 pages. 9000038 362 "Exhibit Y (Filed Under Seal) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-12, filed Dec. 13, 2013, 167 page. 9000038 363 "Exhibit Z to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-13, filed Dec. 13, 2013, 19 pages. 9000038 364 "Exhibit AA (Filed Under Seal) to Declaration Gerald P. Dodson in Support of Dr. James M.Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 115-14, filed Dec. 13, 2013, 65 pages. 9000038 365 "Exhibit BB to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116, filed Dec. 13, 2013, 48 pages. 9000038 366 "Exhibit CC (Part 1a) to Declaration Gerald P. Dodson in Support of Dr. James M.Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116-1, filed Dec. 13, 2013, 70 pages. 9000038 367 "Exhibit CC (Part 1b) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116-2, filed Dec. 13, 2013, 65 pages. 9000038 368 "Exhibit CC (Part 2a) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116-3, filed Dec. 13, 2013, 60 pages. 9000038 369 "Exhibit CC (Part 2b) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116-4, filed Dec. 13, 2013, 76 pages. 9000038 370 "Exhibit CC (Part 3a) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116-5, filed Dec. 13, 2013, 70 pages. 9000038 371 "Exhibit CC (Part 3b) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116-6, filed Dec. 13, 2013, 66 pages. 9000038 372 "Exhibit CC (Part 4a) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116-7, filed Dec. 13, 2013, 70 pages. 9000038 373 "Exhibit CC (Part 4b) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116-8, filed Dec. 13, 2013, 66 pages. 9000038 374 "Exhibit CC (Part 5a) to Declaration Gerald P. Dodson in Support of Dr. James M.Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116-9, filed Dec. 13, 2013, 70 pages. 9000038 375 "Exhibit CC (Part 5b) to Declaration Gerald P. Dodson in Support of Dr. James M. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 116-10, filed Dec. 13, 2013, 51 pages. 9000038 376 "Redacted Public Version--Defendants' Osmotica Kereskedelmi Es Szolgaltato Kft's and Osmotica Pharmaceutical Corp.'s Answer, Defenses, and Counterclaims to Plaintiffs' Amended Complaint", In the United States District Court for the District of Delaware, Case No. 1:13-cv-1104-RGA (Consolidated), Jury Demanded, Doc. No. 121, filed Apr. 4, 2014, 52 pages. 9000038 377 "Defendant Alza Corporation's Administrative Request to File Under Seal Portions of the Claim Construction Reply Brief", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 130, filed Dec. 20, 2013, 3 pages. 9000038 378 "Redacted Defendant Alza Corporation's Claim Construction Reply Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 130-3, filed Dec. 20, 2013, 27 pages. 9000038 379 "Under Seal Defendant Alza Corporation's Claim Construction Reply Brief Pursuant to Patent Local Rule 4-5", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 130-4, filed Dec. 20, 2013, 20 pages. 9000038 380 "Confidential--Filed Under Seal Pursuant to Protective Order, Defendants' Osmotica Kereskedelmi Es Szolgaltato Kft's And Osmotica Pharmaceutical Corp.'s Amended Answer, Defenses, and Counterclaims to Plaintiffs' Amended Complaint", In the United States District Court for the District of Delaware, Case No. 1:13-cv-1104-RGA (Consolidated), Jury Demanded, Doc. No. 144, filed Jun. 6, 2014, 60 pages. 9000038 381 "Confidential Filed Under Seal--Defendant Par Pharmaceutical Inc.'s First Amended Answer and Counterclaims to Alza Corporation and Janssen Pharmaceuticals, Inc.'s Amended Complaint", In the United States District Court for the District of Delaware, Case No. 1:13-cv-1104-RGA (Consolidated), Doc. No. 145, filed Jun. 6, 2014, 141 pages. 9000038 382 "Public Exhibits to Par Pharmaceutical Inc.'s First Amended Answer and Counterclaims to Alza Corporation and Janssen Pharmaceuticals, Inc.'s Amended Complaint", In the United States District Court for the District of Delaware, Case No. 1:13-cv-1104-RGA (Consolidated), Doc. No. 146, filed Jun. 6, 2014, 173 pages. 9000038 383 "Plaintiff's Order Construing Claims Construction", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, Doc. No. 157, filed Apr. 25, 2014, 30 pages. 9000038 384 "Proposed Order Granting Plaintiff Dr. James M. Swanson's Motion For Leave to Amend Inventorship and Invalidity Contentions", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 191-1, filed Jul. 11, 2014, 1 page. 9000038 385 "Declaration of K. Brian Bathurst in Support of Plaintiff Dr. James M. Swanson's Notice of Motion and Motion for Leave to Amend his Inventorship and Invalidity Contentions (N.D.Cal. Patent L.R. 3-6)", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 191-2, filed Jul. 11, 2014, 2 pages. 9000038 386 "Exhibit Claim Chart Invalidity Contentions", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 191-3, filed Jul. 11, 2014, 17 pages. 9000038 387 "Exhibits to Defendants Osmotica's Complaint", 2013, 77 pages. 9000038 388 "Plaintiff Dr. James M. Swanson's Responses to Alza Corporation's Fourth Set of Interrogatories (Original Interrogatory No. 9/New Interrogatory No. 19", In the United States.District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, filed Dec. 13, 2013, 8 pages. 9000038 389 "Plaintiff Dr. James M. Swanson's Responses to Alza Corporation's Third Set of Interrogatories", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, filed Oct. 30, 2013, 48 pages. 9000038 390 "Plaintiff Dr. James M. Swanson's Responses to Alza Corporation's Fifth Set of Interrogatories (Original Interrogatory Nos. 10-12/New Interrogatory Nos. 20-22)", In The United States District Court for the Northern District of California, Case No. 4:12-cv-04579- PJH, filed Apr. 7, 2014, 10 pages. 9000038 391 "Plaintiff Dr. James M. Swanson's Supplemental Responses to Alza Corporation's Fourth Set of Interrogatories (Original Interrogatory No. 9/New Interrogatory No. 19)", In The United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, filed Jan. 23, 2014, 9 pages. 9000038 392 "Plaintiff Dr. James M. Swanson's Supplemental Responses to Alza Corporation's Third Set of Interrogatories", In the United States District Court for the Northern District of California, Case No. 4:12-cv-04579-PJH, filed Jun. 4, 2014, 55 pages. 9000038 393 ALZA Corporation's Claim Construction Presentation, Feb. 3, 2014, 95 pages. 9000038 394 Letter from Amneal Pharmaceuticals, "Notice of Paragraph IV Certification of U.S. Patent 6,919,373, 6,930,129, 8,163,798 and 8,629,179, Concerning ANDA 207515 for Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg", dated Aug. 22, 2014, 14 pages. 9000038 395 Plaintiff Swanson's Claim Construction Presentation, Feb. 3, 2014, 42 pages. 9000038 396 "A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder, The MTA Cooperative Group", Produced in 12-CV-04579, ALZ00004854-4867, Arch Gen. Psychiatry, 1999, 56, 1073-1086. 9000038 397 "Alza Corp. and McNeil PPC, Inc. v. Andrx Pharmaceuticals, LLC and Andrx Corporation, 603 F.3d 935 (Fed. Cir. 2010)", In the United States Court of Appeals, Federal Circuit, No. 2009-1350, Apr. 26, 2010, 935-943. 9000038 398 "Alza Corp. and McNeil PPC, Inc. v. Andrx Pharmaceuticals, LLC and Andrx Corporation, 607 F.Supp.2d 935 (D.Del. 2009)", In the United States District Court for the District of Delaware, Civil Action No. 05-642-JJF, Mar. 30, 2009, 614-660. 9000038 399 "Answer, Defenses and Counterclaims of Mylan Pharmaceuticals Inc. and Mylan Inc. to Plaintiffs' Complaint", In the United States District Court for the Northern District of West Virginia (at Clarksburg), Case No. 1:14-cv-00085-IMK, Doc. No. 11, filed Jul. 29, 2014, 25 pages. 9000038 400 "Birkett, Chapter 12--Designing Dose Regimens, Effects of Varying the Dose Interval, Pocket Guide: Pharmacokinetics Made Easy, 1998, p. 101", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-11, filed Dec. 13, 2013, 1 page. 9000038 401 "Certified Copy of U.S. Appl. No. 60/028,726", In the United States Patent and Trademark Office, filed Sep. 30, 1996, 54 pages. 9000038 402 "Chan et al, Methylphenidate Hydrochloride Given With or Before Breakfast: II. Effects on Plasma Concentration of Methylphenidate and Ritalinic Acid, Pediatrics, 1983, 72(1), 56-59", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-9, filed Dec. 13, 2013, 5 pages. 9000038 403 "Confidential--Attorneys Eyes Only Subject to the Protective Order, Video Deposition of Edward L. Mandell", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, ALZ01491792-1900, dated Sep. 30, 2013, 109 pages. 9000038 404 "Declaration of Plaintiff, James M. Swanson, Ph.D. In Support of Dr. Swanson's Responsive Claim Construction Brief", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 113, filed Dec. 13, 2013, 16 pages. 9000038 405 "Defendant Osmotica's Brief in Opposition to Plaintiffs' Motion to Strike Defenses and Dismiss Counterclaims Alleging Inequitable Conduct", In the United States District Court for the District of Delaware, C.A. No. 13-1104-RGA (Consolidated), filed Apr. 11, 2014, 8 pages. 9000038 406 "Defendant Osmotica's Brief in Opposition to Plaintiffs' Motion to Strike Defenses and Dismiss Counterclaims Alleging Inequitable Conduct", In the United States District Court for the District of Delaware, Case No. 1:13-1104-RGA (Consolidated), Doc. No. 132, filed Apr. 28, 2014, 8 pages. 9000038 407 "Defendant Par Pharmaceutical Inc.'s Answer and Counterclaims to Alza Corporation and Janssen Pharmaceuticals, Inc.'s Amended Complaint", In the United States District Court for the District of Delaware, Case No. 1:13-1104-RGA (Consolidated), Doc. No. 118, filed Mar. 28, 2014, 101 pages. 9000038 408 "Defendant Par Pharmaceutical, Inc.'s Initial Invalidity Contentions for U.S. Patent No. 8,629,179 And Supplemental Invalidity Contentions for U.S. Patent No. 8,163,798", In the United States District Court for the District of Delaware, C.A. No. 13-1104-RGA (Consolidated), filed Apr. 10, 2014, 54 pages. 9000038 409 "Defendant Par Pharmaceuticals Inc.'s Answer and Counterclaims", In the United States District Court for the District of Delaware, Case No. 1:13-cv-1104 (RGA), filed Sep. 9, 2013, 52 pages. 9000038 410 "Defendants Osmotica Kereskedelmi Es Szolgaltato Kft's and Osmotica Pharmaceutical Corp.'s Preliminary Invalidity Contentions for U.S. Patent No. 8,629,179 Under Paragraph 4(D) of the District of Delaware Default Standard for Discovery", In the United States District Court for the District of Delaware, C.A. No. 13-1104-RGA (Consolidated), filed Apr. 10, 2014, 151 pages. 9000038 411 "DTX-153--Perel, et al., Abstracts of Papers Presented at the Ninety-Second Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics", Clinical Pharmacology and Therapeutics, Feb. 1991, 49(2), 3 pages. 9000038 412 "DTX-621--Pelham Jr., et al., Sustained Release and Standard Methylphenidate Effects on Cognitive and Social Behavior in Children With Attention Deficit Disorder", Pediatrics, 1987, 80, 491-501, In the United States District Court for the District of Delaware, Case No. 1:05-cv-000642-JJF, Doc. No. 161-2, filed Jan. 7, 2008, 11 pages. 9000038 413 "DTX-622--Pelham et al., Relative Efficacy of Long-Acting Stimulants on Children With Attention Deficit-Hyperactivity Disorder: A Comparison of Standard Methylphenidate, Sustained-Release Methylphenidate, Sustained-Release Dextroamphetamine, and Pemoline", Pediatrics, Aug. 1990, 86(2), 226-237, In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 161-3, filed Jan. 7, 2008, 12 pages. 9000038 414 "DTX-624--Hubbard et al., Enantioselective Aspects of the Disposition of dl-threo-Methylphenidate after the Administration of a Sustained-Release Formulation to Children with Attention Deficit-Hyperactivity Disorder, Journal of Pharmaceutical Sciences, Nov. 1989, 78(11), 944-947", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 161-4, filed Jan. 7, 2008, 4 pages. 9000038 415 "DTX-626--Angrist, Brain Reward Systems and Abuse: Clinical Effects of Central Nervous System Stimulants: A Selective Update, Engle et al. (Eds)., Seventh International Berzelius Symposium Sponsored by the Swedish Society of Medicine, 1987", In the United States District Court for the District of Delaware, Case No. 1:05-cv-000642-JJF, Doc. No. 161-6, filed Jan. 7, 2008, 21 pages. 9000038 416 "DTX-627--Birmaher et al, Sustained Release Methylphenidate: Pharmacokinetic Studies in ADDH Males, Journal of the American Academy of Child and Adolescent Psychiatry, Sep. 1989, 28(5), 768-772", In the United States District Court for the District of Delaware, Case No. 1:05-cv-000642-JJF, Doc. No. 161-7, filed Jan. 7, 2008, 7 pages. 9000038 417 "DTX-628--Porchet et al., Pharmacodynamic Model of Tolerance: Application to Nicotine, Journal of Pharmacology and Experimental Therapeutics, 1987, 244(1), 231-236", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 161-8, filed Jan. 7, 2008, 6 pages. 9000038 418 DTX-629--Perkins et al., Acute Tolerance to the Cardiovascular Effects of Nicotine, Drug and Alcohol Dependence, 1991, 29, 77-86, In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. 161-9, filed Jan. 7, 2008, 9 pages. 9000038 419 "DTX-630--Greenhill, The Psychiatric Clinics of North America: Pediatric Psychopharmacology, Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder", W.B. Saunders Co., Mar. 1992, 15(1), 29 pages, In the United States District Court for the District of Delaware, Case No. 1:05-cv-000642-JJF, Doc. No. 161-10, filed Jan. 7, 2008, 29 pages. 9000038 420 "DTX-631--Fung, Pharmacokinetic Determinants of Nitrate Action, The American Journal of Medicine, 1984, 22-28", In the United States District Court for the District of Delaware, Case No. 1:05-cv-000642-JJF, Doc. No. 161-11, filed Jan. 7, 2008, 5 pages. 9000038 421 "DTX-635--The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals", 12th Edition, Budavari et al. (Eds.), Merck and Co., Inc., 1996, 4 pages, In the United States.DistrictCourt for the District of Delaware, Case No. 1:05-cv-00642-JJF, Doc. No. 161-15, filed Jan. 7, 2008, 4 pages. 9000038 422 "Exhibit A--Joint Claim Construction Chart", In the United States District Court for the District of Delaware, C.A. No. 13-1104-RGA (Consolidated), Doc. No. 98-1, filed Mar. 4, 2014, 5 pages. 9000038 423 "Exhibit A to Declaration of James M. Swanson, Ph.D.--Curriculum Vitae", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 113-1, filed Dec. 13, 2013, 31 pages. 9000038 424 "Exhibit A1--U.S. Appl. No. 12/581,699: Information Disclosure Statement Signed by Examiner Zohreh Fay", In the United States Patent and Trademark Office, Produced in 12-CV-04579, ALZ01176807-6810, dated Nov. 11, 2011, 5 pages. 9000038 425 "Exhibit A2--U.S. Appl. No. 12/581,699: Information Disclosure Statement Signed by Examiner Zohreh Fay", In the United States Patent and Trademark Office, ALZ01608191-8216, dated Sep. 26, 2012, 27 pages. 9000038 426 "Exhibit AA--U.S. Appl. No. 09/802,709: Reply Pursuant to 37 CFR .sctn.1.1116", In the United States Patent and Trademark Office, Doc. No. OSM(MET)017857-861, filed Oct. 15, 2003, 6 pages. 9000038 427 "Exhibit AAA--Defendants Osmotica Kereskedelmi Es Szolgaltato Kft's and Osmotica Pharmaceutical Corp.'s Preliminary Invalidity Contentions Under Paragraph 4( D) of the District of Delaware Default Standard for Discovery", In the United States District Court for the District of Delaware, C.A. No. 13-1104-RGA (Consolidated), filed 2014, 5 pages. 9000038 428 "Exhibit B--U.S. Patent No. 8,163,798 B2", In the United States Patent and Trademark Office, dated Apr. 24, 2012, 24 pages. 9000038 429 "Exhibit B1--Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Motion for Leave to File an Amended Answer", In the United States District Court for the District of Delaware, Case No. 10-23-LPS (1:10-cv-00023-LPS), Public Version, Doc. No. 107, filed May 19, 2011, 24 pages. 9000038 430 "Exhibit B2--Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Motion for Leave to File an Amended Answer", In the United States District Court for the District of Delaware, Case No. 10-23-LPS (1:10-cv-00023-LPS), Public Version, Doc. No. 107, filed May 19, 2011, 24 pages. 9000038 431 "Exhibit BB--U.S. Appl. No. 09/802,709: Reply Pursuant to 37 CFR .sctn. 1.111", In the United States Patent and Trademark Office, Doc. No. OSM(MET)01792-817, filed Jul. 14, 2004, 7 pages. 9000038 432 "Exhibit BBB--Opening Brief of Plaintiffs-Appellants Alza Corporation and McNeil-PPC, Inc.", In the United States Court of Appeals for the Federal Circuit, No. 2009-1350, filed Aug. 13, 2009, 6 pages. 9000038 433 "Exhibit C--U.S. Appl. No. 10/639,355: Reply Pursuant to 37 CFR .sctn. 1.114", In the United States Patent and Trademark Office, filed Oct. 15, 2009, 10 pages. 9000038 434 "Exhibit C1--Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Opening Brief in Support of Their Motion for Leave to File an Amended Answer", In the United States District Court for the District of Delaware, Case No. 10-23-LPS (1:10-cv-00023-LPS), Public Version, Doc. No. 108, filed May 19, 2011, 25 pages. 9000038 435 "Exhibit C2--Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Opening Brief in Support of Their Motion for Leave to File an Amended Answer", In the United States District Court for the District of Delaware, Case No. 10-23-LPS (1:10-cv-00023-LPS), Public Version, Doc. No. 108, filed May 19, 2011, 25 pages. 9000038 436 "Exhibit CC--U.S. Appl. No. 09/802,709: U.S. Patent No. 6,930,129 Claims", In the United States Patent and Trademark Office, Doc. No. ALZ00946924-30, filed Mar. 8, 2001, 8 pages. 9000038 437 "Exhibit CCC--Order Construing Claims", United States District Court, Northern District of California, No. 12-cv-04579 PJH, Doc. No. 157, filed Apr. 25, 2014, 31 pages. 9000038 438 "Exhibit D--U.S. Appl. No. 60/030,514", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01166388-449, filed Nov. 12, 1996, 63 pages. 9000038 439 "Exhibit D1--Declaration of Richard L. Horwitz, Esq. In Support of Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Motion For Leave To File An Amended Answer", In the United States District Court for the District of Delaware, Case No. 10-23-LPS (1:10-cv-00023-LPS), Public Version, Doc. No. 109, filed May 19, 2011, 5 pages. 9000038 440 "Exhibit D2--Declaration of Richard L. Horwitz, Esq. In Support of Defendants Kremers Urban, LLC and Kudco Ireland, Ltd.'s Motion For Leave o File An Amended Answer", In the United States District Court for the District of Delaware, Case No. 10-23-LPS (1:10-cv-00023-LPS), Public Version, Doc. No. 109, filed May 19, 2011, 5 pages. 9000038 441 "Exhibit DD--U.S. Appl. No. 10/638,977: Reply Pursuant to 37 CFR .sctn. 1.111", In the United States Patent and Trademark Office, filed Sep. 12, 2012, 11 pages. 9000038 442 "Exhibit E--Swanson et al., Effects of Stimulant Medication on Learning in Children with ADHD, Journal of Learning Disabilities, Apr. 1991, 24(4), 14 pages", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-4, filed Dec. 13, 2013, 14 pages. 9000038 443 "Exhibit E--U.S. Appl. No. 60/044,121", In the United Statement Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01166558-617, filed Apr. 22, 1997, 61 pages. 9000038 444 "Exhibit EE--U.S. Appl. No. 10/638,977: Reply Pursuant to 37 CFR .sctn. 1.111", In the United States Patent and Trademark Office, filed Jun. 27, 2013, 4 pages. 9000038 445 "Exhibit F--U.S. Appl. No. 60/031,741", In the United Statement Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01166473-530, filed Nov. 25, 1996, 59 pages. 9000038 446 "Exhibit FF--U.S. Patent No. 7,521,067 B1", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ00898306-313, dated Apr. 21, 2009, 9 pages. 9000038 447 "Exhibit G--U.S. Appl. No. 08/937,336", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01164628-675, filed Aug. 19, 1997, 49 pages. 9000038 448 "Exhibit GG--U.S. Appeal No. 2008-4075: Board Decision on Appeal", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ00785597-614, decided Sep. 24, 2008, 19 pages. 9000038 449 "Exhibit H--U.S. Appl. No. 09/070,666", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01165646-715, filed Apr. 30, 1998, 71 pages. 9000038 450 "Exhibit HH--Pre-Appeal Brief Request for Review", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01169809-812, filed Oct. 6, 2010, 5 pages. 9000038 451 "Exhibit I--U.S. Appl. No. 08/910,593", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01163888-979, filed Jul. 31, 1997, 93 pages. 9000038 452 Exhibit II--Proposed Constructions and Intrinsic Evidence for U.S. Patent Nos. 8,163,798 and 8,629,179, 2014, 8 pages. 9000038 453 "Exhibit J--U.S. Appl. No. 08/967,606", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01163078-140, filed Nov. 10, 1997, 64 pages. 9000038 454 "Exhibit JJ--U.S. Patent No. 8,629,179 B2", In the United States Patent and Trademark Office, dated Jan. 14, 2014, 25 pages. 9000038 455 "Exhibit K--U.S. Patent No. 4,327,725", In the United States Patent and Trademark Office, dated May 4, 1982, 14 pages. 9000038 456 "Exhibit KK--U.S. Appl. No. 12/581,699: Preliminary Amendment", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01605825-854, filed Apr. 26, 2010, 31 pages. 9000038 457 "Exhibit L--U.S. Patent No. 4,612,008", In the United States Patent and Trademark Office, dated Sep. 16, 1986, 22 pages. 9000038 458 "Exhibit LL--U.S. Appl. No. 12/581,699: Preliminary Amendment", In the United States Patent and Trademark Office, Doc. No. ALZ01605706-714, filed Oct. 19, 2009, 10 pages. 9000038 459 "Exhibit M--U.S. Patent No. 4,783,337", In the United States Patent and Trademark Office, dated Nov. 8, 1988, 28 pages. 9000038 460 "Exhibit MM--U.S. Appl. No. 12/581,699: Preliminary Amendment", In the United States Patent and Trademark Office, Doc. No. ALZ01605799-811, filed Oct. 19, 2009, 14 pages. 9000038 461 "Exhibit N--U.S. Patent No. 5,082,668", In the United States Patent and Trademark Office, dated Jan. 21, 1992, 29 pages. 9000038 462 "Exhibit NN--U.S. Appl. No. 12/581,699: Preliminary Amendment", In the United States Patent and Trademark Office, Doc. No. ALZ01606278-312, filed Jan. 21, 2011, 36 pages. 9000038 463 "Exhibit O--Preliminary Amendment", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ011669197-200, filed Aug. 12, 2003, 5 pages. 9000038 464 "Exhibit OO--U.S. Appl. No. 12/581,699: NonFinal Office Action", In the United States Patent and Trademark Office, Doc. No. ALZ01607858-866, dated Apr. 30, 2012, 10 pages. 9000038 465 "Exhibit P--U.S. Appl. No. 10/639,355: NonFinal Office Action", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01169405-408, dated Jan. 22, 2007, 5 pages. 9000038 466 "Exhibit PP--U.S. Appl. No. 12/581,699: Reply Pursuant to 37 CFR .sctn. 1.111", In the United States Patent and Trademark Office, Doc. No. ALZ01608146-181, filed Jul. 25, 2012, 37 pages. 9000038 467 "Exhibit Q--U.S. Appl. No. 10/639,355: Reply Pursuant to 37 CFR .sctn. 1.116", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. Nos. ALZ01169437, ALZ01169439-440, ALZ0116943-444, filed Mar. 25, 2008, 6 pages. 9000038 468 "Exhibit QQ--U.S. Appl. No. 12/581,699: Final Office Action", In the United States Patent and Trademark Office, Doc. No. ALZ01608183, dated Oct. 2, 2012, 9 pages. 9000038 469 "Exhibit R--U.S. Appl. No. 10/639,355: NonFinal Office Action", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01169450-554, dated Jun. 6, 2008, 6 pages. 9000038 470 "Exhibit RR--U.S. Appl. No. 12/581,699: Reply Pursuant to 37 CFR .sctn.1.114", In the United States Patent and Trademark Office, Doc. No. ALZ01608338-346, filed Jun. 6, 2013, 10 pages. 9000038 471 "Exhibit S--U.S. Appl. No. 10/639,355: Reply Pursuant to 37 CFR .sctn.1.111", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. Nos. ALZ01169516-519, ALZ01169529, filed Oct. 14, 2008, 6 pages. 9000038 472 "Exhibit SS--U.S. Appl. No. 12/581,699: Reply Pursuant to 37 CFR .sctn.1.114", In the United States Patent and Trademark Office, Doc. No. ALZ01608348-356, filed Jun. 7, 2013, 10 pages. 9000038 473 "Exhibit T--U.S. Appl. No. 10/639,355: Reply Pursuant to 37 CFR .sctn.1.111", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01169561-565, filed Mar. 20, 2009, 6 pages. 9000038 474 "Exhibit TT--U.S. Appl. No. 12/581,699: NonFinal Office Acton", In the United States Patent and Trademark Office, Doc. No. ALZ01608358-363, dated Jul. 3, 2013, 7 pages. 9000038 475 "Exhibit U--U.S. Appl. No. 10/639,355: Reply Pursuant to 37 CFR .sctn.1.114", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01169579-585, filed Oct. 15, 2009, 8 pages. 9000038 476 "Exhibit UU--Leong et al., Advanced Drug Delivery Reviews", Elsevier, 1988, 1(3), 37 pages. 9000038 477 "Exhibit V--U.S. Appl. No. 10/639,355: Reply Pursuant to 37 CFR .sctn.1.111", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. No. ALZ01169608-612, filed Jan. 7, 2010, 6 pages. 9000038 478 "Exhibit VV--Martin et al., Physical Pharmacy, Physical Chemical Principles in Pharmaceutical Sciences: Chapter 19--Drug Product Design", Lea and Febiger, 4th Edition, 1993, 10 pages. 9000038 479 "Exhibit W--U.S. Appl. No. 10/639,355: Reply Pursuant to 37 CFR .sctn.1.116", In the United States Patent and Trademark Office, Produced in Case No. 12-cv-04579, Doc. Nos. ALZ01169789-791, ALZ01169794-796, filed Jul. 29, 2010, 7 pages. 9000038 480 "Exhibit WW--Ranade et al., Drug Delivery Systems: Chapter 5, Oral Drug Delivery", CRC Press, 1995, 50 pages. 9000038 481 "Exhibit X--U.S. Patent No. 6,919,373 B1", In the United States Patent and Trademark Office, Doc. No. OSM(MET)015525-542, dated Jul. 19, 2005, 19 pages. 9000038 482 "Exhibit XX--Abdou, Remington's Pharmaceutical Sciences: Chapter 31--Dissolution", Mack Publishing Company, 18th Edition, 1990, 18 pages. 9000038 483 "Exhibit Y--U.S. Appl. No. 09/253,317: Reply Pursuant to 37 CFR .sctn.1.116", In the United States Patent and Trademark Office, Doc. Nos. OSM(MET)016709-711, OSM(MET)016737-739, filed Aug. 4, 2003, 7 pages. 9000038 484 "Exhibit YY--Longer et al., Remington's Pharmaceutical Sciences: Chapter 91--Sustained-Release Drug Delivery Systems", Mack Publishing Company, 18th Edition, 1990, 22 pages. 9000038 485 "Exhibit Z--U.S. Patent No. 6,930,129 B2", In the United States Patent and Trademark Office, Doc. No. OSM(MET)016849-865, dated Aug. 16, 2005, 18 pages. 9000038 486 "Exhibit ZZ--Final Report--Protocol C-94-007-01: Pilot Study to Determine-the Effects of Three Patterns of Methylphenidate Delivery on Attention and Behavior in Children with ADHD", Alza Corporation, Doc. No. ALZ00098901-9131, May 1995, 232 pages. 9000038 487 "Gualtieri et al., Clinical Correlates of Methylphenidate Blood Levels, Therapeutic Drug Monitoring, 1984, 6, 379-392", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-2, filed Dec. 13, 2013, 15 pages. 9000038 488 "Highly Confidential--Deposition of Carol a Christopher, Ph.D. taken on Behalf of Defendants", In the United States District Court for the District of Delaware, Case No. 10-23-LPS (1:10-cv-00023-LPS), ALZ01177314-7457, Mar. 7, 2011, 144 pages. 9000038 489 "Highly Confidential--Under Protechtive Order--Deposition of Andrew C. Lam on Behalf of Defendants", In the United States District Court for the District of Delaware, Case No. 1:05-cv-00642-JJF, ALZ00932488-2542, dated Sep. 20, 2006, 55 pages. 9000038 490 "Memorandum and Order Granting Plaintiff's Motion to Dismiss the InEquitable Conduct Counterclaims", In the United States District Court for the District of Delaware, Case No. 1:13-1104-RGA (Consolidated), Doc. No. 139, filed May 27, 2014, 3 pages. 9000038 491 "Minutes Sep. 20, 1993-Sep. 22, 1993 Multimodal Treatment Study of Children with Adhd (MTA) Steering Committee, Twelfth Meeting", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-8, dated Dec. 13, 2013, 37 pages. 9000038 492 "Modi et al., Dose-Proportional and Stereospecific Pharmacokinetics of Methylphenidate Delivered Using an Osmotic, Controlled-Release Oral Delivery System, Journal of Clinical Pharmacology, 2000, 40, 1141-1149", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 115-2, dated Dec. 13, 2013, 10 pages. 9000038 493 "Modi et al., Single- and Multiple-Dose Pharmacokinetics of an Oral Once-a-Day Osmotic Controlled-Release Oros.RTM. (methylphenidate HCI) Formulation, Journal of Clinical Pharmacology, 2000, 40, 379-388", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 115-7, dated Dec. 13, 2013, 10 pages. 9000038 494 "Patrick et al., the Absorption of Sustained-Release Methylphenidate Formulations Formulation Compared to an Immediate-Release, Biopharmaceutics and Drug Disposition, 1989, 10, 165-171", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-1, dated Dec. 13, 2013, 7 pages. 9000038 495 "Physicians' Desk Reference, PDR", Medical Economics Data Production Co., 49th Edition, 1995, 15 pages. 9000038 496 "Physicians' Desk Reference, PDR", Medical Economics Data Production Co., 1996, 2 pages. 9000038 497 "Plaintiff Swanson's Complaint for Correction of Inventorship, Fraud, Breach of Fiduciary Duty, Unjust Enrichment, Invalidity, and Declaration of Unenforceability for Inequitable Conduct in Patent Procurement", In the United States District Court for the Northern District of California, San Fransico Division, Case No. 12-cv-04579, Doc. No. 1, E-Filing, filed Aug. 30, 2012, 15 pages. 9000038 498 "Plaintiff Swanson's First Amended Complaint for Correction of Inventorship, Fraud, Breach of Fiduciary Duty, Fraudulent Concealment, Unfair Competition, Unjust Enrichment, Invalidity, Declaration of Unenforceability for Inequitable Conduct in Patent Procurement, Declaration of Ownership and Constructive Trust", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 31, filed Nov. 14, 2012, 54 pages. 9000038 499 "Plaintiff Swanson's Inventorship Contentions", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 115-8, filed Dec. 13, 2013, 272 pages. 9000038 500 "Plaintiff Swanson's Inventorship Contentions", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 115-9, filed Dec. 13, 2013, 56 pages. 9000038 501 "Plaintiff Swanson's Inventorship Contentions", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 115-10, filed Dec. 13, 2013, 96 pages. 9000038 502 "Plaintiffs' Reply Brief in Support of Motion to Strike Defenses and Dismiss Counterclaims Alleging Inequitable Conduct", In the United States District Court for the District of Delaware, C.A. No. 13-1104-RGA (Consolidated), filed May 8, 2014, 10 pages. 9000038 503 "Plaintiffs' Motion to Strike Defenses and Dismiss Counterclaims Alleging Inequitable Conduct", In the United States District Court for the District of Delaware, C.A. No. 13-1104-RGA (Consolidated), filed Apr. 11, 2014, 4 pages. 9000038 504 "Plaintiffs' Opening Brief in Support of Motion to Strike Defenses and Dismiss Counterclaims Alleging Inequitable Conduct", In the United States District Court for the District of Delaware, C.A. No. 13-1104-RGA (Consolidated), filed Apr. 11, 2014, 18 pages. 9000038 505 "PX3--Certified Copy of U.S. Appl. No. 60/030,514", In the United States Patent and Trademark Office, dated Sep. 18, 2007, 84 pages. 9000038 506 "PX4--Certified Copy of U.S. Appl. No. 60/031,741", In the United States Patent and Trademark Office, dated Sep. 18, 2007, 82 pages. 9000038 507 "PX5--Certified Copy of U.S. Appl. No. 60/044,121", In the United States Patent and Trademark Office, dated Sep. 15, 2007, 83 pages. 9000038 508 "PX6--Certified Copy of U.S. Appl. No. 08/910,593", In the United States Patent and Trademark Office, dated Sep. 18, 2007, 745 pages. 9000038 509 "PX9--Certified Copy of U.S. Patent Application No. 09/070,666", In the United States Patent and Trademark Office, dated Oct. 5, 2007, 782 pages. 9000038 510 "Redacted Plaintiffs' Responses and Objections to Defendant Par Pharmaceutical, Inc.'s and Defendant Osmotica Kereskedelmi Es Szolgaltato Kft's First Set of Joint Rule 33 Interrogatories (Nos. 1-10)", In The United States District Court for the District of Delaware, C.A. No. 13-1104-RGA (Consolidated), filed Dec. 2, 2013, 25 pages. 9000038 511 "Redacted Public Version Jury Demanded--Defendants Osmotica Kereskedelmi Es Szolgaltato Kft's and Osmotica Pharmaceutical Corp.'s Answer, Defenses, and Counterclaims to Plaintiffs' Complaint", In the United States District Court for the District of Delaware, Case No. 1:13-cv-01126 (RGA), Doc. No. 22, filed Sep. 16, 2013, 92 pages. 9000038 512 "Ritalin (Methylphenidate Hydrochloride", FDA Drugs Approvals and Database, 2014, 5 pages. 9000038 513 "Ritalin Hydrochloride Methylphenidate Hydrochloride Tablets USP and Ritalin-SR Methylphenidate Hydrochloride USP Sustained-Release Tablets", Novartis, T2007-23, Apr. 2007, 41 pages. 9000038 514 "Ritalin LA (Methylphenidate Hydrochloride) Extended-Release Capsules", Novartis, 2012, 22 pages. 9000038 515 "Ritalin-SR", FDA Drugs Approvals and Database, 2014, 2 pages. 9000038 516 "Seeman, Pharmacokinetics, 1 page", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-10, dated Dec. 13, 2013, 1 page. 9000038 517 "Sprague, Methylphenidate in Hyperkinetic Children: Differences in Dose Effects on Learning and Social Behavior, Science, 1977, 198, 1274-1276", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-13, dated Dec. 13, 2013, 3 pages. 9000038 518 "Swanson et al., Blood Levels and Tolerance to Stimulants in ADDH Children, Clinical Neuropharmacology, 1986, 9(Suppl-4), S-215, 523-525", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-5, filed Dec. 13, 2013, 3 pages. 9000038 519 "Swanson et al., Effects of Stimulant Medication on Learning in Children with ADHD, Journal of Learning Disabilities, Apr. 1991, 24(4), 14 pp.", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-4, filed Dec. 13, 2013, 14 pages. 9000038 520 "Swanson et al., Intervention Strategies with Hyperactive Children: Task Specificity of Responses to Stimulant Drugs in Laboratory Tests", Gittleman (Ed.), Int'l Journal of Mental.Health, 1979, 8(1), 18 pages, In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 115, filed Dec. 13, 2013, 18 pages. 9000038 521 "Swanson et al., Serum Levels of Nethylphenidate in Hyper.active Children: 1. Half-life Following Oral Administration", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-12, filed Dec. 13, 2013, 21 pages. 9000038 522 "Swanson, Effects of Stimulant Medication on Children with Attention Deficit Hyperactive Disorder: A Review of Reviews, Council for Exceptional Children, Oct. 1, 1993, 60(2), 9 pages", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-7, filed Dec. 13, 2013, 9 pages. 9000038 523 "Swanson, Measurement of Serum Concentrations and Behavioral Response in ADDH Children to Acute Doses of Methylphenidate, 1988, 21 pages", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-3, filed Dec. 13, 2013, 21 pages. 9000038 524 "Swanson, More Frequent Diagnosis of Attention Deficit-Hyperactivity Disorder, The New England Journal of Medicine, Oct. 5, 1995, 333(14), 1 page", In the United States District Court for the Northern District of California, Oakland Division, Case No. 4:12-cv-04579-PJH, Doc. No. 114-6, filed Dec. 13, 2013, 1 page. 9000038 525 Brown et al., "Attention Deficit Hyperactivity Disorder", Produced in 12-CV-04579, ALZ00016282-293, CNS Drugs, 1994, 1(2), 70-81. 9000038 526 Brown, "The Use of Methylphenidate for Cognitive Decline Associated with HIV Disease", Int'l J. Psychiatry in Medicine, 1995, 25(1), 21-37. 9000038 527 Chisum, "Chisum on Patents: A Treatise on the Law of Patentability, Validity and Infringement, vol. 1, Originality-Inventorship .sctn.2.03", Matthew Bender and Company, Inc., 2013, 36 pages. 9000038 528 Diener, "Ritalin Theory and Patient Management: Toxicology of Ritalin", Produced in 12-CV-04579, ALZ01109117-9118, Greenhill et al. (Eds.), Mary Ann Liebert, Inc., 1991, 11 pages. 9000038 529 Dulcan, "Using Psychostimulants to Treat Behavioral Disorders of Children and Adolescents", Produced in 12-CV-04579, PALZ007750-7763, Journal of Child and Adolescent Psychopharmacology, 1(1), 1990, 7-20. 9000038 530 Endicott et al., "Quality of Life Enjoyment and Satisfaction Questionnaire: A New Measure", Produced in 12-CV-04579, ALZ00015604-5609, Psychopharmacology Bulletin, 1993, 29(2), 321-326. 9000038 531 Fung, "Pharmacokinetic Determinants of Nitrate Action", The American Journal of Medicine, Proceedings of a Symposium, 2nd North American Conference on Nitroglycering Therapy, Perspectives and Mechanisms, DTX288, Jun. 22, 1984, 76(6A), 6 pages. 9000038 532 Gill et al., "Immediate Communication: Confirmation of Association Between Attention Deficit Hyperactivity Disorder and a Dopamme Transporter Polymorphism", Produced in 12-CV-04579, ALZ00015657-5659, Molecular Psychiatry, 1997, 2, 311-313. 9000038 533 Greenhill, "Child and Adolescent Psychiatric Clinics of North America: Attention-Deficit Hyperactivity Disorders, the Stimulants", Produced in 12-CV-04579, ALZ00014659-4705, W.B. Saunders Co., Jan. 1995 , 4(1), 47 pages. 9000038 534 Greenhill, "Strategic Interventions for Hyperactive Children: Stimulant-Related Growth Inhibition in Children: A Review", Gittelman (Ed.), M.E. Sharpe, Inc., 1979 and 1981, 27 pages. 9000038 535 Holmes et al., "Psychostimulant Response in AIDS.cndot.Related Complex Patients", J. Clin. Psychiatry, 1989, 50, 5-8. 9000038 536 Letter from Ashby and Geddes, "Redacted Plaintiffs' Responsive Discovery Dispute Letter", Feb. 14, 2014, 5 pages. 9000038 537 Letter from Mylan Pharmaceuticals, "Notification of Paragraph IV Certification Regarding U.S. Patent Nos. 6,919,373, 6,930,129, 8,163, 798, and 8,629,179 Pursuant to Section 505 G)(2)(B)(i)-(ii) of the Federal Food, Drug, and Cosmetic Act", Apr. 1, 2014, 122 pages. 9000038 538 Letter from Osmotica, "Methylphenidate Hydrochloride Extended Release Tablets, 54 mg: Notification of Certification of Invalidity, Unenforceability and/or Noninfringement for U.S. Patent No. 8,629,179 Pursuant to .sctn. 505U)(2)(B)(iv) of the Federal Food, Drug, and Cosmetic Act", Jan. 14, 2014, 84 pages. 9000038 539 Letter from Osmotica, "Methylphenidate Hydrochloride Extended Release Tablets, 54 mg: Notification of Certification of Invalidity, Unenforceability and/or Noninfringement for U.S. Patent Nos. 6,919,373 B1, 6,930,129 B2, and 8,163,798 B2 Pursuant to .sctn. 505G)(2)(B)(iv) of the Federal Food, Drug, and Cosmetic Act", May 17, 2013, 30 pages. 9000038 540 Letter from Osmotica, "Methylphenidate Hydrochloride Extended-Release Tablets, 18 mg, 27mg and 36 mg: Notification of Certification of Invalidity, Unenforceability and/or Noninfringement for U.S. Patent Nos. 6,919,373, 6,930,129, 8,163,798, and 8,629,179 Pursuant to .sctn. SOS(j)(2)(B)(iv) of the Federal Food, Drug, and Cosmetic Act", Apr. 29, 2014, 83 pages. 9000038 541 Letter from Par Pharmaceuticals, "Methylphenidate Hydrochloride Extended Release Tablets for Oral Administration (18 mg, 27 mg, 36 mg, and 54 mg) U.S. Patent No. 8,629,179, Notice of Paragraph IV Certification", Feb. 25, 2014, 21 pages. 9000038 542 Letter from Par Pharmaceuticals, "Methylphenidate Hydrochloride Extended Release Tablets for Oral Administration (18 mg, 27 mg, 36 mg, and 54 mg) U.S. Patent Nos. 6,919,373, 6,930,129, and 8,163,798, Notice of Paragraph IV Certification", May 6, 2013, 38 pages. 9000038 543 Letter from Sandoz, "Notice of Certification Under 21 U.S.C. .sctn. 355(j)(2)(B) (.sctn. 505(j)(2)(B)) of Federal Food, Drug and Cosmetic Act) and 21 C.F.R. .sctn. 314.95 Sandoz Inc.'s Methylphenidate HCI, Tablet, Extended Release 54 mg, Sandoz Inc.'s ANDA 205714", May 5, 2014, 39 pages. 9000038 544 Letter from Sun Pharmaceuticals, "Notification Pursuant to the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(2)(B)(ii) and 21 C.F.R. .sctn. 314.95): ANDA No. 205135 and Concerta Methylphenidate Hydrochloride Extended Release Tablet", Mar. 19, 2014, 36 pages. 9000038 545 Longer et al., "Remington's Pharmaceutical Sciences: Chapter 91--Sustained-Release Drug Delivery Systems", Mack Publishing Company, 1990, 18th Edition, 20 pages. 9000038 546 Parran et al., "Intravenous Methylphenidate Abuse: Prototype for Prescription Drug Abuse", Produced in 12-CV-04579, ALZ00016062-6064, Arch Intern Med., 1991, 151, 781-783. 9000038 547 Pere!, et al., "Correlates of Pharmacokinetics and Attentional Measures in Methylphenidate Treated Hyperactive Children", Produced in 12-CV-04579, ALZ00004759, Clinical Pharmacology and Therapeutics, 1991, 1 page. 9000038 548 Rapport et al., "Attention Deficit Hyperactivity Disorder and Methylphenidate: The Relationship Between Gross Body Weight and Drug Response in Children", Psychopharmacology Bulletin, National Institute of Mental Health, Special Feature: NCDEU Poster Summaries, 1989, 25(2), 8 pages. 9000038 549 Safer et al., "Absence of Tolerance to the Behavioral Effects of Methyiphenidate in Hyperactive and Inattentive Children", Pediatric Pharmacology and Therapeutics, Dec. 1989, 1003-1008. 9000038 550 Sannerud et al., "Ritalin Theory and Practice: Is Ritalin an Abused Drug? Does it Meet the Criteria of a Schedule II Substance?", Produced in 12-CV-04579, ALZ00005140-5157, 2nd Edition, Greenhill et al. (Eds.), Mary Ann Liebert, Inc., 2000, 27 pages. 9000038 551 Solanto, "Neuropsychopharmacological Mechanisms of Stimulant Drug Action in Attention-Deficit Hyperactivity Disorder: A Review and Integration", Produced in 12-CV-04579, ALZ00005326-5351, Behavioural Brain Research, 1998, 94, 127-152. 9000038 552 Soldin et al., "A Liquid-Chromatographic Analysis for Ritalinic Acid [a-Phenyl-a(2-piperidyl) Acetic Acid] in Serum", Clinical Chemistry, 1979, 25(1), 5 pages. 9000038 553 Soldin et al., "Liquid-Chromatographic Analysis for Methylphenidate (Ritalin) in Serum", Clinical Chemistry, 1979, 25(3), 5 pages. 9000038 554 Spencer et al,. "A Double-blind, Crossover Comparison of Methylphenidate and Placebo in Adults with Childhood-Onset Attention-Deficit Hyperactivtty Disorder", Produced in 12-CV-04579, ALZ00015727-5736, Arch Gen Psychiatry, 1995, 52, 434-443. 9000038 555 Stevenson et al., "Stimulant Medication Therapy in the Treatment of Children with Attention Deficit Hyperactivity Disorder", Produced in 12-CV-04579, ALZ000162772-2786, Clinical Pharmacology, Pediatric Clinics of North America, Oct. 1989, 35(5), 1183-1197. 9000038 556 Swanson et al., "A Comparison of Once-Daily Extended-Release Methylphemdate Formulations in Children With Attention-Deficit/Hyperactivity Disorder in the Laboratory School (The Comacs Study)", Produced in Case No. 12-cv-04579, Doc. Nos. ALZ00004843-4853, Pediatrics, Mar. 2004, 113(3), 11 pages. 9000038 557 Swanson et al., "Pharmacokinetic and Pharmacodynamic Properties of Stimulants: Implications for the Design of New Treatments for ADHD", Produced in Case No. 12-cv-04579, Doc. Nos. ALZ00004837-4842, Behavioural Brain Research, 2002, 130, 73-78. 9000038 558 Swanson et al., "Should You Use Stimulants to Treat the Hyperactive Child?", Modern Medicine, Apr. 15, 1978, 11 pages. 9000038 559 Swanson et al., "Time-Response Analysis of the Effect of Stimulant Medication on the Learning Ability of Children Referred for Hyperactivity", Pediatrics, Jan. 1978, 61(1), 9 pages. 9000038 560 Swanson, "Stimulant-Related State-Dependent Learning in Hyperactive Children", American Association for the Advancement of Science, Jun. 1976, 192(4246), 5 pages. 9000038 561 Teicher et al., "Locomotor Activity in Depressed Children and Adolescents: I. Circadian Dysregulation", Journal of the American Academy Child and Adolescent Psychiatry, Jul. 1993, 32(4), 11 pages. 9000038 562 Theeuwes et al., "Systems for Triggered, Pulsed, and Programmed Drug Delivery", 1991, 14 pages. 9000038 563 Theeuwes, "Novel Drug Delivery and its Therapeutic Application: Chapter 30. Triggered, Pulsed and Programmed Drug Delivery", Prescott et al. (Eds.), John Wiley and Sons, 1989, 20 pages. 9000038 564 Voeller, "Clinical Management of Attention Deficit Hyperactivity Disorder", Journal of Child Neurology, 1991, 6, 18 pages. 9000038 565 Volkow et al., "Dopamine Transporter Occupancies in the Human Brain Induced by Therapeutic Doses of Oral Methylphenidate", Produced in Case No. 12-cv-04579, Doc. Nos. ALZ00004887-4893, Am J Psychiatry, 1998, 155, 1325-1331. 9000038 566 Volkow et al., "Is Methylphenidate Like Cocaine? Studies on Their Phannacokinetics and Distribution in the Human Brain", Produced in Case No. 12-cv-04579, Doc. Nos. ALZ00005352-5359, Arch Gen Psychiatry, 1995, 52, 456-463. 9000038 567 Volkow et al., "Temporal Relationships Between the Pharmacoklrletics of Methylphenidate in the Human Brain and its Behavioral and Cardiovascular Effects", Produced in Case No. 12-cv-04579, Doc. Nos. ALZ00004894-4901, Psychopharmacology, 1996, 123, 26-33. 9000038 568 Volkow et al., "Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD", Produced in 12-CV-04579, ALZ00004877-4886, Am J. Psychiatry, 2003, 160, 1909-1918. 9000038 569 Wigal et al., "Reliability and Validity of the SKAMP at ng Scale in a Laboratory School Setting", Produced in Case No. 12-cv-04579, Doc. Nos. ALZ00004902-4908, Psychopharmacology Bulletin, 1998, 34(1), 47-53. 9000038 570 Wigal et al., "Reliability and Validity of the SKAMP at ng Scale in a Laboratory School Setting", Produced in Case No. 12-cv-04579, Doc. Nos. ALZ00021227-33, Psychopharmacology Bulletin, 1998, 34(1), 47-53. 9000038 571 William T. Graham et al. v. John Deere Co. of Kansas City v. Cook Chemical and Colgate-Palmolive Co., et al., Nos. 11, 37, 43, 86 S.Ct. 684, 383 U.S. 101, 1966, 684-707. 9000039 1 Harbige et al. CAS: 145: 306838, 2006. 9000039 2 Shin et al. CAS: 148: 529469, 2008. 9000039 3 Fortin's CAS: 152: 1819, 2009. 9000039 4 Haneda et al. CAS: 153:97755, 2010. 9000039 5 Li et al. CAS: 155:143114, 2010. 9000039 6 Banno et al. "Lymphatic Absorption of Docosahexaenoic Acid Given as Monoglyceride, Diglyceride, Triglyceride, and Ethyl Ester in Rats" J Nutr Sci Vitaminol, vol. 48, 2002, pp. 30-35, XP002395871. 9000039 7 Chang et al. "Monoglycerides from the brown alga Sargassum sagamianum: Isolation, synthesis, and biological activity" Bioorganic & Medicinal Chemistry Letters, vol. 18, 2008, pp. 3589-3592, XP002649776. 9000040 1 Jonasson, Lena et al., Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury, Proc. Natl. Acad. Sci. vol. 85, pp. 2303-2306, 1988. 9000040 2 Guler, O. Kemal et al., Some Empirical equations for oxypolymerization of linseed oil, Progress in Organic Coatings, 51 (2004) 365-371. 9000040 3 Edible Oils. (http://www.chempro.in/fattyacid.htm) accessed Apr. 14, 2014. 9000040 4 International Preliminary Report on Patentability for Application No. PCT/US08/85386, dated Feb. 4, 2009. 9000040 5 International Search Report for Application No. PCT/US09/37364, dated Aug. 27, 2009. 9000040 6 Li, Shengqiao, A paper entitled, "Evaluation of the Biocompatibility and Drug Delivery Capabilities of Biological Oil Based Stent Coatings," by Li, Shengqiao of the Katholieke Universiteit Leuven. 9000040 7 Ogunniyi, D.S., "Castor oil: A vital industrial raw material," Bioresource Technology, vol. 97:1086-1091 (2006). 9000040 8 Redman, L.V. et al., "The Drying Rates of Raw Paint Oil--A Comparison," The Journal of Industrial and Engineering Chemistry, vol. 5(8):630-636 (1913). 9000040 9 Binder et al., "Chromatographic Analysis of Seed Oils. Fatty Acid Composition of Castor Oil," The Journal of the American Oil Chemists' Society, vol. 39:513-517 (1962). 9000040 10 CECW-EE, "Ch. 4: Coating Types and Characteristics," Engineering and Design--Painting: New Construction and Maintenance, pp. 4-1 to 4-24 (1995). 9000040 11 Wikipedia, "Sirolimus," pp. 1-13, available online at http://en.wikipedia.org/wiki/Sirolimus, date accessed May 11, 2011. 9000040 12 Salu, et al. "Addition of Cytochalasin D to a Biocompatible Oil Stent Coating Inhibits Intimal Hyperplasia in a Porcine Coronary Model" Coronary Artery Disease, Current Science 14(8):545-555 (2003). 9000040 13 Supplementary European Search Report for Application No. EP 08877338.7, dated Aug. 16, 2012. 9000040 14 Supplementary European Search Report for Application No. EP09819594.4, dated Aug. 14, 2012. 9000040 15 Non-final Office Action for U.S. Appl. No. 11/525,390 (listed on SB/08 as US 2007/0071798), mailed Jul. 11, 2011. 9000040 16 Notice of Allowance for U.S. Appl. No. 12/182,261 (listed on SB/08 as US US-2009-0047414), mailed Jul. 23, 2012. 9000040 17 Advisory Action for U.S. Appl. No. 12/401,243 (listed on SB/08 as US 2010-0233232), mailed Aug. 27, 2012. 9000040 18 Final Office Action for U.S. Appl. No. 12/581,582 (listed on SB-08 as US 2010/01836972), mailed Aug. 29, 2012. 9000040 19 Ackman, R.G., "Fish Oils", Bailey's Industrial Oil and Fat Products, 6th Edition, 279-317 (2005). 9000040 20 Andes, et al. "Antiproliferative Strategies for the Treatment of Vascular Proliferative Disease", Current Vascular Pharmacology, 1)1): 85-98 (2003). 9000040 21 Jorge, N., "Grasas y Aceites", 48(1): 17-24, (1997). 9000040 22 Lipids, Chapter 19, pp. 1-12 (2002). 9000040 23 Polymerization Merriam-Webster Online Dictionary, retrieved from on Dec. 13, 2009; Merriam-Webster's Inc. 2009; pp. 1. 9000040 24 Winter, et al., "Physical and Chemical Gelation" Encyclopedia of Materials--Science and Technology, vols. 1-11: 6691-6999 (2001). 9000040 25 International Search Report for PCT/US2011/44292, dated Dec. 6, 2011. 9000040 26 Supplementary European Search Report for Application No. EP 12004057, dated Apr. 10, 2013. 9000040 27 International Search Report for International Application PCT/US2013/044653, dated Sep. 4, 2013. 9000040 28 Notice of Allowance for U.S. Appl. No. 11/525,390 (listed on SB/08 as US-2007/0071798), mailed Oct. 4, 2012. 9000040 29 Advisory Action for U.S. Appl. No. 12/581,582 (listed on SB-08 as U.S. Publication No. 2010-0183697), dated Nov. 14, 2012. 9000040 30 Notice of Allowance for U.S. Appl. No. 11/525,390 (listed on SB-08 as U.S. Publication No. US-2007-0071798), dated Nov. 20, 2012. 9000040 31 Notice of Allowance for U.S. Appl. No. 11/525,390 (listed on SB-08 as US-2007/0071798), mailed Nov. 30, 2012. 9000040 32 Non-Final Office Action for U.S. Appl. No. 13/404,487 (listed on SB-08 as US 2012-0213839), dated Dec. 20, 2012. 9000040 33 Non-Final Office Action for U.S. Appl. No. 13/184,512 (listed on SB-08 as 2012-0016038), dated Jan. 31, 2013. 9000040 34 Non-Final Office Action for U.S. Appl. No. 11/978,840 (listed on SB-08 as U.S. No. US-2008-0118550), dated Feb. 19, 2013. 9000040 35 Non-Final Office Action for U.S. Appl. No. 13/682,991 (listed on SB-08 as U.S. Publication No. US- 2013-0074452), dated Mar. 18, 2013. 9000040 36 Notice of Allowance for U.S. Appl. No. 13/404,487 (listed on SB-08 as U.S. Publication No. US- 2012-0213839), dated Apr. 2, 2013. 9000040 37 Non-Final Office Action for U.S. Appl. No. 11/236,943 (listed on SB-08 as U.S. Publication No. US- 2006-0067975), dated Apr. 22, 2013. 9000040 38 Final Office Action for U.S. Appl. No. 13/184,512 (listed on SB-08 as U.S. Publication No. U.S. 2012-0016038), date Jun. 25, 2013. 9000040 39 Non-Final Office Action for U.S. Appl. No. 11/237,264 (listed on SB-08 as U.S. Publication No. US-2006-0067983), dated Jul. 3, 2013. 9000040 40 Non-Final Office Action for U.S. Appl. No. 13/593,656 (listed on SB-08 as U.S. Publication No. US-2012-03115219), dated Jul. 15, 2013. 9000040 41 Notice of Allowance for U.S. Appl. No. 13/682,991 (listed on SB-08 as U.S. Publication No. US 2013-0074452), dated Aug. 1, 2013. 9000040 42 Notice of Allowance for U.S. Appl. No. 11/978,840 (listed on SB-08 as U.S. Publication No. US-2008-0118550), dated Aug. 6, 2013. 9000040 43 Mallegol, "Long-Term Behavior of Oil-Based Varnishes and Paints Photo-and Thermooxidation of Cured Linseed Oil", Journal of the American Oil Chemists' Society, 77:257-263 (2000). 9000040 44 Non-Final Office Action for U.S. Appl. No. 11/237,420 (listed on SB-08 as U.S. Publication No. US-2006-0078586), dated Nov. 12, 2013. 9000040 45 Non-Final Office Action for U.S. Appl. No. 12/075,223 (listed on SB-08 as U.S. Publication No. US-2008-0206305), dated Nov. 12, 2013. 9000040 46 Non-Final Office Action for U.S. Appl. No. 11/980,155 (listed on SB-08 as U.S. Publication No. US-2008-0113001, dated Nov. 12, 2013. 9000040 47 "cure" in Academic Press Dictionary of Science and Technology (1992). 9000040 48 "polymerization" Merriam-Webster Online Dictionary, retrieved from on Dec. 13, 2009; Merriam-Webster's Inc. 2009; pp. 1. 9000040 49 Ahuja et al. "Prevention of Postoperative Intraperitoneal Adhesions--An Experimental Study in Rats", Journal of Indian Pediatric Surgery 2002 7:15-20. 9000040 50 Autosuture, "ParietexTM Composite OS Series Mesh," retrieved online at http://www.autosuture.com/AutoSuture/pagebuilder.aspx?topicID=135734& breadcrumbs=135601:0 (2007). 9000040 51 Camurus, "In our endeavors to create the unique, we start with the best. Your product." 9000040 52 De Scheerder, Ivan K. et al. "Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries," Atherosclerosis, vol. 114:105-114. 9000040 53 Drummond, Calum J. et al., "Surfactant self-assembly objects as novel drug delivery vehicles," Current Opinion in Colliod & Interface Science, vol. 4:449-456 (2000). 9000040 54 Engstrom, Sven, "Drug Delivery from Cubic and Other Lipid-water Phases," Lipid Technology, vol. 2(2):42-45 (1990). 9000040 55 Hwang, Chao-Wei et al, "Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery," Circulation, vol. 104:600-605 2001 . 9000040 56 Mallegol et al., "Drier Influence on the Curing of Linseed Oil," Progress in Organic Coatings 39:107-113 (2000). 9000040 57 Morse, Richard "Molecular Distillation of Polymerized Drying Oils," Industrial and Engineering Chemisry 33:1039-1043 (1941). 9000040 58 Oberhoff, Martin et al, "Local and Systemic Delivery of Low Molecular Weight Heparin Following PTCA: Acute Results and 6-Month Follow-Up of the Initial Clinical Experience With the Porous Balloon (PILOT-Study)," Catheterization and Cardiovascular Diagnosis, vol. 44:267-274 (1998). 9000040 59 Rutkow, Ira M. et al., "`Tension-free` inguinal herniorrhaphy: A preliminary report on the `mesh plug` technique," Surgery, vol. 114:3-8 (1993). 9000040 60 Salu, Koen J. et al, "Addition of cytochalasin D to a biocompatible oil stent coating inhibits intimal hyperplasia in a porcine coronary model," Coronary Artery Disease, vol. 14(8):545-555 (2003). 9000040 61 Scheller, Bruno et al, "Addition of Paclitaxel to Contrast Media Prevents Restenosis After Coronary Stent Implantation," Journal of the American College of Cardiology, vol. 42(8):1415-1420 (2003). 9000040 62 Shahidi, Fereidoon ed.; "Bailey's Industrial Oil and Fats Products" 2005; John Wiley and Sons; vol. 5, Edible Oil and Fat Products: Processing Technologies, pp. 1-15. 9000040 63 Van der Giessen, Willem J. et al, "Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries," Circulation, vol. 94:1690-1697 (1996). 9000040 64 Websters Dictionary Online, Accessed on Feb. 13, 2009, entry for "polymer" p. 1 of 1. 9000040 65 Final Office Action for U.S. Appl. No. 11/236,943 (listed on SB-08 as U.S. Publication No. US-2006-0067975), dated Dec. 4, 2013. 9000040 66 Final Office Action for U.S. Appl. No. 11/237,264 (listed on SB-08 as U.S. Publication No. US-2006-0067983), dated Dec. 17, 2013. 9000040 67 Notice of Allowance for U.S. Appl. No. 13/593,656 (listed on SB-08 as U.S. Publication 2012-03115219), dated Jan. 24, 2014. 9000040 68 Timar Balizsy et al., "Chemical Principals of Textile Conservation," Oxford: Elsevier Science Ltd., 117-119 (1998). 9000040 69 Crivello et al., "Epoxidized triglycerides as renewable monomers in photoinitiated cationic polymerization," Chem. Mater, 1992:692-699. 9000040 70 Encylopedia Britannica Online, "Surface Coating," available online at http://www.britannica.com/EBchecked/topic/575029/surface-coating>, date accessed Jun. 17, 2011. 9000040 71 Supplementary European Search Report for Application No. EP 05 80 2894, dated Jul. 27, 2011. 9000040 72 Supplementary European Search Report in Application No. 05 800 844, dated Aug. 19, 2011. 9000040 73 Supplementary European Search Report in Application No. EP 05 80 4291, dated Jul. 26, 2011. 9000040 74 Supplementary European Search Report in Application No. EP 05 85 8430, dated Aug. 18, 2011. 9000040 75 Final Office Action for U.S. Appl. No. 11/980,155 (listed on SB/08 as US-2008-0113001), mailed Oct. 21, 2011. 9000040 76 Final Office Action for U.S. Appl. No. 11/237,420 (listed on SB/08 as US 2006/0078586), mailed Jul. 13, 2011. 9000040 77 Final Office Action for U.S. Appl. No. 12/182,165 (listed on SB/08 as US 2009-0011116), mailed Apr. 6, 2012. 9000040 78 Final Office Action for U.S. Appl. No. 12/182,261 (listed on SB/08 as US-2009-0047414), mailed Apr. 30, 2012. 9000040 79 Final Office Action for U.S. Appl. No. 12/401,243 (listed on SB/08 as US- 2010- 0233232), mailed Jun. 11, 2012. 9000040 80 Final Office Action for U.S. Appl. No. 11/701,799 (listed on SB/08 as US 2008/0109017), mailed Nov. 23, 2010. 9000040 81 Final Office Action for U.S. Appl. No. 11/978,840 (listed on SB/08 as US 2008/0118550), mailed Jun. 22, 2011. 9000040 82 Final Office Action for U.S. Appl. No. 12/075,223 (listed on SB/08 as US 2008/0206305), mailed Aug. 11, 2011. 9000040 83 Final Office Action for U.S. Appl. No. 11/701,799 (listed on SB/08 as US 2008/0109017), mailed Feb. 13, 2012. 9000040 84 Non-Final Office Action for U.S. Appl. No. 12/182,261 (listed on SB/08 as US 2009-0047414), mailed Dec. 21, 2011. 9000040 85 Non-Final Office Action for U.S. Appl. No. 11/236,908 (listed on SB/08 as US-2006-0067974), mailed Dec. 2, 2011. 9000040 86 Non-Final Office Action for U.S. Appl. No. 11/582,135 (listed on SB/08 as US-2007-0202149), mailed Oct. 14, 2011. 9000040 87 Non-Final Office Action for U.S. Appl. No. 12/182,165 (listed on SB/08 as US 2009-0011116), mailed Jan. 5, 2012. 9000040 88 Non-Final Office Action for U.S. Appl. No. 12/401,243 (listed on SB/08 as US 2010-0233232), mailed Jan. 5, 2012. 9000040 89 Non-Final Office Action for U.S. Appl. No. 11/701,799 (listed on SB/08 as US 2008/0109017), mailed Aug. 17, 2011. 9000040 90 Non-Final Office Action for U.S. Appl. No. 12/581,582 (listed on SB/08 as US 2010-0183697), mailed Mar. 14, 2012. 9000040 91 Notice of Allowance for U.S. Appl. No. 11/236,908 (listed on SB/08 as US-2006-0067974), mailed May 11, 2012. 9000040 92 Notice of Allowance for U.S. Appl. No. 11/582,135 (listed on SB/08 as US 2007-0202149), mailed Jan. 9, 2012. 9000040 93 Uchida, et al., "Swelling Process and Order-Disorder Transition of Hydrogel Containing Hydrophobic Ionizable Groups", Macromolecules, 28, 4583-4586 (1995). 9000040 94 Gutfinger, et al., "Polyphenols in Olive Oils", Journal of the American Oil Chemists Society, 58(11): 966-968 (1981). 9000040 95 Portilla, et al., "Prevention of Peritoneal Adhesions by Intraperitoneal Administration of Vitamin E: An Experimental Study in Rats", Diseases of the Colon and Rectum, 47; 2157-2161 (2005). 9000040 96 Sano, et al., "A controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease", The New England Journal of Medicine, 336; 1216-1222 (1997). 9000040 97 Non Final Office Action for U.S. Appl. No. 12/581,582 (listed on SB-08 as U.S. Publication 2010-0183697), dated May 29, 2014. 9000040 98 Non-Final Office Action for U.S. Appl. No. 13/943,489, dated Jul. 1, 2014. 9000040 99 Final Office Action for U.S. Appl. No. 11/980,155, dated Jul. 21, 2014. 9000040 100 Final Office Action for U.S. Appl. No. 11/237,420, dated Jul. 22, 2014. 9000040 101 Non-Final Office Action for U.S. Appl. No. 11/701,799, dated Jul. 22, 2014. 9000040 102 Final Office Action for U.S. Appl. No. 12/075,223, dated Jul. 22, 2014. 9000040 103 Non-Final Office Action for U.S. Appl. No. 13/843,068, dated Sep. 29, 2014. 9000040 104 Notice of Allowance for U.S. Appl. No. 11/236,943 (listed on SB-08 as U.S. Publication No. US-2006-0067975), dated Oct. 6, 2014. 9000040 105 Non-Final Office Action for U.S. Appl. No. 13/184,512, dated Oct. 10, 2014. 9000040 106 Non-Final Office Action for U.S. Appl. No. 12/075,223, dated Oct. 29, 2014. 9000040 107 Notice of Allowance for U.S. Appl. No. 11/237,264 (listed on SB-08 as U.S. Publication No. US-2006-0067983), dated Mar. 27, 2014. 9000040 108 Notice of Allowance for U.S. Appl. No. 11/237,263 (listed on SB-08 as U.S. Publication No. US-2006-0110457), dated Mar. 27, 2014. 9000040 109 Supplementary European Search Report for Application No. EP 10825447, dated Mar. 31, 2014. 9000040 110 Non Final Office Action for U.S. Appl. No. 12/325,546 (listed on SB-08 as U.S. Publication No. US-2009-0181937), dated Apr. 22, 2014. 9000040 111 Non Final Office Action for U.S. Appl. No. 12/401,243 (listed on SB/08 as US 2010-0233232), mailed May 8, 2014. 9000040 112 Non-Final Office Action for U.S. Appl. No. 11/980,155, dated Nov. 7, 2014. 9000040 113 Notice of Allowance for U.S. Appl. No. 12/325,546 (listed on SB-08 as U.S. Publication No. US-2009-0181937), dated Dec. 8, 2014. 9000040 114 Final Office Action for U.S. Appl. No. 12/581,582, dated Jan. 8, 2015. 9000040 115 Final Office Action for U.S. Appl. No. 12/401,243, dated Jan. 16, 2015. 9000040 116 Non-Final Office Action for U.S. Appl. No. 11/237,420, dated Jan. 21, 2015. 9000040 117 Notice of Allowance for U.S. Appl. No. 13/943,489, mailed Jan. 29, 2015. 9000041 1 Ackerley, et al., A Novel Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors Based on the link of 1.3-dioxane-thrombaxane receptor antagonists and -thromboxane synthase inhibitors, J. Med. Chem. 38:1608-1628 (1995). 9000041 2 Acton et al., 1996. "Identification of scavenger receptor SR-BI as a high density lipoprotein receptor", Science. 271 (5248):518-20. 9000041 3 Ahrens et al., 1967, "A direct method for preparing pyridoxal and 4-pyridoxic acid (1)", J. Haterocycl. Chem.4:625-26. 9000041 4 Alexander, K et al., 1948, "4,4'-Dichlorodibulyl ether and its derivatives from tetrahydrofuran", J. Am. Chem. Soc. 70:1839-42. 9000041 5 Badimon et al., 1992. "Role of High density lipoproteins in the regression of atherosclerosis", Circulation 86 (Suppl):III86-94. 9000041 6 Bailey, et al., 1990, "Convenient general method for the preparation of primary alkeyllithiums by lithium--iodine exchange". J. Org. Chem. 55:5404-06. 9000041 7 Barrans et al., 1996, "Pre-beta HDL; structure and metabolism", Biochim. Biophys. Acta. 1300(2):73-85. 9000041 8 Becker et al., 1982, "Intramolecular photoaddition of terminal allenes to conjugated cyclohexenones", J. Org. Chem.47:3297-3310. 9000041 9 Beilstein Database, Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany, Aug. 28, 1992, BRN 5001278 and 5025574. 9000041 10 Beilstein Database, Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany, Feb. 12, 1993, BRN 5732477. 9000041 11 Beilstein Database, Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany, Nov. 12, 1996, BRN 7473723. 9000041 12 Beilstein Database, Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany, Feb. 27, 1989, BRN 1778991. 9000041 13 Beilstein Database, Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany, Jul. 11, 1989, BRN 2961112. 9000041 14 Beilstein Database, Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany, Feb. 27, 1989, BRN 1741087. 9000041 15 Beilstein Database, Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany, May 4, 1993, BRN 5836264. 9000041 16 Beilstein Database, Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany, Feb. 27, 1989, BRN 1733552. 9000041 17 Beilstein Database, Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany, Feb. 27, 1989, BRN 1784568. 9000041 18 Beilstein Database, Beilstein Institute for organic Chemistry, Frankfurt-Main, Germany, Aug. 28, 1992, BRN 5021975. 9000041 19 Bernady et al., 1979, "Prostaglandins and congeners. 20..sup.1,2 Synthesis of prostaglandins via conjugate addition of lithiummm trans-1-alkenyltrialkylalanate reagents. A novel reagent for conjugate 1,4-addtions", J. Org. Chem. 44:1438-47. 9000041 20 Bhanot el al., 1977. Synthetic Studies on Terpenoids.5.Synlheses of .gamma.- and delta.-Lactones from. beta.-(2,7-Dimelhyl-1 ,2-dihydroxycycloheplyl)propionic Acid. J. Org. Chem. 42:1623-1627. 9000041 21 Bicking, et al. "11, 12-Secoprostaglandins. 1. Acylhydroxyalkanoic acids and related compounds", J. Med. Chem., 1977, pp. 35-43, vol. 20. 9000041 22 Bisgaier el al., 1997. "Attenuation of plasma low density lipoprotein cholesterol by selecl3-hydroxy-3- proliferator activated receptor". J Lipid Res. 39(1 ):17-30. 9000041 23 Bisgaier el al., 1997. "Attenuation of plasma low density lipoprotein cholesterol by selecl3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors in mice of low density lipoprotein receptors", J Lipid Res 38(12):2502-2515. 9000041 24 Bisgaier et al., 1998, "A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor". J Lipid Res. 39(1 ):17-30. 9000041 25 Blatt ed., 1943, "Gilbert Sulfonation and Related Reactions" pp. 135-142, 160-165; Org. Synth. Coli. vol. II, Wiley, NY and Org. Synth. Coil. vol. IV, 1963, Wiley NY 529-531. 9000041 26 Blatt, et al., The reducing action of the Grignard reagent and the synthesis of tertiary aliphatic carbinols, J. AM. Chem. Soc., 1932, pp. 1495-1499, vol. 54. 9000041 27 Bohme, V. and Lener, W., 1955, Annalen der Chemie, 595:169-178 (English language abstract). 9000041 28 Bongini et al.,1979"A simple and practical method for tetrahydropyranylation of alcohols and phenols", Synthesis 618-620. 9000041 29 Brown at al., 1980, "Selective reductions. 26 Lithium triethylborohydride as an exceptionally powerful and selective reducing agent in organic synthesis. Exploration of the reactions with selected organic compounds containing representative functional groups, .sup.1,2". J. Org. Chem 45:1-12. 9000041 30 Brown el al., 1965. "Selective reductions. VII. Reaction of lithium trimelhoxyluminohydride with selected organic compounds containing representative functional groups", J. Am. Chem. Soc. 87:5614-20. 9000041 31 Brown, et al., "Hydroboration, 67. Cyclic hydroboration of acyclic alpha, omega-dienes with 9- Borabicyclo '3.3.1 Inonanelborane-dimethyl sulfide", J. Org. Chem., pp. 1072-1078, vol. 49, No. 6 (1984). 9000041 32 Bruce et al., 1998, "Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport", Annu Rev Nutr. 1998;18:297-330. 9000041 33 Campagna et al., 1994, "Cyclic Amidine Analogues of Taurine and Homotaurine: Synthesis and Effects on Rat Skeletal Muscle", Farmaco. Ed. Sci 49:653-658. 9000041 34 Carothers, 1924, "Platinum oxide as a catalyst in the reduction of organic compounds. V. The preparation of primary alcohols by the catalytic hydrogenation of aldehydes.sup.1" J. Am. Chem. Soc. 46:1675-83. 9000041 35 Cerny et al., 1969, "Properties of Sodium Bis-(2.cndot.MethoxyelhoxLAluminum Hydride", Collect Czech Chem Commn.34:1025-33. 9000041 36 Chadwick et al., 1979, "Reaction between N-Alkylpyrroles and Alkyl-lithium Reagents" J. Chem Soc., Perkin Trans. I 2845. 9000041 37 Chaikin et al., 1949, "Lithium Borohydride as a Reducing Agent", J. Am. Chem. Soc. 71:3245-46. 9000041 38 Chen et el, 1998, "Asymetric total synthesis of phosphatidylinositol 3-phosphate and 4-phosphate derivatives", J. Org. Chem. 63:6511-22. 9000041 39 Comins et al., 1981, RA one pot synthesis of unsymmetrical secondary alcohols from two grignard reagents, Tetrahedron Lett. 22:1085-88. 9000041 40 Corbridge, 1985, "Phosphorus: An Outline of Its Chemistry, Biochemistry and Technology", Studies in Inorganic Chemistry, 3.sup.rd ed, pp. 357-395. 9000041 41 Corey et al., 1967, "A useful method for the conversion of alcohols into iodides", J. Org. Chem. 32: 4160-4161. 9000041 42 Corey et al., 1967, "A useful method for conversion of alcohols into iodides", 1. Org. Chem, 32: 4160-4161. 9000041 43 Corey et al., 1979, "Useful procedures for the oxidation of alcohols involving pyridinum dichromate in aprotic-media", Tetrahedron Lett. 5: 399-402. 9000041 44 Danheiser et al., 1991, "A Practical and Efficient Method for Synthesis of .beta.-Lactones", J. Org. Chem. 56:117685. 9000041 45 Dansky HM, Fisher EA, 1999, "High-density lipoprotein and plaque regression: the good cholesterol gets even better", Circulation 100(17):1762-3. 9000041 46 Decossin et al., 1997. "Subclasses of LpA-1 in coronary artery disease: distribution and cholesterol efflux ability", Eur J Clin Invest. 27(4):299-307. 9000041 47 Desarlo et al., 1971, "Isoxazolin-b-one", J. Chem Soc.86-89. 9000041 48 Eaton et al., 1972, "Hydroxypropylation", J. Org. Chem. 37:1947-50. 9000041 49 Ehlinger, et al., 1980, "Silicon in Synthesis. 10. The (trimethylsilyl)allyl Anion: A .beta.-Acyl anion equivalent for the conversion of aldehydes and ketones into .lambda.-lactone", J. Am. Chem. Soc.102:5004-11. 9000041 50 Fielding & Fielding, 1995, "Molecular physiology of reverse cholesterol transport", J Lipid Res. 36(2):211-28. 9000041 51 Fraser et al., 1985, -Acidity measurements in the THF. V..sup.1 Heteroaromatic compounds containing 5-membered rings, Can. J. Chem 63:3505-09. 9000041 52 Garegg et al., 1980. "Novel Reagent System for converting a Hydroxy-group into an Iodo-group in carbohydrates with Inversion of Configuration", J.C.S. Perkin I 2866-2868. 9000041 53 Gearing et al., 1993. "Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor", Proc. Nett. Acad. Sci. USA 90(4):1440-1444. 9000041 54 Gigg et al., 1967, "The Preparation of Unsymmetrical Diglycerides", J. Chem. Soc., C, 431-434. 9000041 55 Gleiter, et al., Synthesis and properties of 4,4,9,9-tetramethyl-1-oxa-cycloundecane-5,6,7,8-tetrone and 9-tetramethyl-1-oxa-cyclotridecane-6,7,8,9-tetrone, 1996,2(3), pp. 271-277. 9000041 56 Gleiter, et al., Synthesis of 5,510,10-tetrametbyl-1-oxacyclotridecane-6, 7,8,9-tetrone-on the mechanism of the Rubottom reaction, 1995, (9), pp. 1655-1661. 9000041 57 Green and Kehinde, 1975, "An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion", Cell. 5(1):19-27. 9000041 58 Greene. T.W., 1999, "Protection for the Hydroxyl Group, Including 1,2- and 1,3-Diols", Protective Groups in 0. 9000041 59 Harris and Kletzien, 1994, "Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene", Mol Pharmacol. 45(3):439-45. 9000041 60 Hayden and Ma, 1992, "Molecular genetics of human lipoprotein lipase deficiency", Mol Cell Biochem. 113 (2):171-6. 9000041 61 Heyman, et al., 1992. "9-cis retinoic acid is a high affinity ligand for the retinoid X receptor", Cell 68(2):397-406. 9000041 62 Hidaka and Fidge, 1992, "Affinity purification of the hepatic high-density lipoprotein receptor identifies two acidic glycoproteins and enables further characterization of their binding properties", Biochem. J. 15(pt1 ):161-7. 9000041 63 Hirano et al. 1997, "Genetic cholesteryl ester transfer deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity", Arterioscler. Thromb. Vasco Biol. 17(6):1053-1059. 9000041 64 Hoyer et al., 1986, "Catalysis by acidic clay of the protective tetrahydropyranylation of alcohols and phenols", Synthesis 655-57. 9000041 65 Hudlicky, M, 1996, "Reduction of aldehydes and their derivatives", Reductions in Organic Chemistry, 2.sup. nd ed. pp. 137-139. 9000041 66 Hudlicky. M., 1996, "Reduction of esters and lactones of coraboxylic acids", Reductions in Organic Chemistry, 2.sup.nd Ed., pp. 212-217. 9000041 67 Ishibashi et al., 1993, "Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery", J Clin Invest. 92(2):883-93. 9000041 68 Ishibashi, et al., 1994, "Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice", J Clin Invest. 93(5):1885-93. 9000041 69 Isseman and Green, 1990, "Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators", Nature 347(6294):645-650. 9000041 70 Iwai et al., 1966, "Studies on acetylenic compounds. XLIV..sup..1 Synthesis of 3-aminoisaxazoles and 3-hydroxyisoxazoles (3-isoxazolones)", Chem. Pharm. Bull. 14:1277-86. 9000041 71 Johnston et al., 1988. "A new, mild heterogeneous catalyst for the tetrahydropyranylation of alcohols andphelos", Synthesis 393-4. 9000041 72 Katritzky et al., 1993, "Generation and Reactions of sp.sup.2-Carbanionic Centers in the Vicinity of Heterocyclic Nitrogen Atoms", Adv. Het. Chem. 56:155-303. 9000041 73 Keller and Wahli, 1993, "Peroxisome proliferator-activated receptors--A link between endocrinology and Nutrition?", TEM, 4:291-296. 9000041 74 Keller et al., 1993. "Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers", Proc. Natl. Acad. Sci. USA 90(6):2160-2164. 9000041 75 Kessar et al., 1997, "Lewis acid complexion of tertiary animes and related compounds: A strategy for a . alpha.-deprotonation and stereocontrol", Chem. Rev. 97:721-37. 9000041 76 Kletzein et al., 1991, "Enhancement of adipocyte differentiation by an insulin-sensitizing agent", Mol Pharmacol 41 (2):393-398. 9000041 77 Kliewer et al., 1992, "Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors", Nature. 27;358(6389):771-4. 9000041 78 Kurata et al., 1998, "A candidate high density lipoprotein (HDL) receptor, HB2, with possible multiple functions shows sequence homology with adhesion molecules", J. Atherosclerosis and Thrombosis 4(3):112-7. 9000041 79 Kurz et al., 1966, "Evidence for a rate-determining solvation change in methyl transfer to water. Solvent dependence of H.sub.2 0/D.sub.2 O kinetic isotope effects", J. Am. Chem 108:2960-68. 9000041 80 Kurz et at. 1985, "Anomalous selectivities in methyl transfers to water: All explanation using free energy surfaces which model the effects of non-equilibrium solvation", Isr, J. Chem. 26:339-48. 9000041 81 Lagrost et al., 1996, "Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients", J Bioi Chem. 271(32):19058-65. 9000041 82 Landshulz et al., 1996, "Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat", J. Clin. Invest. 98(4):984-995. 9000041 83 Larock, 1989, Comprehensive Organic Transformations; Ch. 6, VCH: New York, pp. 446-448. 9000041 84 Lazarow and Fujiki, 1985, "Biogenesis of peroxisomes", Annu Rev Cell Biol. 1:489-530. 9000041 85 Levin et al., 1992. "9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha", Nature 355(6358):359-61. 9000041 86 Ludwig et al., 1989, "Rapid and efficient synthesis of nucleoside 5'-0-(1-thiotriphosphates), 5'-Triphosphates and 2',3'-Cyclophosphorothioates using 2-Chloro-4H-1,3,2-benzodioxaphosphorin-4-one", J. Org. Chem. 54:631-35. 9000041 87 Maddaford et al., 1993. "A general asymmetric synthesis of (-)-.alpha.-Dimethylretrodendrin and its diaslereomers". J. Org. Chem 58:4132-38. 9000041 88 March, J, 1992, Advanced Organic Chemistry; reactions Mechanisms, and Structure, 4.sup.th ed., pp. 248-272.1196-1198.437-438,920-929. 9000041 89 Masamune et al., 1976, "Tylonolide hemiacetal, the aglycone of tylosin, and its partial synthesis [letter]". J Am Chem Soc. 98(24):7874-5. 9000041 90 Masayuma el al., 2000. "Regio- and diastereocontrol in carbonyl allylation by 1-halobul-2-enes with Tin(II) halides". J Org Chem. 65(2):494-8. 9000041 91 Menger et al., "Synthetically useful oxidations at solid sodium permanganate surfaces", Tetrahedron 1981. Lett. 22:1655-56. 9000041 92 Miyashita et al., 1977, "Pyridinium .rho.-Toluenesulfonate. A mild and efficient catalyst for the tetrahydropyranylation of alcohols", J. Org. Chem 42:3772-74. 9000041 93 Moffet et al., 1963, "2-(1-Pyrrolidyl)Propanol", Org. Synth: Collect 4:834-5. 9000041 94 Mulzer, 1995, Comprehensive Organic Functional Group Transformations Oxford 5 pp. 161. 9000041 95 Myers et al., 1992, "Studies on the thermal generation and reactivity of a class of (.alpha., .pi.)-1,4-biradicals", J. Am. Chem. Soc. 114:9369-86. 9000041 96 Nagano H, et al., "Stereoselectivity in the formation and radical reduction of cyclic bromoacetals, key intermediates for the sythesis of delta-hydroxy-and epsilon-hydroxy-alpha-methylcarboxylic acid esters", Tetrahedron Letters, 2003, pp. 6867-6870, vol. 44, No. 36. 9000041 97 Nan F et al., "Dual Function Glutamate-Related Ligands: Discovery of A Novel, Potent Inhibitor of Glutamate Carboxypeptidase It Possessing mGluR3 Agonist Activity" Journal of Medicinal Chemistry 2000, 43:pp. 772-774. 9000041 98 Nemali et al., 1988, "Comparison of constitutive and inducible levels of expression of peroxisomal beta-oxidalion and catalase genes in liver and extrahepalic lissues of rat", Cancer Res. 48(18):5316-24. 9000041 99 Nystrom et al., 1947, "Reduction of Organic Compounds by Lithium Aluminum Hydride", J. Am. Chem Soc. 69:1197-1199. 9000041 100 Nystrom et al., 1949, "Lithium borohydride as a reducing agent", J. Am. Chem. 71:3245-47. 9000041 101 Ogata et al., 1969, "Kinetics of the baeyer-Villiger reaction of benzaldehydes with perbenzoic acid in aquoorganic solvents", J. Org. Chem 34: 3985-91. 9000041 102 Okamoto el al., 1985, "Synthesis of Alkyl Dihydrogenphosphate by the Reaction of Alcohols and Silyl Polyphosphate", Bull Chem. Soc. Jpn. 58:3393-3394. 9000041 103 Olah et al., 1979, "Transformations with Chlorotrimethylsilane/Sodium Iodide, a Convenient in Situ Iodotrimethylsilane Reagent", J. Org. Chem 44:8, 1247-1251. 9000041 104 Olah et al., 1987, Formylating Agents, Chem Rec. 87:4. 671-686. 9000041 105 Olah et al., 1984, "N-Farmylmorpholine: A New and Effective Formylating Agent for the Preparation of Aldehydes and Oialkyl(I-Formylalkyl)phosphonates from Grignard or Organolithium Reagents", J. Org. Chem 4. 9000041 106 Oster et al., 1983, "Generation and Reactions of the Dianion of 3;Hydroxy-5-methylisoxazole, a convenient. beta.-Keto.Amide Synthon", J. Org. Chem 48:4307-4311. 9000041 107 Parra at al., 1992, "A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study", Arterioscler Thromb. 12:701-707. 9000041 108 Pop et al., 1997, "Allylic and Phenolic Phosphate Esters of Dexanabinol", Org. Prep. And Proc.Int. 29:341-347. 9000041 109 Ramirez et al., 1978, "Phosphorylation by means of cyclic enediol phosphates.sup.1", Acc. Chem. Res. 11:239. 9000041 110 Raunio et al ., 1957, "Addition of Propargyl Acetal to Cyclohexanone in the Presence of Sodamide", J. Org. Chem 22:570. 9000041 111 Reaven, 1993, "Role of insulin resistance in human disease (syndrome X): an expanded definition", Annu Rev Med. 44:121-31. 9000041 112 Reddy and Lalwani, 1983, "Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans", Grit Rev Toxicol. 12(1):1.cndot.58. 9000041 113 Rigotti et al., 1996, Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI). a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal. 9000041 114 Robins and Fasulo, 1997, "High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile", J Clin Invest. 99(3):38D-4. 9000041 115 S.R. Vippagunta, H.G. Brittain, D.J.W. Crant, Crystalline Solids, Advanced Drug Delivery Reviews, 2001, 48, 2-26. 9000041 116 Sam et al., 1972, "Crown Polyether Chemistry. Postassium Permanganate Oxidations in Benzene", J, Am. Chem. Soc. 94:4024. 9000041 117 Sathanur R. Srivinasan et al., "Distribution and Correlates of Non-High-Density Lipoprotein Cholesterol in Children: The Bogalusa Heart Study," Pediatrics, 110, e29 (2002). 9000041 118 Saulnier et al., 1982, "Generation and Reactions of 3-Lilhio-I-(phenylsulfonyl) indole", J. Org. Chem 47:757. 9000041 119 Shirley et al. 1995, "Metalation of pyrrole, 1-methylpyrrole, and 1-phenylpyrrole with n-Butyllithium", J. Org Chem 20:225-31. 9000041 120 Sianesi et al., 1971, "2.4-dihydro-1H-2.1-, 3.4-Dihydro-2H-I.2- und 3.4-Dihydro-1H-2.3-benzothiazin-S.S-dioxid", Chem. Ber.104:1880-91. 9000041 121 Silverman, The Organic Chemistry of Drug Design and Drug Interaction, 1992, pp. 15-22. 9000041 122 Skinner et al., 1995, "Benzoylcyanamide from ethyl benzoyltioncarbomate", J. Am. Chem. Soc. 77:5440-42. 9000041 123 Smith et al., 1957, "Nitrogen Compounds of the Phosphoric and Phosphonic Acids, III, Preparation and Properties of Amides of Phenylphosphonic and Phenylphosphonothioic Acids", J. Org. Chem. 22:265-267. 9000041 124 Song et al., 1999, "Practical asymmetric synthesis of an endothelin receptor antagonist", J. Org. Chem. 64:9658.cndot.67. 9000041 125 Staels and Auwerx, 1998, "Regulation of apo A-I gene expression by fibrates", Atherosclerosis 137 Suppl:SI9-23. 9000041 126 Stevens et al., 1982, "Further studies on the utility of sodium hypochlorite in organic synthesis. Selective oxidation of dials and direct conversion of aldehydes to esters", Tetrahedron Lett. 23:4647-4650. 9000041 127 Stowell et al., 1995, "A new method for the phosphorylation of alcohols and phenols", Tetrahedron Lett. 36 (11):1825.cndot.26. 9000041 128 Sundararaman et al., 1978, "One step conversion of aldehydes to esters", Tetrahedron Lett. 19: 1627-1628. 9000041 129 Sweeney, 1995, "Comprehensive Organic Functional Groups Transformations". Oxford, vol. 2. pp. 104-109. 9000041 130 Sylvia A. McCune and Richard R. Jurin, "Effect of Mevinolin on Cholesterol Metabolism in Obese and Lean Zucker Rats," Biochemical Pharmacology, 36, 875-879 (1987). 9000041 131 Tara Vel et al, 1988, "Interglycosidic sup.13 C- sup 1 H Coupling Constants" Tetrahedeon Lett, 29:199-200. 9000041 132 Tomroka et al., 1995, "Catalytic Asymmetric Conjugate Addition of Grignard Reagents Mediated by Copper (I)-Chiral Bedentale Phosphine Complex", Tetrahedron Lett. 36:4275-4278. 9000041 133 Tontonoz et al., 1994, "Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha", Nucleic Acids Res. 22(25):5628-34. 9000041 134 Uhlmann et al., 1986. "Chemical 5'-phosphorylation of oligonucleotides valuable in automated dna synthesis", Tetrahedron Lett. 27:1023.cndot.26. 9000041 135 Ulrich, et al., 1995, "Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development", Toxicol Lett 82/83:107-15. 9000041 136 Urata et al., 1991. "Transition metal complex catalyzed carbonylation ad organic halides in the presence of molecular sieves instead of base", Tetrahedron Lett. 32:36, 4733-36. 9000041 137 Vamecq and Draye, 1989, "Pathophysiology of peroxisomal beta-oxidation", Essays Biocheln,24:115-225. 9000041 138 Vogtle et al., 1987, "Doubly Clamped Cope Systems", J. Org. Chem. 52:5560.cndot.5564. 9000041 139 West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365. 9000041 140 Williams et al., 1988, "Bromine as an oxidant for direct conversion of aldehydes to esters", Tetrahedron Lett. 29:5087.cndot.90. 9000041 141 Wilson et al., 1982, "A novel, nonoxidative method for the conversion of aldehydes to esters", J. Org. Chem. 47:1360-61. 9000041 142 Wroblewski and Ladue, 1995, "Lactic dehydrogenase activity in blood", Proc. Soc. Exp. Biol. Med. 90:210-213. 9000041 143 Xu et al., 1989, "The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells", Oncogene 4: 807-812. 9000041 144 Yamamoto, "Asymmetric synthesis of 5-and 6-memebered lactones from cyclic substrates bearing a c2-chiral auziliary", J. Org. Chem., 1991, pp. 1112-1119, vol. 35, No. 21. 9000041 145 Yanagisawa et al., 1994, "Allylbarium Reagents: Unprecedented regio- and stereoselective allylation reactions of carbonyl compounds", J. Am. Chem. Soc. 116:6130-6141. 9000041 146 Yoshikawa et al., 1983, "Catalytic Regioselective Dehydrogenalion of Unsymmetrical.alpha . . . omega.-Diols Using Ruthenium Complexes", Tetrahedron lett. 26:2677-2680. 9000041 147 Yoshikawa et al., 1986, "Ruthenium Complex Catalyzed Regioselective Dehydrogenation of Unsymmetrical. alpha . . . omega.-Diols". J. Org. Chem. 51 :2034. 9000041 148 Yu et al., 1988, "A novel reagent for the synthesis of myo-inositol phosphates: n, n-diisopropyl dibenzyl phosphorarnidite", Tetrahedron Lett. 29:979-82. 9000041 149 Yunker et al., 1978, "Alpha-oxygenated fatty acids occurring as amides of 2-methylene-.beta.-alanine in a marine sponge", Tetrahedron lett. 47:4651-52. 9000041 150 Beilstein Report for Compound CAS Registry No. 143508-50-3, based in part on Weber et al. (1992), J. Med. Chem., 35(21): 3755-3773. 9000041 151 Dalton, J.C. et al. (1971) "Type I and Type II Photochemical Reactions of Some Five- and Six-Membered Cycloalkanones," J. Am. Chem. Soc., 93 (26): 7213-21. 9000041 152 Eisch et al. 1978, "Rearrangements of Organometallic Compounds. XVII. Synthesis of lactones via the titanium-catalyzed hydromagnesiation of alkenols," J. Organomet. Chem., 160:C8-C12. 9000041 153 International Search Report, International Application No. PCT/US2003/041411, mailed Dec. 8, 2004 (12 pages). 9000041 154 Jetter, R., "Long-chain alkanediols from Myricaria germanica leaf cuticular waxes," Phytochemistry, 55 (2), 2000, pp. 169-176. 9000041 155 Schaper, U.A. (1980) "Die gemischte Guerbet-Reaktion zwischen cyclischen und acyclischen Alkoholen," Fette, Seifen, Anstrichmittel, Industrieverlag von Hernhaussen kg, 82 (11): 454-456. 9000041 156 Thums et al.,"Epoxidation--a Consequence of Cell Damage," Monatshefte fur Chemie, 128 (4), 1997, pp. 411-420. 9000042 1 Martinez et al. Membrane structure modulation, protein kinase Calpha activation, and anticancer activity of Minerval. Molecular Pharmacology, vol. 67, No. 2, 531-540, 2005. 9000042 2 Adonizio et al. Temozolomide in non-small cell lung cancer: preliminary results of a phase II trial in previously treated patients. Clinical Lung Cancer, vol. 3, No. 4, 254-258, 2002. 9000042 3 "Structure-Activity Relationship and Drug Design." Remington's Pharmaceutical Sciences (Sixteenth Edition). Mack Publishing. 1980. pp. 420-425. 9000042 4 Alemany, R. et al.; "2-Hydroxyoleic Acid A New Hypotensive Molecule," Journal of the American Heart Association, 2004, pp. 249-254, vol. 43, available online Dec. 8, 2003. 9000042 5 Escriba, P.V.; "Membrane-lipid therapy: a new approach in molecular medicine," TRENDS in Molecular Medicine. 2006, pp. 34-43, vol. 12, available online Dec. 1, 2005. 9000042 6 Magrioti, V., et al.; "Synthesis of (S)-.alpha.-Amino Oleic Acid," Lipids, 2002, pp. 223-228, vol. 37. 9000042 7 Chemical Abstracts Service Registry No. 155056-28-3, 9-octadecenoic acid, 2-fluoro-, (9Z)-, Date of entry into the STN Database: May 13, 1994. 9000042 8 Chemical Abstracts Service Registry No. 339170-34-2, 9-octadecenoic acid, 2-hydroxy-, methyl ester, (2S, 9Z)-, Date of entry into STN Database: Jun. 1, 2001. 9000042 9 Chemical Abstracts Service Registry No. 339170-33-1, 9-octadecenoic acid, 2-hydroxy-, methyl ester, (2R, 9Z-, Date of entry into STN Database: Jun. 1, 2001. 9000042 10 Chemical Abstracts Service Registry No. 56472-30-1, 9-octadecenoic acid, 2-hydroxy-, methyl ester, (9Z)-, Date of entry into STN Database: Nov. 16, 1984. 9000042 11 Chemical Abstracts Service Registry No. 760938-73-6, 9-octadecenoic acid, 2-amino-, methyl ester, (2S, 9Z)-, Date of entry into STN Database: Oct. 12, 2004. 9000042 12 Chemical Abstracts Service Registry No. 434938-02-0, 9-octadecenoic acid, 2-amino-, methyl ester, hydrochloride (1:1), (2S, 9Z)-, Date of entry into STN Database: Jun. 28, 2002. 9000044 1 The International Search Report and Written Opinion, issued on May 6, 2013, in the corresponding PCT Patent Application No. PCT/EP2013/053916., pp. 9. 9000044 2 Ulven et al, "Targeting the Prostaglandin D2 Receptors DP and CRTH2 for Treatment of Inflammation," Current Topics in Medicinal Chemistry, vol. 6, No. 1, pp. 1427-1444, 2006, XP008104082., pp. 18. 9000045 1 Abayeh et al., Bull. Soc. Chim. Belg., 103(11): 687-689 (1994). 9000045 2 Antonova et al., Dokl. Bulg. Akad. Nauk., 46 (1): 71-74 (1993). 9000045 3 Caplus Document No. 97:72071, abstract of RO 73988 (1981). 9000045 4 Collings et al., Tetrahedron, 20: 2167-2175 (1964). 9000045 5 Connolly et al., Biochem. Biophys. Res. Com., 223: 42-47 (1996). 9000045 6 Drozd, Z. Org. Khim., 23 (2): 355-365 (1987). 9000045 7 Egan et al., Adv. Prostaglandin, Thromboxane, and Leukotriene Res., 11: 151-157 (1983). 9000045 8 Hori et al., Heterocycles, 9 (10): 1413-1418 (1978). 9000045 9 Mizukami et al., Chem. Pharm. Bull., 13(1): 33-39 (1965). 9000045 10 Nagarajan et al., Indian J. Chem., 12 (3): 227-235 (1974). 9000045 11 Okamoto et al., Nature, 406: 203-207 (2000). 9000045 12 Okamoto et al., Eur. J. Pharmacol., 466: 147-154 (2003). 9000045 13 Simov et al., Khim. Getero. Soed., 9: 1192-1195 (1976). 9000045 14 Shinkai et al., J. Med. Chem., 43: 3566-3572 (2000). 9000045 15 STN Document No. 30:28954 (1936). 9000045 16 STN Document No. 30:28955 (1936). 9000045 17 STN Document No. 31:10413 (1937). 9000045 18 STN Document No. 52:66145 (1958). 9000045 19 STN Document No. 56:13208 (1962). 9000045 20 STN Document No. 57:76819 (1962). 9000045 21 STN Document No. 59:48311 (1963). 9000045 22 STN Document No. 62:3057 (1965). 9000045 23 STN Document No. 62:22523 (1965). 9000045 24 STN Document No. 62:73989 (1965). 9000045 25 STN Document No. 64:11913 (1966). 9000045 26 STN Document No. 67:64283 (1967). 9000045 27 STN Document No. 67:90529 (1967). 9000045 28 STN Document No. 70:37376 (1969). 9000045 29 STN Document No. 71:38898 (1969). 9000045 30 STN Document No. 73:65588 (1970). 9000045 31 STN Document No. 77:152102 (1972). 9000045 32 STN Document No. 81:34416 (1974). 9000045 33 STN Document No. 81:152199 (1974). 9000045 34 STN Document No. 86:43636 (1977). 9000045 35 STN Document No. 89:59393 (1978). 9000045 36 STN Document No. 92:76429 (1980). 9000045 37 STN Document No. 92:182320 (1980). 9000045 38 STN Document No. 93:46693 (1980). 9000045 39 STN Document No. 98:53154 (1983). 9000045 40 STN Document No. 101:72364 (1984). 9000045 41 STN Document No. 102:6270 (1985). 9000045 42 STN Document No. 106:213964 (1987). 9000045 43 STN Document No. 111:134067 (1989). 9000045 44 STN Document No. 113:31865 (1990). 9000045 45 STN Document No. 114:14843 (1991). 9000045 46 STN Document No. 119:270811 (1993). 9000045 47 STN Document No. 119:49289 (1993). 9000045 48 STN Document No. 119:271068 (1993). 9000045 49 STN Document No. 120:217654 (1994). 9000045 50 STN Document No. 120:270251 (1994). 9000045 51 STN Document No. 121:300556 (1994). 9000045 52 STN Document No. 123:56727 (1995). 9000045 53 STN Document No. 125:12380 (1996). 9000045 54 STN Document No. 125:315234 (1996). 9000045 55 STN Document No. 125:346011 (1996). 9000045 56 STN Document No. 126:205418 (1997). 9000045 57 STN Document No. 127:154564 (1997). 9000045 58 STN Document No. 127:171083 (1997). 9000045 59 STN Document No. 128:187834 (1998). 9000045 60 STN Document No. 128:69934 (1998). 9000045 61 STN Document No. 129:230631 (1998). 9000045 62 Vippagunta et al., Adv. Drug Deliv. Rev., 48: 3-26 (2001). 9000045 63 Young et al., Tetrahedron Letters, 25(17): 1753-1756 (1984). 9000046 1 Chabenat et al., "Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate", Meth. Find. Exp. Clin. Pharmacol., vol. 10, No. 5, pp. 311-317 (1988). 9000046 2 Dave et al., "Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation", AAPS PharmSciTech, vol. 5, No. 2, 6 pgs. (2004). 9000046 3 Hou et al., "Gastric retentive dosage forms: a review", Crit. Rev. Ther. Drug Carrier Syst., vol. 20, No. 6, pp. 461-497 (2003). 9000046 4 Mas-Serrano et al., "Kinetic study of acamprosate absorption in rat small intestine", Alcohol Alcohol., vol. 35, pp. 324-330 (2000). 9000046 5 Narendra et al., "Optimization of bilayer floating tablet containing metoprolol tartrate as a model drug for gastric retention", AAPS PharmSciTech, vol. 7, No. 2, 7 pgs. (2006). 9000046 6 Zornoza et al., "Pharmacology of acamprosate: an overview", CNS Drug Reviews, vol. 9, pp. 359-374 (2003). 9000046 7 International Search Report from PCT Patent Application No. PCT/US2011/053769 mailed Apr. 10, 2012, 5 pgs., application now published as WO2012/050922 on Apr. 19, 2012. 9000047 1 Gemignani et al., "Pharmacological study of two new adamantane derivatives", 1979, Farmaco--Edizione Scientifica, vol. 34, Issue: 12, pp. 1029-1038. 9000047 2 Parsons et al., "Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo", Oct. 1995, Neuropharmacology, vol. 34, Issue: 10, pp. 1239-1258. 9000047 3 Bayat et al., "DFT-Based QSAR Prediction of 1-Octanol/Water Partition Coefficient of Adamantine derivatives drugs", J. Chem. Pharm. Res., 2010, vol. 2, Issue 6, pp. 416-423. 9000047 4 Montolio et al., "Identification of Small Molecule Inhibitors of Amyloid .beta.--Induced Neuronal Apoptosis Acting through the Imidazoline I2 Receptor", J. Med. Chem., Oct. 2012, vol. 55, pp. 9838-9846. 9000047 5 Supplementary European Search Report for EP 10-85-2025, dated Sep. 30, 2013. 9000047 6 Adamantane and Protoadamantanealkanamines as Potential Anti-Parkinson Agents:, Journal of Medicinal Chemistry, American Chemical Society, vol. 19, No. 7, Jan. 1, 1976; p. 967-969. 9000048 1 Abrol et al. (2004) "Formulation, Characterization and In Vitro Evaluation of Silymarin-Loaded Microspheres," Drug Deliv. 11:185-191. 9000048 2 Adams et al. (2003) "Amphiphilic Block Copolymers for Drug Delivery," J. Pharm. Sci. 92:1343-1355. 9000048 3 Akkar et al. (2003) "Formulation of Intravenous Carbamzepine Emulsions by SolEmuls Technology," Eur. J. Pharmaceutics Biopharmaceutics 55:305-312. 9000048 4 Akkar et al. (2003) "Intravenous Intraconazole Emulsion Produced by SolEmuls Technology," Eur. J. Pharaceutics Biopharmaceutics 56:29-36. 9000048 5 Akkar et al. (2004) "Solubilizing Poorly Soluble Antimycotic Agents by Emulsification Via a Solvent-Free Process," AAPS PharmSciTech 5(1). 9000048 6 Ashok et al. (2004) "In Vitro Characterization of PEGylated Phospholipid Micelles for Improved Drug Solubilization: Effects of PEG Chain Length and PC Incorporation," J. Pharm. Sci. 93(10):2476-2487. 9000048 7 Benita et al. (1993) "Submicron Emulsions as Colloidal Drug Carriers for Intravenous Administration: Comprehensive Physiocochemical Characterization," J. Pharmaceutical Sci. 82(11):1069-1079. 9000048 8 Benkwitz et al. (2004) "Influence of GABAA Receptor .gamma.2 Splice Variants on Receptor Kinetics and Isoflurane Modulation," Anesthesiology 101:924-936. 9000048 9 Biber et al. (1984) "Intravenous Infusion of Halothane Dissolved in Fat. Haemodynamic Effects in Dogs," Acta Anaesthesiol Scand. 28:385-389. 9000048 10 Bilgicer et al. (2001) "Programmed Self-Sorting of Coiled Coils with Leucine and Hexafluoroleucine Cores," J. Am. Chem. Soc. 123:11815-11816. 9000048 11 Bilgicer et al. (2002) "Synthesis and Thermodynamic Characterization of Self-Sorting Coiled Coils," Tetrahedron 58:4105-4112. 9000048 12 Boileau et al. (1999) "Identification of Transduction Elements for Benzodiazepine Modulation of the GABA(A) Receptor: Three Residues are Required for Allosteric Coupling," J. Neurosci. 19:10213-10220. 9000048 13 Boileau et al. (2003) "Effects of .gamma.2S Subunit Incorporation on GABAA Receptor Macroscopic Kinetics," Neuropharmacology 44:1003-1012. 9000048 14 Bourdon et al. (2000) "A Comparative Study of the Cellular Uptake, Localization and Photoxicity of meta-tetra (hydroxyphenyl) Chlorine Encapsulated in Surface-Modified Submicronic Oil/Water Carriers in HT29 Tumor Cells," J. Photochem. Photobiol. B Biol. 55:164-171. 9000048 15 Burt et al. (1999) "Development of Copolymers of Poly(D,L-Lactide) and Methoxypolyethylene Glycols as Micellar Carriers of Paclitaxel," Coll. Surf. B. Biointerfaces 16:191-171. 9000048 16 Capek, I. (2004) "Degradation of Kinetically-Stable o/w Emulsions," Adv. Colloid Interface Sci. 107:125-155. 9000048 17 Chansri et al. (2006) "Inhibition of Liver Metastasis by all-trans retinoic Acid Incorporated into O/W Emulsions in Mice," Int. J. Pharmaceutics 321(1-2):42-49. 9000048 18 Chesney et al. (2003) "Differential Uptake of Volatile Agents into Brain Tissue in Vitro. Measurement and Application of a Diffusion Model to Determine Concentration Profiles in Brain Slices," Anesthesiology 99:122-130. 9000048 19 Chiari et al. (2004) "Intravenous Emulsified Halogenated Anesthetics Produce Acute and Delayed Preconditioning Against Myocardial Infarction in Rabbits," Anethesiology 101:1160-1166. 9000048 20 Constantinides et al. (2000) "Formulation Development and Antitumor Activity of a Filter-Sterilizable Emulsion of Paclitaxel," Pharmaceutical Research 17(2):175-182. 9000048 21 Cruz et al. (2006) "Physico-Chemical Characterization and In Vivo Evaluation of Indomethacin Ethyl-Ester-Loaded Nanocapsules by PCS, TEM, SAXS, Interfacial Alkaline Hydrolysis and Antiedematogenic Activity," J. Nanoscience Nanotechnol. 6:3154-3162. 9000048 22 Cuignet et al. (2002) "A Second-Generation Blood Substitute (Perflubron Emulsion) Increases the Blood Solubility of Modern Volatile Anesthetics," Anesth. Analg. 95:368-372. 9000048 23 Davis et al. (Apr. 1981) "Ostwald Ripening and the Stability of Emulsion Systems: An Explanation for the Effect of an Added Third Component," J. Colloid Interface Sci. 80(2):508-511. 9000048 24 De Smet et al. (1999) "Ostwald Ripening of Alkane Emulsions in the presence of Surfactant Micelles," Langmuir 15:6745-6754. 9000048 25 Dias et al. (2007) "Pharmacokinetics and Tumor Uptake of a Derivatized Form of Paclitaxel Associated to a Cholesterol-Rich Nanoemulsion (LDE) in Patients in Gynecologic Cancers," Cancer Chemother. Pharmacol. 59:105-111. 9000048 26 Dong et al. (1984) "The Py Scale of Solvent Polarities," Can. J. Chem. 62:2560-2565. 9000048 27 Driscoll, D.F. (2006) "Lipid Injectable Emulsions: Pharmacopeial and Safety Issues," Pharmaceutical Res. 23(9):1959-1969. 9000048 28 Eger, E.I. (1998) "Current and Future Perspectives on Inhaled Anesthetics," Pharmacotherapy 18:895-910. 9000048 29 Eger et al. (1995) "Anesthesia by Intravenous Emulsified Isoflurane in Mice," Can. J. Anesth. 42:173-176. 9000048 30 El-Aasser et al. (2004) "Miniemulsions: Overview of Research and Applications," J. Coating Technol. Res. 1(1):20-31. 9000048 31 Erdlenbruch et al. (2000) "Transient and Controllable Opening of the Blood-Brain Barrier to Cytostatic and Antibiotic Agents by Alkylglycerols in Rats," Exp. Brain. Res. 135:417-422. 9000048 32 Flaim, S.F. (1994) "Pharmacokinetics and Side Effects of Perfluorocarbon-Based Blood Substitutes," Art. Cells Blood Subs. Immob. Biotech. 22(4):1043-1054. 9000048 33 Forster et al. (1998) "Applications of Emulsions," In; Modern Aspects of Emulsion Science, Binks, B. Ed., The Royal Society of Chemistry: Cambridge, pp. 395-426. 9000048 34 Forrest et al. (2006) "In Vitro Release of the mTOR Inhibitor Rapamycin from Poly(ethylene glycol)-b-poly(.epsilon.-caprolactone) Micelles," J. Controlled Release 110:370-377. 9000048 35 Franks et al. (1994) "Molecular and Cellular Mechanisms of General Anesthesia," Nature 367:607-614. 9000048 36 Franks et al. (1996) "Temperature Dependence on the Potency of Volatile General Anesthetics: Implications for in Vitro Experiments," Anesthesiology 84:716-720. 9000048 37 Friberg et al. (1978) "Emulsification and the HLB-Temperature," J. Colloid Interface Sci. 66:367-368. 9000048 38 Fujita et al. (1971) "Fluorocarbon Emulsion as a Candidate for Artificial Blood," Eur. Surg. Res. 3:436-453. 9000048 39 Gabizon et al. (May 1993) "Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmocokinetic Studies in Rodents and Dogs," Pharm. Res. 10(5):703-708. 9000048 40 Greiner et al. (1993) "Fluorinated Surfactants Intended for Biomedical Uses," In; Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications, Filler et al. Eds., Elsevier Science Publishers, pp. 339-380. 9000048 41 Halpern, D.F. (1993) "Recent Developments in Fluorine Substituted Volatile Anesthetics," In; Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications, Filler et al. Eds., Elsevier Science Publishers, pp. 101-133. 9000048 42 Hapfelmeier et al. (2001) "Sevoflurane Potentiates and Blocks GABA-Induced Currents Through Recombinant Alpha(1)ss(2)gamma(2) GABA(A) Receptors: Implications for an Enhanced GABAergic Transmission," Eur. J. Anesthesiology 18:377-383. 9000048 43 Harris et al. (Mar. 2003) "Effect of Pegylation on Pharmaceuticals," Nat. Rev. Drug Disc. 2:214-221. 9000048 44 Higuchi et al. (1962) "Physical Degradation of Emulsions Via the Molecular Diffusion Route and the Possible Prevention Thereof," J. Pharmaceutical Sci. 51(5):459-466 J. Pharm. Sci. 51(5):459-466. 9000048 45 Hoang et al. (Aug. 31, 2004) "Aqueous Solubilization of Highly Fluorinated Molecules by Semifluorinated Surfactants," Langmuir 20(18):7347-7350. 9000048 46 Hoang et al. (2003) "Ostwald Ripening of Alkane in Water Emulsions Stabilized by Hexaethylene Glycol Dodecyl Ether," Langmuir 19:6019-6025. 9000048 47 Hoar et al. (1943) "Transparent Water-in-oil Dispersions: The Oleopathic Hydro-Micelle," Nature 152:102-103. 9000048 48 Holmgren et al. (1998) "Code for Collagen's Stability Deciphered," Nature 392:666-667. 9000048 49 Homgren et al. (1999) "A Hyperstable Collagen Mimic," Chem. Biol. 6(2):63-70. 9000048 50 Hung et al. (2006) "Development and Evaluation of Emulsion-Liposome Blends for Reservation Delivery," J. Nanosci. Nanotechnol. 6:2950-2958. 9000048 51 International Search Report, Corresponding to International Application No. PCT/US05/00100, Mailed Jul. 12, 2006. 9000048 52 International Search Report and Written Opinion, Corresponding to International Application No. PCT/US07/85710, Mailed Sep. 18, 2008. 9000048 53 Ishida et al. (2004) "Biodistribution Characteristics of Galactosylated Emulsions and Incorporated Probucol for Hapatocyte-Selective Targeting of Pipophilic Drugs in Mice," Pharm. Res. 21(6):932-939. 9000048 54 Izquierdo et al. (2002) "Formation and Stability of Nano-Emulsions Prepared Using the Phase Inversion Temperature Method," Langmuir 18:26-30. 9000048 55 Jadhav et al. (2006) "Applications of Microemulsion Based Drug Delivery System," Curr. Drug Deliv. 3:267-273. 9000048 56 Jafari et al. (2006) "Nano-Emulsion Production by Sonication and Microfluidization--A Comparison," Int. J. Food. Properties 9:475-485. 9000048 57 Johannesson et al. (1984) "Halothane Dissolved in Fat as an Intravenous Anesthetic to Rats," Acta Anaesthesiol Scand. 28(4):381-384. 9000048 58 Jones et al. (1999) "Polymeric Micelles: A New Generation of Colloidal Drug Carriers," Eur. J. Pharm. Biopharm. 48:101-111. 9000048 59 Jones et al. (2003) "Toxicological Perspectives on Perfluorinated Compounds," Organohalogen. Comp. 62:311-314. 9000048 60 Kabalnov et al. (1992) "Ostwald Ripening Theory: Applications to Fluorocarbon Emulsion Stability," Adv. Colloid Interface Sci. 38:69-97. 9000048 61 Kabalnov et al. (Dec. 1990) "Solubility of Fluorocarbons in Waster as a Key Parameter Determining Fluorocarbon Emulsion Stability," J. Fluorine. Chem. 50(3):271-284. 9000048 62 Kabalnov et al. (1996) "Macroemulsion Stability: The Oriented Wedge Theory Revisited," Langmuir 12:276-292. 9000048 63 Kalyanasundaram et al. (1976) "Environmental Effects on Vibronic Bans Intensities in Pyrene Monomer Fluorescence and their Application in Studies of Micellar Systems," J. Am. Chem. Soc. 99:2039-2044. 9000048 64 Kalyanasundaram, K. (1988) "Pyrene Fluorescence as a Probe of Fluorocarbon Micelles and their mixed Micelles with Hydrocarbon Surfactants," Langmuir 4:942-945. 9000048 65 Kawamoto et al. (1992) "Acute Pulmonary Edema After Intravenous Liquid Halothane in Digs," Anesth. Analg. 74:747-752. 9000048 66 Kennedy et al. (2004) "The Toxicology of Perfluorooctanoate," Crit. Rev. Tox. 34:351-384. 9000048 67 Khan et al. (2006) "Multiple Emulsions: An Overview," Curr. Drug. Deliv. 3:429-443. 9000048 68 Kim et al. (2002) "Pharmocokinetic and Pharmocodynamic Evaluation of Cyclosporin A O/W-Emulsion in Rats," Int. J. Pharmaceutics 249(1-2):149-156. 9000048 69 Kissa, E. (2001) "Polymeric Fluorinated Surfactants," In; Fluorinated Surfactants and Repellents, 2nd ed., Surfactant Science Series, vol. 97, Marcel Dekker, Inc. pp. 15-28. 9000048 70 Komori et al. (2007) "Alteration of Therapeutic Efficacy of Lipid Micro Spheres Incorporating Prostaglandin E1 by Mixing with Aqueous Solution," J. Pharmaceutical Sci. 96(4):935-943. 9000048 71 Kopriva et al. (1969) "An Anesthetic Accident: Cardiovascular Collapse from Liquid Halothane Delivery," Anesthesiology 30:246-247. 9000048 72 Krafft et al. (1998) "Highly Fluorinated Amphiphiles and Colloidal Systems, and Their Applications in the Biomedical Field. A Contribution," Biochimie 80:489-514. 9000048 73 Krafft, M.P. (2001) "Fluorocarbons and Fluorinated Amphiphiles in Drug Delivery and Biomedical Research," Adv. Drug Del. Rev. 47:209-228. 9000048 74 Krafft et al. (1994) "Supramolecular Assemblies from Single Chain Perfluoroalkylated Phosphorylated Amphiphiless," Coll. Surf. A 84:113-119. 9000048 75 Krafft et al. (1991) "Detrimental Effect of Excess Lecithin on the Stability of Fluorocarbon/Lecithin Emulsions," J. Phys. Chem. 95:5673-5676. 9000048 76 Krafft, M.P. (2004) "Applications of Fluorous Compounds in Materials Chemistry," Handbook of Fluorous Chemistry, Gladysz et al. Eds., Wiley-VCH: Weinheim, CH. 12, pp. 478-504. 9000048 77 Krasowski et al. (2000) "The Actions of Ether, Alcohol and Alkane General Anesthetics on GABA and Glycine Receptors and the Effects of TM2 and TM3 Mutations," Brit. J. Pharmacol. 129:731-743. 9000048 78 Krishna et al. (1993) "Pharmacokinetics, Efficacy and Toxicity of Parenteral Haalofantrine in Uncomplicated Malaria," Brit. J. Clin. Pharmacol. 36:585-591. 9000048 79 Krishnadas et al. (Feb. 2003) "Sterically Stabilized Phospholipid Mixed Micelles: In Vitro Evaluation as a Novel Carrier for Water-Insoluble Drugs," Pharm. Res. 20(2):297-302. 9000048 80 Kwon et al. (1994) "Block Copolymer Micelles as Vehicles for Hydrophobic Drugs," Colloids Surf. B. Biointerfaces 2:429-434. 9000048 81 Kwon, G.S. (2003) "Polymeric Micelles for Delivery of Poorly Water-Soluble Compounds," Crit. Rev. Ther. Drug Carrier Syst. 20:357-403. 9000048 82 Kwon et al. (2003) "Polymeric Micelles for the Delivery of Polyene Antibiotics," Polymeric Mater. Sci Eng. 89:50-51. 9000048 83 Lance et al. (1995) "Structure and Toxicity of Amphotericin B/triglyceride Emulsion Formulations," J. Antimicrob. Chemother. 36(1):119-128. 9000048 84 Lau et al. (2004) "The Developmental Toxicity of Perfluoroalkyl Acids and their Derivatives," Tox. Appl. Pharm. 198:231-241. 9000048 85 Lavasanifar et al. (2001) "Micelles Self-Assembled from Poly(thylene oxide)-bloxk-poly-(N-hexyl stearate L-Aspartamide) by a Solvent Evaporation Method: Effect on the Solubilization and Haemolytic Activity of Amphotericin B," J. Control. Rel. 77:155-160. 9000048 86 Lavasanifar et al. (2002) "Poly(ethylene Oxide)-Block-Poly(L-Amino Acid) Micelles for Drug Delivery," Adv. Drug Del. Rev. 54:169-190. 9000048 87 Lifshitz et al. (1961) "The Kinetics of Precipitation from Supersaturated Solid Solutions," J. Phys. Chem. Solids 19(1-2):35-50. 9000048 88 Liu et al. (2007) "Preparation of Poly(butylene-co-.epsilon.-caprolactone carbonate) and Their use as Drug Carriers for a Controlled Delivery System," J. Polym. Sci. A Polym. Chem. 45(11):2152-2160. 9000048 89 Liu et al. (2006) "Formation and Stability of Paraffin Oil-in-Water Nano-Emulsions Prepared by the Emulsion Inversion Point Method," J. Colloid Interface Sci. 303:557-563. 9000048 90 Lixin et al. (2006) "A Less Irritant Norcantharidin Lipid Microspheres: Formulation and Drug Distribution," Int. J. Pharmaceutics 323(1-2):161-167. 9000048 91 Lo et al. (1987) "The Disposition and Bioavailability of Intravenous and Oral Nelbuphine in Healthy Volunteers," J. Clin. Pharmacol. 27:866-873. 9000048 92 Lukyanov et al. (May 7, 2004) "Micelles from Lipid Derivatives of Water-Soluble Polymers as Delivery Systems for Poorly Soluble Drugs," Adv. Drug Deliv. Rev. 56(9):1273-1289. 9000048 93 Madhusudhan et al. (2007) "1-O-alkylglycerol Stabilized Carbamazepine Intravenous o/w Nanoemulsions for Drug Targeting in Mice," J. Drug Targeting 15(2):154-161. 9000048 94 Martin et al. (2005) "Synthesis and Self-Assembly of Amphiphilic Semifluorinated Calix[4]arenes," Supramol. Chem. 17:9-15. 9000048 95 Martin et al. (2005) "Solution Self-Assembly and Solid-State Properties of Fluorinated Amphiphilic Calix[4]arenes," Chem. Comm. 39:4964-4966. 9000048 96 Martin et al. (2006) "Synthesis and pH-Dependent Self-Assembly of Semifluorinated Calix[4]arenes," Tetrahedron 63(25):5539-5547. 9000048 97 Mason et al. (2006) "Nanoemulsions: Formation, Structure and Physical Properties," J. Phys. Condens. Matter 18:R635-R666. 9000048 98 Medina et al. (2001) "Use of Ultrasound to prepare Lipid Emulsions of Lorazepam for Intravenous Injection," Int. J. Pharmaceutics 216(1-2):1-8. 9000048 99 Messina et al. (1998) "Perfluorocarbon-Hydrocarbon Self-Assembly. Part 3. Liquid Phase Interactions Between Perfluoroalkylhalides and Heteroatom Containing Hydrocarbons," Tetrahedron Lett. :9069-9072. 9000048 100 Miller, C.A. (2006) "Spontaneous Emulsification Recent Developments with Emphasis on Self-Emulsification," In; Emulsions and Emulsion Stability, 2nd ed., Sjonlom, J. Ed., Marcel Dekker: New York, 132:107-126. 9000048 101 Monduzzi, M. (1998) "Self-Assembly in Fluorocarbon Surfactant Systems," Curr. Opin. Coll. Int. Sci. 3:467-477. 9000048 102 Mosqueira et al. (2006) "Surface-Modified and Conventional Nanocapsules as Novel Formations for Parental Delivery of Halofantrine," J. Nanosci. Nanotechnol. 6:3193-3202. 9000048 103 Mosqueira et al. (2004) "Efficacy and Pharmacokinetics of Intravenous Nanocapsule Formulations of Halofantrine in Plasmodium berghei-Infected Mice," Antimicrobial Agents Chemother. 48:1222. 9000048 104 Mozzi et al. (2002) "The Use of Lipid Emulsions for the IV Administration of a New Water Soluble Polyene Antibiotic, SPK-843," J. Antimicrob. Chemother. 49(2):321-325. 9000048 105 Muller et al. (2004) "SolEmuls--Novel Technology for the Formulation of I.V. Emulsions with Poorly Soluble Drugs," Int. J. Pharmaceutics 269(2):293-302. 9000048 106 Musser et al. (1999) "The Anesthetic and Physiologic Effects of an Intravenous Administration of a Halothane Lipid Emulsion (5% vol/vol)," Aneth. Analg. 88:671-675. 9000048 107 Nakajima, H. (1997) "Microemulsions in Cosmetics," In; Industrial Applications of Microemulsions, Solans et al. Eds., Marcel Decker: New York, pp. 175-197. 9000048 108 Neil et al. (2000) "Towards the Nonstick Egg: Designing Fluorous Proteins," Chem. Biol. 7:R153-R157. 9000048 109 Norden et al. (2001) "Physiocochemical Characterization of a drug-Containing Phospholipid-Stabilized o/w Emulsion for Intravenous Administration," Eur. J. Pharmaceutical Sci. 13(4):393-401. 9000048 110 Oda et al. (2000) "Aggregation Properties and Mixing Behavior of Hydrocarbon, Fluorocarbon, and Hybrid Hydrocarbon-Fluorocarbon Cations Dimeric Surfactants," Langmuir 16:9759-9769. 9000048 111 Office Action, Corresponding to U.S. Appl. No. 11/028,948, Mailed Aug. 1, 2008. 9000048 112 Ozpolat et al. (2003) "Pharmacokinetics of Intravenously Administered Liposomal All-Trans-Retinoic Acid (ATRA) and Orally Administered ATRA in Healthy Volunteers," J. Phram. Pharmaceutical Sci. 6:292-301. 9000048 113 Palakurthi et al. (2005) "Biodisposition of PEG-Coated Lipid Microspheres of Indomethacin in Arthritic Rats," Int. J. Pharmaceutics 290(1-2):55-62. 9000048 114 Percec et al. (2002) "Cell Membrane as a Model for the Design of Semifluorinated Ion-Selective Nanostructures Supramolecular Systems," Tetrahedron 58:4031-4040. 9000048 115 Petsev et al. (1995) "Flocculation of Deformable Emulsion Droplets. II. Interaction Energy," J. Colloid Interface Sci. 176:201-213. 9000048 116 Pohlmann et al. (2002) "Spray-Dried Indomethacin-Loaded Polyester Nanocapsules and Nanospheres Development, Stability Evaluation and Nanotstructure Models," Eur. J. Pharmaceutical Sci. 16(4-5):305-312. 9000048 117 Primo et al. (2007) "Binding of Photophysical Studies of Biocompatible Magnetic Fluid in Biological Medium and Development of Magnetic Nanoemulsion: A New Candidate for Cancer Treatment," J. Magnetism Magnetic Mater. 310:2838-2840. 9000048 118 Ravey et al. (1988) "Comparative Study of Fluorinated and Hydrogenated Nonionic Surfactants," Prog. Colloid Poly. Sci. 76:234-241. 9000048 119 Riess J.G. (2002) "Fluorous Micro- and Nanophases with a Biomedical Perspective," Tetrahedron 58:4113-4131. 9000048 120 Riess, J.G. (2004) "Fluorous Materials for Biomedical Uses," In; Handbook of Fluorous Chemistry, Wiley-VCH, pp. 521-573. 9000048 121 Riess, J.G. (2001) "Oxygen Carriers (Blood Substitutes)-Raison d'Etre, Chemistry and Some Physiology," Chem. Rev. 101:2797-2919. 9000048 122 Riess, J.G. (1994) "Highly Fluorinated Systems for Oxygen Transport, Diagnosis and Drug Delivery," Colloids Surf. A. 84:33-48. 9000048 123 Reiss et al. (1992) "Stabilization of Fluorocarbon Emulsions by Sugar-Derived Perffluoroalkylated Surfactants and Co-surfactants," Prog. Colloid Polym. Sci. 88:123-130. 9000048 124 Reiss, J.G. (2005) "Understanding the Fundamentals of Perfluoroccarbons and Perfluorocarbon Emulsions Relevant to In Vivo Oxygen Delivery," Artificial Cells Blood Subdtitutes Biotechnol. 33:47-63. 9000048 125 Rosier et al. (2001) "Advanced Drug Delivery Devices Via elf-Assembly of Amphiphilic Block Copolymers," Adv. Drug Del. Rev. 53:95-108. 9000048 126 Salager et al. (1982) "Surfactant-Oil-Water Systems Near the Affinity Inversion. Part I: Relationship Between Equilibrium Phase Behavior and Emulsion Type and Stability," J. Dispersion Sci. Technol. 3:279-292. 9000048 127 Sandison et al. (1970) "An Experimental Study of Pulmonary Damage Associated with Intravenous Injection of Halothane in Dogs," Br. J. Anaesth. 42:419-423. 9000048 128 Sarker, D.K. (2005) "Engineering of Nanoemulsions for Drug Delivery," Curr. Drug Deliv. 2:297-310. 9000048 129 Schmutz et al. (2003) "Fluorinated Vesicles Made from Combinations of Phospholipids and Semifluorinated Alkanes. Direct Experimental Evidence of the Location of Semifluorinated Alkane Within the Bilayer," Langmuir 19:4889-1894. 9000048 130 Schulman et al. (1959) "Mechanism of Formation and Structure of Micro Emulsions by Electron Microscopy," J. Phys. Chem. 63:1677-1680. 9000048 131 Seki et al. (2004) "A Nanometer Lipid Emulsion, Lipid Nano-Sphere (LNS), as a Parental Drug Carrier fro Passive Drug Targeting," Int. J. Pharmaceutics 273(1-2):75-83. 9000048 132 Sharma et al. (1988) "Novel Compositions of Emulsified Perfluorocarbons for Biological Uses," Biomat. Art. Cells Art. Org. 16:447-450. 9000048 133 Shawer et al. (2002) "VLDL-Resembling Phospholipid-Submicron Emulsion for Cholesterol-Based Targeting," J. Pharmaceutical Sci. 91(6):1405-1413. 9000048 134 Shinoda et al. (1968) "The Effect of Temperature on the Phase Equilibria and the Types of Dispersions of the Ternary System Composed of Water, Cyclohexane, and Nonionic Surfactant," J. Colloid Interface Sci. 26:70-74. 9000048 135 Slaughter et al. (2007) "Synthesis and Self-Assembly Properties of a Novel [poly9ethylene glycol0}-Fluorocarbon-Phospholipid Triblock Copolymer," Tetrahedron Lett. 48:3879-3882. 9000048 136 Smart, B.E. "Characteristics of C-F Systems," In; Organofluorine Chemistry: Principles and Commercial Applications, Plenum Press, New York, pp. 57-88. 9000048 137 Smart, B.E. (1983) "Fluorocarbons," In; The Chemistry of Functional Groups, Supplement D, John Wiley and Sons, pp. 603-655. 9000048 138 Solans et al. (2003) "Nano-Emulsions: Formation, Properties and Applications," In; Adsorption and Aggregation of Surfactants in Solution, Marcel Dekker, Inc.: New York, pp. 525-554. 9000048 139 Solans et al. (2005) "Nano-Emulsions," Curr. Opin. Colloid Interface Sci. 10:102-110. 9000048 140 Strippoli et al. (2000) "Anticandidal Activity of SPA-S-843, a New Polyenic Drug," J. Antomicrob. Chemother. 45:235-237. 9000048 141 Sutton et al. (1971) "Accidental Intravenous Injection of Halothane," Br. J. Anaest. 43:513-519. 9000048 142 Swanson et al. (1953) "Ultra-Short-Acting Thiobarbituric Acids," Proc. Soc. Exp. Biol. Med. 82:212-215. 9000048 143 Tadros et al. (2004) "Formation and Stability of Nano-Emulsions," Adv. Colloid Interface Sci. 108-109:303-318. 9000048 144 Tang et al. (2001) "Stabilization of Coiled-Coil Peptide Domains by Introduction of Trifluoroleucine," Biochemistry 40:2790-2796. 9000048 145 Taylor, P. (1998) "Ostwald Ripening in Emulsions," Adv. Colloid Interface Sci. 75:107-163. 9000048 146 Taylor, P. (2003) "Ostwald Ripening in Emulsions. Estimation of Solution Thermodynamics of the Disperse Phase," Adv. Colloid Interface Sci. 106:261-285. 9000048 147 Teixeira et al. (2005) "Development and Characterization of PLGA Nanospheres and Nanocapsules Containing Xanthone and 3-Methoxyxanthone," Eur. J. Pharmaceutics Biopharmaceutics 59:491-500. 9000048 148 Thurmond et al. (1999) "Shell Cross-Linked Polymer Micelled: Stabilized Assemblies with great Versatility and Potential," Coll. Surf B 16:45-54. 9000048 149 Tiwari et al. (2006) "Preparation and In Vitro Characterization of Multifunction nanoemulsions for Simultaneous MR Imaging and Targeted Drug Delivery," J. Biomed. Nanotechnol. 2:217-224. 9000048 150 Torchilin, V.P. (2001) "Structure and Design of Polymeric Surfactant-Based Drug Delivery Systems," J. Controlled Release 73:137-172. 9000048 151 Ueda et al. (2004) "Prolonged Circulation of Menatetrenone by Emulsions with Hydrogenated Castor Oils in Rats," J. Controlled Release 95(1):93-100. 9000048 152 van Etten et al. (Nov. 1995) "Sterically Stabilized Amphotericin B-Liposomes: Toxicity and Biodistribution in Mice," J. Controlled Release 37(1-2):123-129. 9000048 153 Vierling et al. (Feb. 2001) "Highly Fluorinated Amphiphiles as Drug and Gene Carrier and Delivery Systems," J. Fluorine Chem. 107(2):337-354. 9000048 154 Wang et al. (2006) "Submicron Lipid Emulsion as a Drug Delivery System for Nalbuphine and Its Prodrugs," J. Controlled Release 115(2):140-149. 9000048 155 Watkins et al. (1993) "Falciparum Malaria: Differential Effects of Antimalarial Drugs on Ex Vivo Parasite Viability During the Critical Early Phase of Therapy," Am. J. Trop. Med. Hygiene 49:106. 9000048 156 Weers et al. (1994) "The Effect of Molecular Diffusion on Initial Particle Size Distributions in Phospholipid-Stabilized Fluorocarbon Emulsions," Colloids Surf. A Physiochem. Eng. Aspects 84:81-87. 9000048 157 Wu et al. (1996) "Potentiation by Sevoflurane of the .gamma.-Aminobutyric Acid Induced Chloride Current in Acutely Dissociated CA1 Pyramidal Neurons from Rat Hippocampus," Brit. J. Pharmacol. 119:1013-1021. 9000048 158 Xue et al. (1997) "Perfectly Staggered and Twisted Difluorormethylsene Groups in Perfluoroalkyl Chains: Structure of M[C4F9SO2NSO2C4F9] (M=Na, K)," Angew. Chem. Int. Ed. Engl. 36:1331-1333. 9000048 159 Yeeprae et al. (2005) "Biodistribution Characteristics of Mannosylated and Fucosylated O/W Emulsions in Mice," J. Drug Targeting 13(8):479-487. 9000048 160 Yeeprae et al. (2006) "Effect of Mannose Density on Mannose Receptor-Mediated Cellular Uptake of Mannosylated O/W Emulsions by Macrophages," J. Controlled Release 114(2):193-201. 9000048 161 Yu et al. (2001) "mTOR, a Novel Target in Breast Cancer: The Effect of CCO-779, an mTOR Inhibitor, in Preclinical Models of Breast Cancer," Endocrine-Related Cancer 8:249-258. 9000048 162 Zalipsky, S. (1993) "Synthesis of an End-Group Functionalized polyethylene glycol-Lipid Conjugate for Preparation of Polymer-Grafted Liposomes," Bioconj. Chem. 4(4):296-299. 9000048 163 Zarif et al. (1993) "Alkyl and Perfluooalkyl Glycolipid-Based Supramolecular Assemblies," Coll. Surf. A 84:107-112. 9000048 164 Zhang et al. (1996) "Development of Amphiphilic Diblock Copolymers as Micellar Carriers of Taxol," Int. J. Pharmaceutics 132:195-206. 9000048 165 Zhou et al. (2006) "The Efficacy and Safety of Intravenous Emulsified Isoflurane in Rats," Anesth. Analg. 102:129-134. 9000048 166 Zimmerman et al. (1994) "Potentiation of GABAA Receptor Cl- Current Correlates with in Vivo Anesthetic Potency," J. Pharmacol. Experim. Ther. 270:987-991. 9000048 167 Adams et al. (2003) "Relative Aggregation State and Hemolytic Activity of Amphotericin B Encapsulated by Poly(Ethylene Oxide)-Block-poly(N-hexyl-L-aspartamide)-acyl Conjugate Micelled: Effects of Acyl Chain Length," J. Control. Release 87:23-32. 9000048 168 Buszello et al. (2000) Emulsions as Drug Delivery Systems, In; Pharmaceutical Emulsions and Suspensions, Nielloud et al. Eds., Marcel Dekker: New York, 105:191-228. 9000048 169 Cuignet et al. (2002) "A Second-Generation Blood Substitute (Perflubron Emulsion) Increases the Blood Solubility of Modern Volatile Anesthetics In Vitro," Anesth Analg. 95:368-372. 9000048 170 Definition of the Word "Derivative," http://www.merriamwebster.com/dictionary/derivative , Downloaded Jan. 27, 2011. 9000048 171 Ettmayer et al. (May 6, 2004) "Lessons Learned from Marketed and Investigational Prodrugs," J. Med. Chem.47(10):2393-2404. 9000048 172 Fast et al. (Oct. 2008) "Fluoropolymer-Based Emulsions for the Intravenous Delivery of Sevoflurane," Anesthesiology 109(4):651-656. 9000048 173 Ferstandig, L.L. (1995) "Fluorinated Anesthetics," In; Chemistry of Organic Fluorine Compounds II: A Critical Review, Hudlicky et al. Eds., ACS Monograph No. 18, American Chemical Society, Washington, D.C., pp. 1133-1137. 9000048 174 Hillaireau et al. (2006) "Polymeric Nanoparticles as Drug Carriers," In; Polymers in Drug Delivery, Uchegbu et al. Eds., CRC: Boca Raton, pp. 101-110. 9000048 175 Office Action Corresponding to U.S. Appl. No. 11/972,061, Mailed Feb. 8, 2011. 9000048 176 Office Actions and Response Corresponding to U.S. Appl. No. 11/028,948, Mailed between Aug. 1, 2008 and Apr. 15, 2009. 9000048 177 Riess et al. (1988) "Design, Synthesis and Evaluation of Fluorocarbons and Surfactants for in Vivo Applications New Perfluoroalkylated Polyhydroxylated Surfactants," Biomat. Art. Cells Art. Org. 16(1-3):421-430. 9000048 178 Stella, V.J. (2004) "Prodrugs as Therapeutics," Exp. Opin. Ther. Patents. 14(3):277-280. 9000048 179 Strickley, R.G. (Feb. 2004) "Solubilizing Excipients in Oral and Injectable Formulations," Pharm. Res. 21(2):201-230. 9000048 180 Testa et al. (1996) "Prodrugs Revisited: The `Ad Hoc` Approach as a Complement to Ligand Design," Med. Res. Rev. 16(3):233-241. 9000048 181 Testa, B. (2004) "Prodrugs Research: Futile or Fertile," Biochemical Pharmacology 68:2097-2106. 9000048 182 Torchilin, V.P. (2004) "Targeted Polymeric Micelled for Delivery of Poorly Soluble Drugs," CLMS Cell. Mol. Life Sci. 61:2549-2559. 9000048 183 van den Temple, M. (1953) "Stability of Oil-In-Water Emulsions II; Mechanism of the Coagulation of an Emulsion," Recl. Tray. Chim. Pays-Bas 72:433-441. 9000048 184 Walstra et al. (1998) "Emulsion Formation," In; Modern Aspects of Emulsion Science, Binks, B. Ed., The Royal Society of Chemistry: Cambridge, pp. 56-99. 9000048 185 Wang et al. (2007) "Formulation, Preparation and Evaluation of Flunarizine-Loaded Lipid Microspheres," J. Pharm. Pharmacol. 59:351-357. 9000048 186 Weers et al. (1994) "Room Temperature Stable Perfluorocarbon Emulsions with Acceptable Half-Lives in the Reticuloendotherlial System," Art. Cells Blood Subs. Immob. Biotech. 22(4):1175-1182. 9000048 187 Wolff, M.E. (1994) Burger's Medicinal Chemistry and Drug Discovery vol. 1., Principles and Practice, 5th Ed. pp. 975-977. 9000048 188 Written Opinion Corresponding to International Application No. PCT/US05/00100, Mailed Jul. 12, 2006. 9000048 189 Yu et al. (2006) "Formulation and Evaluation of Nimodipine-Loaded Lipid Microspheres," J. Pharm. Pharmacol. 8:1429-1435. 9000048 190 Supplementary European Search Report corresponding to European Patent Application No. EP07871604, completed Apr. 10, 2013. 9000048 191 Hsu, et al., "Diminution of Phagocytosed Perfluorocarbon Emulsions Using Perfluoroalkylated Polyethylene Glycol Surfactant," May 18, 2001, Biochemical and Biophysical Research Communications, vol. 283, Issue 4, pp. 776-781. 9000048 192 Notice of Reasons for Rejection corresponding to Japanese Patent Application No. P2009-539451, dispatched Dec. 11, 2012 (includes English translation). 9000049 1 American Botanical Council. Scientific and Clinical Monogrpah for Pycnogenol. 2008. 9000049 2 Richelle M1, Bortlik K, Liardet S, Hager C, Lambelet P, Baur M, Applegate LA, Offord EA. A food-based formulation provides lycopene with the same bioavailability to humans as that from tomato paste. J Nutr. Mar. 2002;132(3):404-8. 9000049 3 Segger et al., "Supplementation with Evelle.RTM. improves skin smoothness and elasticity in a doubleblind, placebo-controlled study with 62 women," Journal of Dermatological Treatment, 2004, pp. 222-226, vol. 15. 9000049 4 Choi et al., "Cosmeceuticals," Seminars in Cutaneous Medicine and Surgery, 2006, pp. 163-168, Elsevier Inc. 9000049 5 Liu et al., "The scavenging capacity and synergistic efforts of lycopene, vitamin E, vitamin C, and .beta.-carotene mixtures on the DPPH free radical," LWT, 2008, pp. 1344-1349, vol. 41, Elsevier Ltd. 9000049 6 Fuchs et al., "Modulation of UV-Light-Induced Skin Inflammation By D-Alpha-Tocopherol and L-Ascorbic Acid: A Clinicalstudy Using Solar Simulated Radiation,"Free Radical Biology & Medicine, 1998, pp. 1006-1012, vol. 25, No. 9, Elsevier Science Inc. 9000049 7 Rohdewald, "A review of the French maritime pine bark extract (Pycnogenol.RTM.), a herbal medicationwith a diverse clinical pharmacology," International Journal of Clinical Pharmacology and Therapeutics, vol. 40, No. 4, Apr. 2002, pp. 158168. 9000049 8 International Search Report for International Patent Application No. PCT/IB2009/05489, mailed on Feb. 3, 2010 (w/ English translation). 9000050 1 Liermann, J.C., et al. J. Nat. Prod. vol. 71 pp. 1654-1656. Published online Sep. 5, 2008. 9000050 2 Liermann, J.C. et al (Journal of Natural Products vol. 71, pp. 1654-1646, published on line Sep. 5, 2008. 9000050 3 Abdel-Magid et al., "Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures," J Org Chem 61(11): 3849-3862, 1996. 9000050 4 Bryant et al., "Improved Hydroxylamine Method for the Determination of Aldehydes and Ketones. Displacement of Oxime Equilibria by Means of Pyridine," J Am Chem Soc 57: 52-61, 1935. 9000050 5 Dess et al., "A Useful 12-I-5 Triacetoxyperiodinane (the Dess-Martin Periodinane) for the Selective Oxidation of Primary or Secondary Alcohols and a Variety of Related 12-I-5 Species," J Am Chem Soc 113(19): 7277-7287, 1991. 9000050 6 Hayashi et al., "Remarkably Mild and Efficient Intramolecular Friedel-Crafts Cyclization Catalyzed by In(III)," Organic Letters 9(7): 1311-1314, 2007. 9000050 7 Kantorowski et al., "Expansion to Seven-Membered Rings," Tetrahedron 56: 4317-4353, 2000. 9000050 8 Wang et al., "Lipase-Catalyzed Irreversible Transesterifications Using Enol Esters as Acylating Reagents: Preparative Enantio--and Regioselective Syntheses of Alcohols, Glycerol Derivatives, Sugars, and Organometallics," J Am Chem Soc 110(21): 7200-7205, 1988. 9000050 9 Wong et al., "Organocatalytic Oxidation. Asymmetric Epoxidation of Olefins Catalyzed by Chiral Ketones and Iminium Salts," Chem Rev 108(9): 3958-3987, 2008. 9000051 1 Jul. 25, 2011 Written Opinion issued in International Patent Application No. PCT/IB2011/052280. 9000051 2 Mar. 8, 2011 Preliminary Search Report issued in French Patent Application No. FR1002233. 9000051 3 Mar. 8, 2011Written Opinion issued in French Patent Application No. FR1002233 (w/translation). 9000051 4 Jan. 26, 2012 Search Report issued in International Patent Application No. PCT/IB2011/052281. 9000051 5 U.S. Appl. No. 13/700,029, in the name of Cavazzuti et al., filed Jan. 30, 2013. 9000051 6 U.S. Appl. No. 13/691,134, in the name of Cavazzuti et al., filed Nov. 30, 2012. 9000051 7 Office Action issued in Chinese Patent Application No. 201180037044.6 dated Dec. 13, 2013 (with partial translation). 9000051 8 Oct. 10, 2014 Office Action issued in Chinese Application No. 201180036985.8 (with English translation). 9000051 9 Nov. 3, 2014 Office Action issued in U.S. Appl. No. 13/700,029. 9000051 10 Jan. 27, 2015 Office Action issued in U.S. Appl. No. 13/691,134. 9000052 1 International Search Report and Written Opinion mailed Apr. 19, 2010, Application No. PCT/IB2009/054584 filed Oct. 19, 2009. 9000052 2 Database WPI Week 200709, Thomson Scientific, London, GB; AN 2007-086839, XP002570077 & JP 2006-342096 A, Dec. 21, 2006, abstract. 9000052 3 Database WPI Week 197929, Thomson Scientific, London, GB; AN 1979-53715B, XP002570078 & JP 54-073136 A, Jun. 12, 1979, abstract. 9000053 1 Moinard-Checot et al., "Mechanism of nanocapsules formation by the emulsion-diffusion process", J Colloid Interface Sci 317:458-468 (2008), available online Oct. 3, 2007. 9000053 2 International Search Report and Written Opinion for PCT/US2009/047676. 9000053 3 Brown, A.; Smith, C.; Rennie, A., Physical Review E., vol. 62, No. 1, pp. 951-960, Jul. 2000. 9000053 4 Hernandez, C. et al.; The Journal of Physical Chemistry C Letters, 2007, 111, 4477-4480, published on Web Feb. 13, 2007. 9000053 5 Hernandez, Carlos, et al.; Soft Materials, 5(1): 1-11, 2007. 9000053 6 Hernandez, Carlos, et al.; Soft Materials, 5(1): 13-31, 2007. 9000053 7 Higurashi, H. et al; Appl. Phys. Lett. 64 (17), Apr. 25, 1994. 9000053 8 Manoharan, V. et al.; Science, vol. 301, Jul. 25, 2003. 9000053 9 Py, Charlotte; The American Physical Society, PRL 98, 156103-1-156103-4 (2007). 9000053 10 Rothemund, P. vol. 440, Mar. 16, 2006, doi:10.1038, Nature04586. 9000053 11 Sullivan, Matt et al., Journal of Physics Condensed Matter 15 (2003) S11-S18. 9000053 12 Whitesides, George et al., PNAS, vol. 99, No. 8, pp. 4769-4774, Apr. 16, 2002. 9000053 13 Meleson et al., Formation of Concentrated Nanoemulsions by Exteme Shear, Soft Mater 2004, 2, 109. 9000053 14 Mason, T. G. New fundamental concepts in emulsion rheology, Curr Opin. Colloid Interface Sci. 1999, 4, 231. 9000053 15 Durian et al., Multiple Light-Scattering Probes of Foam Structure and Dynamics, Science 1991, 252, 686. 9000053 16 Gopal et al., Relaxing in foam, Phys. Rev. Lett. 2003, 91. 9000053 17 Mason et al., Monodisperse Emulsions: Properties and Uses, Encyclopedia of Emulsion Technology; Marcel Dekker: New York, 1996; vol. 4. 9000053 18 Mason et al., Nanoemulsions: Formation, Structure, and Physical Properties, J. Phys.: Condens. Matter 18 R635-R666 (2006). 9000053 19 Mason et al., Osmotic Pressure and Viscoelastic Shear Moduli of Monodisperse Emulsions, Phys. Rev. E 56, 3150-3166 (1997). 9000053 20 Webster et al., Stabilization of Emulsions by Trapped Species, Langmuir 14, 2068 (1998). 9000054 1 Dae-Ok Kim and Chang Yong Lee, Comprehensive Study on Vitamin C Equivalent Antioxidant Capacity (VCEAC) of Various Polyphenolics in Scavenging a Free Radical and its Structural Relationship, Critical Reviews in Food Science and Nutrition, 44:253-273 (2004). 9000054 2 European Search Report for EP Application No. 12175764.5, dated Feb. 22, 2013. 9000054 3 International Search Report and Written Opinion for International Application No. PCT/US2009/052258, mailed Mar. 15, 2010. 9000054 4 Alderman, D. A., "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms," Int. J. Pharm. Tech. & Prod. Mfr., 5(3):1-9 (1984). 9000054 5 Bamba, M. et al., "Release Mechanisms in Gelforming Sustained Release Preparations," International Journal of Pharmaceutics, 2:307-315 (1979). 9000054 6 Berge, S. M. et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, 66(1):1-19 (1977). 9000054 7 Blackburn et al., "Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHr1 antagonists," Bioorg. & Med. Chem. Lett. 16:2621-2627 (2006). 9000054 8 Boarland et al., "Monosubstituted Pyrimidines, and the Action of Thiourea on Chloropyrimidines," J. Chem. Soc., 1218-1221 (1951). 9000054 9 Brown, et al., "Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure-Activity Relationships of 1,6-Disubstituted Indoles and Indazoles," J. Med. Chem. 33(6):1771-1781 (1990). 9000054 10 Buck, L. et al., "A Novel Multigene Family May Encode Odorant Receptors: A Molecular Basis for Odor Recognition," Cell, 65(1):175-187 (1991). 9000054 11 Calkins, N. L., "2,1-benzothiazines: preparation and reactivity," [Thesis], University of Missouri, Columbia (2010). 9000054 12 Campillo et al., "A study of peculiar tautomerism of pyridol[2,3-c][1,2,6]thiadiazine 2,2-dioxide system," J Mol. Struct., 678:83-89 (2004). 9000054 13 Chandrashekar, J. et al., "T2Rs Function as Bitter Taste Receptors," Cell, 100:703-711 (2000). 9000054 14 Cheng, C. C. et al., "Potential Purine Antagonists. XII. Synthesis of 1-Alkyl(aryI)-4,6-disubstituted Pyrazolo[3,4-d]pyrimidines," Journal of Organic Chemistry, 23(1):852-861 (1958). 9000054 15 Chien et al., "Nucleosides XI. Synthesis and Antiviral Evaluation of 5'-Alkylthio-5'-deoxy Quinazolinone Nucleoside Derivatives as S-Adenosyl-L-homocysteine Analogs," chem. Pharm. Bull., 52(12):1422-1426 (2004). 9000054 16 Clauss et al., "Cycloadditionen von Halogensulfonylisocyanaten an Acetylene," Tetrahedron Lett. 2:119-122 (1970). 9000054 17 Corbett et al., "Novel 2,2-Dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as Non-Nucleside Reverse Transcriptase Inhibitors," Biorg. Med. Chem. Lett., 10:193-195 (2000). 9000054 18 Dominguez et al., "Efficient synthesis of 4,4-disubstituted-3,4-dihydro-1H-2,1,3-benzothiadiazine 2,2-dioxides," Tetrahedron Lett., 41:9825-9828 (2000). 9000054 19 Dorwald, F. Z., Preface: In "Side reactions in organic synthesis: A guide to successful synthesis design," Weinheim: WILEY-VCH Verlag Gmbh & Co. KGaA (2005). 9000054 20 Doucet-Personeni, C. et al., "A Structure-Based Design Approach to the Development of Novel, Reversible AChE Inhibitors," J. Med. Chem., 44:3203-3215 (2001). 9000054 21 During, M. J. et al., "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," Ann. Neurol., 25:351-356 (1989). 9000054 22 Elmegeed et al., "Novel synthesizes aminosteroidal heterocycles intervention for inhibiting iron-induced oxidative stress," Eur. J. Med. Chem. 40:1283-1294 (2005). 9000054 23 El-Sherbeny et al., "Novel Pyridothienopyrimidine and Pyridothienothiazine Derivatives as Potential Antiviral and Antitumor Agents," Med. Chem. Res. 10:122-135 (2000). 9000054 24 Fan et al., "Transient Silylation of the Guanosine O6 and Amino Groups Facilitates N-Acylation," Organic Letters, 6(15):2555-2557 (2004). 9000054 25 Francis et al., "Anxiolytic Properties of Certain Annelated [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-ones," J. Med. Chem. 34:2899-2906 (1991). 9000054 26 Garcia-Munoz et al., "Synthesis of Purine-Like Ring Systems Derived From 1,2,6-Thiadiazine 1,1-Dioxide," J. Heterocyclic Chem., 13:793-796 (1976). 9000054 27 Goya et al., "Fused 1,2,6-Thiadiazines: Tetrahydrobenzo[b]thieno[2,3-c] [1,2,6]thiadiazine 2,2-Dioxides," Arch. Pharm. (Weinheim) 317:777-781 (1984). 9000054 28 Goya et al., "Aminopyrido [2,3-c] [1,2,6] Thiadiazine 2,2-Dioxides: Synthesis and Physico-chemical Properties," Chemica Scripta, 26:607-611 (1986). 9000054 29 Goya et al., "Synthesis of 2S-Dioxo Isosteres of Purine and Pyrimidine Nucleosides IV. Selective Glycosylation of 4-Amino-5H-Imidazo [4,5-c] -1,2,6-Thiadiazine 2,2-Dioxide," Nucleosides & Nucleotides, 6(3), 631-642 (1987). 9000054 30 Goya and Paez, "Pteridine Analogues; Synthesis and Physico-Chemical Properties of 7-Oxopyrazino [2,3-c][1,2,6] thiadiazine 2,2-Dioxides," Liebigs Ann. Chem., 121-124 (1988). 9000054 31 Goya and Martinez, "Synthesis and Cytostatic Screening of an SO2 Analogue of Doridosine," Arch. Pharm., 321:99-101 (1988). 9000054 32 Goya et al., CAPLUS Accession No. 1987:18628, 2 pages, abstract of ES 531159 A1 (1985). 9000054 33 Harris, N. V. et al., "Antifolate and antibacterial activities of 5-substituted 2,4-diaminoquinazolines," Journal of Medicinal Chemistry, 33(1):434-444 (1990). 9000054 34 Hauser et al., "Synthesis of 5-Phenyl-4,6-Dimethyl-2-Pyrimidol and Derivatives from the Cyclization of Urea with 3-Phenyl-2,4-Pentanedione," J. Org. Chem. 18:588-593 (1953). 9000054 35 Hirohashi, T. et al. "Nuclear magnetic resonance studies of bicyclic thiophene derivatives. I ring current effects of the benzene ring on the H.alpha. and H.beta. signals of the thiophene ring in benzoylthiophene, thienopyrimidine, and thienodiazepine derivatives," Bulletin of the Chemical Society of Japan, 48(1):147-156 (1975). 9000054 36 Hirota et al., "Synthesis and Biological Evaluation of 2,8-Disubstituted 9-Benzyladenines: Discovery of 8-Mercaptoadenines as Potent Interferon-Inducers," Bioorg. Med. Chem. 11:2715-2722 (2003). 9000054 37 Hoon, M. A. et al., "Putative Mammalian Taste Receptors: A Class of Taste-Specific GPCRs with Distinct Topographic Selectivity," Cell, 96:541-551 (1991). 9000054 38 Howard, M. A. et al., "Intracerebral drug delivery in rats with lesion-induced memory deficits," J. Neurosurg., 71:105-112 (1989). 9000054 39 Hu et al., "Organic Reactions in Ionic Liquids: Gewald Synthesis of 2-Aminothiophenes Catalyzed by Ethylenediammonium Diacetate," Synthetic Communication 34:3801-3806 (2004). 9000054 40 Jordan, V. C., "Tamoxifen: A Most Unlikely Pioneering Medicine," Nature Reviews: Drug Discovery, 2:205-213 (2003). 9000054 41 Jung et al., "Discovery of Novel and Potent thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors," J. Med. Chem. 49:955-970 (2006). 9000054 42 Kamal et al., "Cyclization of 2-(Carbamoyloxy)- and 2-(Sulfamoyloxy)benzoates Mediated by Liver Microsomes," J. Org. Chem. 53:4112-4114 (1988). 9000054 43 Kanuma, K. et al., "Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1," Bioorg. & Med. Chem. Lett. 15(17):3853-3856 (2005). 9000054 44 Keith, "Synthesis and Reduction of some 1H-2,1,3-Benzothiadiazin-4(3H)one 2,2-Dioxides,"J. Heterocyclic Chem., 15:1521-1523 (1978). 9000054 45 Kyte, J. et al., "A Simple Method for Displaying the Hydropathic Character of a Protein," J. Mol. Biol., 157:105-132 (1982). 9000054 46 Langer, R. et al., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," J. Macromol. Sci. Rev. Macromol Chem. 23:61-126 (1983). 9000054 47 Langer, R., "New Methods of Drug Delivery," Science, 249:1527-1533 (1990). 9000054 48 Lee et al., "Acetonitrile-Mediated Synthesis of 2,4-Dichloroquinoline from 2-Ethynyl-aniline and 2,4-Dichloroquinazoline from Anthranilonitrile," Synlett, 2006 No. 1:65-68 (2006). 9000054 49 Leistner, S. et al., "Polycyclic azines with heteroatoms in the 1- and 3-positions, Part 22. A facile synthesis of 2-(alkylthio)-4-aminothieno[2,3-d]pyrimidi nes," Archiv. der Pharmazie (Weinheim, Germany), 322(4):227-230 (1989). 9000054 50 Levy, R. J. et al., "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," Science, 228:190-192 (1985). 9000054 51 Li et al., "Human receptors for sweet and umami taste," Proc. Natl. Acad. Sci. USA 99:4692-4696 (2002). 9000054 52 Linkies et al., "Ein neues Verfahren zur Herstellung von 6-Methyl-1,2,3-oxathiazin-4(3H)-on-2,2-dioxid Kaliumsalz (Acesulfam-K)," Synthesis 405-406 (1990). 9000054 53 Liu et al., "Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies," Bioorg. & Med. Chem. Lett. 17:668-672 (2007). 9000054 54 Martinez et al., "Benzothiadiazine Dioxide Dibenzyl Derivatives as Potent Human Cytomegalovirus Inhibitors: Synthesis and Comparative Molecular Field Analysis," J. Med. Chem., 43:3218-3225 (2000). 9000054 55 Meyer, Jr. and Skibo, "Synthesis of Fused [1,2,6]Thiadiazine 1,1-Dioxides as Potential Transition-State Analogue Inhibitos of Xanthine Oxidase and Guanase," J. Med. Chem., 22(8):944-948 (1979). 9000054 56 Nie, Y. et al., "Distinct Contributions of T1R2 and T1R3 Taste Receptor Subunits to the Detection of Sweet Stimuli," Current Biology, 15(21):1948-1952 (2005). 9000054 57 Pal et al., "Synthesis and Cyclooxygenase-2 (COX-2) Inhibiting Properties of 1,5-Diarylpyrazoles Possessing N-Substitution on the Sulfonamide (-SO2NH2) Moiety," Letters in Drug Design & Discovery 2:329-340 (2005). 9000054 58 PubChemCompound, datasheet[online compound summary], Retrieved from the Internet: --rcs> [May 11, 2012]. 9000054 59 Rad-Moghadam et al., "One-pot Three-component Synthesis of 2-Substituted 4-Aminoquinazolines," J. Heterocyclic Chem. 43:913-916 (2006). 9000054 60 Rasmussen et al., "The Electrophilic Addition of Chlorosulfonyl Isocyanate to Ketones. A Convenient Synthesis of Oxazines, Oxathiazines, and Uracils," J. Org. Chem. 38:2114-2115 (1973). 9000054 61 Reddy et al., "An Efficient Synthesis of 3,4-Dihydro-4-Imino-2(1H)-Quinazolinones," Synthetic Commun. 18:525-530 (1988). 9000054 62 Rosowsky and Modest, Quinazolines. III. Synthesis of 1,3-Diaminobenzo[f]quinazoline and Related Compounds, J. Org. Chem., 31:2607-2613 (1966). 9000054 63 Saudek, C. D. et al., "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," N. Engl. J. Med., 321(9):574-579 (1989). 9000054 64 Seijas et al., "Microwave enhanced synthesis of 4-aminoquinazolines," Tetrahedron Lett. 41:2215-2217 (2000). 9000054 65 Sharma et al., "Synthesis and QSAR studies on 5-[2-(2-methylprop 1-enyl)-1H benzimidazol-1yl]-4,6-diphenyl-pyrimidin-2-(5H)-thione derivatives as antibacterial agents," Eur. J. Med. Chem. 41:833-840 (2006). 9000054 66 Silve, C. et al., "Delineating a Ca2+ Binding Pocket within the Venus Flytrap Module of the Human Calcium Sensing Receptor," The Journal of Biological Chemistry, 280(45):37917-37923 (2005). 9000054 67 Smith, M. B. et al., "March's Advanced Organic Chemistry. Reactions, Mechanisms, and Structure," Fifth Edition, John Wiley & Sons, Inc., pp. 479-480, 506-507, 510-511, 576-577, 862-865, 1179-1180 and 1552-1553 (2001). 9000054 68 Spatola, Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, 7:267-357, Marcell Dekker, Peptide Backbone Modifications, NY (1983). 9000054 69 Srivastava et al., "Solid Phase Synthesis of Structurally Diverse Pyrimido[4,5-d] Pyrimidines for the Potential Use in Combinatorial Chemistry," Bioorg. Med. Chem. Lett., 9:965-966 (1999). 9000054 70 Thurmond, J. et al., "Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy," Journal of Medicinal Chemistry, 51(3):449-469 (2008). 9000054 71 Tripathi et al., "Reaction of Flavanones with Chlorosulphonyl Isocyanate," Indian J. Chem. Sect. B, 26B:1082-1083 (1987). 9000054 72 Trivedi and Bruns, "C2,N6--Distributed Adenosines: Synthesis and Structure-Activity Relationships," Journal of Medicinal Chemistry, 32(8):1667-1673 (1989). 9000054 73 Uehling et al., "Biarylaniline Phenethanolamines as Potent and Selective .beta.3 Adrenergic Receptor Agonists," J. Med. Chem. 49:2758-2771 (2006). 9000054 74 Verma, R. K. et al., "Osmotically Controlled Oral Drug Delivery," Drug Development and Industrial Pharmacy, 26(7):695-708 (2000). 9000054 75 Verschoyle et al., "Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," British J. Cancer 80, Suppl. 2:96 Abstract No. P269 (1999). 9000054 76 Vippagunta, S. R. et al., "Crystalline solids," Advanced Drug Delivery Reviews, 48:3-26 (2001). 9000054 77 Wilson, "Traceless Solid-Phase Synthesis of 2,4-Diaminoquinazolines," Org. Lett. 3:585-588 (2000). 9000054 78 Winkler et al., "Synthesis and microbial transformation of .beta.-amino nitriles," Tetrahedron 61:4249-4260 (2005). 9000054 79 Wright, "The Synthesis of 2,1,3-Benzothiadiazine 2,2-Dioxides and 1,2,3-Benzoxathiazine 2,2-Dioxides," Journal of Organic Chemistry 30(11):3960-3962 (1965). 9000054 80 Xu, L. et al., "Purine and Pyrimidine Nucleotides Inhibit a Noninactivating K+ Current and Depolarize Adrenal Cortical Cells through a G Protein-Coupled Receptor," Molecular Pharmacology, 55:364-376 (1999). 9000054 81 Yoshizawa et al., "Efficient solvent-free Thrope reaction," Green Chem. 4:68-70 (2002). 9000054 82 Zunszain, P. A. et al., "Search for the pharmacophore in prazosin for Transport-P," Bioorganic & Medicinal Chemistry, 13:3681-3689 (2005). 9000056 1 International Search Report, issued in corresponding International Application No. PCT/CN2010/001408, Jul. 2009. 9000056 2 Written Opinion, issued in corresponding International Application No. PCT/CN2010/001408, Jul. 2009. 9000060 1 International Search Report Issued Aug. 17, 2010 in PCT/JP10/062159 Filed Jul. 20, 2010. 9000060 2 Combined Chinese Office Action and Search Report issued Jan. 4, 2013, in Chinese Patent Appplication No. 201080035168.6 with English translation. 9000060 3 Japanese Notification of Reasons for Refusal issued Dec. 11, 2013 in co-pending Japanese Patent Application No. 2009-190726, filed on Aug. 20, 2009, and English translation thereof, 6 pages. 9000060 4 U.S. Appl. No. 14/342,295, filed Feb. 28, 2014, Shima, et al. 9000061 1 Saunders and Frisch, "Polyurethanes Chemistry and Technology," vols. I and II, John Wiley and Sons, New York, NY 1962. US (too voluminous). 9000061 2 Gum, Reese, Ulrich, Reaction Polymers, Oxford University Press, publishers, New York, NY (1992) US (Too voluminous). 9000061 3 Klempner and Sendijarevic, Polymeric Foams and Foam Technology, Hanser Gardner Publications, Cincinnati, OH (2004) US (Too voluminous). 9000061 4 Ralph C. Downing., "Fluorcarbon Refrigerants Handbook," Prentice Hall, Chapter 3 (1988), pp. 17 to 34. (US). 9000061 5 Perry Romanowski, "Polyurethane," Gale Edit--How Plastics are Made--Volumes-Polyurethane, http://www.gale-edit.com/products/volumes/polyurethane.htm (Jan. 2, 20067) US. 9000061 6 Saunders and Frisch, "Polyurethanes Chemistry & Technology," vol. XVI, Part I and Part II Technology, John Wiley and Sons, New York, NY (1962), pp. 193 to 201 and 219 to 223. US. 9000061 7 Jan H. Schutt, "Polyurethane Foam Industry Prepares for `Zero ODP`," Plastics Technology--Online article (http://www/plasticstechnology.com/articles/19911 fa3.html) (Jan. 2, 2006) US. 9000061 8 M. Bogdan, J. Ling, D. Williams, "Next Generation (LGWP) of Blowing Agent for Spray Foam Applications" Proceedings of Center for the Polyurethanes Industry (CPI) (2009) US. 9000061 9 J. Ling, D. Williams, "Evaluation of HBA-2, a Low GWP Blowing Agent, in Pour-in-place Panel Applications" Proceedings of Center for the Polyurethanes Industry (CPI) (2010) US. 9000062 1 Machine Translation of EP1138709A1. Oct. 4, 2001. 9000063 1 Bell et al., "Biomedical Membranes from Hydrogels and Interpolymer Complexes", Biopolymers II, 1995, 122, 125-175. 9000063 2 Chang et al., "Highly Protein-Resistant Coatings from Well-Defined Diblock Copolymers Containing Sulfobetaines", Langmuir, 2006, 22, 2222-2226. 9000063 3 Chapman et al., "Polymeric Thin Films that Resist the Adsorption of Proteins and the Adhesion of Bacteria", Langmuir, 2001, 17(4), 1225-1233. 9000063 4 Chen et al., "Controlling Antibody Orientation on Charged Self-Assembled Monolayers", Langmuir, 2003, 19, 2859-2864. 9000063 5 Chen et al., "Strong Resistance of Oligo(phosphorylcholine) Self-Assembled Monolayers to Protein Adsorption", Langmuir, 2006, 22, 2418-2421. 9000063 6 Chen et al., "Strong Resistance of Phosphorycholine Self-Assembled Monolayers to Protein Adsorption: Insights into Nonfouling Properties of Zwitterionic Materials", J. am. Chem. Soc., 2005, 127, 14473-14478. 9000063 7 Cheng et al, "Inhibition of Bacterial Adhesion and Biofilm Formation on Zwitterionic Surfaces", Biomaterials, 2007, 28, 4192-4199. 9000063 8 Cheng et al., "Thickness-Dependent Properties of Polyzwitterionic Brushes", Macromolecules, 2008, 41, 6317-6321. 9000063 9 Cheng et al., "Zwitterionic Carboxybetaine Polymer Surfaces and their Resistance to Long-Term Biofilm Formation", Biomaterials, 2009, 30, 5234-5240. 9000063 10 Du et al., "Grafted Poly-(ethylene glycol) on Lipid Surfaces Inhibits Protein Adsorption and Cell Adhesion", Biochimica et Biophysica Acta, 1997, 1326, 236-248. 9000063 11 Feng et al., "Adsorption of Fibrinogen and Lysozyme on Silicon Grafted with Poly(2-methacryloyloxyethyl Phosphorylcholine) via Surface-Initiated Atom Transfer Radical Polymerization", Langmuir, 2005, 21, 5980-5987. 9000063 12 Feng et al., "Atom-Transfer Radical Grafting Polymerization of 2-Methacryloyloxyethyl Phosphorylcholine from Silicon Wafer Surfaces", Wiley, InterScience, 2004, 2931-2942. 9000063 13 Fujimoto et al., "Ozone-Induced Graft Polymerization onto Polymer Surface", Journal of Polymer Science, 1993, 31, 1035-1043. 9000063 14 Goda et al., "Biomimetic Phosphorylcholine Polymer Grafting from Polydimethylsiloxane Surface Using Photo-Induced Polymerization", Biomaterials, 2006, 27, 5151-5160. 9000063 15 Harder et al., "Molecular Conformation in Oligo(ethylene glycol)-Terminated Self-Assembled Monolayers on Gold and Silver Surfaces Determines Their Ability to Resist Protein Adsorption", J. Phys. Chem. B., 1998, 102, 426-436. 9000063 16 Haynie et al., "Antimicrobial Activities of Amphipilic Peptides Covalently Bonded to a Water-Insoluble Resin", Antimicrobial Agents and Chemotherapy, 1995, 39(2), 301-307. 9000063 17 Ignatova et al., "Combination of Electrografting and Atom-Transfer Radical Polymerization for Making the Stainless Steel Surface Antibacterial and Protein Antiadhesive", Langmuir, 2005-2006, 22, 255-262. 9000063 18 Ishihara et al., "Photoinduced Graft Polymerization of 2-Methacryloyloxyethyl Phosphorylcholine on Polyethylene Membrane Surface for Obtaining Blood Cell Adhesion Resistance", Colloids and Surfaces B: Biointerfaces, 2000, 18, 325-335. 9000063 19 Ishihara et al., "Protein Adsorption from Human Plasma is Reduced on Phopholipid Polymers", J. Biomed. Mater. Res., 1991, 25(11), 1397-1407. 9000063 20 Jiang et al., "Blood Compatibility of Polyurethane Surface Grafted Copolymerization with Sulfobetaine Monomer", Colloids and Surfaces B: Biointertaces, 2004, 36, 27-33. 9000063 21 Jiang, "Zwitterionic Separation Materials for Liquid Chromatography and Capillary Electrophoresis Synthesis, Characterization and Application for Inorganic Ion and Biomolecule Separations", PhD Dissertation, Umea University, Umea, Sweden, 2003, 63 pages. 9000063 22 Jin et al., "Protein-Resistant Polyurethane Prepared by Surface-Initiated Atom Transfer Radical Graft Polymerization (ATRgP) of Water-Soluble Polymers: Effects of Main Chain and Side Chain Lengths of Grafts", Colloids and Surfaces B: Biointerfaces, 2009, 70, 53-59. 9000063 23 Jin et al., "Protein-Resistant Polyurethane via Surface-Initiated Atom Transfer Radical Polymerization of Oligo(ethylene glycol) Methacrylate", Wiley Periodicals, Inc., 2009, 1189-1201. 9000063 24 Jun et al., "Surface Modification of Segmented Poly( ether urethane) by Grafting Sulfo Ammonium Zwitterionic Monomer to Improve Hemocompatibilities", Colloids and Surfaces B: Biointerfaces, 2003, 28, 1-9. 9000063 25 Kang e al., "Surface Modification and Functionalization of Electroactive Polymer Films via Grafting of Polyelectrolyte, Polyampholyte and Polymeric Acids", Journal of Materials Science, 1996, 31, 1295-1301. 9000063 26 Kildal et al., "Peroxide-Initiated Grafting of Acrylamide on to Polyethylene Surfaces," J. Appl. Polymer Sci., 1992, 44, 1893-1898. 9000063 27 Lai, "The Role of Bulky Polysiloxanylalkyl Methacrylates in Polyurethane-Polysiloxane Hydrogels", Journal of Applied Polymer Science, 1996, 60, 1193-1199. 9000063 28 Li et al., "Protein Adsorption on Alkanethiolate Self-Assembled Monolayers: Nanoscale Surface Structural and Chemical Effects", Langmuir, 2003, 19, 2974-2982. 9000063 29 Li et al., "Protein Adsorption on Oligo(ethylene glycol)-Terminated Alkanethiolate Self-Assembled Monolayers: The Molecular Basis for Nonfouling Behavior", J. Phys. Chem. B, 2005, 109, 2934-2941. 9000063 30 Liu et al., "Grafting of Zwitterion from Cellulose Membranes via ATRP for Improving Blood Compatibility", Biomacromolecules, 2009, 10, 2809-2816. 9000063 31 Lowe et al., "Well-Defined Sulfobetaine-Based Statistical Copolymers as Potential Antibioadherent Coatings", J. Biomed Mater Res, 2000, 52, 88-94. 9000063 32 Massia et al., "Immobilized RGD Peptides on Surface-Grated Dextran Promote Biospecific Cell Attachment", J. Biomed Mater Res, 2001, 56, 390-399. 9000063 33 Michel et al., "Influence of PEG Architecture on Protein Adsorption and Conformation", Langmuir, 2005, 21, 12327-12332. 9000063 34 Nichols et al., "Tear Film, Contact Lens, and Patient-Related Factors Associated with Contact Lens-Related Dry Eye", Invest Ophthalmol Vis Sci., 2006, 47, 1319-1328. 9000063 35 Odian, "Principles of Polymerization: Polymerization Mechanism, Typesof Polymers and Polymerizations", John Wiley & Sons, Inc., 4th Ed., 2004, 3 pages. 9000063 36 Sakharov et al., "Caralytic Oxidative Deformylation of Polyethylene Glycols with the Participation of Molecular Oxygen", Kinetics and Catalysis, 2001, 42(5), 662-668. 9000063 37 Salim et al., "Studies of Electroosmotic Flow and the Effects of Protein Adsorption in Plasmapolymerized Microchannel Surfaces", Electrophoresis 2009, 30, 1877-1887. 9000063 38 Tada et al., "Anti-Biofouling Properties of Polymers with a Carboxybetaine Moiety", Macromolecular Biosciences, 2009, 9, 63-70. 9000063 39 Vermette et al., "Tissue Engineering Intelligence Unit 6: Biomedical Applications of Polyurethanes", (entire book) Eurekah.com, 2001, 284 pages. 9000063 40 Villa-Diaz et al., "Synthetic Polymer Coatings for Long-Term Growth of Human Embryonic Stem Cells", Nature Biotechnology, 2010, 28(6), 581-584. 9000063 41 Wang et al., "Antifouling Ultrafiltration Membrane Composed of Polyethersulfone and Sulfobetaine Copolymer", Journal of Membrane Science, 2006, 280, 343-350. 9000063 42 Wang et al., "Highly Efficient Antifouling Ultrafiltration Membranes Incorporating Zwitterionic Poly( [ 3-( Methacryloylamino )Propyl ]-Dimethyl( 3-Sulfopropyl) Ammonium Hydroxide)", Journal of Membrane Science, 2009, 340, 164-170. 9000063 43 Weinstock et al., "Rapid, Nondestructive Estimation of Surface Polymer Layer Thickness Using Attenuated Total Reflection Fourier Transform Infrared (ATR FT-IR) Spectroscopy and Synthetic Spectra Derived from Optical Principles", Applied Spectroscopy, 2012, 66(11), 1311-1319. 9000063 44 West et al., "The Biocompatibility of Crosslinkable Copolymer Coatings Containing Sulfobetaines and Phosphobetaines", Biomaterials, 2004, 25, 1195-1204. 9000063 45 Wozney et al., "Novel Regulators of Bone Formation: Molecular Clones and Activities", Science, Research Articles, 1988, 242, 1528-1534. 9000063 46 Yuan et al., "Chemical Graft Polymerization of Sulfobetaine Monomer on Polyurethane Surface for Reduction in Platelet Adhesion", Colloids and Surfaces B: Biointerfaces, 2004, 39, 87-94. 9000063 47 Yuan et al., "Grafting Sulfobetaine Monomer onto the Segmented Poly(Ether-Urethane) Surface to Improve Hemocompatibility", J. Biomater. Sci. Polymer Edn, 2002, 13(10), 1081-1092. 9000063 48 Yuan et al., "Improvement of Blood Compatibility on Cellulose Membrane Surface by Grafting Betaines", Colloids and Surfaces B: Biointerfaces, 2003, 30, 147-155. 9000063 49 Yuan et al., "Platelet Adhesion onto Segmented Polyurethane Surfaces Modified by Carboxybetaine", J. Biomater. Sci. Polymer Edn, 2003, 14(12), 1339-1349. 9000063 50 Yuan et al., "Polyurethane Vascular Catheter Surface Grafted with Zwitterionic Sulfobetaine Tnonomer Activated by Ozone", Colloids and Surfuces B: Biointetfaces, 2004, 35, 1-5. 9000063 51 Yuan et al., "Surface Modification of SPEU Films by Ozone Induced Graft Copolymerization to Improve Hemocompatibility", Colloids and Surfaces B: Biointerfaces, 2003, 29, 247-256. 9000063 52 Yuan et al., "Grafting Sulfobetaine Monomer Onto Silicone Surface to Improve Hemocompatability", Polymer International, Jan. 2004, 53(1), 121-126. 9000063 53 Zhang et al., "Blood Compatibility of Surfaces with Superflow Protein Adsorption", Biomaterials, 2008, 29, 4285-4291. 9000063 54 Zhang et al., "Chemical Modification of Cellulose Membranes with Sulfo Ammonium Zwitterionic Vinyl Monomer to Improve Hemocompatibility", Colloids and Surfaces B: Biointerfaces, 2003, 30, 249-257. 9000063 55 Zhang et al., "Nonfouling Behavior of Polycarboxybetaine-Grafted Surfaces: Structural and Environmental Effects," Biomacromolecules, 2008, 9, 2686-2692. 9000063 56 Zhang et al., "Superlow Fouling Sulfobetaine and Carboxybetaine Polymers on Glass Slides", Langmuir, 2006, 22(24), 10072-10077. 9000063 57 Zhang et al., "Surface Grafted Sulfobetaine Polymers via Atom Transfer Radical Polymerization as Superlow Fouling Coatings", J. Phys. Chemistry B, 2006, 110, 10799-10804. 9000063 58 Zhang et al., "The Hydrolysis of Cationic Polycarboxybetaine Esters to Zwitterionic Polycarboxybetaines with Controlled Properties", Biomaterials, 2008, 29, 4719-4725. 9000063 59 Zheng et al., "Molecular Simulation Study of Water Interactions with Oligo (Ethylene Glycol)-Terminated Alkanethiol Self-Assembled Monolayers", Langmuir, 2004, 20, 8931-8938. 9000063 60 Zheng et al., "Strong Repulsive Forces between Protein and Oligo (Ethylene Glycol) Self-Assembled Monolayers: A Molecular Simulation Study", Biophysical Journal, 2005, 89, 158-166. 9000063 61 Zhou et al., "Platelet Adhesion and Protein Adsorption on Silicone Rubber Surface by Ozone-Induced Grafted Polymerization With Carboxybetaine Monomer", Colloids and Surfaces B: Biointerfaces, 2005, 41, 55-62. 9000064 1 Gun-Young Jung et al.; "Vapor-Phase Self-Assembled Monolayer for Improved Mold Release in Nanoimprint Lithography"; Langmuir 2005, vol. 21, pp. 1158-1161. 9000066 1 Chart BMEN 343 Polymer Tg chart. 9000066 2 Water Transport in Polylactic Acid (PLA), Siparsky et al. Journal of Environmental Polymer Degradation, vol. 5, No. 3, 1997. 9000066 3 Andriano, et al., `Processing and characterization of absorbable polylactide polymers for use in surgical implants,` Journal of Applied Biomaterials, 5(2):133-140 (1994). 9000066 4 Asano, et al., `In vivo characteristics of low molecular weight copoly(D.L-lactic acid) formulations with controlled release of LH-RH agonist,` Biomaterials, 10(8):569-573 (1989). 9000066 5 Barca, et al., `Resorbable poly-L-lactic acid mini-staples for the fixation of Akin osteotomies,` The Journal of Foot and Ankle Surgery, 36(2):106-111 (1997). 9000066 6 Bartenev et al.; On the theory of biaxial orientation of amorphous polymers, Mechanics of Composite Materials, 1973, vol. 6, p. 671-677. 9000066 7 Bertrand, et al., Biocompatibility Aspects of New Stent Technology, JACC, 32(3):562-571 (1998). 9000066 8 Celikkaya, et al., `Poly(DL-lactide)/Poly(ethylene glycol) Copolymer Particles. I. Preparation and Characterization,` Journal of Applied Polymer Science, 61: 1439-1446 (1996). 9000066 9 D. Hull and T. W. Clyne, `An introduction to composite materials,` Second Edition, Cambridge University Press, Table of Contents, (1996) 8 pages. 9000066 10 D. Wheeler, et al., `Effect of bioactive glass particle size on osseous regeneration of cancellous defects,` J. Biomed. Materials Research, 41(4):527-533 (1998). 9000066 11 Daniels, et al., `Mechanical properties of biodegradable polymers and composites proposed for internal fixation of bone,` J. Applied Biomaterials, 1 :57-78 (1990). 9000066 12 Dauner, et al. `Resorbable continuous-fiber reinforced polymers for osteosynthesis,` J. Materials Science Materials in Medicine, 9: 173-179 (1998). 9000066 13 Eling, et al., `Biodegradable Materials of Poly(L-Lactic Acid): 1. Melt-Spun and Solution-Spun Fibres,` Polymer, 23:1587-1593 (1982). 9000066 14 Fambri, et al., `Biodegradable fibres of poly(I-lactic acid) produced by melt spinning,` Polymer, 38:79-85 (1997). 9000066 15 Frenger, `Biomedical Uses of Shape Memory Polymers,` Biomed. Sci. Instrum., 29:47-50 (1993). 9000066 16 Fukuzaki, et al., Synthesis of copoly(D,L-Lactic acid) with relatively low molecular weight and in vitro degradation, Japan Atomic Energy Research Institute, Gunma, Jpn, European Polymer Journal,25(10):1019-1026 (1989). 9000066 17 Gautier, et al., `Poly(a-hydroxyacids) for application in the spinal cord: Resorbability and biocompatibility with adult rate Schwann cells and spinal cord,` Journal of Biomedical Materials Research, 42(4):642-654 (1998). 9000066 18 Giardino, et al., `Experimental evaluation of a resorbable intramedullary plug for cemented total hip replacement,` Biomaterials, 18(13):907-913 (1997). 9000066 19 Gogolewsji, et al., `Resorbable materials of poly(L-lactide). II Fibers spun from solutions of poly(L-lactide) in good solvents,` J. Appl. Polymer Sci., 28:1045-1061 (1983). 9000066 20 Grijpma et al., `Chain Entanglement Mechanical Properties and Drawability of Poly (Lactide),` Colloid Polym Sci., 272:1068-1081 (1994). 9000066 21 Haers, et al., `Biodegradable polyactide plates and screws in orthognathic surgery,` Technical Note, Journal of Cranio-Maxillofacial Surgery, 26(2):87-91 (1998). 9000066 22 Hyon, et al., `Effects of residual monomer on the degradation of DL-lactide polymer,` Hyon, Jamshidi & Ikeda, Polymer International, 46:196-202 (1998). 9000066 23 J. West et al, `Bioactive Polymers, Synthetic biodegradable polymer scaffolds,` Chapter 5, pp. 83-95, Anthony Atala and David J. Mooney, Editors; Joseph P. Vacanti and Robert Langer, Associate Editors, Birkhauser (1997). 9000066 24 Kaitian, et al., `Poly(D,L-Lactic Acid) Homopolymers: Synthesis and Characterization,` Turkish Journal of Chemistry, 20:43-53 (1996). 9000066 25 Kister, et al., `Effects of morphology, conformation and configuration on the IR and Raman spectra of various poly(lactic acid)s,` Polymer, 39(2): 267-273 (1998). 9000066 26 Koelling, et al., `In vitro real-time aging and characterization of poly(L/D-lactic acid),` Proceedings of the 1997 1ffh Southern Biomedical Engineering Conference (Cat. No. 97TH8270), pp. 197-201. 9000066 27 Kontio, et al., `Fibrous wound repair associated with biodegradable poly-L/D-lactide copolymers implants: study of the expression of tenascin and cellular fibronectin,` Journal of Materials Science-Materials in Medicine, 9:10:603-609 (1988). 9000066 28 Kricheldorf, et al., `Polyactones: 32. High-molecular weight polylactides by ring-opening polymerization with dibutylmagnesium or butylmagnesium chloride,` Polymer, 36(15):2995-3003 (1995). 9000066 29 L. L. Hench, `Bioactive materials: The potential for tissue regeneration,` J. Biomed. Materials Research, 41(4):511-518 (1998). 9000066 30 Losken, et al., `Memory of DL-polylactic acid biodegradable plates,` Ann. Plast. Surg., 32(6):606-611 (1994). 9000066 31 MacDonald, et al., `Enzymatic degradability of poly(lactide): Effects of chain stereochemistry and material crystallinity,` Macromolecules, 29(23):7356-7361 (1996). 9000066 32 Mainil-Varlet, et al., `Effect of in vivo and in vitro degradation on molecular and mechanical properties of various low-molecular weight polylactides,` Journal of Biomedical Materials Research, 36(3):360-380 (1997). 9000066 33 Matsumura, et al., `Novel ring opening polymerization of lactide by lipase,` Macromol. Symp., 130:285-304 (1998). 9000066 34 Mauduit, J. et al.; "Hydrolytic degradation of films prepared from blends of high and low molecular weight poly (DL lactic acid)s" Journal of Biomedical Materials Research, 1996, vol. 30, p. 201-207. 9000066 35 Morita, et al., `Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid)implants,` Biological & Pharmaceutical Bulletin, 21 (2): 188-190 (1998). 9000066 36 Okihara, et al., Crystal structure of stereocomplex of poly(L-lactide) and poly(D-lactide), Journal of Macromolecular Science-Physics, B30(1 and 2): 119-140 (1991). 9000066 37 Okuzaki, et al., Mechanical Properties and Structure of the Zone-Drawn Poly(I-lactic acid) Fibers, Journal of Polymer Science, Part B, Polymer Physics, 37:991-996 (1999). 9000066 38 Oriented Polymer Materials, Edited by Stoyko Fakirov, published by Huthig & Wepf Verlag Zug, Heidelberg, Oxford CTIUSA, Table of Contents pp. v, viii, ix-xix (1996). 9000066 39 Penning, et al., `Preparation and properties of absorbable fibres from I-lactide copolymers,` Polymer, 34(5):942-951 (1993). 9000066 40 Pitt, et al., `Modification of the rates of chain cleavage of polY(e-caprolactone) and related polyesters in the solid state,` Journal of Controlled Release, 4:283-292 (1987). 9000066 41 Pitto, et al., "Comparison of fixation of the femoral component without cement and fixation with use of a bone-vacuum cementing technique for the prevention of fat embolism during total hip arthroplasty," J. Bone Joint Surg., 81-A(6).about.831-843 (1999). 9000066 42 Rak, et al., `The preparation and characterization of poly(D,L-lactic acid) for use as a biodegradable drug carrier,` (1985) liverpool Poly tech., liverpool, UK, Pharmaceutica Acta Helvetiae, 60:(5-6):162-169. 9000066 43 Ristic, et al., `An investigation of synthesis and degradation of poly(D,L-lactide) and controlled release of albumin from biodegradable poly(D,L-lactide) cylinders,` ICheaP-2, the second Italian conference on chemical and process engineering, Florence, pp. 559-563 (1995). 9000066 44 Schliephake, et al., `Reconstruction of the mandible by prefabricated autogenous bone grafts,` Int. J. Oral Maxillofac. Surg., 26:244-252 (1997). 9000066 45 Stahelin, et al., Clinical degradation and biocompatibility of different bioabsorbable interference screws: a report of six cases: Arthroscopy: The Journal of Arthroscopic & Related Surgery, 13(2):238-244 (1997). 9000066 46 Steendam, et al., The role of elastic relaxation in drug delivery from poly(DL-lactic acid) based tablets. A shape memory phenomenon: Proceedings of the International Symposium on Controlled Release of Bioactive Materials, 25:128-129 (1998). 9000066 47 Stevels, et al., `Blends van blok copolymeren die een poly(L-lactide) of poly(D-lactide) blok bevatten,` Biomedical Science and Engineering Meeting, pp. 107-110 (1994). 9000066 48 Tagl, "Thesis--The morselized and impacted bone graft animal experiments on proteins, impaction and load," Acta Orthop. Scand. Suppl., 290:1-40 (2000). 9000066 49 Temenoff et al., "Injectable biodegradable materials for orthopedic tissue engineering," Biomaterials, 21 :2405-2412 (2000). 9000066 50 Tschakaloff, et al., `Degradation kinetics of biodegradable DL-polyactic acid biodegradable implants depending on the site of implantation,` International Journal of Oral and Maxillofacial Surgery, 23(6 Pt2 ):443-445 (1994). 9000066 51 Zegzula, et al., `Bone Formation with Use of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2,` The Journal of Bone and Joint Surgery, 79:1778-1790 (1997). 9000066 52 Zhang, Biodegradable lactide polymers: synthesis, degradation, and controlled drug release properties (drug release), Queen's University at Kingston, Canada, vol. 55/01-B of Dissertation Abstracts International, p. i-xv, 1-179 (Oct. 1993). 9000066 53 Office Action for Japanese Application No. 2010504268 dated Jul. 17, 2012, 6 pages. 9000066 54 Office Action for Japanese Application No. 2010504268 dated Jan. 8, 2013, 4 pages. 9000066 55 Japanese Office Action dated Jun. 19, 2012 for JP Application 2010-504182. p. 1-6. 9000066 56 Examination Report for counterpart Australian Application No. 2008242737 dated Aug. 10, 2012, pp. 1-3. 9000066 57 Atkins, G., Haynes, D.R., Howie, D.W., & Findlay, D.M., Role of polyethylene particles in peri-prosthetic osteolysis: A Review, World of Journals of Orthopedics, 2(10), Oct. 18, 2011, pp. 93-101. 9000066 58 Hill, R.G., "Biomedical Polymers: Biomaterials, artificial organs and tissue engineering", Imperial College London, UK, date unknown but prior to the date of this application, 7 pages. 9000066 59 Vert, M., Li, S.M., Spenlehaur, G., Guerin, P., "Pioresorbability and biocompatibility of aliphatic polyesters", Journal of Materials Science: Materials in Medicine 3, 1992, pp. 432-446. 9000066 60 English Translation, Decision to Reject the Amendments, and Decision of Rejection for Japanese Patent Application No. 2010-504268 dated Oct. 1, 2013, 11 pages. 9000066 61 Steendam, et al. The role of elastic relaxation in drug delivery from poly(DL-lactic acid) based tablets. A shape memory phenomenon: Proceedings of the International Symposium on Controlled Release of Bioactive Materials, 25:128-129 (1998). 9000066 62 Stevels, et al., "Blends can clok copolumeren die een poly(L-lactide) of poly(D-ladtide) blok bevatten", Biomedical Science and Engineering Meeting, pp. 107-110 (1994). 9000066 63 Structure and Properties of Oriented Polymers, Ed. I. M. Ward, Department of Physics, University of Leads, England, a Halsted Press Book, John Wiley & Sons, New York-Toronto (1975) Table of Contents. 9000066 64 Summary of the Office Action, dated Mar. 19, 2012, 1 page. 9000066 65 Tagl, "These--The morselized and impacted bone graft animal experiments on proteins, impaction and load", Acta Orthop. Scan. Suppl., 290:1-40 (2000). 9000066 66 Temenoff, et al., "Injectable biodegradable materials for orthopedic tissue engineering", Biomaterials, 21:2405-2412 (2000). 9000066 67 Tschakaloff, et al., "Degradation kinetics of biodegradable DL-polyactic acid biodegradable implants depending on the site of implantation", International Journal of Oral and Maxillofacial Surgery, 23(6):443-445 (1994). 9000066 68 Tsuji, et al., Stereocomplex formation between enantiomeric poly(lactic acid). VIII. Complex Fibers spun from mixed solution of poly(D-lactic acid) and poly(L-lactic acid), Journal of Applied Polymer Science, 51(2):337-344 (1994). 9000066 69 West, J., "Bioactive Polymers, Synthetic biodegradable polymer scaffolds", Chapter 5, pp. 83-95, Anthony Atala and David J. Mooney, Editors; Joseph P. Vacanti and Robert Langer, Associate Editors, Birkhauser (1997). 9000066 70 Zegula, et al. "Bone Formation with Use of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2", The Journal of Bone and Joint Surgery, 79:1778-1790 (1997). 9000066 71 Zhang, Biodegradable lactide polmers: synthesis, degradation, and controlled drug release properties (drug release), Queen's University at Kingston, canada, vol. 55/01-B of Dissertation Abstracts International, p. i-xv, 1-179 (Oct. 1993). 9000066 72 International Search Report and Written Opinion for PCT/US2008/060783 dated Jul. 23, 2008. 9000066 73 International Preliminary Report on Patentability and Written Opinion for PCT Application No. PCT/GB2012/052478 dated Apr. 8, 2014, 14 pages. 9000066 74 International Search Report for PCT Application No. PCT/GB2012/052478 dated Jun. 20, 2013, 5 pages. 9000066 75 International Preliminary Report on Patentability and Written Opinion for PCT Application No. dated Apr. 8, 2014, 6 pages. 9000066 76 International Search Report for PCT Patent Application No. PCT/GB2012/052470 dated Feb. 22, 2013, 2 pages. 9000066 77 International Search Report for PCT Application No. PCT/GB2012/052475 dated Mar. 8, 2013, 3 pages. 9000066 78 International Search Report and Written Opinion for PCT Application No. PCT/GB2012/052475 dated Apr. 8, 2014, 10 pages. 9000066 79 International Preliminary Report on Patentability and Written Opinion for PCT Application No. PCT/GB2012/052480 dated Apr. 8, 2014, 12 pages. 9000066 80 International Search Report for PCT Application No. PCT/GB2012/052480 dated May 31, 2013, 4 pages. 9000066 81 International Search Report and Written Opinion for PCT/US2008/060783 dated Jul. 23, 2008, 2 pages. 9000066 82 Andriano et al., "Processing and characterization of absorbable polyactide polymers for use in surgical implants", Journal of Applied Biomaterials, 5(2):133-140 (1994). 9000066 83 Barca et al., "Resorbable poly-L-lactic acid in mini-staples of the fixation of Akin osteotomies", The Journal of Foot and Ankle Surgery, 36(2)106-111 (1997). 9000066 84 Bartenev et al., On the theory of biaxial orientation of amorphous polymers, Mechanics of Composite Materials, 1973, co. 6, p. 671-677. 9000066 85 Bertrand et al., "Biocompatibility Aspects of New Stent Technology", JACC, 32(3):562-571 (1998). 9000066 86 Celikkaya et al., "Poly(DL-lactide)Poly(ethylene glycol) Copolymer Particles. I preparation and Characterization", Journal of Applied Polymer Science, 61:1439-1446 (1996). 9000066 87 D. Hull and T.W. Clyne, "An introduction to composite materials," Second Edition, Cambridge University Press, Table of Contents, (1996), 8 pages. 9000066 88 D. Wheeler et al., "Effect of bioactive glass particle size on osseous regeneration of cancellous defects", J. Biomed. Materials Research, 41(4):527-533 (1998). 9000066 89 Daniels et al., "Mechanical properties of biodegrabable polymers and compisites proposed for internal fixation of bone, "J. Applied Biomaterials, 1:57-78 (1990). 9000066 90 Dauner et al., "Resorbable continuous-fiber polymers for osteosynthesis", J Materials Science Materials in Medicine, 9:173-179 (1998). 9000066 91 Eling, et al., "Biodegradable Materials of poly(I-lactic acid):1. Melt-Spun and Solution-Spun Fibres", Polymer, 23:1587-1593 (1982). 9000066 92 Farnbri, et al., "Biodegradable fibres of poly(I-lactic acid) produced by melt spinning", Polymer, 38: 79-85 (1997). 9000066 93 First Japanese Office Action for Application No. 2010-503579 dated Mar. 6, 2012, 6 pages. 9000066 94 First Office Action for Patent Application No. JP 2010-504201, mail dated Mar. 19, 2013, 5 pages. 9000066 95 Frenger, "Biomedical Uses of Shape Memory Polymers", Miomed. Sci. Instrum., 29:47-50 (1993). 9000066 96 Fukuzaki et al., Synthesis of copoly(D, L-Lactic acid) with relatively low molecular weight and in vitro degradation, Japan Atomic Energy Research Institute, Gunma, Jpn, European Polymer Journal, 25(10):1019-1026 (1989). 9000066 97 Gautier et al., "Synthesis of copoly(a-hydroxyacids) for application in the spinal cord: Resorbability and biocompatibility with adult rate Schwann cells and spinal cord", Journal of Biomedican materials Research, 42(4):642-654 (1998). 9000066 98 Giardino et al., "Experiemental evaluation of a resorbable intramedullary plug for cemented total hip replacement", Biomaterials, 18(13)907-913 (1997). 9000066 99 Gogolewski et al., "Resorbable materials of poly(L-lactide). II Fibers spun from solutions of poly(L-lactide) in good solvents", J Appl. Polymer Sci., 28:1045-1061, (1983). 9000066 100 Grijpma et al., "Chain Entanglement Mechanical Properties and Drawability of Poly (Lactide)", Colloid Polym Sci., 272:1068-1081 (1994). 9000066 101 Haers et al., "Biodegradable polyactide plates and screws in othognathic surgery", Technical Note, Journal of Cranio-Maxillofacial Surgery, 26(2):87-91 (1998). 9000066 102 Hench, L.L., "Bioactive materials: The potential for tissue regeneration", J. Biomed. Materials Research, 41(4):511-518 (1998). 9000066 103 Hyon et al., "Effects of residual monomer on the degradation of DL-lactide polymer", Hyon, Jamshidi & Ikada, Polymer International, 46:196-202 (1998). 9000066 104 International Search Report and Written Opinion for PCT/GB2008/001331 dated Aug. 25, 2008. 9000066 105 International Search Report and Written Opinion for PCT/US2008/060401 dated Jan. 9, 2009. 9000066 106 Kaitian, et al., "Poly(D,L-lactic Acid) Homopolymers: Synthesis and characterization", Turkish Journal of Chemistry, 20:43-53 (1996). 9000066 107 Kister, et al., "Effects of morphology, conformation and configuration on the IR and Raman spectra of various poly (lactic acid)s", 39(2):267-273 (1998). 9000066 108 Koelling, et al., "In vitro real-time aging and characterization of poly(L/D-lactic acid)", Proceedings of the 1997 1ffh Southern Biomedical Engineering Conference (Cat. No. 97TH8270), pp. 197-201. 9000066 109 Kontio, et al., "Fibrous wound repair associated with biodegradable poly-L/D-lactide copolymers implants: study of the expression of tenascin and cellular fibronectin", Journal of Materials Science--Materials in Medicine, 9:10:603-609 (1988). 9000066 110 Kricheldorf, et al., "Polyactones: 32. High-molecular weight polyactides by ring-opening polymerization with dibutylmagnesuim or butylmagnesium chloride", Polymer, 36(15):2995-3003 (1995). 9000066 111 Losken, et al., "Memory of DL-polylacitc acid biodegradable plates", Ann. Plast. Surg., 32(6):606-611 (1994). 9000066 112 MacDonald, et al., "Enzymatic degradability of poly(lactide): Effects of chain stereochemistry and material crystallinity", Macromolecules, 29(23):7356-7361 (1996). 9000066 113 Mainil-Varlet, et al. "Effect on in vitro degradation on molecular and mechanical properties of various low-molecular weight polulactides", Journal of Biomedical Research, 36(3):360-380 (1997). 9000066 114 Matsumura, et al., "Novel ring opening polymerization of lactide by lipase", Macromol. Symp., 130:285-304 (1998). 9000066 115 Mauduit, et al., "Hydrolytic degradation of films prepared from blends of high and low molecular weight poly (DL lactic acid)s" Journal of Biomedical Materials Research, 1996, vol. 30, p. 201-207. 9000066 116 Mitsura Momma, et al., "Long Bone Intramedullary Fixation Method Using Shape Memory Anchoring Nails--An Attempt at a Biomechanical Test And The Application Thereof to Proximal Humeral Fractures," Journal of the Eastern Japan Association of Orthopaedics and Traumatology, vol. 12, No. 4, pp. 385-390 and back cover, 2000, 8 pages. 9000066 117 Morita, et al., "Intravitreous delivery of dexamethasone sodium m-sulfobnenzoate from poly(DL-lactic acid) implants", Biological & Pharmaceutical Bulletin, 21(2):188-190 (1998). 9000066 118 Notice of Reasons for Rejection for Japanese Patent Application No. 2010-504201 dated Nov. 26, 2013, 10 pages and English Translation thereof. 9000066 119 Ofer Nativ, et al. "Bladder Neck Suspension Using Bone Anchors for the Treatment of Female Stress Incontinence," ASAIO Journal, vol. 43, No. 3, pp. 204-208 and cover, May-Jun. 1997, 6 pages. 9000066 120 Okihara, et al., Crystal structure of stereocomplex of poly(D-lactide), Journal of Macomolecular Science-Physics, B30 (1 and 2):119-140 (1991). 9000066 121 Okuzaki, et al., Mechanical Properties and Structure of the Zone-Drawn Poly(L-lactic acid) Fibers, Journal of Polymer Science, Part B, Polymer Physics, 37:991-996 (1999). 9000066 122 Oriented Polymer Materials, edited by Stoyko Fakirov, published by Huthig & Wepf Verlag Zug, Heidelberg, Oxford CTIUSSA, Table of Contents pp. v, viii, ix-xix (1996). 9000066 123 PCT/GB2008/001331 International Preliminary Report on Patentability with Written Opinion dated Oct. 20, 2009, 8 pages. 9000066 124 Penning, et al. "Preparation and properties of absorbable fibres from I-lactide copolymers", Polymer, 34(5):942-951 (1993). 9000066 125 Pitt, et al. "Modification of the rates of chain cleavage of Poly(e-caprolactone) and related polyesters in the solid state", Journal of Controlled Release, 4:283-292 (1987). 9000066 126 Pitto, et al., "Comparison of finxation of the femoral componenet without cement and fixation with use of a bone-vaccuum cementing technique for the prevention of fat embolism during total hip anthroplasty", J. Bone Joint Surg., 81A(6):831-843 (1999). 9000066 127 Rak et al., "The preparation and characterization fo poly(D,L-lactic acid) for use as a biodegradable drug carrier", (1985) liverpool Poly tech, liverpool UK, Pharmaceutica Acta Hevetiae, 60:(5-6):162-169. 9000066 128 Ristic et al., "An investigation of synthesis and degradation of poly(D,L-lactide) and controlled release of albumin from biodegradable poly (D,L-lactide) cylinders," IcheaP-2, the second Italian conference on chemical procedures and process engineering, Florence, pp. 559-563 (1995). 9000066 129 Schliephake, et al., "Reconstruction on the mandible by prefabricated autogenous bone grafts", Int. J. Oral Maxillofacial. Surg., 26:244-252 (1997). 9000066 130 Second Japanese Office Action for Application No. 2010-503579 dated Feb. 19, 2013, 3 pages. 9000066 131 Stahelin, et al. Clinical degradation and biocompatibility of different bioabsorbable interference screw: a report of six cases: Arthroscopy: The Journal of Arthroscopic & Related Surgery, 13(2):238-244 (1997). 9000067 1 Machine translation of JP 2002-113549 A, Apr. 16, 2002. 9000068 1 Machine Translation of WO 2004092284, (Oct. 2004). 9000068 2 International Search Report and Written Opinion in German dated Feb. 2007 issued in corresponding PCT Application No. PCT/EP2006/007737. 9000068 3 KEN-REACT Reference Manual Titanate, Zirconate and Aluminate Coupling Agents, 2. Uberarbeitete Ausgabe, Sommer 1993, S. 2-21. 9000068 4 Hans-Georg Elias, "Malcromolekiile" 4th Edition, Huthig & Wepf Verlag Basel (1981). 9000068 5 Greiwe et al., "Paints and Printing Inks," Coating, vol. 11 (1997). 9000068 6 Kiehl, A., et al. "Encapsulated Aluminum Pigments," Progress in Organic Coatings, vol. 37, pp. 179-183 (1999). 9000068 7 Notice of Reasons for Rejection dated Mar. 27, 2012 in corresponding Japanese Patent Application No. 2008-524447 (with English translation). 9000068 8 Japanese Office Action dated Jul. 2, 2013 in corresponding Japanese Patent Application No. 2008-524447 (with English language translation). 9000068 9 First Examination Report dated Feb. 24, 2014 issued in corresponding Indian Patent Application No. 820/DELNP/2008. 9000069 1 Zhe Liu, Yunhui Zhao, Jianwei Zhou & Xiaoyan Yuan, "Synthesis and Characterization of Core-Shell Polyacrylate Latex Containing Fluorine/Silicone in the Shell and the Self-Stratification Film", Colloid Polymer Science, 2012, p. 203-211, vol. 290, Springer, Tianjin, China. 9000069 2 Xuejun Cui, Shuangling Zhong, Haitao Zhang, Qiang Qu, Junfeng Li and Hongyan Wang, "Preparation and Characterization of Polytetrafluoroethylene-Polyacrylate Core-Shell Nanoparticles," Polymers for Advanced Technologies, May 8, 2007, 544-548, vol. 18, John Wiley & Sons, Ltd., China. 9000069 3 R.R. Thomas, K.G. Lloyd, K.M. Stika, L.E. Stephans, G.S. Magallanes, V.L. Dimonie, E.D. Sudol and M.S. El-Aasser, "Low Free Energy Surfaces Using Blends of Fluorinated Acrylic Copolymer and Hydrocarbon Acrylic Copolymer Latexes," Macromolecules, Oct. 21, 2000, 8828-8841, vol. 33, American Chemical Society. 9000069 4 W. Ming, M. Tian, R.D. Van De Grampel, F. Melis, X. Jia, J. Loos, and R. Van Der Linde, "Low Surface Energy Polymeric Films from Solventless Liquid Oligoesters and Partially Fluorinated Isocyanates," Macromolecules Jul. 30, 2002, 6920-6929, vol. 35, American Chemical Society. 9000069 5 Su Chen, Weicai Yan and Li Chen, "Compatibility and Morphology of the Fluoropolymer/Polyacrylate Latex Interpenetrating Polymer Networks," Polymer Preprints, 2003, 712, vol. 44(2), Chemical College, Nanjing, China. 9000069 6 A. Toussaint, "Self-stratifying coatings for plastic substrates (Brite Euram Project R1 1B 0246 C(H))," Progress in Organic Coatings, 1996, 183-195, vol. 28, E.L. Sevier, Belgium. 9000069 7 Tosko A. Misev, "Thermodynamic Analysis of Phase Separation in Selfstratifying Coatings--Solubility Parameters Approach," Journal of Coatings Technology, Apr. 1991, No. 795, vol. 63. 9000069 8 C. Carr, "Multilayered Paint Films from Single Coat Systems," The Paint Research Association, 1990, Middlesex, United Kingdom. 9000069 9 Shiyuan Cheng, Yanjun Chen and Zhengguo Chen, "Core-Shell Latex Containing Fluorinated Polymer Rich in Shell," Journal of Applied Polymer Science, 2002, 1147-1153, vol. 85, Wiley Periodicals, Inc., Wuhan, China. 9000069 10 Peter Hupfield, Eiji Kitaura, Tetsuya Masutani, and Masaru Nagato, "Chemical Partners--Synergy between Fluorine and Silicone Enhances Stain Resistance of Coatings.", 8th Nurnberg Congress, Creative Advances in Coatings Technology, Nuremberg, Germany. 9000069 11 Chaocan Zhang and Yanjun Chen, "Investigation of Fluorinated Polyacrylate Latex with Core-Shell Structure," Polymer International, 2005, 1027-1003, vol. 54, Society of Chemical Industry, Wuhan, China. 9000069 12 Jurgen Scheerder, Nico Visscher, Tijs Nabuurs, and Ad Overbeek, Novel, "Water-Based Fluorinated Polymers with Excellent Antigraffiti Properties," JCT Research, Oct. 8, 2005, No. 8, vol. 2. 9000069 13 Vladimir V. Verkholantsev, "Exploiting Self-Stratification.", ECJ, Jan./Feb. 2005. 9000069 14 V.V Verkholantsev, "Heterophase and Self-Stratifying Polymer Coatings," Progress in Organic Coatings, 1995, 31-52, vol. 26, Elsevier Science, Isreal. 9000069 15 Marek W. Urban, "Why Organic Coatings Stratify--Challenges and Opportunities of Locally Varying Coating Properties," ECJ, 2003, pp. 36 & 38, No. 1-2. 9000069 16 V.V. Verkholantsev, "Self-Stratifying Coatings for Industrial Applications," Pigment and Resin Technology, 2003, 300-306, vol. 32--No. 5, Emerald Group Publishing. 9000069 17 Vladimir Verkholantsev, "Self-Stratifying Coatings," Dec. 2000, European Coatings Journal. 9000069 18 V. Verkholantsev and M. Flavian, "Polymer Structure and Properties of Heterophase and Self-Stratifying coatings," Progress in Organic Coatings, 1996, 239-246, vol. 29, E.I. Sevier, Isreal. 9000069 19 V.V. Verkholantsev, "Coatings Based on Polymer/Polymer Composites," Journal of Coatings Technology, Jun. 1992, 51-59, vol. 64 No. 809. 9000069 20 Chris Carr, Sue Benjamin and Derek J. Walbridge, "Fluorinated Resins in Self-Stratifying Coatings," European Coatings Journal, 1995, pp. 262-266, No. 4. 9000069 21 P. Vink and T.L. Bots, "Formulation Parameters Influencing Self-Stratification of Coatings," Progress in Organic Coatings, 1996, 173-181, vol. 28, E.L. Sevier, Netherlands. 9000069 22 D.J. Walbridge, "Self-Stratifying Coatings--an overview of a European Community Research Project," Progress in Organic Coatings, 1996, 155-159, vol. 28, E.L. Sevier, Middlesex, United Kingdom. 9000069 23 A.M. Joly, "Statistical Treatment of Data from the European Community Research on Self-Stratification," Progress in Organic Coatings, 1996, 209-222, vol. 28, E.L. Sevier, Cedex, France. 9000069 24 Yanjun Chen and Hui Zhou, "Effect of Particle Size on Self-Organized Film-Formation of Emulsifier-Free Fluorinated Polyacrylates Latex Blends," Polymer Preprints, 2009, 200, vol. 50(1), The American Chemical Society, Wuhan, China. 9000069 25 Xiao Xinyan, and Liu Jianfei, "Synthesis and Characterization of Fluorine-Containing Polyacrylate Emulsion with Core-Shell Structure," Chinese Journal of Chemical Engineering, 2008,626-630, vol. 16(4), Guangzhou, China. 9000069 26 Yang Tingting, Peng Hui, Cheng Shiyuan, and In Jun Park, "Soap-Free Emulsion Copolymerization of Perfluoroalkyl Acrylates in the Presence of a Reactive Surfactant," Journal of Applied Polymer Science, Feb. 27, 2007, 2438-2444, vol. 104, Wiley Periodicals, Inc., Taejon, South Korea. 9000069 27 Jiri George Drobny, "Fluoropolymers in Automotive Applications," Polymers for Advanced Technologies, Nov. 29, 2006, 117-121, vol. 18, John Wiley & Sons, Ltd., New Hampshire, USA. 9000069 28 Pei-Yuan Huang, Yu-Chou Chao, and Yih-Tyan Liao, "Enhancement of the Water Repellency Durability of the Fabrics Treated by Fluorinated Nanocopolymer Emulsions," Institute of Organic and Polymeric Materials, Journal of Applied Polymer Science, Feb. 27, 2007, 2451-2457, vol. 104, Wiley Periodicals, Inc., Taipei, Taiwan. 9000069 29 Yanjun Chen, Shiyuan Cheng, Yifeng Wang, & Chaocan Zhang, "Chemical Components and Properties of Core-Shell Acrylate Latex Containing Fluorine in the Shell and Their Films," Journal of Applied Polymer Science, 2006, 107-114, vol. 99, Wiley Periodicals, Inc., Wuhan, China. 9000069 30 Francesca Signori, Massimo Lazzari, Valter Castelvetro, & Oscar Chiantore, "Copolymers of Isopropenyl Alkyl Ethers and Fluorinated Acrylates, and Fluoracrylates: Influence of Fluorine on Their Thermal, Photochemical, and Hydrolytic Stability," Macromolecules, Feb. 2, 2006, 1749-1758, vol. 39, American Chemical Society. 9000069 31 Yanjun Chen, Chaocan Zhang, & Xinxin Chen, "Emulsifier-Free Latex of Fluorinated Acrylate Copolymer," European Polymer Journal, Oct. 6, 2005, 694-701, vol. 42, E.L. Sevier, Wuhan, China. 9000069 32 Dmitry A. Kulikov, Eugene A. Indeikin, and Vladimir B. Manerov, "Benefits of incompatibility, Layer Separation in Mixed Polymer Systems can Improve Adhesion," European Coatings Journal, 2008, pp. 20-25. 9000069 33 E.I. Dupont De Nemours and Company, DuPont Zonyl Fluoroadditives, Technical Information, Date Unknown. 9000069 34 Tosoh F-Tech, Inc., Fluorester, 2,2,2-Trifluoroethyl Methacrylate, Date Unknown. 9000069 35 Osaka Organic Chemical Industry Ltd., Specialty Monomers, 2) Fluorine-Contained Monomers, Date Unknown. 9000070 1 Raj et al., "VCMT Rotors Improve Mixing Time, Throughput," Rubber & Plastics News, pp. 1-8, Feb. 24, 2003. 9000071 1 European Search Report dated Feb. 4, 2015 in European Application No. 13165059.0. 9000072 1 "Design properties for molded, corn-based DDGS-filled phenolic resin", R.A. Tatara, K.A. Rosentrater, S. Suraparaju, pp. 9-15, Industrial Crops and Products 29 (2009) 9-15. 9000072 2 "Compression Molding of Phenolic Resin and Corn-based DDGS Blends", R.A. Tatara, S.Suraparaju, K.A. Rosentrater, J Polym Environ (2007), pp. 1-7, published online Apr. 11, 2007, copyright Springer Science +Business Media, LLC, 2007. 9000072 3 "Analytical and Experimental Studies of Properties of Ethanol Coproduct-Filled Plastics", Otieno et al., pp. 1-12, Proceedings of the 2006 IJME--INTERTECH Conference. 9000072 4 "Chemical modification of zein by bifunctional polycaprolactone (PCL)", Wu et al., pp. 1-11, Polymer 44 (2003) 3909-3919, copyright 2003 Elsevier Science Ltd. 9000072 5 "Preliminary Studies on Converting Agricultural Waste into Biodegradable Plastics, Part I: Corn Distillers' Dry Grain", Schilling et al., pp. 1-8, Journal of Polymers and the Environment, vol. 12, No. 4, Oct. 2004. 9000072 6 "Preliminary Studies on Converting Agricultural Waste into Biodegradable Plastics, Part II: Corncobs", Schilling et al., pp. 1-7, Journal of Polymers and the Environment, vol. 13, No. 1, Jan. 2005. 9000072 7 "Preliminary Studies on Converting Agricultural Waste into Biodegradable Plastics, Part IV: Polysaccharide Containing Natural Materials", Schilling et al., pp. 1-9, Journal of Polymers and the Environment, vol. 13, No. 3, Jul. 2005. 9000072 8 "Pretreatment of Lignocellulosic Wastes to Improve Ethanol and Biogas Production: A Review", Mohammad J. Taherzadeh and Keikhosro Karimi, pp. 1621-1651, International Journal of Molecular Sciences, 2008, 9. 9000072 9 "Overview of biomass pretreatment for cellulosic ethanol production", Yi Zheng, Zhongli Pan, Ruihong Zhang, pp. 51-68, Int. Journal of Agricultural and Biological Engineering, vol. 2, No. 3, Sep. 2009. 9000072 10 "Preparation of Biodegradable Flax Shive Cellulose-based Superabsorbent Polymer Under Microwave Irradiation", Hao Feng, Jian Le and Lijuan Wang, pp. 1484-1495, peer-reviewed article, BioResources 5(3), published May 26, 2010. 9000072 11 "Efficient Enzymatic in Situ Saccharification of Cellulose in Aqueous-Ionic Liquid Media by Microwave Pretreatment", Li et al., pp. 4494-4504, peer-reviewed article, BioResources 6(4), published Sep. 15, 2011. 9000072 12 "Microwave Assisted Enzymatic Hydrolysis of Corn Stalks for L-lactic Acid Production", Yang Xue-Xin, Fang Gui-Zhen, pp. 712-715, Advanced Materials Research vols. 113-114 (2010). 9000072 13 "Biobased Materials", Amar K, Mohanty, Michigan State University, pp. 1-24, Presentation at Mid-Tech II, May 11, 2006. 9000074 1 International Search Report and Written Opinion, PCT/EP2010/067329, mailed Feb. 17, 2011. 9000074 2 International Preliminary Report on Patentability, PCT/EP2010/067329, issued May 15, 2012. 9000075 1 Ciemniecki et al. Polymer Blends with Hydroxypropyl Lignin. ACS Symp. Ser. 1989. pp. 452-463. 9000075 2 Pouteau et al. Lignin-Polymer blends: evaluation of compatibility by image analysis. C. R. Biologies 327 (2004) 935-943. 9000075 3 Doherty et al. Value-adding to cellulosic ethanol: lignin polymers. Industrial Crops and Products 33 (2011) 259-276. 9000075 4 Ciemniecki et al. Polymer Blends with Hydroxypropyl Lignin. ACS Symposium Series, ACS, Chapter 35. pp. 452-463. 1989. 9000075 5 U.S. Appl. No. 14/066,669, filed Oct. 29, 2013, entitled "Injection of a Chemical Reagent Into a Process Stream That Contains Lignin," Inventor(s): Nhiem Cao, et al. 9000075 6 U.S. Appl. No. 14/066,666, filed Oct. 29, 2013, entitled "Blending Lignin With Thermoplastics and a Coupling Agent or Compatibilizer," Inventor(s): Nhiem Cao, et al. 9000075 7 Fang, Changing, et al., "Characterization of Polypropylene-polyethylene Blends Made of Waste Materials with Compatibilizer and Non-Filler," Composites: Part B: Engineering, vol. 44, Dec. 2013; pp. 498-505; .COPYRGT.2013 Elsevier Ltd. All Rights Reserved. 9000075 8 Liu, Zhao, et al., "Extraction of Lignin from Pulping Black Liquor by Organic Acid," Materials Science Forum, vols. 620-622 (2009) pp. 571-574; .COPYRGT. 2009 Trans Tech Publications, Switzerland doi: 10.4028/www.scientific.net/MFG.620-622.571. 9000075 9 Marais, Andrew, et al., "Toward an Alternative Compatibilizer for PLA/Cellulose Composites: Grafting of Xyloglucan with PLA," Carbohydrate Polymers, vol. 89, Issue 4, Aug. 1, 2012; pp. 1038-1043; .COPYRGT. 2012 Elsevier Ltd. All Rights Reserved. 9000075 10 Pandey, Krishna K., et al.; "Dimensional Stability, UV Resistance, and Static Mechanical Properties of Scots Pine Chemically Modified with Alkylene Epoxides," BioResources, Feb. 10, 2010, vol. 5, No. 2, pp. 598-615. 9000075 11 PCT Sep. 4, 2013 International Search Report and Written Opinion of the International Searching Authority from Application Serial No. PCT/US2013/040684. 9000075 12 Poursorkhabi, Vida, et al., "Extraction of Lignin from a Coproduct of the Cellulosic Ethanol Industry and Its Thermal Characterization," BioResources, vol. 8, Issue 4, Nov. 2013; pp. 5083-5101. 9000075 13 Sailaja, R.R.N., et al., "Mechanical and Thermal Properties of Compatibilized Composites of Polyethylene and Esterified Lignin," Materials and Design, vol. 31, Issue 9, Oct. 2010; pp. 4369-4379; .COPYRGT. 2010 Elsevier Ltd. All Rights Reserved. 9000075 14 Tomani, Per, "The Lignoboost Process," Cellulose Chemistry and Technology, vol. 44, No. 1-3 (2010); pp. 53-58. 9000075 15 Wu, Leo C.-F., et al., "Engineering Plastics from Lignin. I. Synthesis of Hydroxypropyl Lignin," Journal of Applied Polymer Science, vol. 29, 1111-1123 (Apr. 1984); 13 pages. 9000075 16 Zhang, Ai-Ping, "Extraction, Purification, and Characterization of Lignin Fractions from Sugarcane Bagasse," BioResources, vol. 8, Issue 2, May 2013; pp. 1604-1614. 9000075 17 PCT Aug. 6, 2013 International Search Report and Written Opinion of the International Searching Authority from Application Serial No. PCT/US2013/040685 8 pages. 9000075 18 PCT Aug. 6, 2013 International Search Report and Written Opinion of the International Searching Authority from Application Serial No. PCT/US2013/040683 10 pages. 9000075 19 Ciemniecki, S. L., et al., "Multiphase Materials with Lignin: 1. Blends of Hydroxypropyl Lignin with Poly(methyl methacrylate)," Polymer, Jun. 1988, vol. 29, pp. 1021-1029; .COPYRGT. 1988 Butterworth & Co. (Publishers) Ltd.; 9 pages. 9000075 20 De Oliveira, W., et al., "Multiphase Materials with Lignin. 11. Starlike Copolymers with Caprolactonc," Macromolecules 1994, vol. 27, No. 1; .COPYRGT. 1994 American Chemical Society; 7 pages. 9000075 21 Glasser, W.G., et al., "Engineering Plastics from Lignin. 11. Characterization of Hydroxyalkyl Lignin Derivatices," Journal of Applied Polymer Science, 1984, vol. 29; .COPYRGT. 1984 John Wiley & Sons, Inc.; 16 pages. 9000075 22 Li, J., et al., "Thermal and Mechanical Properties of Biodegradable Blends of Poly(L-lactic acid) and Lignin," Polymer International 2003, vol. 52, pp. 949-955; May 12, 2003; 7 pages. 9000075 23 Li, Y., et al., "Alkylated Draft Lignin-Based Thermoplastic Blends with Aliphatic Polyesters," Macromolecules 2002, vol. 35, No. 26, pp. 9707-9715; Nov. 21, 2002. 9000075 24 Sahoo, S., et al., "Enhanced Properties of Lignin-Based Biodegradable Polymer Composites Using Injection Moudling Process," Composites: Part A. 201, vol. 42, pp. 1710-1718, Jul. 28, 2011; 9 pages. 9000075 25 U.S. Appl. No. 13/892,227, filed May 10, 2013, entitled "Chemical Modification of Lignin and Lignin Derivatives," Inventor(s): Nhiem Cao, et al. 9000075 26 U.S. Appl. No. 13/892,228, filed May 10, 2013, entitled "Chemical Modification of Lignin and Lignin Derivatives," Inventor(s): Nhiem Cao, et al. 9000075 27 U.S. Appl. No. 13/892,234, filed May 10, 2013, entitled "Chemical Modification of Lignin and Lignin Derivatives," Inventor(s): Nhiem Cao, et al. 9000075 28 Jain, Rajesh K., et al., "Lignin Derivatives; II. Functional Ethers," Holzforschung, vol. 47, No. 4, 1993; pp. 325-332; .COPYRGT. Copyright 1993 by Walter de Gruyter-Berlin-New York. 9000075 29 Lora, Jairo H., et al., "Recent Industrial Applications of Lignin: A Sustainable Alternative to Nonrenewable Materials," Journal of Polymers and the Environment, vol. 10, Nos. 1/2--pp. 39-48; .COPYRGT. 2002 Plemum Publishing Corporation. 9000075 30 PCT-2014-11-11 IPRP and Written Opinion of the International Searching Authority from PCT/US2013/040682. 9000075 31 PCT-2014-11-11 IPRP and Written Opinion of the International Searching Authority from PCT/US2013/040683. 9000075 32 PCT-2014-11-11 IPRP and Written Opinion of the International Searching Authority from PCT/US2013/040684. 9000075 33 PCT-2014-11-11 IPRP and Written Opinion of the International Searching Authority from PCT/US2013/040685. 9000075 34 PCT Dec. 12, 2013 International Search Report from International Application PCT/US2013/040682; 4 pages. 9000075 35 PCT Feb. 24, 2014 International Search Report with Written Opinion from International Application PCT/US2013/067384; 13 pages. 9000075 36 PCT Feb. 5, 2014 International Search Report and Written Opinion from International Application No. PCT/US2013/067401. 9000075 37 Luo, Feng, et al., "Effects of Compatibilizers on the Mechanical Properties of Low Density Polyethylene/Lignin Blends," Chinese Journal of Polymer Science, Nov. 2009, vol. 27, No. 6, pp. 833-842. 9000075 38 Mariotti, Nicholas, et al., "New Vio-composites Containing Industrial Lignins," Proceedings of the 55th International Convention of Society of Wood Science and Technology, Aug. 27-31, 2012, pp. 1-9. 9000075 39 USPTO Feb. 27, 2014 Non-Final Office Action from U.S. Appl. No. 13/892,227. 9000075 40 USPTO May 7, 2014 Notice of Allowance from U.S. Appl. No. 13/892,227. 9000075 41 USPTO Feb. 28, 2014 Notice of Allowance from U.S. Appl. No. 13/892,234. 9000075 42 USPTO Mar. 13, 2014 Non-Final Office Action from U.S. Appl. No. 13/892,228. 9000075 43 USPTO Jun. 26, 2014 Final Office Action from U.S. Appl. No. 13/892,228. 9000075 44 USPTO Sep. 15, 2014 Non-Final Office Action from U.S. Appl. No. 13/892,228. 9000079 1 Rextac 2730 Technical Data Sheet, no date. 9000079 2 Olabisi, Olagoke. Handbook of Thermoplastics. Plastics Engineering, Marcel Dekker, Inc., vol. 41, Mar. 19, 1997, pp. 16-17, 23-25, 27. 9000081 1 Yusuke Imai et al,"Transparent poly based nanocomposites with high refractive index nanoparticles", European Polymer Journal 45 (2009) 630-638. 9000081 2 Shinichi Kawasaki, et al, "Synthesis and Chemical,Physical,and Optical Properties of 9,9 Diarylfluorene Based Poly", Macromolecules 2007, 40, 5284-5289. 9000083 1 Cannon et al., "Sinterable Ceramic Powders from Laser-Driven Reaction: I, Process Description and Modeling," J. Am. Ceramic Society 65 (7):324-329 (1982). 9000083 2 Cannon et al., "Sinterable Ceramic Powders from Laser-Driven Reaction: II, Powder Characteristics and Process Variables," J. Am. Ceramic Society 65(7):330-335 (1982). 9000083 3 Goldstein et al., "Observation of Melting in 30 .ANG. Diameter CdS Nanocrystals", Mat. Res. Soc. Symp. Proc., 206:271-274 (1991). 9000083 4 Thomas, "The Determination of Log Normal Particle Size Distributions by Dynamic Light Scattering", Journal of Colloid and Interface Science, 117(1):187-192 (May 1987). 9000083 5 Koglin, "Assessment of the Degree of Agglomeration in Suspensions," Powder Technology 17(2):219-227 (Jul. 1, 1977). 9000084 1 Hartness, T. et al., "The characterization of low cost fiber reinforced thermoplastic composites produced by the DRIFT.TM. process," Composites: Part A: Applied Science and Manufacturing, Aug. 2001, vol. 32, pp. 1155-1160, ISSN 0010-4361. 9000084 2 International Search Report and Written Opinion for International Application No. PCT/US2009/047983, mail date Jun. 11, 2010, 7 pages. 9000084 3 Yoon, B.S. et al., "Continuous Glass-Fiber Reinforced nylon 6 by Using a New Impregnation Die," Polymer Composites, Oct. 1997, published online Apr. 15, 2004, vol. 18, vol. 5, pp. 656-662, ISSN 0272-8397. 9000085 1 Baek, Jong-Beom, Christopher B. Lyons, and Loon-Seng Tan. Covalent Modification of vapour-grown carbon nanofibers via direct Friedel-Crafts acylation in polyphosphoroic acid. May 19, 2004. Journal of Materials Chemistry. DOI: 10.1039/b401401d. Available online at: http://www.rsc.org/ej/JM/2004/B401401D/. 9000085 2 Pyrograf III Product Website. (2001) Availble Online at: www.apsci.com/ppi-pyro3.html. 9000085 3 Bussi et al . (Partially Miscible Blends of Epoxy Resin and Epoxidized Rubber: Structural Characterization of the Epoxidized Rubber and Mechanical Properties of the Blends, Journal of Applied Polymer Science, vol. 53, 441-454 (1994)). 9000085 4 U.S. Appl. No. 11/475,032, filed Jun. 27, 2006 in the name of Noguchi et al. 9000085 5 U.S. Appl. No. 11/475,033, filed Jun. 27, 2006 in the name of Noguchi et al. 9000085 6 U.S. Appl. No. 11/594,933, filed Nov. 9, 2006 in the name of Noguchi et al. 9000085 7 U.S. Appl. No. 11/785,875, filed Apr. 20, 2007 in the name of Noguchi et al. 9000085 8 U.S. Appl. No. 11/475,032, in the name of Toru Noguchi et al, filed Jun. 27, 2006. 9000085 9 U.S. Appl. No. 11/475,033, in the name of Toru Noguchi et al, filed Jun. 27, 2006. 9000085 10 Hwang, D. G. et al., "Artificial Intelligence Heat Absorbing/Radiating Engineering Plastic," Database WPI Week 200414, Derwent Publications Ltd., XP-002430929 (2003). 9000085 11 Liu, Luqi et al., "Rubbery and Glassy Epoxy Resins Reinforced with Carbon Nanotubes," Composites Science and Technology, vol. 65, pp. 1861-1868 (Sep. 2005). 9000085 12 Epikote Resin 862 Product Bulletin, Resolution Performance Products, SC:1183-2, pp. 1-10, Sep. 2002. 9000085 13 Epikote Resin 828 Starting Formulation No. 8024, Resolution Performance Products, SC:1547-01, pp. 1-3, Nov. 2001. 9000085 14 Office Action dated Nov. 26, 2010 in U.S. Appl. No. 11/785,875. 9000085 15 Office Action dated Sep. 2, 2009 in U.S. Appl. No. 12/326,490. 9000085 16 U.S. Appl. No. 11/987,254, filed Nov. 28, 2007 in the name of Toru Noguchi et al. 9000085 17 U.S. Appl. No. 12/327,396, filed Dec. 3, 2008 in the name of Toru Noguchi et al. 9000085 18 U.S. Appl. No. 12/326,509, filed Dec. 2, 2008 in the name of Tow Noguchi et al. 9000085 19 U.S. Appl. No. 12/326,490, filed Dec. 2, 2008 in the name of Toru Noguchi et al. 9000085 20 U.S. Appl. No. 11/785,875, filed Apr. 20, 2007 in the name of Toru Noguchi et al. 9000085 21 Jun. 10, 2010 Office Action issued in U.S. Appl. No. 11/785,875. 9000085 22 Jan. 18, 2011 Office Action issued in U.S. Appl. No. 12/326,490. 9000085 23 Apr. 28, 2010 Office Action issued in U.S. Appl. No. 12/326,490. 9000085 24 Aug. 20, 2010 Notice of Allowance issued in U.S. Appl. No. 11/785,875. 9000085 25 Nov. 11, 2012 Communication issued in European Application No. 08 791 047.7. 9000085 26 Dec. 12, 2013 Office Action issued in Chinese Application No. 200880130280.0 (with English Translation). 9000085 27 Nov. 12, 2012 Communication issued in European Application No. 08 791 047.7. 9000085 28 Dec. 25, 2012 Office Action issued in Japanese Application No. 200880130280.0 (with English translation). 9000085 29 Feb. 10, 2014 Office Action issued in U.S. Appl. No. 12/326,490. 9000085 30 Oct. 27, 2011 Office Action issued in U.S. Appl. No. 11/785,875. 9000085 31 Apr. 26, 2012 Office Action issued in U.S. Appl. No. 11/785,875. 9000085 32 Office Action dated Mar. 20, 2013 issued in Korean Patent Application No. 10-2011-7003075 (with translation). 9000085 33 May 6, 2011 Office Action issued in U.S. Appl. No. 11/785,875. 9000085 34 Apr. 3, 2013 European Office Action issued in European Application No. 08 791 047.7. 9000085 35 Apr. 24, 2013 Notification of Decision of Rejection issued in Chinese Application No. 200880130280.0 (with English translation). 9000085 36 May 28, 2013 Notice of Pre-Appeal Reexamination Result issued in Korean Application No. 10-2011-7003075 (with English translation). 9000085 37 Gary G. Tibbetts et al., "A review of the fabrication and properties of vapor-grown carbon nanofiber/polymer composites," ScienceDirect, Composites Science and Technology, 67, 2007, pp. 1709-1718. 9000085 38 Jun. 27, 2012 Supplementary European Search Report issued in 08791047.7. 9000085 39 Jul. 5, 2012 European Examination Report issued in 08791047.7. 9000085 40 Aug. 30, 2012 Korean Office Action cited in Application No. 10-2011-7003075 (with English translation). 9000085 41 Jun. 22, 2011 Notification of Refusal issued in Japanese Application No. 2007-155078 with English-language translation. 9000085 42 U.S. Appl. No. 11/385,670 filed in the name of Toru Noguchi et al. 9000085 43 Jul. 27, 2011 Notification of Reasons for Refusal issued in Japanese Application No. 2008-161922 with English-language translation. 9000085 44 Jul. 25, 2013 Office Action issued in European Application No. 08 791 047.7. 9000085 45 Dec. 25, 2012 Office Action issued in Chinese Application No. 200880130280.0 (with English translation). 9000087 1 Lai Mingfang et al. "Study on strengthening the interface compatibility of heat-resistant resin blends", Gongcheng Suliao Yingyong, 2000, 28(11), p. 1-3--CAS 135:331971 + attached CAS Abstract in English language. 9000087 2 Kancheng Mai et al. "Double melting phenomena of poly(phenylene sulfide) and its blends", Gaofenzi Xuebao, 1994, (2), p. 229-33--CAS 122:162231 + attached CAS Abstract in English language. 9000088 1 Matsuo et al: "Introduction of amino groups into the interlayer space of graphite oxide using 3-aminopropylethoxysilanes", Carbon, Elsevier, Oxford, GB, vol. 45, No. 7, Jun. 1, 2007, pp. 1384-1390. 9000088 2 Organometallics, vol. 13(9), 1994, (Muehleisen, Mathias; Tacke, Reinhold), pp. 3740-3742. 9000088 3 Russian Journal of Applied Chemistry; vol. 82, Issue 5, pp. 928-930; Journal 2009; by V. M. Farzaliev, M. T. Abbasova, A. A. Ashurova, G. B. Babaeva, N. P. Ladokhina and Ya. M. Kerimova. 9000088 4 The Russian Chemical Bulletin, vol. 44(2), 1995, pp. 374-375. 9000088 5 The Vanderbilt Rubber Handbook (1978), pp. 344 through 346. 9000088 6 Journal of Membrane Science, vol. 129(2), 1997, Barbiou, Mihai et al, pp. 197-207. 9000088 7 European Journal of Organic Chemistry, vol. 13, 2006, (Bianco, Alberto et al.), pp. 2934-2941. 9000088 8 Gasparrini, F. et al., "Molecular recognition of p-tert-butylcalixarenes by surface-linked fullerenes C60 and C70", Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, vol. 57, No. 32, Aug. 6, 2001, pp. 6997-7002. 9000088 9 Bianco et al., "Molecular recognition by a silica-bound fullerene derivative", J. Am. Chem. Soc. 1997, vol. 119, pp. 7550-7554. 9000088 10 Brunauer et al., Adsorption of Gases in Multimolecular Layers, Feb. 1938, pp. 309-319, vol. 60. 9000088 11 Chemische Berichte, vol. 120(4), 1987, Brueckmann, Ralf, et al., pp. 635-641. 9000089 1 Acros MSDS Dibutyltin Diacetate product No. 75959 Creation Date Jun. 1999. 9000089 2 C. Uglea OligomerTechnology and Applications, Marcel Dekker New York 1998 pp. 252-253. 9000089 3 Winship, Toxicity of Tin and its Compounds Adverse Drug Reac Acute Poisoning Rev 1988 Spring vol. 7 No. 1 pp. 19-38 Abstract From Pub Med--{http://www.ncbi.nlm.nih.gov/pubmed/3291572}. 9000089 4 S.G. Temel, et al., "A New Material for Prevention of Epidural Fibrosis After Laminectomy," J Spinal Disord Tech, Jun. 2006, pp. 270-275, vol. 19, No. 4. 9000090 1 "Product Testing & Calibration Unit." Malaysian Rubber Board. Sep. 24, 2008 . 9000090 2 UKIPO Examination Reports dated Dec. 1, 2010 and Jun. 23, 2011 for GB2436566. 9000090 3 Applicant's Aug. 18, 2011 Response to UKIPO Examination Reports for GB2436566, including clean and marked up copies of changes to Specification and Claims. 9000092 1 International Search Report (PCT/ISA/210) issued on Feb. 22, 2010, by European Patent Office as the International Searching Authority for International Application No. PCT/EP2009/067550. 9000094 1 International Search Report in counterpart International Application No. PCT/KR2011/008986 dated Jul. 30, 2012, pp. 1-4. 9000094 2 European Search Report in commonly owned European Application No. 09174487, dated Feb. 16, 2010, pp. 1-5. 9000094 3 European Office Action in commonly owned European Application No. 09174487, dated May 11, 2011, pp. 1-4. 9000094 4 Office Action in commonly owned U.S. Appl. No. 12/980,668 mailed Oct. 5, 2012, pp. 1-12. 9000095 1 Chiang Journal of Polymer Science XXXVI, 91-103 (1959). 9000095 2 Peacock "The Handbook of Polyethylene" 2000. 9000095 3 M. Fleissner, "Slow Crack Growth and Creep Rupture Strength of Polyethylene Pipe," Kunststoffe German Plastics, vol. 77, p. 45-50 (1987) with English language translation. 9000096 1 PCT/US2011/038347, International Search Report dated Sep. 12, 2011. 9000096 2 PCT/US2011/038347, International Preliminary Report on Patentability dated Dec. 2, 2013. 9000096 3 PCT/US2011/038347, Written Opinion of the International Searching Authority dated Sep. 12, 2011. 9000096 4 Japanese Office Action Jan. 21, 2015; from JP counterpart Application No. 2014-512809. 9000097 1 PCT International Search Report & Written Opinion mailed Oct. 8, 2012, for PCT/EP2012/063200. 9000099 1 Snapshot of IDES Melt flow Rate Website retrieved Mar. 11, 2006 retrieved online from the Internet Archive: http://web.archive.org/web/20060311042246/http://www.ides.com/property--descriptions/ASTMD1238.asp. 9000099 2 Machine Translation of JP 06-472459. 9000099 3 Exchange and Free Radical Grafting Reactions in Reactive Extrusion, Makromol. Chem., Macromol. Symp., 1993, 75, 137-157. 9000099 4 Control of Degradation Reactions during Radical Functionalization of Polypropylene in the Melt, Macromolecules, 2004, 37, 8414-8423. 9000099 5 Heterogeneous Grafting of Maleic Anhydride and .alpha.-Methylstyrene from Atactic Polypropylene, Die Angewandte Makromolekulare Chemie, 1997, 251, 37-48 (Nr. 4326). 9000099 6 Radical Mediated Modification of Polypropylene; Selective Grafting Via Polyally Coagents, J. Polym. Sci.: Part A: Poly.Chem. 2005, 43, 4882-4893. 9000099 7 Reactive Extrusion: A New Tool for the Diversification of Polymeric Materials, Macromol. Symp., 87, 37-58 (1994). 9000099 8 Study on Styrene-Assisted Melt Free-Radical Grafting of Maleic Anhdride onto Polypropylene, Polymer, 2001, 42, 3419-3425. 9000099 9 Radical reactions on Polypropylene in the Solid State, Progress in Polymer Science, 2002, 27, 1195-1282. 9000099 10 Alternating Copolymer Graft Copolymers v. "Carboxylation" of Polymers by In-situ Spontaneous Bulk Polymerization of Styrene-Maleic Anhydride Complex, Polymer Letters Edition, vol. 10, 95-100 (1972). 9000099 11 Alternating Copolymer Grafting onto Polymer Films by a Vapor-Phase Grafting Technique, Polymer Letters Edition, vol. 10, 823-828 (1972). 9000099 12 Abstract: Japanese Publication JP 06172459. 9000100 1 Cahn, A.; 5th World Conference on Detergents, 2003, p. 182. 9000100 2 Tadros, T.F.; Applied Surfactants: Principles and Applications, 2005, p. XIX-17. 9000100 3 Myers, D.; Surfactant Science and Technology, 2006, p. 64. 9000100 4 "International Search Report in PCT/EP2011/001096", Jun. 28, 2011 , 2 pgs. 9000101 1 U.S. Appl. No. 13/938,256, filed Jul. 10, 2013. 9000102 1 Popoola, V.A.; Journal of Applied Polymer Science, 1988, vol. 36, p. 1677-1683. 9000102 2 Schiers, J., et al.; Modern Polyesters, 2003, p. 166-167. 9000102 3 International Search Report for PCT/US2012/051180, mailed Feb. 27, 2013. 9000104 1 Dean A. Zimmerman et al., "Polymerization of Poly(p-phenylene sulfide) from a Cyclic Precursor," POLYMER, 1996, vol. 37, No. 14, pp. 3111-3116. 9000108 1 Green T.W., and Wuts, Peter G.M. Protective Groups in Organic Systhesis, 3rd, Wiley-Interscience, New York, 1999. 9000108 2 Randall, J.C., "A Review of High Resolution Liquid 13Carbon Nuclear Magnetic Resounance Characterizations of Ethylene-Based Polymers" JMS-Rev. Macromol. Chem. Phys., C29, 201-317, 1989. 9000108 3 Odian, G. , "Stereochemistry of Polymerization" Principles of Polymerization, Second Edition, John Wiley and Sons, 1970, 619-728. 9000108 4 Soave, G. "Equilibrium constants from a modified Redlich-Kwong Equation of State" Chemical Engineering Science, 1972, vol. 27, 1197-1203. 9000108 5 PCT/US2010/035096 International Search Report and Written Opinion of the International Search Authority, Feb. 18, 2011. 9000108 6 PCT/US2010/035096, International Preliminary Report on Patentability, Nov. 29, 2012. 9000108 7 Japanese Office Action dated Jul. 8, 2014 for counterpart Japanese Application No. 2013-511220. 9000108 8 Response to Japanese Office Action dated Nov. 10, 2014 for counterpart Japanese Application No. 2013-511220. 9000109 1 PCT/EP2012/053523 International Search Report dated May 21, 2012 (3 pages). 9000109 2 PCT/EP2012/053524 International Search Report dated May 21, 2012 (2 pages). 9000110 1 International Search Report Issued Sep. 21, 2010 in PCT/JP10/63866 Filed Aug. 17, 2010. 9000110 2 U.S. Appl. No. 14/241,738, filed Feb. 27, 2014, Ishiwata. 9000111 1 EPO English abstract of JP 02265907 A. 9000111 2 Office Action issued by JPO on Jul. 23, 2013, in connection with corresponding Japanese Patent Application No. 2008-229629. 9000112 1 International Search Report issued in International Appln. No. PCT/KR2011/007681 on May 16, 2012, 2 pages. 9000112 2 F. Bauer et al.: "UV Curable Acrylate Nanocomposites: Properties and Applications," Journal of Polymer Research (2005), vol. 12, pp. 483-491, Sep. 21, 2005. 9000112 3 H. Zou et al.: "Polymer/Silica Nanocomposites: Preparation, Characterization, Properties, and Applications," J. Chem. Rev. 2008, vol. 108, pp. 3893-3957, Aug. 23, 2008. 9000112 4 F. Bauer et al."Preparation of Scratch and Abrasion Resistant Polymeric Nanocomposites by Monomer Grafting onto Nanoparticles, 3a Effect of Filler Particles and Grafting Agents," Macromol. Mater. Eng. 2002,, vol. 287, pp. 546-552, Aug. 2002. 9000113 1 Mathot, et al., "Heat capacity, enthalpy and crystallinity of polymers from DSC and determination of the DSC peak base line", Thermochimia Acta, vol. 151 Sep. 1989 , 241-259. 9000113 2 Peacock, Andrew J. , "Handbook of Polyethylene", Exxon Chemical Company, Baytown, Texas Marcel Dekker Inc., New York/Basel 2000 , 7-10. 9000113 3 Wild, L , "Temperature rising elution fractionation", Adv. Polymer Sci. 98 1990 , 1-47. 9000113 4 Wild, L et al., "Determination of Branching Distributions in Polyethylene and Ethylene Copolymers", Journal Polymer Sci. Part B 1982 , 441-456. 9000113 5 Benoit, H. Rempp et al., "A Universal Calibration for Gel Permeation Chromatography", Journal of Polymer Sci., Phys. Ed. 5 1967 , 753-759. 9000114 1 PCT International Search Report & Written Opinion mailed Nov. 7, 2011, for PCT/EP2011/063266. 9000115 1 KR application 10-2009-0070574, Jul. 2009, machine translation. 9000116 1 International Search Report dated Apr. 1, 2008 for International Application No. PCT/JP2008/050373, 2 pages. 9000116 2 Notification of First Office Action in CN Appln No. 200880001349 dated Jan. 20, 2011. 9000116 3 Office Action Japanese Patent Application No. 2008-554040 dated May 14, 2013. 9000119 1 Coatings formulation: an international textbook, Bodo Muller and Urlich Poth, Vincentz Network GmbH & Co KG, 2006, pp. 99. 9000119 2 Paint and coating testing manual: fourteenth edition of the Gardner-Sward handbook, J. V. Koleske, ASTM International, 1995, pp. 90. 9000119 3 International Search Report (PCT/ISA/210) issued on Nov. 16, 2010, by Japanese Patent Office as the International Searching Authority for International Application No. PCT/JP2010/004901. 9000120 1 HCAPLUS accession No. 1987:121036 for European Patent No. 200,678 A2, Nov. 5, 1986, Bagga et al., two pages. 9000120 2 Xingming, Cheng, et al., CN1687229A-Chinese Abstract, "Method for preparing composition of epoxy resin for packaging semiconductor", Oct. 26, 2005. 9000120 3 Zhixiong, Huang, et al., CN1651542-Chinese Abstract, "Epoxy resin binding agent for sand paper and its preparation method", Aug. 10, 2005. 9000121 1 U.S. Appl. No. 13/588,299 claims. 9000121 2 WO 2007/028752 translation. 9000121 3 International Search Report Issued Sep. 2, 2010 in PCT/EP10/60044 Filed Jul. 13, 2010. 9000122 1 Park et al. (Journal of Membrane Science 229 (2004) 117-127. 9000123 1 International Search Report for corresponding International Application No. PCT/JP2011/067276, Sep. 20, 2011. 9000123 2 Japanese Office Action for corresponding JP Application No. 2012-527700, Nov. 13, 2012. 9000123 3 Combined Chinese Office Action and Search Report issued Jul. 22, 2014 in Patent Application No. 201180037956.3 (with English translation of categories of cited documents). 9000123 4 Frank W. Mercer, et al., "Synthesis and properties of new alternating copolyethers containing pendent cyano groups", Polymer, vol. 35, No. 24, 1994, pp. 5355-5363 and Cover Page. 9000124 1 Bardelli et al., A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J Biol Chem. Oct. 8, 1999;274(41):29274-81. 9000124 2 Date et al., HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett. Dec. 22, 1997;420(1):1-6. 9000124 3 Hanessian et al., Synthesis of a Versatile Peptidomimetic Scaffold. Methods in Molecular Medicine 23: 161-174, 1999. 9000124 4 Hart et al., Cyclophilin Inhibition by a (Z)-Alkene cis-Proline Mimic. J Org Chem 64: 2998-2999, 1999. 9000124 5 Holmes et al., Site specific 1:1 opioid: albumin conjugate with in vitro activity and long in vivo duration. Bioconjug Chem 11: 439-444, 2000. 9000124 6 Parr et al., Hepatocyte growth factor activators, inhibitors and antagonists and their implication in cancer intervention. Histol Histopathol. Jan. 2001;16(1):251-68. Review. 9000124 7 Thomas et al., A peptide sequence on carcinoembryonic antigen binds to a 80kD protein on Kupffer cells. Biochem Biophys Res Commun 188: 671-677, 1992. 9000124 8 GENBANK Submission; NIH/NCBI, Accession No. AB011541; Nakayama et al.; Aug. 22, 1998. 3 pages. 9000124 9 Nakayama et al., Identification of high-molecular-weight proteins with multiple EGF-like motifs by motif-trap screening. Genomics. Jul. 1, 1998;51(1):27-34. 9000125 1 Rajendran, Lawrence et al., "Raft Association and Lipid Droplet Targeting of Flotillins are Independent of Caveolin", Biol. Chem., vol. 388, pp. 307-314; Mar. 2007. 9000125 2 Alvarado, J.A. et al., "A New Insight Into the Cellular Regulation of Aqueous Outflow", www.bjophthalmol.com, Dec. 13, 2007, XP-002462343, pp. 1500-1505. 9000125 3 Freeman, Michael R. et al., "Transit of Hormonal and EGF Receptor-Dependent Signals Through Cholesterol-Rich Membranes" www.elsevier.com, Steroids 72 (2007) pp. 210-217. 9000125 4 Marquez, Diana C., et al., Estrogen Receiptors in Membrane Lipid Rafts and Signal Transduction in Breast Cancer Molecular and Cellular Endocrinology 246 (2006) pp. 91-100. 9000125 5 Helms, J. Bernd and Zurzolo, Chiara; Lipids As Targeting Signals: Lipid Rafts and Intracellular Trafficking; Traffic 2004, vol. 5, Blackwell Munksgaard, pp. 247-254. 9000125 6 Chini, B and Parent, M; "G-Protein Coupled Receptors in Lipid Rafts and Caveolae: How, When and Why Do They Go There" Journal of Molecular Endocrinology (2004) 32, pp. 325-338. 9000125 7 Triantafilou, Kathy and Triantafilou, Martha; "Lipid-Raft-Dependent Coxsackievirus B4 Internalization and Rapid Targeting to the Golgi", Virology 326 (2004) pp. 6-19. 9000125 8 Pohl, Jurgen et al; "Long-Chain Fatty Acid Uptake Unto Adipocytes Depends on Lipid Raft Function", Biochemistry 2004, 43, pp. 4179-4187. 9000125 9 Dermine, Jean-Francois et al, "Flotillin-1-Enriched Lipid Raft Domains Accumulate on Maturing Phagosomes", The Journal of Biological Chemistry, vol. 276, No. 21, May 25, 2001, pp. 18507-18512. 9000125 10 Kurzchalia, Teymuras V. and Parton, Robert G., "Membrane Microdomains and Caveolae", Current Opinion in Cell Biology, 1999, pp. 424-431. 9000126 1 Deneke et al. "Regulation of cellular glutathione" Am J Physiol. Oct. 1989;257(4 Pt 1):L163-73. 9000126 2 Japanese Patent Office, International Search Report in International Patent Application No. PCT/JP2011/059776 (Jul. 12, 2011) English translation. 9000126 3 Jelsch et al., "The Oxidized Form of Glutathione," Acta Crystallographica Section C, 55: 1538-1540 (1999). 9000126 4 European Patent Office, Extended European Search Report in European Patent Application No. 11772056.5 (Jan. 2, 2014). 9000127 1 MacCallum et al. (1996). J. Mol. Biol. 262:732-745. 9000127 2 De Pascalis et al. (2002). Journal of Immunology. 169:3076-3084. 9000127 3 Casset et al. (2003). Biochemical and Biophysical Reseaerch Communications. 307:198-205. 9000127 4 Chen et al. (1999). J. Mol. biol. 293:865-881. 9000127 5 Wu et al. (1999). J. Mol. Biol. 294:151-162. 9000127 6 Rudikoff et al. (1982). PNAS. 79:1979-1983. 9000127 7 Echtenacher et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis." Journal of Immunology, Dec. 1, 1990, vol. 145, No. 11, pp. 3762-3766. 9000127 8 Fisher et al., Treatment of Septic Shock with the Tumor Necrosis Factor Receptor: Fc Fusion Protein.: The New England Journal of Medicine, 1996, vol. 334, No. 26, pp. 1697-1702. 9000127 9 Gibot et al., "A Soluble Form of the Triggering Receptor Expressed on Myeloid Cells-1 Modulates the Inflammatory Response in Murine Sepsis," The Journal of Experimental Medicine, Dec. 6, 2004, Vo. 200 No. 11 pp. 1419-1426. 9000127 10 Griffin et al., "Abnormal Hear Rate Characteristics Preceding Neonatal Sepsis and Sepsis-Like Illness," Pediatric Research, 2003, vol. 53, No. 6, pp. 920-926. 9000127 11 Hiscott et al., "Characterization of a Functional NF-kB Site in the Human Interleukin 1b Promoter: Evidence for a Positive Autoregulatory Loop," Molecular and Cellular Biology, Oct. 1993, vol. 13 No. 10, pp. 6231-6240. 9000127 12 Hotchkiss et al., "The Pathophysiology and Treatment of Sepsis," The New England Journal of Medicine, Jan. 9, 2003, pp. 138-150. 9000127 13 Keane et al., "Tuberculosis Associated with infliximab, a Tumor Necrosis Factor a-Neutralizing Agent," The New England Journal of Medicine, Oct. 11, 2001, vol. 345, No. 15, pp. 1098-1104. 9000127 14 Kelker et al., "Crystal Structure of Human Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) at 1.47 A," J. Mol. Biol. 2004, vol. 342, pp. 1237-1248. 9000127 15 Lantz et al., "Characterization In Vitro of a Human Tumor Necrosis Factor-binding Protein: A Soluble Form of a Tumor Necrosis Factor Receptor," J. Clin. Invest., Nov. 1990, vol. 89, pp. 1396-1402. 9000127 16 Lolis et al., "Therapeutic Approaches to Innate Immunity:Severe Sepsis and Septic Shock," Nature Reviews Drug Discovery, Aug. 2003, vol. 2, pp. 635-645. 9000127 17 NCBI Reference Sequences (RefSeq) NP--061113 (2 pgs). 9000127 18 Radaev et. al., "Crystal Structure of the Human Myeloid Cell Activation Receptor TREM-1," Structure, Dec. 2003, vol. 11, pp. 1527-1535. 9000127 19 Riedemann et al., "Novel strategies for the treatment of sepsis," Nature Medicine, May 2003, vol. 9, No. 5, pp. 517-524. 9000127 20 Stone, Richard, "Search for Sepsis Drugs Goes on Despite Past Failures." Science, Apr. 15, 1994, vol. 264, pp. 365-367. 9000127 21 Thoma-Uszynski et al., "Induction of Direct Antimicrobial Activity Through Mammalian Toll-Like Receptors," Science, Feb. 23, 2001, vol. 291, pp. 1544-1547. 9000127 22 Tsuji et al., "Simultaneous Onset of Accute Inflammatory Response, Sepsis-Like Symptoms and Intestinal Mucosal Injury After Cancer Chemotherapy," Int. J. Cancer, 2003, vol. 107, pp. 303-308. 9000127 23 Urban et al., "NF-kB contacts DNA by a heterodimer of the p50 and p65 subunit," The EMBO Journal, 1991, vol. 10, No. 7, pp. 1817-1825. 9000127 24 Van Zee et al., "Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo," Proc. Natl. Acad. Sci. USA, Jun. 1992, vol. 89, pp. 4845-4849. 9000127 25 Vincent et al., "Clinical Trials of Immunomodulatory Therapies in Severe Sepsis and Septic Shock," Clin. Infect. Dis., Apr. 15 2002, vol. 34, pp. 1084-1093. 9000127 26 Warren, H. Sha, M.D., "Strategies for the Treatment of Sepsis," The New England Journal of Medicine, Mar. 27, 1997, vol. 336, No. 13, pp. 952-953. 9000127 27 Wasmuth et al., "Patient with acute on chromic liver failure display `sepsis-like` immune paralysis," Journal of Hepatology, 2005, vol. 42, pp. 195-201. 9000127 28 Zwaveling et al., "High plasma tumor necrosis factor (TNF)-a concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-a, interferson-g, and melphalan," Crit Care Med, 1996, vol. 24, No. 5, pp. 765-770. 9000127 29 DATABASE EMBL, Sequence from Patent WO200283856-A2, Sep. 17, 2003 "Human G-protein coupled receptor phosphorylation site peptide SEQ ID 131", retrieved from EBI Database accession No. ABJ38803. 9000127 30 DATABASE EMBL, Sequence information from JP2000116377-A, Oct. 10, 2000 "N-terminus of porcine trypsin", retrieved from EBI Database accession No. AAB03087. 9000127 31 Wheeler et al., "Treating Patients with Severe Sepsis" NEJM 1999, 340: 207-214. 9000127 32 Attwood. "The Babel of Bioinformatics" Science 2000; 290: 471-473. 9000127 33 The Merck Manuals Online Medical Library (online). Whitehouse Station, NJ: Merck Research Laboratories, 2006-2007. (Retrieved on Nov. 19, 2007). Retrieved from the Internet: . 9000127 34 Standen et al. "Septic Shock" N. Engl. J. Med. 2000, 343: 447-448. 9000127 35 Redl et at, "Animal Models as the Basis of Pharmacologic Intervention in Trauma and Sepsis Patients," World J. Surg. 1996, 20: 487-492. 9000127 36 Mori et al., "A novel amino acid substitution at the receptor-binding site on the hemagglutinin of H3N2 influenza A viruses isolated from 6 cases with acute encephalopathy during the 1997-1998 season in Tokyo," Archives of Birology 1999, 144: 147-155. 9000127 37 Gencic et al., "Conservative amino acid substitution in the myelin proteolipid protein of jimpymsd mice," The Journ. of Neuroscience 1990, 10: 117-124. 9000127 38 Schenk et al., "Trem-1 - Expressing Intestinal Macrophages Crucially Amplify Chronic Inflammation in Experimental Colitis and Inflammatory Bowel Diseases," The Journ. of Clinical Investigation, 2007, vol. 117, No. 10, pp. 3097-3106. 9000127 39 Proudfoot, "Transcriptional interference and termination between duplicated ; ; globin gene constructs suggests a novel mechanism for gene regulation," Nature, (1986), 322: 562 ;. 9000127 40 NCBI Reference Sequences (RefSeq) NP--067381 (2 pgs); ; ;. 9000127 41 Canton et al., "NKp44, atriggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily, " J. Exp. Med. 189(5), (1999), pp. 787-796. 9000127 42 Carrell et al., "A Novel Procedure for the Synthesis of Libraries Containing Small Organic Molecules" Angew. Chem. Int. Ed. Engl., (1994), 33:2059 & 2061. 9000127 43 Cella et al., "Anovel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing", J. Exp. Med., vol. 185(10), (1997), pp. 1743-1751. 9000127 44 Chen et al., "Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo.", Proc. Natl. Acad. Sci. USA, (1994), 91:3054-3057. 9000127 45 Cho et al., "An unnatural biopolymer ", Science, (1993), 261:1303. 9000127 46 Chomel et al., "Bartonella henselae Prevalence in Domestic Cats in California: Risk Factors and Association between Bacteremia and Antibody Titers.", Journal of Clinical Microbiology, vol. 33(9), (Sep. 1995), pp. 2445-2450. 9000127 47 Cohen et al., "[42] Receptor-mediated transport of DNA into eukaryotic cells", Meth. Enzymol., (1993), 217:618-644. 9000127 48 Clowes et al., "Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes.", J. Clin. Invest., (1994), 93:644-651. 9000127 49 Cohen et al., "Emerging Technologies for Sequencing Antisense Oligonucleotides: Capillary Electrophoresis and Mass Spectrometry," Adv. Chromatogr., (1996), 36:127-162. 9000127 50 Colberre-Garapin et al., "A new dominant hybrid selective marker for higher eukaryotic cells", J. Mol. Biol., (1981) 150:1. 9000127 51 Cotton et al., "Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations", Proc. Natl. Acad. Sci. USA, (1988), 85:4397. 9000127 52 Cotton, "Current methods of mutation detection", Mutat. Res., (1993), 285:125-144. 9000127 53 Cox et al., "IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils," Am. J. Physiol. Lung Cell Mol Physiol., (1996), 271:L566-L571. 9000127 54 Cronin et al., "Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays", Human Mutation, (1996), 7:244-255. 9000127 55 Cruikshank et al., J. Acquired Immune Deficiency Syndromes and Human Retrovirology, (1997) 14:193. 9000127 56 Cull et al., "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor.", Proc. Natl. Acad. Sci. USA, (1992), 89:1865-1869. 9000127 57 Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands.", Proc. Natl. Acad. Sci. USA, (1990), 87:6378-6382. 9000127 58 Daws et al., "Cloning and Characterization of a Novel Mouse Myeloid DAP12-Associated Receptor Family, " Eur. J. Immunol. 2001, 31:783-791. 9000127 59 Devlin, "Random peptide libraries: a source of specific protein binding molecules ",Science, (1990), 249:404-406. 9000127 60 Dewitt et al., "Diversomers": an approach to nonpeptide, nonoligomeric chemical diversity, Proc. Natl. Acad. Sci. USA, (1993), 90:6909. 9000127 61 Dietrich et al., "Signal-regulatory protein .beta.1 is a DAP12-associated activation receptor expressed in myeloid cells." J. Immunol. 164:9, 2000. 9000127 62 Doerks et al., "Protein annotation: detective work for function prediction", Trends in Genetics, vol. 14(6), (Jun. 1998), pp. 248-250. 9000127 63 Downey et al., "Intracellular signaling in neutropohil priming and activation," Semin Cell Bio. 6:345-356, 1995. 9000127 64 Echtenacher et al., "Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis," J. Immunol. 145:3762-6, 1990. 9000127 65 Echtenacher et al. "Critical protective role of mast cells in a model of acute septic peritonitis", Nature, (1996), 381:75-7. 9000127 66 Edlund et al., "Cell-specific expression of the rat insulin gene: evidence for role of two distinct 5' flanking elements", Science, (1985) 230:912-916. 9000127 67 Erb et al., "Recursive deconvolution of combinatorial chemical libraries",Proc. Natl. Acad. Sci. USA, (1994), 91:11422. 9000127 68 Eskandari et al., "Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture of endotoxemia", J. Immunol., (1992), 148:2724-30. 9000127 69 Facchetti et al., "Suppurative Granulomatous Lymphadenitis; Immunohistochemical Evidence for a B-cell-Associated Granuloma," Am. J. Surg. Pathol., (1992), 16: 955-61. 9000127 70 Felici, "Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector ", J. Mol. Biol., (1991), 222:301-310. 9000127 71 Fell et al., "Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human IL-2.", J. Immunol., (1991), 146:2446-2452. 9000127 72 Finn et al., Synthesis and Properties of DNA-PNA Chimeric Oligomers Nucleic Acids Res., (1996), 24(17): 3357-63. 9000127 73 Fodor, "Multiplexed biochemical assays with biological chips", Nature, (1993), 364:555-556. 9000127 74 Forster et al., "CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organ," Cell 99:23-33, 1999. 9000127 75 Gallop et al., "Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries", J. Med. Chem., (1994), 37:1233. 9000127 76 Gasparini et al., "Restriction site generating-polymerase chain reaction (RG-PCR) for the probeless detection of hidden genetic variation: application to the study of some common cystic fibrosis mutations", Mol. Cell Probes, (1992), 6:1. 9000127 77 Gaultier et al.,"a-DNA IV: a-anomeric and b-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding" Nucleic Acids Res., (1987), 15:6625-6641. 9000127 78 Gelrud et al., "Interaction of Tumor Necrosis Factor-a and Granulocyte Colony-Stimulation Factor on Neutrophil Apoptosis, Receptor Expression, and Bactericidal Function" Proc. Assoc. Am. PHYSICIANS, (1996), 108:455-456. 9000127 79 Gentz et al., "Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis", Proc. Natl. Acad. Sci. USA, (1989), 86:821-824. 9000127 80 Gibbs et al., "Detection of single DNA base differences by competitive oligonucleotide priming" Nucleic Acids Res., (1989), 17:2437-2448. 9000127 81 Gibot et al., "Plasma Level of Trigering Receptor Expressed on Myeloid Cells-1: Its Diagnostic Accuracy in Patients with Suspected Sepsis," (2004), pp. 9-16. 9000127 82 Gibot et al., "Soluble Triggering Receptor Expressed on Myeloid Cells and the Diagnosis of Pneumonia, " The New England Journal of Medicine, (2004), pp. 451-458. 9000127 83 Gillies et al., "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes", J. Immunol. Methods, (1989), 125:191-202. 9000127 84 Gillies et al., "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells", Proc. Natl. Acad. Sci. USA., (1992), 89:1428-1432. 9000127 85 Gingras et al., "TREM-1, MDL-1, and DAP12 Expression is Associated with a Mature Stage of Myeloid Development," Molecular Immunology 38 (2001) pp. 817-824. 9000127 86 Glauser et al., "Septic shock: pathogenesis," Lancet 338:732-6, 1991. 9000127 87 Goldspiel et al., "Human Gene Therapy," Clinical Pharmacy, (1993), 12:488-505. 9000127 88 Gon et al. Microbiol. Immunol., (1996) 40:463-465. 9000127 89 Griffin et al., "DNA sequencing", Appl. Biochem. Biotechnol., (1993), 38:147-159. 9000127 90 Grossman & Wilson, "Retroviruses: delivery vehicle to the liver", Curr. Opin. In Genetics and Devel., (1993), 3:110-114. 9000127 91 Arts Rob J W et al. "Trem-1 interaction with the LPS/TLR4 receptor complex" European Cytokine Network. 2011. vol. 22(1). p. 11-14. 9000127 92 R& D Systems: "Human Trem-1 Antibody." Internet Citation. Retrieved Nov. 27, 2012. http://www.rndsystems.com/Products/MAB1278. 9000127 93 Eleanor Molloy. "Triggering Receptor Expressed on Myeloid Cells (TREM) Family and the Application of its Antagonists." Recent Patents on Anti-Infective Drug Discovery. vol. 4(1). 2009. pp. 51-56. 9000127 94 Nagihan Bostanci et al. "Involvement of the TREM-1/DAP12 pathway in the innate immune responses to" Molecular Immunology. vol. 49(1) pp. 387-394. 9000127 95 Tessarz et al. "The TREM-1-DAP12 pathway." Immunology Letters. vol. 116(2) pp. 111-116. 9000127 96 Mohamadzadeh et al. "Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by Marburg and ebola viruses." Journal od Virology. 2006. vol. 80(14). pp. 7235-7244. 9000127 97 Weintraub et al., "Anti-sense RNA as a molecular tool for genetic analysis," Reviews--Trends in Genetics, (1986), vol. 1(1), pp. 22-25. 9000127 98 Wells, "Additivity of Mutational Effects in Proteins", Biochemistry, vol. 29(37), (Sep. 18, 1990), pp. 8509-8517. 9000127 99 Wigler et al., "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells," Cell, (1977), 11: 223. 9000127 100 Wigler et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene," Natl. Acad. Sci. USA, (1980), 77: 3567. 9000127 101 Wilmut et al., "Viable offspring derived from fetal and adult mammalian cells," Nature, (1997), 385: 810-813. 9000127 102 Wilson et al., "The structure of an antigenic determinant in a protein", Cell, vol. 37(3), (1984), pp. 767-778. 9000127 103 Winoto & Baltimore, "A novel, inducible and T cell-specific enhancer located a the 38' end of the T cell receptor a locus," Embo J., (1989), 8: 729-733. 9000127 104 Wu & Wu, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," J. Biol. Chem., (1987), 262: 4429-4432. 9000127 105 Wu & Wu, "Delivery systems for gene therapy," Biotherapy, (1991), 3: 87-95. 9000127 106 Yamashita, "Inhibitory and stimulatory functions of paired Ig-like receptor (PIR family in RBL-2H3 Cells," J. Immunol. 161, (1998), pp. 4042-4047. 9000127 107 Zervos et al., "Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites," Cell, (1993), 72: 223-232. 9000127 108 Zijlstra et al., "Germ-line transmission of a disrupted b2-microglobulin gene produced by homologous recombination in embryonic stem cells," Nature, (1989), 342: 435-438. 9000127 109 Zon, "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," Pharm. Res., (1988), 5: 539-549. 9000127 110 Zuckermann et al., "Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid Library," J. Med.Chem., (1994), 37: 2678. 9000127 111 Basic Methods in Molecular Biology, Elsevier Science Publishing Co., New York, (1986), pp. 75-78 and 84-87. 9000127 112 Current Protocols in Molecular Biology, John Wiley & Sons, New York, (1989), Supp 24, 6.3.1-6.3.6. 9000127 113 NCBL Sequence Viewer Accession No. D78812 (Jul. 20, 2006). 9000127 114 NCBL Sequence Viewer Accession No. AI337247 (Mar. 18, 1999). 9000127 115 NCBL Sequence Viewer Accession No. AW139572 (Oct. 30, 1999). 9000127 116 NCBL Sequence Viewer Accession No. AW274906 (Jan. 3, 2000). 9000127 117 NCBL Sequence Viewer Accession No. AW139573 (Oct. 30, 1999). 9000127 118 NCBL Sequence Viewer Accession No. AW394041 (Feb. 4, 2000). 9000127 119 NCBL Sequence Viewer Accession No. AI621023 (Dec. 14, 1999). 9000127 120 NCBL Sequence Viewer Accession No. AI186456 (Oct. 28, 1998). 9000127 121 NCBL Sequence Viewer Accession No. AI968134 (Aug. 25, 1999). 9000127 122 NCBL Sequence Viewer Accession No. AI394092 (Mar. 30, 1999). 9000127 123 NCBL Sequence Viewer Accession No. AI681036 (Dec. 16, 1999). 9000127 124 NCBL Sequence Viewer Accession No. AI962750 (Mar. 8, 2000). 9000127 125 NCBL Sequence Viewer Accession No. AA494171 (Aug. 19, 1997). 9000127 126 NCBL Sequence Viewer Accession No. AA099288 (May 11, 1997). 9000127 127 NCBL Sequence Viewer Accession No. AW139363 (Oct. 30, 1999). 9000127 128 NCBL Sequence Viewer Accession No. AW135801 (Oct. 29, 1999). 9000127 129 NCBL Sequence Viewer Accession No. AA101983 (May 11, 1997). 9000127 130 NCBL Sequence Viewer Accession No. AF196329 (May 24, 2000). 9000127 131 NCBL Sequence Viewer Accession No. AF213457 (May 23, 2000). 9000127 132 NCBL Sequence Viewer Accession No. N41388 (Jan. 24, 1996). 9000127 133 Sharif and Knapp, "From expression to signaling: Roles of TREM-1 and TREM-2 in innate immunity and bacterial infection," Immunobiology, vol. 213, No. 9-10, pp. 701-713 (2008). 9000127 134 Turnbull et al., "Cutting Edge: TREM-2 Attenuates Macrophage Activation," J. Immunol., vol. 177, pp. 3520-3524 (2006). 9000127 135 Adrie et al., "Postresuscitation disease after cardiac arrest: a sepsis-like syndrom?", Current Opinion in Critical Care, Jun. 2004, vol. 10, pp. 208-212. 9000127 136 Begum et al., "Mycobacterium bovis BCG Cell Wall-Specific Differentially Expressed Genes Identified by Differential Display and cDNA Subtraction in Human Macrophages," Infection and Immunity, Feb. 2004, pp. 937-948. 9000127 137 Beleharski et al., "ARole for Triggering Receptor Expressed on Myeloid Cells-1 in Host Defense During the Early-Induced and Adaptive Phases of the Immune Response," The Journal Immunology, 2003, vol. 170, pp. 3812-3818. 9000127 138 Bone et al., "Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis," Jun. 1992, vol. 101, pp. 1644-1655. 9000127 139 Cohen, Jonathan, "TERM-1 in sepsis, "The Lancet, Sep. 8, 2001, vol. 358, pp. 776-778. 9000127 140 Cohen, Jonathan, "The immunopathogenesis of sepsis, " Nature, Dec. 19/26, 2002, vol. 420, pp. 885-891. 9000127 141 Collart et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four kB-Like Motifs and Constitutive and Inducible Forms of NF-kB, " Molecular and Cellular Biology, Apr. 1990, vol. 10, No. 4, pp. 1498-1506. 9000127 142 Colonna et al., TREM-1 (Triggering Receptor Expressed on Myeloid Cells): A New Player in Acute inflammatory Responses, Journal of Infectious Diseases, 2003, 187, suppl. 2: pp. S397-S401. 9000127 143 Colonna et al., "TREMS in the Immune System and Beyond." Nature Reviews Immunology, Jun. 2003, vol. 3, No. 6, pp. 445-453 (printed as pp. 1-9). 9000127 144 Dinarello et al., "Proinflammatory and Ant-inflammatory Cytokines as Mediators in the Pathogenesis of Septic Shock," Chest, Dec. 1997, vol. 112, No. 6, pp. 321S-329S. 9000127 145 Echtenacher et al., "Tumor Necrosis Factor-Dependen Adhesions as a Major Protective Mechanism Early in Septic Peritonitis in Mice." Infection and Immunity, Jun. 2001, vol. 69, No. 6, pp. 3550-3555. 9000127 146 Coskun et al , Endocrinology, "Fibroblast Growth Factor 21 Corrects Obesity in Mice", 2008, vol. 149, No. 12, pp. 6018-6027. 9000127 147 Erickson et al., Journal of Lipid Research, "Nonalcoholic Fatty Liver Disease", 2008, Volume--, Number--, pp. S412-S416. 9000127 148 Grundy et al., Circulation, "Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition", 2004, vol. 109, Number--, pp. 433-438. 9000127 149 Kharitonenkov et al., Endocrinology, "The Metabolic State of Diabetic Monkeys Is Regulated by Fibroblast Growth Factor-21", 2007, vol. 148, No. 2, pp. 774-781. 9000127 150 Kharitonenkov et al., Journal of Clinical Investigation, "FGF-21 As a Novel Metabolic Regulator", 2005, vol. 115, Number--, pp. 1627-1635. 9000127 151 Knudsen, L.B., Journal of Medicinal Chemistry, "Glucagon-Like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", 2004, vol. 47, No. 17, pp. 4128-4134. 9000127 152 Micanovic et al., Journal of Cellular Physiology, "Different Roles of N- and C- Termini in the Functional Activity of FGF21", 2009, vol. 219, No. 2, pp. 227-234. 9000127 153 Nauck, M.A et al., Regulatory Peptides, "Glucagon-Like Peptide 1 and Its Derivatives in the Treatment of Diabetes", 2005, vol. 128, No. 2, pp. 135-148. 9000127 154 Xu et al., Diabetes, "Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice", 2009, vol. 58, No. 1, pp. 250-259. 9000127 155 Yie et al., FEBS Letters, "FGF21 N- and C-Termini Play Different Roles in Receptor Interaction and Activation", 2009, vol. 583, No. 1, pp. 19-24. 9000127 156 Abravaya et al., "Detection of point mutations with a modified ligase chain reaction (Gap-LCR)" Nucleic Acids Res., (1995), 23:675-682. 9000127 157 Aderem et al., "Toll-Olike receptors in the induction of the innate immune response." Nature, 406:782-7. 9000127 158 Alexander et al., "A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice", J. Exp. Med., 173:1029-32, 1991. 9000127 159 Ames et al., "Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins", J. Immunol. Methods, vol. 184(2), (1995), pp. 177-186. 9000127 160 Amman et al., "Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli ", Gene, (1988), 69:301-315. 9000127 161 Appelmelk et al., "Use of mucin and hemoglobin in experimental murine Gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region", Antonie Van Leeuwenhoek, (1986), 52:537-42. 9000127 162 Arnon et al., "Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy", in Monoclonal Antibodies and Cancer Therapy, Reisfeld et al., eds., Alan R. Liss, Inc., (1985), pp. 243-256. 9000127 163 Baker et al., "NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals", Hum Immunol., 61:18-27. 2000. 9000127 164 Bakker et al., "DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming." Immunity 13:345-53. 2000. 9000127 165 Bakker et al., "Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells, "Proc. Natl. Acad. Sci. USA 96:9792, 1999. 9000127 166 Baldwin et al., "Analysis Results, and Future Prospective of the Therapeutic Use of the Radiolabeled Antibody in Cancer Therapy", in Monoclonal Antibodies for Cancer Detection and Therapy, eds. Adacemic Press, (1985, pp. 303-316. 9000127 167 Banerji et al., "A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes", Cell, (1983), 33:729-740. 9000127 168 Barany,"Genetic disease detection and DNA amplification using cloned thermostable ligase", Proc. Natl. Acad. Sci. USA, (1991), 88:189. 9000127 169 Baldari et al., "A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1b in Saccharomyces cerevisiae," Embo J., (1987), 6:229-234. 9000127 170 Bartel et al., Bio Techniques, (1993), 14:920-924. 9000127 171 Bartel et al., "Isolation of new ribozymes from a large pool of random sequences",Science, (1993), 261:1411-1418. 9000127 172 Bauer et. al., "Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA", Science, 285:727-9, 1999. 9000127 173 Benda et al., "Differentiated Rat Glial Cell Strain in Tissue Culture," Science, (1968), 161:370-371. 9000127 174 Better et al., "Escherichia coli secretion of an active chimeric antibody fragment," Science, (1988), 240:1041-1043. 9000127 175 Beutler et al., "Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin", Science, 229:869-71, 1985. 9000127 176 Beutler, B., "Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity", Curr. Opin. Microbiol., vol. 3 (1), (2000), pp. 23-28. 9000127 177 Boesen et al., "Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr1 gene," Biotherapy, (1994), 6:291-302. 9000127 178 Bolin et al., "Survey of cell lines in the American Type Culture Collection for bovine viral diarrhea virus", J. Virol. Methods, (1994), 48: 211-221. 9000127 179 Bone, "The pathogenesis of sepsis," Ann. Intern. Med. 115:457-69, 1991. 9000127 180 Bordelon-Riser et al., "Necessity for two human chromosomes for human chorionic gonadotropin production in human-mouse hybrids", Somatic Cell Genetics, (1979), 5:597-613. 9000127 181 Bork & Bairoch, "Go hunting in sequence databases but watch out for the traps", Trends in Genetics, (1996)vol. 12(10), pp. 425-427. 9000127 182 Bork, "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome Research, (2000), 10:398-400. 9000127 183 Bouchon et al., "Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutroophils and monocytes", J. Immunol., vol. 164 (10). May 15, 2000), pp. 4991-4995. 9000127 184 Bouchon et al., "TREM-1 amplifies inflammation and is a crucial mediator of septic shock", Nature, vol., 410(6832), (Apr. 26, 2001), pp. 1103-1107. 9000127 185 Bout et al., "Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium", Human Gene Therapy, (1994), 5:3-10. 9000127 186 Bradley, Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., IRL, Oxford, (1987), pp. 113-152. 9000127 187 Bradley, "Modifying the mammalian genome by gene targeting", Current Opinion in Bio Technology, (1991), 2:823-829. 9000127 188 Brenner, "Errors in genome annotation", Trends in Genetics, vol. 15(4), (Apr. 1999), pp. 132-133. 9000127 189 Brinkman et al., "Phage display of disulfide-stabilized Fv fragments", J. Immunol. Methods, (1995), 182:41-50. 9000127 190 Burton et al., "Human Antibodies from Combinatorial Libraries ", Advances in Immunology, (1994), 57:191-280. 9000127 191 Byrne & Ruddle, "Multiplex gene regulation: a two-tiered approach to transgene regulation in transgenic mice", Proc. Natl. Acad. Sci. USA, (1989), 86:5473-5477. 9000127 192 Calame et al., "Transcriptional controlling elements in the immunoglobulin and T cell receptor loci", Adv. Immunol., vol. 43, (1988), pp. 235-275. 9000127 193 Calandra et al., J. Immunol., (2000), 145:3762-6. 9000127 194 Calandra et al., "Protection from septic shock by neutralization of macrophage migration inhibitory factor, " Nat. Med., 6:164-70, 2000. 9000127 195 Campes & Tilghman, "Postnatal repression of the alpha-fetoprotein gene is enhancer independent", Genes Dev., (1989), 3:537-546. 9000127 196 Guatelli et al., "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication", Proc. Natl. Acad. Sci. USA, (1990), 87:1874-1878. 9000127 197 Haapala et al., "Isolation from cats of an endogenous type C virus with a novel envelope glycoprotein.", J. Virol., (1985), 53:827-833. 9000127 198 Hammerling et al., Moloclonal Antibodies and T-Cell Hybridomas, Elsevier, New York, (1981) pp. 563-681. 9000127 199 Harlow et al., Antibodies: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, (1988). 9000127 200 Haselhoff et al., "Simple RNA enzymes with new and highly specific endoribonuclease activities", Nature, (1988), 334: 585-591. 9000127 201 Hayashi, "PCR-SSCP: A method for detection of mutations ", Genet. Anal. Tech. Appl., (1992), 9:73-79. 9000127 202 He et al., "Expression of O6-Methylguanine-DNA Methyltransferase in Six Human Medulloblastoma Cell Lines ", Cancer Res., (1992), 52:1144-1148. 9000127 203 Hebert et al., "Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids.", J. Immunol., (1996), 157:3105-3115. 9000127 204 Helene, "The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides" Anticancer Drung Des., (1991), 6(6):569-84. 9000127 205 Helene, "Control of Gene Expression by Triple Helix-Forming Oligonucleotides. The Antigene Strategy", Ann. N. Y. Acad. Sci., (1992), 660:27-36. 9000127 206 Hellstrom et al., "Antibodies for Drug Delivery" in Controlled Drug Delivery, 2nd edition, Robinson et al., eds., Marcel Dekker, Inc., (1987), pp. 623-653. 9000127 207 Hoffman et al., "Phylogenetic perspectives in innate immunity", Science, vol. 284(5418), 1999, pp. 1313-1318. 9000127 208 Houghten, Bio Techniques, (1992), 13:412-421. 9000127 209 Hsu et al., "Detection of DNA point mutations with DNA mismatch repair enzymes", Carcinogenesis, (1994), 15:1657-1662. 9000127 210 Huston et al., "Protein engineering of single-chain Fv analogs and fusion proteins", Methods in Enzymology, (1991), 203-46-88. 9000127 211 Hyrup et al., "Peptide Nucleic Acids (PNA): Synthesis, properties and potential applications", Bioorganic & Medicinal Chemistry, 1996, 4(1): 5-23. 9000127 212 Inoue et al., "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides" Nucleic Acids Res., (1987), 15: 6131-6148. 9000127 213 Inoue et al., "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H", FEBS Lett., (1987), 215: 327-330. 9000127 214 Iwabuchi et al., Oncogene, (1993), 8: 1693-1696. 9000127 215 Jespers et al., Bio Technology, (1988), 12: 899-903. 9000127 216 Jobling & Holmes, "Analysis of structure and function of the B Subunit of cholera toxin by the use of site-directd mutagenesis", Molecular Microbiology, vol. 5(7), pp. 1755-1767. 9000127 217 Katsuura et al., "CD48 expression on leukocytes in infectious diseases: flow cytometric analysis of surface antigen", Acta Paediatr Jpn., vol. 40(6), 1998, pp. 580-585. 9000127 218 Kaufman et al., Embo J., (1987), 6: 187-195. 9000127 219 Keen et al., "Rapid detection of single base mismatches as heteroduplexes on Hydrolink gels", Trends Genet., (1991), 7:5. 9000127 220 Kessel & Gruss, "Murine developmental control genes", Science, (1990), 249: 374-379. 9000127 221 Kettleborough et al., "Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments", Eur. J. Immunol., vol. 24(4), 1994, pp. 952-958. 9000127 222 Kiem et al., Retrovirus-Mediated Gene Transduction into Canine Peripheral Blood Repopulating Cells, Blood, (1994), 83: 1467-1473. 9000127 223 Knappik et al., Biotechniques, (1994), 17(4): 754-761. 9000127 224 Kohler, "Immunoglobulin chain loss in hybridoma lines", Proc. Natl. Acad.Sci. USA, (1980), 77: (4) 2197. 9000127 225 Koller & Smithies, "Inactivating the beta 2-microglobulin locus in mouse embryonic stem cells by homologous recombination", Proc. Natl. Acad. Sci. USA (1989), 86: 8932-8935. 9000127 226 Kozal et al., "Extensive polymorphisms observed in HIV?1 clade B protease gene using high?density oligonucleotide arrays ", Nature Medicine, (1996), 2: 753-759. 9000127 227 Kozarsky & Wilson, "Gene therapy: adenovirus vectors", Current Opinion in Genetics and Development, (1993), 3: 499-503. 9000127 228 Krol et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences" Bio/Techniques, (1988), 6: 958-976. 9000127 229 Kruse et al., "Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses", In Vitro Cell. Dev. Biol., (1992), 28A: 609-614. 9000127 230 Kubagawa et al., "Biochemical nature and cellular distribution of the paird immunoglobulin-like receptors, PIR-B." J. Exp. Med 189:309, 1999. 9000127 231 Kunkel et al., "Rapid and efficient site-specific mutagenesis without phenotypic selection", Methods Enzymol., (1987), 154: 367-82. 9000127 232 Kurjan & Herskowitz, "Structure of a yeast pheromone gene (MF?): A putative ?-factor precursor contains four tandem copies of mature ?-factor", Cell (1982), 30: 933-943. 9000127 233 Kwoh et al., "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format", Proc. Natl. Acad. Sci. USA, (1989), 86: 1173-1177. 9000127 234 Lakso et. al., "Targeted oncogene activation by site-specific recombination in transgenic mice", Proc. Natl. Acad. Sci. USA, (1992) 89: 6232-6236. 9000127 235 Lam, Nature, "A new type of synthetic peptide library for identifying ligand-binding activity", (1991), 354: 82-84. 9000127 236 Lam, "Mini-review. Application of combinatorial library methods in cancer research and drug discovery", Anticancer Drug Des., (1997), 12: 145. 9000127 237 Landegran et al., "A ligase-mediated gene detection technique", Science, (1988), 241: 1077-1080. 9000127 238 Lane et al., "CD40 ligand-independent B cell activation revealed by CD40 ligand-deficient T cell clones: evidence for distinct activation requirements for antibody formation and B cell proliferation", Eur. J. Immunol., (1995), 6: 1788. 9000127 239 Lanier et al., "NK cell receptors," Annu. Rev. Immunol., 16: 359 (1998). 9000127 240 Lanier, LL, "Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells", Nature, vol. 391 (6668), (1998), pp. 703-707. 9000127 241 Lemaitre et al., "Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site", Proc. Natl. Acad. Sci. USA, (1987), 84: 648-652. 9000127 242 Letsinger et al., "Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture", Proc. Natl. Acad. Sci. USA, (1989), 86: 6553-6556. 9000127 243 Li et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality," Cell, (1992), 69: 915. 9000127 244 Queen & Baltimore, "Immunoglobulin gene transcription is activated by downstream sequence elements," Cell, (1983), 33: 741-748. 9000127 245 Radany et al., "Directed establishment of rat brain cell lines with the phenotypic characteristics of type 1 astrocytes," Proc. Natl. Acad. Sci. USA, (1992) 89: 6467-6471. 9000127 246 Rheinwald, "Chapter 15 Serial Cultivation of Normal Human Epidermal Keratinocytes," Meth. Cell Bio., (1980), 21A: 229. 9000127 247 Riechmann et al., "Reshaping human antibodies for therapy," Nature, (1988), 332: 323. 9000127 248 Roguska et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing," Proc. Natl. Acad. Sci. USA, (1994), 91: 969-973. 9000127 249 Rosenbaum & Reissner, "Temperature-gradient gel electrophoresis: Thermodynamic analysis of nucleic acids and proteins in purified form and in cellular extracts," Biophys. Chem., (1987), 26:235-246. 9000127 250 Rosenberg et al., "Inflammation," in Fundamental Immunology, 4th Ed. W. E. Paul, ed., p. 1051, 1999. 9000127 251 Rosenfeld et al., "Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo," Science, (1991), 252: 431-434. 9000127 252 Rosenfeld et al., "In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium," Cell, (1992), 68:143-155. 9000127 253 Rothe et al., "Mice lacking the tumour necrosis factor rector receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes" Nature, vol. 364, (1993), pp. 798-802. 9000127 254 Saiki et al., "Analysis of enzymatically amplified b-globin and HLA-DQa DNA with allele-specific oligonucleotide probes," Nature, (1986), 324: 163. 9000127 255 Saiki et al., "Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes," Proc. Natl. Acad. Sci. USA, (1989), 86:6230. 9000127 256 Saleeba et al., "Chemical cleavage of mismatch to detect mutations," Methods Enzymol., (1992), 217: 286-295. 9000127 257 Sallusto et al., "Efficient peresentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulation factor plus interleukin 4 and downregulated by tumor necrosis factor alpha", J. Exp. Med., 1994, vol. 179(4), pp. 1109-1118. 9000127 258 Salmons & Gunzberg, "Targeting of Retroviral Vectors for Gene Therapy," Human Gene Therapy, (1993), 4: 129-141. 9000127 259 Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY , (1990), Chapters 16 & 17. 9000127 260 Sanger, "DNA sequencing with chain-terminating inhibitors," Proc. Natl. Acad. Sci. USA, (1977), 74: 5463. 9000127 261 Santerre et al., "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells," Gene, (1984), 30: 147. 9000127 262 Sawai et al., "Direct Production of the Fab Fragment Derived From the Sperm Immobillizing Antibody Using Polymerase Chain Reaction and cDNA Expression Vectors," AJRI, (1995), 34:26-34. 9000127 263 Schultz et al., "Expression and secretion in yeast of a 400-kda envelope glycoprotein derived from epstein-barr virus," Gene, (1987), 54: 113-123. 9000127 264 Scott & Smith, "Searching for peptide ligands with an epitope library," Science, (1990), 249: 386-390. 9000127 265 Seed, "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2," Nature, (1987), 329: 840. 9000127 266 Shu et al., "Secretion of a single-gene-encoded immunoglobulin from myeloma cells", Proc. Natl. Acad. Sci. USA, vol. 90(17), (1993), pp. 7995-7999. 9000127 267 Skerra et al., "Assembly of a functional immunoglobulin Fv fragment in Escherichia coli ", Science, vol. 240(4855), (1988), pp. 1038-1041. 9000127 268 Skolnick & Fetrow, "From gene to protein structure and function: novel applications of computational approaches in the genomic era", Trends in Biotech, vol. 18(1), (2000) pp. 34-39. 9000127 269 Smith et al., "Production of human beta interferon in insect cells infected with a baculovirus expression vector," Mol. Cell Biol., (1983), 3: 2156-2165. 9000127 270 Smith & Johnson, "Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase," Gene, (1988), 67: 31-40. 9000127 271 Smith & Zhang, "The challenges of genome sequence annotation or `The devil is in the details`", Nature Biotechnology, vol. 15 (Nov. 1997), pp. 1222-1223. 9000127 272 Springer et al., "Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm," Cell, 76: 301, 1994. 9000127 273 Stemple & Anderson, "Isolation of a stem cell for neurons and glia from the mammalian neural crest," Cell, (1992), 71:973-985. 9000127 274 Studnicka et al., "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues," Protein Engineering, (1994), 7(6):805-814. 9000127 275 Sugimoto et al., "Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies", J. Natl. Cancer Inst., vol. 73(1), (1984), pp. 51-57. 9000127 276 Szybalska & Szybalski, "Genetics of human cell lines, IV. DNA-mediated heritable transformation of a biochemical trait," Proc. Natl. Acad. Sci. USA, (1962), 48: 2026. 9000127 277 Thomas & Capecchi, "Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells," Cell, (1987), 51: 503. 9000127 278 Thorpe et al., "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates," Immunol. Rev., (1982), 62: 119-58. 9000127 279 Thorpe, Antibody Carriers of Cytotoxic Agents in Cencer Therapy: A Review, in Monoclonal Antibodies 84: Biological and Clinical Applications, Pinchera et al., eds., (1985), pp. 475-506. 9000127 280 Tolstoshev, "Gene Therapy, Concepts, Current Trials and Future Directions," Ann. Rev. Pharmacol. Toxicol., (1993), 32: 573-596. 9000127 281 Tomasello et al., "Combined natural killer cell and dendritic cell functional deficiency in KASRAP/DAP12 loss-of-function mutant mice", Immunity 13: 355-64, 2000. 9000127 282 Tomic et al., "A rapid and simple method for introducing specific mutations into any position of DNA leaving all other positions unaltered," Nucleic Acids Res., (1990), 18(6): 1656. 9000127 283 Tracey et al., "Shock and tissue injury induced by recombinant human cachectin." Science 234-470-4 1986. 9000127 284 Traunecker et al., "Myeloma based expression system for production of large mammalian proteins," Trends Biotechnol., vol. 9, (1991), pp. 109-113. 9000127 285 Trowbridge et al., "Establishment and characterization of ferret cells in culture," In Vitro, (1982), 18: 952-960. 9000127 286 Ulevitch et al., "Recognition of Gram-negative bacteria and endotoxin by the innate immune system," Curr. Opin. Immunol, vol. 11, (1999), pp. 19-22. 9000127 287 Upender et al., "Megaprimer Method for In Vitro Mutagenesis Using Parallel Templates," Biotechniques, (1995), 18 (1): 29-30, 32. 9000127 288 Van Keuren et al., "Regional assignment of human liver-type 6-phosphofructokinase to chromosome 21q22.3 by using somatic cell hybrids and a monoclonal anti-L antibody," Hum. Genet., (1986), 74:34-40. 9000127 289 Wada et al., "Codon usage tabulated from the GenBank genetic sequence data," Nucleic Acid Res., (1992), 20: 2111-2118. 9000127 290 Wakayama et al., "Mice cloned from embryonic stem cells," Proc. Natl. Acad. Sci. USA, (1999), 96: 14984-14989. 9000127 291 Walsh et al., "Gene Therapy for Human Hemoglobinopathies," Proc. Soc. Exp. Biol. Med., (1993), 204: 289-300. 9000127 292 Wang et al., "A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions," Gene Therapy, (1995), 2: 775-783. 9000127 293 Wang et al., "HMG-1 as a late mediator of endotoxin lethality in mice", Science, vol. 285, (1999), pp. 248-251. 9000127 294 Lizardi et al., "Exponential amplification of recombinant-RNA hybridization probes," Nature Biotechnology, (1988), 6: 1197-1202. 9000127 295 Loeffler & Behr, "Gene transfer into primary and established mammalian cell lines with lipopolyamine-coated DNA," Meth. Enzymol., (1993), 217: 599-618. 9000127 296 Lonberg et al., "Human antibodies from transgenic mice", Int. Rev. Immunol., vol. 13(1), (1995) pp. 65-93. 9000127 297 Lowy et al., "Isolation of transforming DNA: Cloning the hamster aprt gene," Cell, (1980), 22: 817. 9000127 298 Lucklow & Summers, "High level expression of nonfused foreign genes with Autographa californica nuclear polyhedrosis virus expression vectors," Virology, (1989), 170: 31-39. 9000127 299 Madura et al., "N-recognin/Ubc2 interactions in the N-end rule pathway," J. Biol. Chem., (1993), 17: 5973-88. 9000127 300 Mag et al., "Synthesis and selective cleavage of oligodeoxyribonucleotldes containing non-chiral intemucieotlde phosphoramidate linkages," Nucleic Acids Res., (1989), 17: 5973-88. 9000127 301 Maher, "DNA Triple-Helix Formation: An Approach to Artificial Gene Repressors?," Bioassays, (1992), 14(12): 807-15. 9000127 302 Malaviya et al., "Mast cell modulation of neutorphil influx and bacterial clearance at sites of infection thrugh TNF-alpha", Nature, 381, (1996), pp. 77-80. 9000127 303 Mastrangeli et al., "Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer," J. Clin. Invest., (1993), 91: 225-234. 9000127 304 Maxam & Gilbert, "A new method for sequencing DNA," Proc. Natl. Acad. Sci. USA, (1977), 74: 560. 9000127 305 McNamara et al., "Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice", J. Surg. Res., 54, (1993), 316-21. 9000127 306 Medzhitov et al., "Innate immunity", N. Engl. J. Med., vol. 343, (2000), pp. 338-344. 9000127 307 Michael et al., Biotechniques, (1994), 16(3): 410-412. 9000127 308 Miller et al., "Use of retroviral vectors for gene transfer and expression," Meth. Enzymol., (1993), 217: 581-599. 9000127 309 Morgan & Anderson, "Human Gene Therapy," Ann. Rev. Biochem., (1993), 62: 191-217. 9000127 310 Morrison et al., "Endotoxins and disease mechanisms." Annu. Rev. Med. 38: 417-32, 1987. 9000127 311 Morrison, "Transfectomas provide novel chimeric antibodies," Science, (1985), 229: 1202. 9000127 312 Mulligan, "The basic science of gene therapy," Science, (1993), 260: 926-932. 9000127 313 Mulligan & Berg, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase," Proc. Natl. Acad. Sci. USA, (1981), 78: 2072. 9000127 314 Mullinax et al., Bio Techniques, (1992), 12(6): 864-869. 9000127 315 Myers et al., "Detection of single base substitutions in total genomic DNA," Nature, (1985), 313: 495. 9000127 316 Myers et al., "Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes," Science, (1985), 230: 1242. 9000127 317 Nakajima et al., "Human myeloid cells express and activating ILT receptor (ILTI) that associates with Fc receptor y-chain," J. Immunol. 162: 5. (1999), pp. 5-8. 9000127 318 Nakajima et al., "2B4: an NK cell activating receptor with unique specificity and signal transduction mechanism", Humm Immunol., vol. 61, (2000), pp. 39-43. 9000127 319 Nakazawa et al., "UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement," Proc Natl. Acad. Sci. USA, (1994), 91: 360-364. 9000127 320 Naramura et al., "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells," Immunol. Lett., (1994), 39: 91-99. 9000127 321 Nathan & Ding, "TREM-1: A new regulator of innate immunity in sepsis syndrome", Nature Medicine, vol. 7(5), May, 2001), pp. 530-532. 9000127 322 Nederman et al., "An in vitro bioassay for quantitation of human interferons by measurements of antiproliferative activity on a continuous human lymphoma cell line." Biologicals, vol. 18(1), (1990), pp. 29-34. 9000127 323 Ngo et al., "The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox", (Mar. 2, 1995), pp. 492-495. 9000127 324 Nicoletti et al., "A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry," J. Immunol. Methods, (1991), 139: 271-279. 9000127 325 O'Gorman et al., "Recombinase-mediated gene activation and site-specific integration in mammalian cells," Science, (1991), 251: 1351-1355. 9000127 326 O'Hare et al., "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase," Proc. Natl. Acad. Sci. USA, (1981), 78: 1527. 9000127 327 Ohlsson et al., "Interleukin-1 receptor antagonist reduces mortality from endotoxin shock", Nature, vol. 348, (1990), pp. 550-552. 9000127 328 OI et al., "Chimeric Antibodies," Bio Techniques, (1986), 4: 214-221. 9000127 329 Oishi et al., "Inhibition of Neutrophil Apoptosis by Antioxidants in Culture Medium," Scand. J. Immunol., (1997), 45: 21-27. 9000127 330 Oliveira et al., "Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole", Brazilian Journal of Medical and Biological Research, vol. 35(7), (Jul. 2002), pp. 789-798. 9000127 331 Olopade et al., "Molecular Analysis of Deletions of the Short Arm of Chromosome 9 in Human Gliomas," Cancer Res., (1992), 52: 2523-2529. 9000127 332 Orita et al., "Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms," Proc. Natl. Acad. Sci. USA, (1989), 86: 2766. 9000127 333 Owerbach et al., "Genetics of the large, external, transformation-sensitive (LETS) protein: assignment of a gene coding for expression of LETS to human chromosome 8," Proc. Natl. Acad. Sci. USA, (1978), 75: 5640-5644. 9000127 334 Padlan, "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties," Molecular Immunology, (1991), 28(4/5): 489-498. 9000127 335 Pajunen et al. "Assignment of the gene coding for both the beta-subunit of prolyl 4-hydroxylase and the enzyme disulfide isomerase to human chromosome region 17p11--qter," Cytogenet. Cell Genet., ( 1988), 47: 37-41 (Abstract). 9000127 336 Perry-O'Keefe et al., "Peptide nucleic acid pre-gel hybridization: An alternative to Southern?hybridization," Proc. Natl. Acad. Sci. USA, (1996), 93: 14670-675. 9000127 337 Persic et al., "An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries", Gene, vol. 187(1), (1997), pp. 9-18. 9000127 338 Peschon et al., "TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation", J. Immunol., vol. 160, (1998), pp. 943-952. 9000127 339 Petersen et al., A PNA-DNA linker synthesis of N-((4,4?-dimethoxytrityloxy)ethyl)-N-(thymin-1-ylacetyl)glycine, Bioorganic Med. Chem. Lett., (1995), 5: 1119-1124. 9000127 340 Pfeffer et al., "mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection", Cell, vol. 73, (1993) pp. 457-467. 9000127 341 Pinkert et al., "An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice," Genes Dev., (1987), 1: 268-277. 9000127 342 Pittelkow & Scott, "New Techniques for the In Vitro Culture of Human Skin Keratinocytes and Perspectives on Their Use for Grafting of Patients With Extensive Burns," Mayo Clinic Proc., (1986), 61: 771. 9000127 343 Prosser, "Detecting single-base mutations," Tibtech, (1993), 11: 238-246. 9000127 344 Bouchon et al, Journal of Immunology, "Cutting Edge: Inflammatory Responses Can Be Triggered by TERM-1, A Novel Receptor Expressed on Neutrophils and Monocytes", 2000, vol. 164, No. 10, pp. 4991-4995. 9000127 345 Bouchon et al, Nature, "TREM-1Amplifies Inflammation and Is a Crucial Mediator of Septic Shock", 2001, vol. 410, Number , pp. 1103-1107. 9000127 346 J. Phua et al, European Respiratory Journal, "Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Acute Respiratory Infections", 2006, vol. 28, Number , pp. 695-702. 9000127 347 Jun Kuai et al, Rheumatology, "TREM-1 Expression Is Increased in the Synovium of Rheumatoid Arthritis Patients and Induces the Expression of Pro-Inflammatory Cytokines", 2009, vol. 48, Number , pp. 1352-1358. 9000127 348 Mirjam Schenk, Journal of Clinical Investigation, "TREM-1--Expressing Intestinal Macrophages Crucially Amplify Chronic Inflammation in Experimental Colitis and Inflammatory Bowel Diseases", 2007, vol. 117, Number , pp. 3097-3106. 9000127 349 Yousuke Murakami et al, Arthritis and Rheumatism, "Intervention of an Inflammation Amplifier, Triggering Receptor Expressed on Myeloid Cells 1, for Treatment of Autoimmune Arthritis", 2009, vol. 60, No. 6, pp. 1615-1623. 9000127 350 LS Bio/LifeSpan BioSciences, Inc., Pglyrpl / pgrp antibody (Is-c579) http://www.lsbio.com/Antibodies/PGLYRP1-PGRP-Antibody-LS-C579/2801. 9000127 351 LS Bio/LifeSpan BioSciences, Inc,Pglyrp1 / pgrp antibody (Is-c38137) http://www.lsbio.com/Antibodies/PGLYRP1-PGRP-Antibody-LS-C38137/37645. 9000127 352 LS Bio/LifeSpan BioSciences, Inc.,Pglyrp1 1 pgrp antibody (Is-c578) http://www.lsbio.com/Antibodies/PGLYRP1-PGRP-Antibody-LS-C578/2800. 9000127 353 Ghosh Amit et al.,A Novel Antimicrobial Peptidoglycan Recognition Protein in the Cornea, Journal:Invest. Ophthalmol. Vis. Sci. Year Sep. 2009 vol. 50 No. 9 pp. 4185-4191. 9000127 354 Dziarski Roman et al. , Mammalian peptidoglycan recognition proteins (PGRPs) in innate immunity, Journal Innate Immunity, Year 2010, vol. 16 No. 3, pp. 168-174,. 9000127 355 LS Bio/LifeSpan BioSciences, Inc.,Pglyrp1 / pgrp antibody (Is-b4940), http://www.lsbio.com/Antibodies/PGLYRP1-PGRP-Antibody-LS-B4940/128350. 9000127 356 Abcam,Anti-PGRPS antibody [188C424] (ab13903), http://www.abcam.com/PGRPS-antibody-188C424-ab13903.html. 9000127 357 Kang Daiwu et al.,A peptidoglycan recognition protein in innate immunity conserved from insects to humans, Journal :Proc. Natl. Acad. Sci. USA, Year 1998, vol. 95, pp. 10078-10082. 9000127 358 Haselmayer Phillipp et al. TREM-1 ligand expression on platelets enhances neutrophil activation, Journal : Blood, Year 2007 vol. 110,pp. 1029-1035. 9000127 359 Dziarski Roman et al, Peptidoglycan recognition in innate immunity, Journal :Innate Immunity, Year Oct. 2005 vol. 11 No. 5 pp. 304-310. 9000127 360 Pant S.D. et al,Bovine PGLYRP1 polymorphisms and their association with resistance to Mycobacterium avium ssp. paratuberculosis, Journal :Animal Genetics, Year Aug. 20, 2010, vol. 42, pp. 354-360. 9000127 361 Dziarski Roman et al.The peptidoglycan recognition proteins (PGRPs), Journal :Genome BiologyYear 2006, vol. 7 pp. 232.1-232.13. 9000127 362 Steiner Hakan , Peptidoglycan recognition proteins:On and off switches for innate immunity, Journal :Immunological Reviews ,Year 2004, vol. 198 pp. 83-96. 9000127 363 Larin Sergey S et al .Immunotherapy with autologous tumor cells engineered to secrete Tag7/PGRP, an innate immunity recognition molecule, Journal :The Journal of Gene Medicine Year 2004;vol. 6 pp. 798-808. 9000127 364 Kang Daiwu et al,.A peptidoglycan recognition protein in innate immunity conserved from insects to humans, Journal: Proc. Natl. Acad. Sci. USA, Year Aug. 1998, vol. 95, pp. 10078-10082. 9000127 365 Guan Rongjin et al ,Crystal Structure of Human Peptidoglycan Recognition Protein S (PGRP-S) at 1.70 A Resolution, Journal :Journal of Molecular Biology.Year 2005, vol. 347,pp. 683-691. 9000127 366 A. Osanai et al.,Mouse Peptidoglycan Recognition Protein PGLYRP-1 Plays a Role in the Host Innate Immune Response against Listeria monocytogenes Infection, Journal: INFECTION and IMMUNITY,Year Dec. 6, 2010 vol. 79, No. 2, pp. 858-866, XP055060881. 9000127 367 Gimano D Amatngalim et al: Cathelicidin Peptide LL-37 Modulates TREM-1 Expression and Inflammatory Responses to Microbial Compounds,Journal : INFLAMMATION, Year,Sep. 2, 2010, vol. 34, No. 5 pp. 412-425. 9000127 368 Arts Rob J W et al: "TREM-1 interaction with the LPS/TLR4 receptor complex.", Journal :European Cytokine Network,Year Mar. 2011, vol. 22, No. 1.pp. 11-14. 9000127 369 S. Gibot et al. Modulation of the Triggering Receptor Expressed on the Myeloid Cell Type 1 Pathway in Murine Septic Shock,Journal: INFECTION and IMMUNITY,Year May 1 2006 vol. 74, No. 5,pp. 2823-2830. 9000127 370 Ramanathan B et al: Cloning of porcine triggering receptor expressed on myeloid cells-1 (TREM-1) and its induction by lipopolysaccharide, peptidoglycan, and Salmonella enterica serovar Typhimurium, infection. ( 2004). 9000127 371 Thekla Poukoulidou et al. TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen,Journal : BMC Infectious Diseases, Year Nov. 4, 2011 vol. 11, No. 1, p. 309(1-8). 9000127 372 Julien Royet et al: "Peptidoglycan recognition proteins: modulators of the microbiome and inflammation",Journal: Nature Reviews Immunology,Year :Dec. 2011 pp. 837-851. 9000127 373 Dziarski R, Peptidoglycan recognition proteins (PGRPs), Journal :Molecular Immunology, Year 2004, vol. 40 pp. 877-886. 9000127 374 Saha et al., PGLYRP-2 and Nod2 Are Both Required for Peptidoglycan-Induced Arthritis and Local Inflammation, Journal :Cell Host & Microbe, Year 2009,vol. 5 pp. 137-150. 9000127 375 Saha et al.Peptidoglycan Recognition Proteins Protect Mice from Experimental Colitis by Promoting Normal Gut Flora and Preventing Induction of Interferon-y, Journal : Cell Host and Microbe, Year 2010, vol. 8, pp. 147-162. 9000128 1 Colman, PM. Research in Immunology, Elsevier, NY, 145(1):33-36, 1994. 9000128 2 Paul, WE. Fundamental Immunology, 3rd ed. Raven Press, NY, Chap. 9, pp. 292-295, 1993. 9000128 3 Rudikoff S. et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982. 9000129 1 Almenoff et al., "Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors" Molecular Microbiology, 8(5), pp. 865-873 (1993). 9000129 2 Bakre et al., "Homologous desensitization of the human guanylate cyclase C receptor. Cell-specific regulation of catalytic activity." Eur. J. Biochem. 267:179-187 (2000). 9000129 3 Belisle et al., "Characterization of Monoclonal Antibodies to Heat-Labile Enterotoxin Encoded by a Palsmid from a Clinical Isolate of Escherichia coli", Infection and Immunity, pp. 1027-1032 (1984). 9000129 4 Bhandari et al., "Functional inactivation of the human guanylyl cyclase C receptor: modeling and mutation of the protein kinase-like domain." Biochemistry 40:9196-9206 (2001). 9000129 5 Birbe et al., "Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract." Hum Pathol. 36(2):170-179 (2005). 9000129 6 Buc et al., "Guanylyl cyclas C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxin as a potential protein-delivering vehicle for colorectal cancer cells", European Journal of Cancer, vol. 41 pp. 1618-1627 (2005). 9000129 7 Camci, C. et al. Peripheral blood guanylyl cyclase c (GCC) expressions are associated with prognostic parameters and response to therapy in colorectal cancer patients. Tumour. Biol. 32, 1265-1270 (2011). 9000129 8 Carrithers et al., "Diarrhea or colorectal cancer: can bacterial toxins serve as a treatment for colon cancer?" Proc. Natl. Acad. Sci. USA 100:3018-3020 (2003). 9000129 9 Carrithers et al., "Escherichia coli Heat-Stable Enterotoxin Receptors--A Novel Marker for Colorectal Tumors" Dis Colon Rectum, vol. 39, pp. 171-181 (1996). 9000129 10 Carrithers et al., "Escherichia coli Heat-Stable Toxin Receptors in Human Colonic Tumors" Gastroenterology vol. 107, pp. 1653-1661 (1994). 9000129 11 Carrithers et al., "Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues." Proc Natl Acad Sci U S A. 93(25):14827-14832 (1996). 9000129 12 Chang et al., "Guanylyl cyclas C as a biomarker for targeted imagining and therapy of metastatic colorectal cancer" Biomarkers Med., 3(1), 33-45 (2009). 9000129 13 De Sauvage et al., "Primary structure and functional expression of the human receptor for Escherichia coli heat-stable enterotoxin." J Biol Chem. 266(27):17912-17918 (1991). 9000129 14 Debruyne et al., "Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells." Gastroenterology 130, pp. 1191-1206 (2006). 9000129 15 Doronina et al., "Novel peptide linkers for hightly potent antibody-auristatin conjugate" Bioconjug Chem. 19(10): 1960-1960 (2008). 9000129 16 Extended European Search Report from European Serial No. 10825726 dated May 7, 2013. 9000129 17 Frick et al. "Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer" Expert. Rev. Mol. Diagn. 5, pp. 701-713 (2005). 9000129 18 Gali, et al. "Chemical synthesis of Escherichia coli ST(h) analogues by regioselective disulfide bond formation: biological evaluation of an 111In-DOTA-Phe19-STh analogue for specific targeting of human colon cancers" Bioconjug. Chem. 13, pp. 224-231 (2002). 9000129 19 Guarino et al., "Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes." Dig Dis Sci 32: 1017-1026 (1987). 9000129 20 Gussow et al., "Humanization of monoclonal antibodies" Methods in Enzymology, vol. 203, pp. 99-121 (1991). 9000129 21 Holm et al., "Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1" Annu. Rev. Biophys. Chem., vol. 16, pp. 139-159 (1987). 9000129 22 International Preliminary Report on Patenability from International Application Serial No. PCT/US13/38542 mailed Mar. 20, 2014. 9000129 23 International Preliminary Report on Patentability from corresponding International Application No. PCT/US10/53686 dated Mar. 10, 2011. 9000129 24 International Search Report from corresponding International Application No. PCT/US10/53686 dated Mar. 10, 2011. 9000129 25 Kloeters et al., "Uroguanylin inhibits proliferation of pancreatic cancer cells" Scandinavian J. of Gastroenterology, 43, pp. 447-455 (2008). 9000129 26 Knoop et al., "Pharmacologic action of Escherichia coli heat-stable (STa) enterotoxin." J. Pharmacol. Toxicol. Methods 28:67-72 (1992). 9000129 27 Liu et al., "In vivo imaging of human colorectal cancer using radiolableled analogs of the uroguanylin peptide hormone" Anticancer Research, pp. 293777-293784 (2009). 9000129 28 Mann et al., "Mice lacking the guanylyl cyclase C receptor are resistant to STa-induced intestinal secretion." Biochem Biophys Res Commun 239: 463-466 (1997). 9000129 29 Mao et al., "Ectopic expression of guanylyl cyclase C in gastric cancer as a potential biomarker and therapeutic target" Journal of Digestive Diseases, vol. 10, pp. 272-285 (2009). 9000129 30 McCallum et al., "Antibody-antigen Interactions: Contact Analysis and Binding Site Topography" J. Mol. Biol., vol. 262 (5) pp. 732-745 (1996). 9000129 31 Nandi et al., "Epitope conservation and immunohistochemical localization of the guanylin/stable toxin peptide receptor, guanylyl cyclase C." J. Cell. Biochem. 66:500-511 (1997). 9000129 32 Nandi et al., "Expression of the extracellular domain of the human heat-stable enterotoxin receptor in Escherichia coli and generation of neutralizing antibodies." Protein Expr. Purif. 8:151-159 (1996). 9000129 33 Nandi et al., "Topological mimicry and epitope duplication in the guanylyl cyclase C receptor." Protein Sci. 7:2175-2183 (1998). 9000129 34 Park et al., "Ectopic Expression of Guanylyl Cyclas C in Adenocarcinomas of the Esophagus and Stomach", Cancer Epidermiol Biomarkers Prey, vol. 11, pp. 739-744 (2002). 9000129 35 Pitari et al., "Bacterial enterotoxins are associated with resistance to colon cancer." Proc Natl Acad Sci USA 100: 2695-2699 (2003). 9000129 36 Pitari et al., "Interruption of homologous desensitization in cyclic guanosine 3',5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins." Cancer Res. 65(23):11129-11135 (2005). 9000129 37 Rudikoff et al., "Single Amino acid substitution altering antigen-binding specificity" Proc. Natl. Acad. Sci., USA vol. 79, pp. 1979-1983 (1982). 9000129 38 Sargent et al., "Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis" Ann. Surg. Oncol., 18, pp. 3261-3270 (2011). 9000129 39 Schulz et al., "A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer", Clin Cancer Res. 12, pp. 4545-4552 (2006). 9000129 40 Search Report from corresponding Kenya Application No. KE/P/2012/001534 dated Jun. 25, 2014. 9000129 41 Singh et al., "Isolation and expression of a guanylate cyclase-coupled heat stable enterotoxin receptor cDNA from a human colonic cell line." Biochem Biophys Res Commun. 179(3):1455-1463 (1991). 9000129 42 Snook et al., "Guanylyl Cyclase C- Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity" J. Natl. Cancer Inst., vol. 100, pp. 950-961 (2008). 9000129 43 Urbanski et al., "Interalization of E. coli ST mediated by guanylyl cyclase C in T84 human colon carcinoma cells", Biochimica eta Biophysica Acta., 1245, pp. 29-36 (1995). 9000129 44 Vaandrager et al., "Guanylyl cyclase C is an N-linked glycoprotein receptor that accounts for multiple heat-stable enterotoxin-binding proteins in the intestine." J Biol Chem. 268(3):2174-2179 (1993). 9000129 45 Vijayachandra et al., "Biochemical characterization of the intracellular domain of the human guanylyl cyclase C receptor provides evidence for a catalytically active homotrimer." Biochemistry 39:16075-16083 (2000). 9000129 46 Wiegand et al., "Human guanylin: cDNA isolation, structure, and activity." FEBS Lett. 311:150-154 (1992). 9000129 47 Wolfe et al., :In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand J Nucl. Med. 43, pp. 392-399 (2002). 9000129 48 Written Opinion from corresponding International Application No. PCT/US10/53686 dated Mar. 10, 2011. 9000130 1 Aerts et al. et al., "Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Yes Uptake Assessed with PET" J Nucl Med 50:123-131 ( 2009). 9000130 2 Baca et al., "Antibody Humanization Using Monovalent Phage Display" J Biol Chem 272(16):10678-10684 ( 1997). 9000130 3 Bernhard et al., "Cysteine analogs of recombinant barley ribosome inactivating protein form antibody conjugates with enhanced stability and potency in vitro" Bioconjug Chem (5), 2:126-132 (Mar. 1994). 9000130 4 Better et al., "Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties" J Biol Chem 269(13):9644-9650 (Apr. 1 1994). 9000130 5 Borjesson et al., "Performance of Immuno-Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients" Clin Cancer Res 12(7):2133-2140 ( 2006). 9000130 6 Carter et al., "Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy" P Natl Acad Sci USA 89(10):4285-4289 (May 1992). 9000130 7 CellTiter-Glo Luminescent Cell Viability Assay (Technical Bulletin No. 288), Madison, WI:Promega Corp., pp. 1-11 (Feb. 2004). 9000130 8 Chang et al., "High-Level Secretion of Human Growth Hormone by Escherichia coli" Gene 55:189-196 ( 1987). 9000130 9 Chmura et al., "Antibodies with infinite affinity" P Natl Acad Sci USA 98(15):8480-8484. (Jul. 17, 2001). 9000130 10 Collaborative Computational Project, No. 4, "The CCP4 Suite: Programs for Protein Crystallography" Acta Cryst D50:760-763 ( 1994). 9000130 11 Corneillie et al., "Converting Weak Binders into Infinite Binders" Bioconjugate Chem 15(6):1389-1391 ( 2004). 9000130 12 Dennis et al., "Albumin binding as a general strategy for improving the pharmacokinetics of proteins" J Biol Chem 277(38):35035-35043 (Sep. 20, 2002). 9000130 13 Dijkers et al., "Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging" J Nucl Med 50(6):974-981 (Jun. 2009). 9000130 14 Doronina et al. et al., "Development of potent monoclonal antibody auristatin conjugates for cancer therapy" Nat Biotechnol 21:778-784 ( 2003). 9000130 15 Eigenbrot et al., "X-Ray Structures of the Antigen-Binding Domains From Three Variants of Humanized Anti-p185HER2 Antibody 4D5 and Comparison With Molecular Modeling" J Mol Biol 229:969-995 ( 1993). 9000130 16 Gagnon et al., "High-throughput in vivo Screening of Targeted Molecular Imaging Agents" P Natl Acad Sci USA 106(42):17904-17909 (Oct. 2009). 9000130 17 Gerstner et al., "Sequence Plasticity in the Antigen-binding Site of a Therapeutic Anti-HER2 Antibody" J Mol Biol 321:851-862 ( 2002). 9000130 18 Gill et al., "A Modular Platform for the Rapid Site-Specific Radiolabeling of Proteins with 18F Exemplified by Quantitative Positron Emission Tomography of Human Epidermal Growth Factor Receptor 2" J Med Chem 52:5816-5825 ( 2009). 9000130 19 Govindan et al., "Deferoxamine as a chelator for 67 Ga in the preparation of antibody conjugates" Nucl Med Biol 32:513-519 (Apr. 14, 2005). 9000130 20 Greenwood et al., "Engineering multiple-domain forms of the therapeutic antibody Campath-1H: effects on complement lysis" Therapeutic Immunology 1(5):247-255 (Oct. 1994). 9000130 21 Hafner et al., "Noncompetitive Immunoassay of Small Analytes at the Femtomolar Level by Affinity Probe Capillary Electrophoresis: Direct Analysis of Digoxin Using a Uniform-Labeled scFv Immunoreagent" Anal Chem 72(23):5779-5786 (Dec. 1, 2000). 9000130 22 Hausner et al., "In vivo positron emission tomography (PET) imaging with an alphavbeta6 specific peptide radiolabeled using 18F-`click` chemistry: evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl- and 2[18F]fluoropropionyl-peptides" J Med Chem. 51(19):5901-4 ( 2008). 9000130 23 Hausner et al., "Targeted In vivo Imaging of Integrin .alpha. v.beta. 6 with an Improved Radiotracer and Its Relevance in a Pancreatic Tumor Model" Cancer Res 69(14):5843-5850 (Jul. 2009). 9000130 24 Hausner et al., "Use of a Peptide Derived from Foot-and-Mouth Disease Virus for the Noninvasive Imaging of Human Cancer: Generation and Evaluation of 4-[18F]Fluorobenzoyl A20FMDV2 for In vivo Imaging of Integrin .alpha.:\v.beta. 6 Expression with Positron Emission Tomography" Cancer Res 67(16):7833-7840 (Aug. 2007). 9000130 25 Ho et al., "Site-Directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction" Gene 77(1):51-59 ( 1989). 9000130 26 Ito et al., "A general method for introducing a series of mutations into cloned DNA using the polymerase chain reaction" Gene 102(1):67-70 (Jun. 15, 1991). 9000130 27 Junutula et al., "Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epiderman Growth Factor Receptor 2-Positive Breast Cancer" Clinical Cancer Research 16:4769-4778 (Aug. 30, 2010). 9000130 28 Junutula et al., "Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs" J Immunol Methods 332:41-52 ( 2008). 9000130 29 Junutula et al., "Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index" Nat Biotechnol 26(8):925-32 (Aug. 2008). 9000130 30 Kabat et al. US Department of Health and Human Services, Public Health Service, NIH 4th edition,:160 and 294 ( 1987). 9000130 31 Kanno et al., "Assembling of engineered IgG-binding protein on gold surface for highly oriented antibody immobilization" J Biotechnol 76(2-3):207-214 (Jan. 21, 2000). 9000130 32 King et al., "Facile synthesis of maleimide bifunctional linkers" Tetrahedron Lett 43:1987-1990 ( 2002). 9000130 33 Kumaresan et al., "Evaluation of Ketone-Oxime Method for Developing Therapeutic On-Demand Cleavable Immunoconjugates" Bioconjugate Chem 19:1313-1318 ( 2008). 9000130 34 Lambert, "Drug-conjugated monoclonal antibodies for the treatment of cancer" Curr Opin Pharmacol 5(5):543-549 (Oct. 2005). 9000130 35 Lewis et al., "Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions" Bioconjug Chem 9(1):72-86 (Jan. 1998). 9000130 36 Liu, "Bifunctional Coupling Agents for radiolabeling of Biomolecules and Target Specific Delivery of Metallic Radionuclides" Adv Drug Deliver Rev 60:1347-1370 ( 2008). 9000130 37 Lowman, "Phage display of peptide libraries on protein scaffolds" Methods Molecular Biology 87:249-264 ( 1998). 9000130 38 Lund et al., "Expression and characterization of truncated forms of humanized L243 IgG 1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I" Eur J Biochem 267(24):7246-7257 (Dec. 2000). 9000130 39 MacCallum et al., "Antibody-antigen interactions: contact analysis and binding site topography" J Mol Biol 262:732-745 ( 1996). 9000130 40 Meijs et al., "A Facile Method for the Labeling of Proteins with Zirconium Isotopes" Nucl Med Biol 23:439-448 ( 1996). 9000130 41 Meijs et al., "Zirconium-Labeled Monoclonal Antibodies and Their Distribution in Tumor-Bearing Nude Mice" J Nucl Med 38(1):112-118 (Jan. 1997). 9000130 42 Miller, "Syntheses and Therapeutic Potential of Hydroxamic Acid Based Siderophores and Analogues" Chem Rev 89:1563-1579 ( 1989). 9000130 43 Nagengast et al., "In Vivo VEGF Imaging with Radiolabled Bevacizumab in a Human Ovarian Yes Tumor Xenograft" J Nucl Med 48:1313-1319 ( 2007). 9000130 44 Olafsen et al., "Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting" Protein Eng Des Sel 17(4):315-323 (Apr. 2004). 9000130 45 Patent Corporation Treaty, `PCT/US2010/055465` International Search Report. 9000130 46 Payne, "Progress in Immunoconjugate Cancer Therapeutics" Cancer Cell 3:207-212 (2003). 9000130 47 Perk et al., "89Zr as a PET Surrogate Radioisotope for Scouting Biodistribution of the Therapeutic Radiometals 90Y and 177Lu in Tumor-Bearing Nude Mice After Coupling to the Internalizing Antibody Cetuximab" J Nucl Med 46(10:1898-1906 (Nov. 2005). 9000130 48 Perk et al., "Preparation and Evaluation of 89Zr-Zevalin for Monitoring of 90Y-Zevalin Biodistribution with Positron Emission Tomography" Eur J Nucl Med Mol Imaging 33:1337-1345 ( 2006). 9000130 49 Perk et al., "Quantitative PET Imaging of Met-expressing Human Cancer Xenografts with 89Zr-labeled Monoclonal Antibody DN30" Eur J Nucl Med Mol Imaging 35:1857-1867 ( 2008). 9000130 50 Renard et al., "Deriving Topological Constraints from Functional Data for the Design of Reagentless Fluorescent Immunosensors" J Mol Biol 326:167-175 ( 2003). 9000130 51 Roux et al., "Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry" J Immunol 161(8):4083-4090 (Oct. 15, 1998). 9000130 52 Rudikoff et al., "Single amino acids substitution altering antigen-binding specificity" P Natl Acad Sci USA 79:1979-1983 (Mar. 1982). 9000130 53 Schelte et al., "Differential Reactivity of Maleimide and Bromoacetyl Functions with Thiols: Application to the Preparation of Liposomal Diepitope Constructs" Bioconjugate Chem 11:118-123 ( 2000). 9000130 54 Senter, "Immunoconjugates comprised of drugs with impaired cellular permeability: a new approach to targeted therapy, Abstract No. 623" Proceedings of the American Association for Cancer Research, (2004). 9000130 55 Shen et al., "Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates" Nature Biotechnology 30(2):184-190 (Feb. 2012). 9000130 56 Shopes, "A Genetically Engineered Human IgG With Limited Flexibility Fully Initiates Cytolysis Via Complement" Mol Immunol 30(6):603-609 ( 1993). 9000130 57 Singh et al., "Labeling of antibodies by in situ modification of thiol groups generated from selenol-catalyzed reduction of native disulfide bonds" Anal Biochem 304(2):147-156 (May 15, 2002). 9000130 58 Stimmel et al., "Site-specific Conjugation on Serine--Cysteine Variant Monoclonal Antibodies" J Biol Chem 275(39):30445-50 (Sep. 29, 2000). 9000130 59 Sun et al., "Enabling ScFvs as multi-drug carriers: a dendritic approach" Bioorg Med Chem 11(8):1761-1768 (Apr. 17, 2003). 9000130 60 Sun et al., "Syntheses of dendritic linkers containing chlorambucil residues for the preparation of antibody-multidrug immunoconjugates" Bioorg Med Chem Lett 12(16):2213-2215 (Aug. 19, 2002). 9000130 61 Tartis et al., "Dynamic MicroPET Imaging of Ultrasound Contrast Agents and Lipid Delivery" J Control Release 131:160-166 ( 2008). 9000130 62 Tinianow et al., "Site-specifically 89Zr-labeled Monoclonal Antibodies for ImmunoPET" Nucl Med Biol 37:289-297 ( 2010). 9000130 63 Trail et al., "Monoclonal Antibody Drug Immunoconjugates for Targeted Treatment of Cancer" Cancer Immunol Immunother 52328-337 ( 2003). 9000130 64 Tu et al., "Protein footprinting at cysteines: probing ATP-modulated contacts in cysteine-substitution mutants of yeast DNA topoisomerase II" P Natl Acad Sci USA 96(9):4862-4867 (Apr. 27, 1999). 9000130 65 Verel et al., "89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies" J Nucl Med 44(8):1271-1281 (Aug. 2003). 9000130 66 Verel et al., "Quantitative 89Zr Immuno-PET for In Vivo Scouting of 90Y-Labeled Monoclonal Antibodies in Xenograft-Bearing Nude Mice" J Nucl Med 44(10):1663-1670 (Oct. 2003). 9000130 67 Vosjan et al., "Conjugation and Radiolabeling of Monoclonal Antibidies with Zirconium-89 for PET Imaging Using the Bifunctional Chelate p-isothiocyanatobenzyl-desferrioxamine" Nat Protoc 5(4):739-743 ( 2010). 9000130 68 Wu et al. et al., "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues" J Mol Biol 294:151-162 ( 1999). 9000130 69 Wu et al., "Arming antibodies: prospects and challenges for immunoconjugates" Nat Biotechnol 23(9):1137-1146 (Sep. 23, 2005). 9000130 70 Xu et al,, "Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry" Analytical Biochemistry 412:56-66 ( 2011). 9000130 71 Zhang et al., "Complete disulfide bond assignment of a recombinant immunoglobulin G4 monoclonal antibody" Anal Biochem 311(1):1-9 (Dec. 1, 2002). 9000130 72 Lyons et al., "Site-specific attachment to recombinant antibodies via introduced surface cysteine residues" Protein Engineering 3(8):703-708 (1990). 9000130 73 Voynov et al., "Design and application of antibody cysteine variants" Bioconjug Chem 21(2):385-392 (Feb. 2010). 9000130 74 (PCT ISR for PCT/US2011/039386 dated Nov. 2, 2011). 9000130 75 Chen et al., "Charge-based analysis of antibodies with engineered cysteines From multiple peaks to a single main peak" mAbs 1(6):563-571 ( Nov./Dec. 2009). 9000130 76 Gomez et al., "Triple Light Chain Antibodies: Factors That Influence Its Formation in Cell Culture" Biotechnology and Bioengineering 105(4):748-760 (Mar. 1, 2010). 9000131 1 MacCallum et al, J. Mol. Biol., 1996, 262, 732-745. 9000131 2 Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295. 9000131 3 Rudikoff et al, PNAS, Mar. 1982, 79/6:1979-1983. 9000131 4 Colman P.M. Research in Immunology, 1994, 145:33-36. 9000131 5 Padlan et al, PNAS, 1989, 86:5938-5942. 9000131 6 Bendig, Methods: A Companion to Methods in Enzymology, 1995, 8:83-93. 9000131 7 Casset et al, BBRC, 2003, 307:198-205. 9000131 8 Zhang et al, Analytical Biochemistry, 2012, 430:185-192. 9000131 9 Przedpelski et al, Infection and Immunity, Jul. 2013, 81/7:2638-2644. 9000131 10 Amersdorfer & Marks (2000) "Phage libraries for generation of anti-botulinum scFv antibodies" Meth. Mol. Biol. 145:219-240. 9000131 11 Arndt, et al. (2005) "The structure of the neurotoxin-associated protein HA33/A from Clostridium botulinum suggests a reoccurring beta-trefoil fold in the progenitor toxin complex" J. Mol. Biol. 346(4):1083-1093. 9000131 12 Baldwin, et al. (2005) "Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E" Infect. Immun. 73(10): 6998-7005. 9000131 13 Bartels, et al. (1994) "Specific antibodies against the Zn(2+)-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum A neurotoxin" J Biol. Chem. 269(11): 8122-8127. 9000131 14 Bendig (1995) "Humanization of Rodent Monoclonal Antibodies by CDR Grafting" Methods: Companion to Methods in Enzymology 8:83-93. 9000131 15 Berzofsky, et al. (1993) "Immunogenicity and Antigen Structure" Fundamental Immunology 3rd edition, Ed. William E. Paul, Chapter 8, p. 242. 9000131 16 Black & Dolly (1986) "Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves" J. Cell Biol. 103(2):521-534. 9000131 17 Bowmer (1963) "Preparation and Assay of the International Standards for Clostridium botulinum Types A, B, C, D and E Antitoxins" Bull. World Health Organ. 29:701-709. 9000131 18 Brown, et al. (1997) "Identification and Characterization of a Neutralizing Monoclonal Antibody against Botulinum Neurotoxin Serotype F, Following Vaccination with Active Toxin" Hybridoma 16(5):447-456. 9000131 19 Byrne & Smith (2000) "Development of vaccines for prevention of botulism" Biochimie 82(9-10): 955-966. 9000131 20 Casset, et al. (2003) "A peptide mimetic of an anti-CD4 monoclonal antibody by rational design" Biochem Biophys. Res Comm. 307(1):198-205. 9000131 21 Cenci Di Bello, et al. "Antagonism of the Intracellular Action of Botulinum Neurotoxin Type A with Monoclonal Antibodies That Map to Light-Chain Epitopes" Eur. J. Biochem. 219(1-2):161-169, 1994. 9000131 22 Chen, et al. (1998) "Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species" Infect. Immun. 66(6):2420-2425. 9000131 23 Colcher et al. (1990) "In vivo tumor targeting of a recombinant single-chain antigen-binding protein" J. Natl. Cancer Inst. 82(14):1191-1197. 9000131 24 Daniels-Holgate & Dolly (1996) "Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain" J. Neurosci. Res. 44(3):263-271. 9000131 25 Dixit et al. (2005) "Characterization of Clostridium sp. RKD producing botulinum-like Neurotoxin" Syst. Appl. Microbiol. 28(5):405-414. 9000131 26 Dixit et al. (2006) Development of an immunodetection test for a botulinum-like neurotoxin produced by Clostridium sp. Indian J Med Res. 124(3):355-362. 9000131 27 Doellgast, et al. (1993) "Sensitive enzyme-linked immunosorbent assay for detection of Clostridium botulinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay" J. Clin. Microbiol. 31(9):2402-2409. 9000131 28 Doellgast, et al. (1997) "Sensitive assay for measurement of antibodies to Clostridium botulinum neurotoxins A, B, and E: use of hapten-labeled-antibody elution to isolate specific complexes" J. Clin. Microbiol. 35(3):578-583. 9000131 29 Dolly, et al. (1984) "Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization" Nature (London) 307(5950):457-460. 9000131 30 Emanuel, et al. (1996) "Directing antigen specificity towards botulinum neurotoxin with combinatorial phage display libraries" J. Immunol. Meth. 193(2):189-197. 9000131 31 Ferreira, et al. (1987) "Monoclonal Antibody for the Detection of Clostridium botulinum Type A toxin" Mol. Cell Probes 1(4):337-345. 9000131 32 Ferreira, et al. (1990) "Monoclonal antibody to type F Clostridium botulinum toxin" Appl. Environ Microbiol. 56(3):808-811. 9000131 33 Fitzsimmons, et al. (2000) "Inhibition of tetanus toxin fragment C binding to ganglioside G(T1b) by monoclonal antibodies recognizing different epitopes" Vaccine 19(1):114-121. 9000131 34 Foote & Milstein (1991) "Kinetic maturation of an immune response" Nature 352(6335):530-532. 9000131 35 Fotinou, et al. (2001) "The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin" J. Biol. Chem. 276(34):32274-32281. 9000131 36 Garcia-Rodriguez, et al. (2007) "Molecular evolution of antibody specificity and cross reactivity for type A botulinum neurotoxins" Nature Biotech. 25(1):107-116. 9000131 37 Gibson, et al. (1988) "Evaluation of a monoclonal antibody-based immunoassay for detecting type B Clostridium botulinum toxin produced in pure culture and an inoculated model cured meat system" J. Appl. Bacterial. 64(4):285-291. 9000131 38 Gill (1982) "Bacterial Toxins: A Table of Lethal Amounts" Mol. Biol. Rev. 46(1):86-94. 9000131 39 Hallis, et al. (1993) "Characterization of Monoclonal Antibodies to Botulinum" Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, ed. DasGupta, B. R. Plenum, New York., pp. 433-436. 9000131 40 Hathaway, et al. (1984) "Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E" J. Infect. Dis. 150(3):407-412. 9000131 41 Hatheway & Dang (1994) "Immunogenicity of the Neurotoxins of Clostridium botulinum" Therapy with Botulinum Toxin ed. Jankovic & Hallet, Marcel Dekker, New York, pp. 93-107. 9000131 42 Hildebrand & Archer (1961) "Evidence Concerning Liquid Structure" PNAS USA 47(12):1881-1882. 9000131 43 Hildebrand, et al. (1961) "Distribution and Particle Size of Type A Botulinum Toxin in Body Fluids of Intravenously Injected Rabbits" Proc. Soc. Exp. Biol. Med. 107(2):284-289. 9000131 44 Huston, et al. (1996) "Single-chain Fv radioimmunotargeting" Q. J. Nucl. Med. 40(3):320-333. 9000131 45 Koriazova & Montal (2003) "Translocation of botulinum neurotoxin light chain protease through the heavy chain channel" Nat. Struct. Biol. 10(1):13-18. 9000131 46 Kozaki, et al. (1986) "The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin" Infect Immun. 52(3):786-791. 9000131 47 Lacy, et al. (1998) "Crystal structure of botulinum neurotoxin type A and implications for toxicity" Nat. Struct. Biol. 5(10): 898-902. 9000131 48 Lang, et al. (1993) "Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin" J. Immunol. 151(13):466-472. 9000131 49 Levy, et al. (2007) "Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display" J. Mol. Biol. 365(1):196-210. 9000131 50 Lipps & Khan (2000) "Antigenic cross reactivity among the venoms and toxins from unrelated diverse sources" Toxicon. 38(7):973-980. 9000131 51 MacCallum, et al. (1996) "Antibody-antigen Interactions: Contact Analysis and Binding Site Topography" J. Mol. Biol. 262(5):732-45. 9000131 52 Mahant, et al. (2000) "The current use of botulinum toxin" J. Clin. Neurosci. 7(5):389-394. 9000131 53 Marchev & Marcheva (1982) "[Production of MonoSpecific Type A Botulinum Toxin and Antiserum Using a Column Chromatographic Method]" Vet. Med. Nauki. 19(1):57-63. 9000131 54 Middlebrook & Brown (1995) "Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins" Curr. Top. Microbiol. Immunol. 195:89-122. 9000131 55 Montecucco & Schiavo (1995) "Structure and function of tetanus and botulinum neurotoxins" Q. Rev. Biophys. 28(4):423-472. 9000131 56 Montecucco (1986) "How do Tetanus and Botulinum Toxins Bind to Neuronal Membranes?" Trends Biochem. Sci. 11(8):314-317. 9000131 57 Montero-Julian, et al. (1995) "Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies" Blood 85(4): 917-924. 9000131 58 Noah, et al. (1995) "Production of Monoclonal Antibodies Specific to Clostridium botulinum Type B Neurotoxin" J. AOAC Int. 78(2):381-385. 9000131 59 O'Connell, et al. (2007) "Production of a recombinant antibody fragment in whole insect larvae" Mol Biotechnol. 36(1): 44-51. 9000131 60 Oguma, et al. (1982) "Four different monoclonal antibodies against type C1 toxin of Clostridium botulinum" Infect. Immun. 38(1):14-20. 9000131 61 Oguma, et al. (1984) "Analysis of antigenicity of Clostridium botulinum type C1 and D toxins by polyclonal and monoclonal antibodies" Infect Immun. 43(2):584-588. 9000131 62 Palys, et al. (2006) "Conversion of a mouse Fab into a whole humanized IgG antibody for detecting botulinum toxin" Hum Antibodies 15(4):125-132. 9000131 63 Park, et al. (2003) "Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin" J. Voice. 17(2):255-264. 9000131 64 Pless, et al. (2001) "High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A" Infect. Immun. 69(1):570-574. 9000131 65 Reichert (2001) "Monoclonal antibodies in the clinic" Nat. Biotechnol. 19(9):819-822. 9000131 66 Schengrund (1999) "What is the Cell Surface Receptor(s) for the Different Serotypes of Botulinum Neurotoxin?" J Toxicol.--Toxin Rev. 18(1):35-44. 9000131 67 Schiavo, et al. (1992) "Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin" Nature (London) 359(6398):832-835. 9000131 68 Schiavo, et al. (1993) "Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E" J. Biol. Chem. 268(32):23784-23787. 9000131 69 Schier, et al. (1995) "In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library" Immunotechnology, 1(1):73-81. 9000131 70 Schmidt & Stafford (2005) "Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity" Biochemistry 44(10):4067-4073. 9000131 71 Sharma, et al. (2006) "Detection of type A, B, E, and F Clostridium botulinum neurotoxins in foods by using an amplified enzyme-linked immunosorbent assay with digoxigenin-labeled antibodies" Appl Environ. Microbiol. 72(2):1231-1238. 9000131 72 Simpson (1980) "Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction" J. Pharmacol. Exp. Ther. 212(1):16-21. 9000131 73 Tacket et al. (1984) "Equine antitoxin use and other factors that predict outcome in type A foodborne botulism" Am. J. Med. 76(5):794-798. 9000131 74 Tsuzuki, et al. (1988) "Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B, C1, D, and E toxins and tetanus toxin" Infect Immun. 56(4):898-902. 9000131 75 Volk, et al. (1984) "Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule" Infect. Immun. 45(3):604-609. 9000131 76 Williams, et al. (1983) "Radioiodination of botulinum neurotoxin type A with retention of biological activity and its binding to brain synaptosomes" Eur. J. Biochem., 131(2):437-445. 9000131 77 Wu, et al. (2001) "Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A" Appl. Environ. Microbiol. 67(7):3201-3207. 9000131 78 Zwick, et al. (2001) "Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies" J. Virol. 75(24):12198-12208. 9000131 79 Arnon (1993) "Clinical Trial of Human Botulism" Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, ed. DasGupta, B. R. Plenum, New York., pp. 477-482. 9000131 80 Arnon et al. (2001) "Botulinum toxin as a biological weapon: medical and public health management" JAMA 285(8):1059-1070. 9000131 81 Black & Gunn (1980) "Hypersensitivity reactions associated with botulinal antitoxin" Am. J. Med. 69(4): 567-570. 9000131 82 Franz, et al. (1993) "Efficacy of Prophylactic and Therapeutic Administration of Antitoxin for Inhalation Botulism" Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, ed. DasGupta, B. R. Plenum, New York., pp. 473-476. 9000131 83 Hatheway (1995) "Botulism: the present status of the disease" Curr Top. Microbiol. Immunol, 195:55-75. 9000131 84 Hibbs, et al. (1996) "Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt" Clin. Infect. Dis. 23(2):337-340. 9000131 85 Kozaki, et al. (1998) "Characterization of Clostridium botulinum type B neurotoxin associated with infant botulism in japan" Infect. Immun. 66(10):4811-4816. 9000131 86 Lacy & Stevens (1999) "Sequence homology and structural analysis of the clostridial neurotoxins" J. Mol. Biol. 291(5):1091-1104. 9000131 87 Middlebrook & Franz (1997) "Botulinum Toxins" Medical Aspects of Chemical and Biological Warfare Ed. Sidell, et al. TMM publications, Washington, D.C., Chapter 33, pp. 643-654. 9000131 88 Oguma et al. (1990) "Infant botulism due to Clostridium botulinum type C toxin" Lancet 336(8728):1449-1450. 9000131 89 Siegel (1988) "Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay" J. Clin. Microbiol. 26(11):2351-2356. 9000131 90 Sonnabend, et al. (1981) "Isolation of Clostridium botulinum type G and identification of type G botulinal toxin in humans: report of five sudden unexpected deaths" J. Infect. Dis. 143(1):22-27. 9000131 91 Almquist, et al. (2006) "Expression of an anti-botulinum toxin A neutralizing single-chain Fv recombinant antibody in transgenic tobacco" Vaccine 24(12):2079-2086. 9000131 92 Amersdorfer (1997) "Molecular Characterization of Murine Humoral Immune Response to Botulinum Neurotoxin Type A Binding Domain as Assessed by Using Phage Antibody Libraries" Infect. Immun. 65(9):3743-3752. 9000131 93 Amersdorfer, et al. (2002) "Genetic and Immunological Comparison of Anti-Botulinum Type A Antibodies from Immune and Non-Immune Human Phage Libraries" Vaccine 20(11-12):1640-1648. 9000131 94 Atassi, et al. (1996) "Mapping of the Antibody-Binding Regions on Botulinum Neurotoxin H-Chain Domain 855-1296 with Antitoxin Antibodies from Three Host Species" J. Protein Chem. 15(7):691-699. 9000131 95 Bavari, et al. (1998) "Identifying the principal protective antigenic determinants of type A botulinum neurotoxin" Vaccine 16(19):1850-1856. 9000131 96 Boder, et al. (2000) "CDR loops can be grafted onto a different scFV framework without loss of affinity" Proc. Natl. Acad. Sci. USA 97:10701-10705. 9000131 97 Boles, et al. "Recombinant C Fragment of Botulinum Neurotoxin B Serotype (rBoNTB (HC)) Immune Response and Protection in the Rhesus Monkey" Toxicon 47(8):877-884, 2006. 9000131 98 Caton, et al. (1986) "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin" EMBO J. 5(7):1577-1587. 9000131 99 Chen, et al. (1997) "Antibody Mapping to Domains of Botulinum Neurotoxin Serotype A in the Complexed and Uncomplexed Forms" Infect. Immun. 65(5):1626-1630. 9000131 100 Coleman et al. (2004) FASEB Journal 18(8):Suppl. S:C174, Meeting abstract, Abstract Only. 9000131 101 Colman (1994) "Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions" Res. Immunol. 145(1):33-36. 9000131 102 Dolimbek, et al. (2008) "Immune recognition of botulinum neurotoxin B: Antibody binding regions on the heavy chain of the toxin" Mol. Immunol. 45(4):910-924. 9000131 103 Emanuel, et al. (2000) "Recombinant antibodies: a new reagent for biological agent detection" Biosen. Bioelectron. 14(10-11):751-759. 9000131 104 Gozales, et al. (2005) "grafting of murine complementarity determining regions (CDRs) onto the variable light and variable heavy frameworks of human immunoglobulin molecules" Tumour Biol. 26:31-43. 9000131 105 Hall (2004) "Novel Application of an in Vitro Technique to the Detection and Quantification of Botulinum Neurotoxin Antibodies" J. Immunol. Methods 288(1-2):55-60. 9000131 106 Jung & Pluckthun (1997) "Improving in Vivo Folding and Stability of a Single-Chain Fv Antibody Fragment by Loop Grafting" Protein Eng. 10(8):959-66. 9000131 107 Kozaki, et al. (1995) "Immunological characterization of the neurotoxin produced by Clostridium botulinum type A associated with infant botulism in Japan" Microbiol. Immunol. 39(10):767-774. 9000131 108 Lebecque & Gearhart (1990) "Boundaries of somatic mutation in rearranged immunoglobulin genes: 5' boundary is near the promoter, and 3' boundary is approximately 1 kb from V(D)J gene" J. Exp. Med. 172(6):1717-1727. 9000131 109 Levy, et al. (1989) "Early onset of somatic mutation in immunoglobulin VH genes during the primary immune response" J. Exp. Med. 169(6):2007-2019. 9000131 110 Mah, et al. (2003) "Recombinant anti-botulinum neurotoxin A single-chain variable fragment antibody generated using a phage display system" Hybrid Hybridomics. 22(5):277-283. 9000131 111 Marks (2004) "Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization" Mov. Disord. 19(Suppl. 8):S101-S108. 9000131 112 McHeyzer-Williams (1993) "B Lymphocyte Biology" Fundamental Immunology, 3rd Edition, Ed. William E. Paul Raven Press: NY, Chapter 9, pp. 292-295. 9000131 113 McKean, et al. (1978) "Mechanisms of antibody diversity: multiple genes encode structurally related mouse .kappa. variable regions" PNAS USA 75(8):3913-3917. 9000131 114 Mowry, et al. (2004) "Production and purification of a chimeric monoclonal antibody against botulinum neurotoxin serotype A" Protein Expr. Purif. 37(2):399-408. 9000131 115 Mullaney, et al. (2001) "Epitope Mapping of Neutralizing Botulinum Neurotoxin A Antibodies by Ohage Display" Infect. Immun. 69(10):6511-6514. 9000131 116 Nowakowski, et al. "Potent Neutralization of Botulinum Neurotoxin by Recombinant Oligoclonal Antibody" PNAS USA 99(17):11346-11350, Aug. 20, 2002. 9000131 117 Oshima (1997) "Immune Recognition of Botulinum Neurotoxin Type A: Regions Recognized by T cells and Antibodies against the Protective H(C) Fragment (residues 855-1296) of Toxin" Mol. Immunol. 34(14):1031-1040. 9000131 118 Razai, et al. (2005) "Molecular evolution of antibody affinity for sensitive detection and neutralization of botulinum neurotoxin type A" J. Mol. Biol. 351(1):158-169. 9000131 119 Rudikoff, et al. (1982) "Single Amino Acid Substitution Altering Antigen-Binding Specificity" PNAS USA 79(6):1979-1983. 9000131 120 Schier, et al. (1996) "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site" J. Mol. Biol. 263(4):551-567. 9000131 121 Scotcher, et al. "Characterization of the Epitope Region of F1-2 and F1-5, Two Monoclonal Antibodies to Botulinum Neurotoxin Type A" Hybridoma 28(5):315-325, 2009. 9000131 122 Shone, et al. (1985) "Monoclonal antibody-based immunoassay for type A Clostridium botulinum toxin is comparable to the mouse bioassay" Appl Environ Microbiol. 50(1):63-67. 9000131 123 Smith, et al. (2005) "Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization" Infect. Immun. 73(9):5450-5457. 9000131 124 Stark & Caton (1991) "Antibodies that are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions" J. Exp. Med. 174(3):613-624. 9000131 125 Weigert, et al. (1978) "Rearrangement of genetic information may produce immunoglobulin diversity" Nature 276(5690):785-790. 9000131 126 Dong et al. (2010) "A Single-Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic Alpha-Exosite Binding Region" J Mol Biol 397(4):1106-1118. 9000131 127 Gilsdorf et al. (2006) "Expression Purification, and Characterization of Clostridium botulinum Type B Light Chain" Protein Expr Purif 46(2):256-267. 9000131 128 Goldman et al. (2008) "Thermostable Llama Single Domain Antibodies for Detection of Botulinum A Neurotoxin Complex" Anal Chem 80(22):8583-8591. 9000131 129 Lee et al. (2008) "Production and characterization of monoclonal antibody to botulinum neurotoxin type B light chain by phage display" Hybridoma (Larchmt) 27(1):18-24. 9000131 130 Liu et al. (2007) "Isolation of Anti-Toxin Single Domain Antibodies from a Semi-Synthetic Spiny Dogfish Shark Display Library" BMC Biotechnol 7:78. 9000131 131 Meng et al. (2012) "Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein" Anal Biochem 430(2):141-150. 9000131 132 Padlan et al. (1989) "Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex" Proc Natl Acad Sci USA 86:5938-5942. 9000131 133 Swaminathan & Eswaramoorthy (2000) "Structural Analysis of the Catalytic and Binding Sites of Clostridium botulinum Neurotoxin B" Nat Struct Biol 7(8):693-699. 9000131 134 Thanongsaksrikul et al. (2010) "A V H H That Neutralizes the Zinc Metalloproteinase Activity of Botulinum Neurotoxin Type A" J Biol Chem 285(13):9657-9666. 9000131 135 Yang et al. (2004) "Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B" Toxicon 44(1):19-25. 9000132 1 Janeway et al., Immunobiology, 3rd edition, 1997, Garland Press, pp. 3:1-3:11. 9000132 2 Rudikoff et al., Proc Natl Acad Sci USA, 1982, 79:1979-1983. 9000132 3 Portolano et al., J. Immunol., 1993, 150:880-887. 9000132 4 Fundamental Immunology, William E. Paul, M.D. ed., 3d ed. 1993, p. 242. 9000132 5 Akiyama et al.; Determination of platelet-activating factor acetylhydrolase activity by blotting, beta-radioluminescence, and ultrahigh-sensitivity television camera detection; Analytical Biochemistry; 218(2):295-299; May 1, 1994. 9000132 6 Akiyama et al.; Identification of a Major PAF Acetylhydrolase in Human Serum/Plasma as a 43 kDa Glycoprotein Containing about 9 kDa Asparagine-Conjugated Sugar Chain(s); Journal of Biochemistry; 123(5):786-789; May 1998. 9000132 7 Akiyama et al.; New Serum PAF acetylhydrolase detection method used with the Blotting Method and Beta of 3Hacetyl-PAF; Proceedings of Japanese Conference on the Biochemistry of Lipids; 36:43-46; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1994; English abstract. 9000132 8 Artsaenko et al.; Expression of a single-chain Fv antibody against abscisic acid creates a wilty phenotype in transgenic tobacco; Plant J; 8(5):745-50; Nov. 1995. 9000132 9 Balafa et al.; Urine of Patients with Nephrotic Syndrome Contains the Plasma Type of PAF-Acetylhydrolase Associated with Lipoproteins; Nephron Physiology; 97(3):45-52; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 2004. 9000132 10 Balestrieri et al.; Measurement of Platelet-Activating Factor Acetylhydrolase Activity by Quantitative High-Performance Liquid Chromatography Determination of Courmarin-Derivatized 1-0-alkyl-2-sn-lysoglyceryl-3-phosphorylcholine; Analytical Biochemistry; 233(2): 145-50; Jan. 1996. 9000132 11 Ballantyne et al.; Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study; Arch Intern Med.; 165(21):2479-84; Nov. 28, 2005. 9000132 12 Ballantyne et al.; Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study; Circulation; 109:837-42; Feb. 2004. 9000132 13 Bell et al.; Systematic Screening of the LDL-PLA2Gene for Polymorphic Variants and Case-Control Analysis in Schizophrenia; Biochem and Biophys Res Commun.; 241(3):630-635; Dec. 29, 1997. 9000132 14 BISC 429; BISC 429: Experimental Techniques II Separation Methods. Acid Phosphatase-Enzyme Assay; Siman Fraser University available at www.sfu.ca/bisc/bisc-429/enzymeassay.html#intro, including Image if Google search showing that the document as been available since Jan. 31, 2002. 9000132 15 Blake et al.; Inflammatory bio-markers and cardiovascular risk prediction; J Intern Med; 252(4):283-94; Oct. 2002. 9000132 16 Blankenberg et al.; Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis; J. Lipid Res.; 44:(7) 1381-1386; May 1, 2003. 9000132 17 Blankenberg et al.; Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis; J Lipid Res; 44(7):1381-6; Jul. 2003. 9000132 18 Boyd et al.; 2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2; Bioorg Med Chem Lett; 10(4):395-398; Feb. 21, 2000. 9000132 19 Boyd et al.; N-1 Substituted Pyrimidin-4-Ones: Novel, Orally Active Inhibitors of Lipoprotein-Associated Phospholipase A2; Bioorg Med Chem Lett; 10(22):2557-2561; Nov. 20, 2000. 9000132 20 Bravata et al.; Thrombolysis for acute stroke in routine clinical practice; Arch Intern Med; 162(17):1994-2001; Sep. 23, 2002. 9000132 21 Brites et al.; Paraoxonase 1 and Platelet-Activating Factor Acetylhydrolase Activities in Patients with Low HDL-Cholesterol Levels with or without Primary Hypertriglyceridemia; Archives of Medical Research; 35(3):235-240; May-Jun. 2004. 9000132 22 Busby et al.; SB-253514 and analogues: novel inhibitors of lipoprotein associated phospholipase A2 produced by Pseudomonas fluorescens DSM 11579. II. Physico-chemical properties and structure elucidation; J Antibiot; 53(7):670-6; Jul. 2000. 9000132 23 Caron et al.; Engineered humanized dimeric forms of IgG are more effective antibodies; J Exp Med; 176(4):1191-5; Oct. 1, 1992. 9000132 24 Carter et al.; Humanization of an anti-p185HER2 antibody for human cancer therapy; Proc Natl Acad Sci USA; 89(10):4285-9; May 15, 1992. 9000132 25 Casas et al.; PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry; Circulation; 121(21):2284-93; Jun. 1, 2010. 9000132 26 Caslake et al.; Lipoprotein-associated Phospholipase A2 platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease; Atherosclerosis; 150(2): 413-9; Jun. 2000. 9000132 27 Cayman Chemical, Ann Arbor, MI; PAF Acetylhydrolase Assay Kit; Catalog No. 760901; Cayman Chemical Company, Ann Harbor, MI; Jun. 22, 2005. 9000132 28 Chari et al.; Immunoconjugates containing novel maytansinoids: promising anticancer drugs; Cancer Res; 52(1):127-31; Jan. 1, 1992. 9000132 29 Clynes et al.; Fc receptors are required in passive and active immunity to melanoma; Proc Natl Acad Sci USA; 95(2):652-6; Jan. 20, 1998. 9000132 30 Cucchiara et al.; Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA; Stroke; 40(7):2332-6.; Jul. 2009. 9000132 31 Dada et al; LP-PLA2: an emerging biomarker of coronary heart disease; Expert Review of Molecular Diagnostics; 2(1): 17-22; Jan. 2002. 9000132 32 Davies; The pathophysiology of acute coronary syndromes; Heart; 83:361-6; Mar. 2000. 9000132 33 Deigner et al.; Novel reversible, irreversible and fluorescent inhibitors of plateletactivating factor acetylhydrolase as mechanistic probes; Atherosclerosis; 144(1):79-90; May 1999. 9000132 34 Diadexus Inc.; Enzyme Immunoassay for the Quantitative Determination of Lp-PLA2 in Human Plasma and Serum; Aug. 2005. 9000132 35 Eaton; Cholesterol testing and management: a national comparison of family physicians, general internists, and cardiologists; J Am Board Fam Pract; 11(3):180-6; May-Jun. 1998. 9000132 36 Elkind et al.; High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke; Arch Intern Med; 166(19):2073-80; Oct. 23, 2006. 9000132 37 Eppstein et al.; Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor; Proc Natl Acad Sci USA; 82(11):3688-92; Jun. 1985. 9000132 38 Evan et al.; Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product; Mol Cell Biol; 5(12):3610-6; Dec. 1985. 9000132 39 Field et al.; Purification of a RAS-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method; Mol Cell Biol; 8(5):2159-65; May 1988. 9000132 40 Flegar-Mestric et al.; Serum platelet-activating factor acetylhydriolase activity in patients with angiographically established cerebrovascular stenosis; Clinical Chemistry and Laboratory Medicine; Proceesing of the IFFCC-FESCC European Congress; 15'h Barcelona, Spain: 369-372; Publisher Monduzzi Editore, Bologna, Italy; Jun. 1-5, 2003 (Abstract only). 9000132 41 Fujimura et al.; Serum platelet-activating factor acetylhydrolase activity in rats with gastric ulcers induced by water-immersion stress; Scand J Gastroenterol Suppl.; 24(162):59-62; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1989. 9000132 42 Furie et al.; Lipoprotein-associated phospholipase A2 activity predicts early stroke recurrence [abstract]; Stroke; 38(2):458; Feb. 2007. 9000132 43 Furukawa et al.; Platelet-Activating FactorRlnduced Ischemic Bowel Necrosis: The Effect of Platelet-Activating Factor Acetylhydrolase; Pediatr Res.; 34(2):237-41; Aug. 1993. 9000132 44 Glass et al.; Atherosclerosis: The road ahead; Cell; 104:503-16; Feb. 23, 2001. 9000132 45 Gorelick; Lipoprotein-associated phospholipase A2 and risk of stroke; Am J Cardiol; 101(12A):34F-40F; Jun. 16, 2008. 9000132 46 Graham et al.; Characteristics of a human cell line transformed by DNA from human adenovirus type 5; J Gen Virol; 36(1):59-72; Jul. 1977. 9000132 47 Grallert et al.; Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies; Eur Heart J; 33(2):238-51.; Jan. 2012. 9000132 48 Griffiths et al.; Human anti-self antibodies with high specificity from phage display libraries; EMBO J.; 12(2):725-34; Feb. 1993. 9000132 49 Grissom et al.; Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome; Critical Care Medicine; 31(3):770-775, Mar. 2003. 9000132 50 Guss et al.; Structure of the IgG-binding regions of streptococcal protein; G EMBO J; 5(7):1567-75; Jul. 1986. 9000132 51 Hakkinen et al.; Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions; Arterioscler Thromb Vasc Biol; 19(12):2909-17; Dec. 1999. 9000132 52 Hemmings et al.; Platelet-Activating Factor Acetylhydrolase Activity in Peritoneal Fluids of Women with Endometriosis; Obstetrics and Gynecology; 81(2):276-279; Feb. 1993. 9000132 53 Henderson et al.; Recombinant Human Platelet-Activating Factor-Acetylhydrolase Inhibits Airway Inflammation and Hyperreactivity in Mouse Asthma Model; J Immunol; 164(6):3360-3367; Mar. 15, 2000. 9000132 54 Hendrickson et al.; Intramolecularly Quenched BODIPY-Labeled Phospholipids Analogs in Phospholipase A2 and Platelet-Activating Factor Acetylhydrolase assays and in Vivo Fluorescence Imaging; Analytical Biochemistry; 276 (1):27-35; Dec. 1999. 9000132 55 Heron; Deaths: Leading Causes for 2004; Nat'l Vital Stat Rep; 56(5):1-95; Nov. 20, 2007. 9000132 56 Herrmann et al.; Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome; Eur Heart J; 30(23):2930-8; Dec. 2009. 9000132 57 Hiramoto et al.; A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke; Stroke; 28(12):2417-20; Dec. 1997. 9000132 58 Hoffman et al.; Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study); J Thromb Haemost; 7(1):41-8; Jan. 2009. 9000132 59 Holliger et al.; Diabodies: small bivalent and bispecific antibody fragments; Proc Natl Acad Sci USA; 90(14):6444-8; Jul. 15, 1993. 9000132 60 Hwang et al.; Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study; Proc Natl Acad Sci USA; 77(7):4030-4; Jul. 1980. 9000132 61 Ibe et al.; Platelet Activating Factor Acetylhydrolase Activity in Lamb Lungs is Up-Regulated in the Immediate Newborn Period; Molecular Genetics and Metabolism; 69(1):46-55; Jan. 2000. 9000132 62 Imaizumi et al.; Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from healthy habitual cigarette smokers; Heart and Vessels; 5(2):81-86; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1990. 9000132 63 Ito et al.; Serum PAF-Acetylhydrolase (PAF-AH) in Hepatobiliary Disease; Japanese Pharmacology and Therapeutics; 30/Suppl. 2; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 2002. 9000132 64 Ito et al.; Serum PAF-Acetylhydrolase (PAF-AH) in Hepatobiliary Disease; Japanese Pharmacology and Therapeutics; 30/Suppl. 2.; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 2002; Abstract--Science Links Japan (1 page). 9000132 65 Izake et al.; Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation; Br J Dermatol.; 134(6):1060-4; Jun. 1996. 9000132 66 Jakobovits et al.; Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production; Proc Natl Acad Sci USA; 90(6):2551-5; Mar. 15, 1993. 9000132 67 Karkabounas et al.; Quantitative Fluorescence Determination of Phospholipase A2 and PAF Acetylhydrolase in Biological Fluids using High Performance Liquid Chromatography; Chemistry and Physics of Lipids; 130(1):69-70; Jun. 2004. 9000132 68 Karlan Research Products Corporation, Santa Rosa, CA; Auto PAF-AH Serum (plasma) platelet-activating factor (PAF) acetylhydrolase assay--Instruction Manual; (date of publication unknown; available to applicants at least as of Sep. 16, 2005). 9000132 69 Kawamura, Y.; A Simple Measurement of Plasma Platelet-Activating Factor (PAF) Acetylhydrolase, Normal Level Activity, and Distribution Among Lipoprotein Fractions; Japanese Journal of Clincal Pathology; 35(10)1149-1153; Oct. 1987. 9000132 70 Kawamura, Y.; A Simple Measurement of Plasma Platelet-Activating Factor (PAF) Acetylhydrolase, Normal Level Activity, and Distribution Among Lipoprotein Fractions; Japanese Journal of Clinical Pathology; 35(10):1149-1153; Oct. 1987; Abstract- HCAPLUS (1 Page). 9000132 71 Khovidhunkit et al.; Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome; Metabolism.; 48(12):1524-31; Dec. 1999. 9000132 72 Kirschbaum B.; Platelet Activating Factor Acetylhydrolase activity in the urine of patients with renal disease; Clinical Chimica Acta; 199(2):139-146; Jun. 14, 1991. 9000132 73 Kitsiouli et al.; Differential Determination of Phospholipase A2 ane P AFAcetylhydrolase in Biological Fluids Using Fluorescent Substrates; Journal of Lipid Research; 40(12):2346-2356; Dec. 1999. 9000132 74 Koenig et al.; Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men from the General Population; Circulation; 110(14):1903-1908; Oct. 2004. 9000132 75 Kosaka et al.; Serum platelet-activating factor acetylhydrolasse (PAF-AH) activity in more than 3000 healthy Japanese; Clinica Chimica Acta; 313(1-2):179-183; Oct. 2001. 9000132 76 Kosaka et al.; Spectrophotometric Assay for Serum Platelet-Activating Factor Acetylhydrolase Activity; Clinica Chimica Acta; 296(1-2):151-161; Jun. 2000. 9000132 77 Kruse et al.; The lle198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma; Am J Hum Genet; 66(5):1522-30; May 2000. 9000132 78 Kujiraoka et al.; Altered Distribution of Plasma PAF-AH between HDLs and other Lipoproteins in Hyperlipidemia and Diabetes Mellitus; Journal of Lipid Research; 44(10):2006-14; Oct. 2003. 9000132 79 Lindahl et al.; Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease; N Engl J Med; 343(16):1139-47; Oct. 19, 2000. 9000132 80 Lutz-Freyermuth et al.; Quantitative determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II of U1 RNA; Proc Natl Acad Sci USA; 87(16):6393-7; Aug. 1990. 9000132 81 MacPhee et al.; Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor; Biochem J; 338:479-87; Mar. 1, 1999. 9000132 82 Martin et al.; Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting; J Biol Chem; 257(1):286-8; Jan. 10, 1982. 9000132 83 Mather; Establishment and characterization of two distinct mouse testicular epithelial cell lines; Biol Reprod; 23(1):243-52; Aug. 1980. 9000132 84 Matsuzaki, Masaharu; Measurement Methods of Platelet Activating Factor (PAF) and PAF Acetylhydrolase (PAFAH) Activity; SRL Hokan; 13(3): 36-41; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1989; English translation of introduction. 9000132 85 McManus et al.; PAF, a Putative Mediator of Oral Inflammation; Crit Rev Oral Biol Med.; 11(2):240-258; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 2000. 9000132 86 Min et al., Platelet-Activating Factor Acetylhydrolases:? Broad Substrate Specificity and Lipoprotein Binding Does Not Modulate the Catalytic Properties of the Plasma Enzyme; Biochemistry; 40(15): 4539-4549; Apr. 17, 2001. 9000132 87 Miwa et al.; "Serum platelet-activating factor (PAF) acetylhydrolase of children with bronchial asthma," Japanese Journal of Inflammation; 8 (4):327- 333; Dec. 1988; Abstract--HCAPLUS (1 Page). 9000132 88 Miwa et al.; Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum P AF acetylhydrolase and respiratory symptoms in asthmatic children; Journal of Clinical Investigation; 82(6): 1983-1991; Dec. 1988. 9000132 89 Miwa et al.; On Development of a Measurement Method of Serum PAF Acetylhydrolase Activity Using an Automatic Analyser, and the Clinical Significance of Serum PAF Acetylhydrolase Defect; Proceedings of Japanese Conference on the Biochemistry of Lipids; 34:305-308; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1992; English Abstract. 9000132 90 Miwa et al.; Serum platelet-activating factor (PAF) acetylhydrolase of children with bronchial asthma; Japanese Journal of Inflammation; 8(4):327-333; Dec. 1988. 9000132 91 Morrison et al.; Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains; Proc Natl Acad Sci USA; 81*21):6851-5; Nov. 1984. 9000132 92 Muguruma et al.; the central role of PAF in necrotizing enterocolitis development; Adv Exp Med Biol.; 407:379-82; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1997. 9000132 93 No authors listed, Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial-Europe Study Group; N Engl J Med; 335(3): 145-50; Jul. 18, 1996. 9000132 94 No authors listed, Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group; N Engl J. Med; 333(24): 1581-7; Dec. 14, 1995. 9000132 95 Packard et al.; Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease; N Engl J Med; 343(16):1148-55; Oct. 19, 2000. 9000132 96 Patrick et al.; Reduced PAF-Acetyihydrolase Activity is Associated with Postinjury Multiple Organ Failure; Shock; 7(3):170-174; Mar. 1997. 9000132 97 Pritchard et al.; The Degradation of Platelet-Activating Factor in the Plasma of a Patient with Familial High Density Lipoprotein Deficiency (Tangier Disease); Blood; 66(6):1476-1478; Dec. 1985. 9000132 98 Rattan et al., Protein synthesis, posttranslational modifications, and aging, Ann N Y Acad Sci.; 663:48-62; Nov. 21, 1992. 9000132 99 Ridker et al.; Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events; N Engl J Med; 347(20):1557-65; Nov. 14, 2002. 9000132 100 Riehl et al.; Platelet-activating factor acetylhydrolases in Caco-2 cells and epithelium of normal and ulcerative colitis patients; Gastroenterology; 109(6): 1826-1834; Dec. 1995. 9000132 101 Rosamond et al.; Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee; Circulation; 117(4):e25-146; Jan. 29, 2008. 9000132 102 Santos et al.; Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index; Vasc Med; 9(3):171-6; May 2004. 9000132 103 Saougos et al.; Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2; Arterioscler Thromb Vasc Biol; 27(10):2236-43; Oct. 2007. 9000132 104 Sarchielli et al.; Platelet-Activating Factor (PAF) in Internal Jugular Venous Blood of Migraine without Aura Patients Assessed During Migraine Attacks; Cephalagia; 24(8):623-630; Aug. 2004. 9000132 105 Satoh et al.; Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma; Am J Respir Crit Care Med.; 159(3):974-9; Mar. 1999. 9000132 106 Satoh et al.; Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke; Stroke; 23(8); pp. 1090-1092; Aug. 1992. 9000132 107 Satoh et al; Platelet-activating factor (PAF) acetylhydrolase and plasma lipoproteins: Relative distribution of the activity among lipoprotein classes; Journal of Japan Atherosclerosis Society; 16(4):501-504; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1988. 9000132 108 Schindler et al.; Fluorophore-labeled ether lipids: substrates for enzymes of the plateletactivating factor cycle in peritoneal polymorphonuclear leukocytes; Analytical Biochemistry; 174(2):477-84; Nov. 1, 1988. 9000132 109 Seifter et al.; Analysis for protein modifications and nonprotein cofactors; Methods Enzymol.;182:626-46; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1990. 9000132 110 Serebruany et al.; Depressed Plasma Platelet- Activating Factor Acetylhydrolasein Patients Presenting with Acute Myocardial Infarction; Cardiology; 90(2):127-130; Oct. 1998. 9000132 111 Servillo et al.; Simultaneous Determination of Lysophospholipids by High-performance Liquid Chromatography with Fluorescence Detection; Journal of Chromatography; 689(2):281-286; Feb. 1997. 9000132 112 Shalaby et al.; Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene; J Exp Med; 175(1):217-25; Jan. 1, 1992. 9000132 113 Skinner et al.; Use of the Glu-Glu-Phe C-terminal epitope for rapid purification of the catalytic domain of normal and mutant ras GTPase-activating proteins; J Biol Chem; 266(22):14163-6; Aug. 5, 1991. 9000132 114 Stafforini et al.; Human macrophages secrete platelet-activating factor acetylhydrolase; Journal of Biological Chemistry; 265(17); pp. 9682-9687; Jun. 1990. 9000132 115 Song et al.; Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations; Pharmacogenomics J; 12(5):425-31; Oct. 2012. 9000132 116 Stafforini et al.; Human Plasma Platelet-Activating Factor Acetylhyrolase. Purification and Properties; Journal of Biological Chemistry; 262(9):4223-4230; Mar. 25, 1987. 9000132 117 Stafforini et al.; Platelet-Activating Factor Acetylhydrolase in Human erythrocytes; Methods in Enzymology; 197:411-425; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1991. 9000132 118 Stafforini et al.; Platelet-activating Factor Acetylhydrolases; J. Biol. Chem.; 272(29): 17895-17898; Jul. 18, 1997. 9000132 119 Stremler et al.; An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma; J. Biological Chemistry; 264(10); pp. 5331-5334; Apr. 1989 9000132 120 Tew et al.; Mechanism of Inhibition of LDL Phospholipase A2 by Monocyclic-?-lactams. Burst Kinetics and the Effect of Stereochemistry; Biochemistry; 37(28):10087-10093; Jul. 14, 1998. 9000132 121 Tew et al.; Purification, Properties, Sequencing, and Cloning of a Lipoprotein-Associated, Serine-Dependent Phospholipase Involved in the Oxidative Modification of Low-Density Lipoproteins; Arterioscler Thromb Vasc Biol. 16(4):591-599; Apr. 1996. 9000132 122 Thirkettle et al.; SB-253514 and Analogues; Novel Inhibitors of Lipoprotein-Associated Phospholipase A2 Produced by Pseudomonas fluorescens DSM 11579; J. Antibiotics; vol. 53(7):664-669; Jul. 2000. 9000132 123 Thirkettle, Jan; SB-253514 and Analogues; Novel Inhibitors of Lipoprotein Associated Phospholipase A2 Produced by Pseudomonas fluorescens DSM 11579. III. Biotransformation Using Naringinase; J. Antibiotics; vol. 53(7):733-735; Jul. 2000. 9000132 124 Tjoelker et.; Anti-inflammatory properties of a platelet-activating factor acetylhydrolase; Nature 374, 549-553; Apr. 6, 1995. 9000132 125 Traunecker et al.; Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells; EMBO J; 10(12):3655-9; Dec. 1991. 9000132 126 Tselepis et al.; Association of the inflammatory state in active juvenile rheumatoid arthritis with hypoRhigh-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity; Arthritis Rheum.; 42(2):373R383, Feb. 1999. 9000132 127 Tselepis et al.; Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase; Atheroscler Suppl.; 3(4):57-68; Dec. 2002. 9000132 128 Tsuji et al.; The presence of platelet-activating factor-acetylhydrolase in human middle ear effusions; ORL J Otorhinolaryngol Relat Spec.; 60(1):25-9; Jan.-Feb. 1998. 9000132 129 Tsukioka et al.; Increased Plasma Level of Platelet-Activating Factor (P AF) and Decreased Serum PAF etylhydrolase (PAFAH) Activity in Adults with Bronchial Asthma; Journal of Investigational Allergology and Clinical Immunology; 6(1):22-29; Jan.-Feb. 1996. 9000132 130 Unno et al.; Single Nucleotide Polymorphism (G994?T) in the Plasma Platelet-Activating Factor-Acetylhydrolase Gene is Associated with Graft Patency of Femoropopliteal Bypass; Surgery; 132(1):66-71; Jul. 2002. 9000132 131 Urlaub et al.; Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity; Proc Natl Acad Sci USA; 77(7):4216-20; Jul. 1980. 9000132 132 Washburn et al.; Novel general approach for the assay and inhibition of hydrolytic enzymes utilizing suicide-inhibitory bifunctionally linked substrates (SIBLINKS): Exemplified by a phospholipase A2 assay; J. Am. Chem. Soc.; 112; pp. 2040-2041; Feb. 1990. 9000132 133 Washburn et al.; Suicide-inhibitory bifunctionally linked substrates (SIBLINKS) as phospholipase A2 inhibitors; J. Biological Chemistry; 266(8); pp. 5042-5048; Mar. 1991. 9000132 134 Waterhouse et al.; Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires; Nucleic Acids Res; 21(9):2265-6; May 11, 1993. 9000132 135 Winkler et al.; Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes; J Clin Endocrinol Metab; 89(3):1153-9; Mar. 2004. 9000132 136 Wold, Finn; Posttranslational Protein Modifications: Perspectives and Prospects; Posttranslational Covalent Modification of Proteins; B.C. Johnson, Ed.; Academic Press, New York; pp. 1-12; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1983. 9000132 137 Wolff et al.; Monoclonal antibody homodimers: enhanced antitumor activity in nude mice; Cancer Res.; 53(11):2560-5; Jun. 1, 1993. 9000132 138 Yoon et al.; Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy; Clinical Genetics; 62(2):128-134; Aug. 2002. 9000132 139 Yoshida et al.; Platelet-activating factor acetylhydrolase in red cell membranes. Does decreased activity impair erythrocyte deformability inischemic stroke patients?; Stroke; 24(1); pp. 14-18; Jan. 1993. 9000132 140 Zalewski et al.; Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis. Biology, Epidemiology, and Possible Therapeutic Target; Arterioscler Thromb Vasc Biol; 25(5):923-931; May 2005. 9000132 141 NCBI RefSeqID: NM--001168357; Homo sapiens phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (PLA2G7), transcript variant 2, mRNA; www.ncbi.nlm.nih.gov/nuccore/ NM--001168357.1?report=gbwithparts& log$=seqview; 5pgs; downloaded Aug. 27, 2013. 9000132 142 NCBI RefSeqID: NP--005075; platelet-activating factor acetylhydrolase precursor [Homo sapiens ]; http://www.ncbi.nlm.nih.gov/protein/ NP--005075.3; 3pgs; downloaded Aug. 27, 2013. 9000132 143 NCBI RefSeqID: NM--005084; Homo sapiens phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (PLA2G7), transcript variant 1, mRNA; http://www.ncbi.nlm.nih.gov/nuccore/ NM--005084; 5pgs; ; downloaded Aug. 27, 2013. 9000132 144 NCBI RefSeqID: NP--001161829; platelet-activating factor acetylhydrolase precursor [Homo sapiens]; http://www.ncbi.nlm.nih.gov/protein/NP--001161829; 3pgs; downloaded Aug. 27, 2013. 9000132 145 NCNI Entrez GeneID: 7941 (PLA2G7); PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) [ Homo sapiens (human) ]; http://www.ncbi.nlm.nih.gov/gene/7941; 9pgs; downloaded Aug. 27, 2013. 9000132 146 Miller et al.; U.S. Appl. No. 13/839,041 entitled "Lipotrotein-associated phospholipase A2 antibody composition and methods of use," filed Mar. 15, 2013. 9000132 147 Blake et al.; A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women; J Am Coll Cardiol.; 1;38(5):1302-1306; Nov. 2001. 9000132 148 Chothia et al.; Canonical structures for the hypervariable regions of immunoglobulins; J Mol Biol; 196(4):901-917; Aug. 20, 1987. 9000132 149 Chothia et al.; Structural repertoire of the human VH segments; J Mol Biol; 227(3):799-817; Oct. 5, 1992. 9000132 150 Clark et al.; Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset; The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke'JAMA; 282(21):2019-2026; Dec. 1, 1999. 9000132 151 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III); JAMA; 285(19):2486-2497; May 16, 2001. 9000132 152 Hopp et al.; A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification; Nature Biotechnology; 6:1204-10; Oct. 1988. 9000132 153 Katzan et al.; Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience; JAMA; 283(9):1151-8; Mar. 1, 2000. 9000132 154 Lusis; Atherosclerosis; Nature; 407(6801):233-41; Sep. 14, 2000 (Author Manuscript). 9000132 155 Marks et al.; By-passing immunization. Human antibodies from V-gene libraries displayed on phage; J Mol Biol; 222(3):581-597; Dec. 5, 1991. 9000132 156 Martin et al.; GAP domains responsible for ras p21-dependent inhibition of muscarinic atrial K+ channel currents; Science; 255(5041):192-194; Jan.10, 1992. 9000132 157 Morimoto et al.; Single-step purification of F(ab')2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW; J Biochem Biophys Methods; 24(1-2):107-17; Mar. 1992. 9000132 158 Muhlestein et al.; The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia; The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study, J Am Coll Cardiol.; 48(2):396-401; Jul. 18, 2006. 9000132 159 Oei et al.; Lipoprotein-associated phospholipase A2 is associated with risk of coronary heart disease and stroke; The Rotterdam Study ( ) European Society of Cardiology Congress 2004; pp. 570-575; Aug.-Sep. 2004. 9000132 160 Riechmann et al.; Reshaping human antibodies for therapy; Nature; 332 (6162):323-7; Mar. 24, 1988. 9000132 161 Rosensen; Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome; Am Heart J.; 155(3):499.e.9-499.e16; Mar. 2008. 9000132 162 Smith et al.; Identification of common molecular subsequences; J Mol Biol; 147(1):195-197; Mar. 25, 1981. 9000132 163 Albert et al.; The effect of statin therapy on lipoprotein associated phospholipase A2 levels; Atherosclerosis; 182(1):193-198; Sep. 2005. 9000132 164 Alberts et al.; Risk of Stroke and Elevated Levels of Lipoprotein-Associated Phospholipase A2, Abstracts From the 2008 International Stroke Conference; Stroke; 39(2):642; Feb. 2008. 9000132 165 Anderson; Human gene therapy; Science; 256(5058):808-813; May 8, 1992. 9000132 166 Barnes et al.; Methods for growth of cultured cells in serum-free medium; Anal Biochem; 102(2):255-270; Mar. 1, 1980. 9000132 167 Blackie et al.; The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2; Bioorg Med Chem Lett.; 13(6):1067-1070; Mar. 23, 2003. 9000132 168 Bloomer et al.; 1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A(2); Bioorg Med Chem Lett.; 11(14):1925-1929; Jul. 23, 2001. 9000132 169 Boyd et al.; Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones; Bioorg Med Chem Lett.; 12(1):51-55; Jan. 7, 2002. 9000132 170 Boyd et al.; The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2; Bioorg Med Chem Lett.; 11(5):701-704; Mar. 12, 2001. 9000132 171 Brennan et al.; Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments; Science; 229(4708):81-83; Jul. 5, 1985. 9000132 172 Brodeur et al.; (Chap. 4) Mouse-human myeloma partners for the production of heterohybridomas; in Monoclonal Antibody Production Techniques and Applications; Marcel Dekker, Inc., New York; pp. 51-63; -'1987(year of pub. sufficiently earlier than effective US filing date and any foreign priority date). 9000132 173 Bruggemann et al.; Designer mice: the production of human antibody repertoires in transgenic animals; Year Immunol; 7:33-40; Feb. 1993. 9000132 174 Capel et al.; Heterogeneity of human IgG Fc receptors; Immunomethods; 4 (1):25-34; Feb. 1994. 9000132 175 Carpenter et al.; Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages; FEBS Lett.; 505(3):357-63; Sep. 21, 2001. 9000132 176 Carter et al.; High level Escherichia coli expression and production of a bivalent humanized antibody fragment; Biotechnology; 10(2):163-167; Feb. 1992. 9000132 177 Chothia et al.; Structural determinants in the sequences of immunoglobulin variable domain; J Mol Biol; 278(2):457-479; May 1, 1998. 9000132 178 Clackson et al.; Making antibody fragments using phage display libraries; Nature; 352(6336):624-628; Aug. 15, 1991. 9000132 179 Cunningham et al.; High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis; Science; 244(4908):1081-1085; Jun. 2, 1989. 9000132 180 Daeron; Fc receptor biology; Annu Rev Immunol; 15:203-234; Apr. 1997. 9000132 181 De Haas et al.; Fc gamma receptors of phagocytes; J Lab Clin Med; 126 (4):330-341; Oct. 1995. 9000132 182 Donnan et al.; Streptokinase for acute ischemic stroke with relationship to time of administration; Australian Streptokinase (ASK) Trial Study Group, JAMA. 276(12):961-966; Sep. 25, 1996. 9000132 183 Fecker et al.; Expression of single-chain antibody fragments (scFv) specific for beet necrotic yellow vein virus coat protein or 25 kDa protein in Escherichia coli and Nicotiana benthamiana; Plant Mol Biol; 32 (5):979-986; Dec. 1996. 9000132 184 Fraker et al.; Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril; Biochem Biophys Res Commun; 80:849-857; Feb. 28,1978. 9000132 185 Gabizon et al.; Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times; J Natl Cancer Inst; 81(19):1484-1488; Oct. 4, 1989. 9000132 186 Gazzano-Santoro et al.; A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody; J Immunol Methods; 202(2):163-171; Mar. 28, 1997. 9000132 187 Goding; Monoclonal Antibodies: Principles and Practice; Academic Press; pp. 103; 1986 (year of pub. sufficiently earlier than effective US filing date and any foreign priority date). 9000132 188 Goodman et al.; (Chap. 6) Immunoglobulin Proteins; in Stites et al. (eds.); Basic and Clinical Immunology, 8th Ed.; Appleton & Lange, Norwalk, CT.; pp. 66-79; Jan. 1, 1994. 9000132 189 Gruber et al.; Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli; J Immunol; 152(11):5368-5374; Jun. 1, 1994. 9000132 190 Guyer et al.; Immunoglobulin binding by mouse intestinal epithelial cell receptors; J Immunol; 117(2):587-593; Aug. 1976. 9000132 191 Hacke et al.; Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke; The European Cooperative Acute Stroke Study (ECASS), JAMA; 274(13):1017-1025; Oct. 4, 1995. 9000132 192 Hacke et al.; Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II); Lancet; 352(9136):1245-1251; Oct. 17, 1998. 9000132 193 Ham et al.; Media and growth requirements; Methods Enzymol; 58:44-93; 1979 (year of pub. sufficiently earlier than effective US filing date and any foreign priority date). 9000132 194 Hiatt et al.; Production of antibodies in transgenic plants; Nature; 342 (6245):76-78; Nov. 2, 1989. 9000132 195 Jakobovits et al.; Germ-line transmission and expression of a human-derived yeast artificial chromosome; Nature; 362(6417):255-258; Mar. 18, 1993. 9000132 196 Johnson et al.; Human antibody engineering; Curr Opin Struct Biol; 3 (4):564-571; Aug. 1993. 9000132 197 Jones et al.; Replacing the complementarity-determining regions in a human antibody with those from a mouse; Nature; 1321(6069):522-525; May 1986. 9000132 198 Kearney et al.; A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines; J Immunol; 123(4):1548-1550; Oct. 1979. 9000132 199 Kohler et al.; Continuous cultures of fused cells secreting antibody of predefined specificity; Nature; 256(5517):495-497; Aug. 7, 1975. 9000132 200 Kostelny et al.; Formation of a bispecific antibody by the use of leucine zippers; J Immunol; 148(5):1547-1553; Mar. 1, 1992. 9000132 201 Kozbor et al.; A human hybrid myeloma for production of human monoclonal antibodies; J Immunol; 133(6):3001-3005; Dec. 1984. 9000132 202 Kuvin et al.; Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease; Am J Cardiol.; 98(6):743-745; Sep. 15, 2006. 9000132 203 Leach et al.; Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy; Farmaco.; 56(1-2):45-50; Jan.-Feb. 2001. 9000132 204 Libby et al.; Macrophages and atherosclerotic plaque stability; Curr Opin Lipidol.; 7(5):330-335; Oct. 1996. 9000132 205 Lindmark et al.; Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera; J Immunol Methods; 62(1):1-13; Aug. 12, 1983. 9000132 206 MacPhee; Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target; Curr Opin Pharmaco;. 1(2):121-125; Apr. 2001. 9000132 207 Marks et al.; By-passing immunization: building high affinity human antibodies by chain shuffling; Biotechnology; 10(7):779-783; Jul. 1992. 9000132 208 MAST-I Group (Italy); Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group; Lancet; 346(8989):1509-1514; Dec. 9, 1995. 9000132 209 Mather et al.; Culture of testicular cells in hormone-supplemented serum-free medium; Ann N Y Acad Sci; 383:44-68; Jun. 1982. 9000132 210 McAfferty et al.; Phage antibodies: filamentous phage displaying antibody variable domains; Nature; 348(6301):552-554; Dec. 6, 1990. 9000132 211 Miller et al.; Epitope binning of murine monoclonal antibodies by a multiplexed pairing assay; J Immunol Methods; 365(1-2):118-125; Feb. 28, 2011. 9000132 212 Milstein et al.; Hybrid hybridomas and their use in immunohistochemistry; Nature; 305:537-540; Oct. 1983. 9000132 213 Munson et al.; Ligand: a versatile computerized approach for characterization of ligand-binding systems; Anal Biochem; 107(1):220-239; Sep. 1, 1980. 9000132 214 National Institute of Health (NIH), Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults; Sep. 1998. 9000132 215 Neuberger et al.; Recombinant antibodies possessing novel effector functions; Nature; 312:604-608; Dec. 1984. 9000132 216 Owen et al.; Synthesis of a functional anti-phytochrome single-chain Fv protein in transgenic tobacco; Biotechnology; 10(7):790-794; Jul. 1992. 9000132 217 Paborsky et al.; Mammalian cell transient expression of tissue factor for the production of antigen; Protein Eng; 3(6):547-553; May 1990. 9000132 218 Pearson; Searching protein sequence libraries: comparison of the sensitivity and selectivity of the Smith-Waterman and FASTA algorithms; Genomics; 11(3):635-650; Nov. 1991. 9000132 219 Pinto et al.; Natural product derived inhibitors of lipoprotein associated phospholipase A2, synthesis and activity of analogues of SB-253514; Bioorg Med Chem Lett.; 10(17):2015-2017; Sep. 4, 2000. 9000132 220 Pluckthun; Chap. 11: Antibodies from escherichia coli; in: Rosenberg et al.; The Pharmacology of Monoclonal Antibodies, vol. 113; Springer-Verlag; New York, NY; pp. 269-315; 1994 (year of pub. sufficiently earlier than effective US filing date and any foreign priority date). 9000132 221 Pluckthun; Mono- and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding; Immunol Rev; 130:151-188; Dec. 1992. 9000132 222 Presta et al.; Humanization of an antibody directed against IgE; J Immunol; 151(5):2623-2632; Sep. 1, 1993. 9000132 223 Presta; Antibody engineering; Curr Opin Struc Biol; 2(4):593R596; Aug. 1992. 9000132 224 Ravetch et al.; Fc receptors; Annu Rev Immunol; 9:457-492; Apr. 1991. 9000132 225 Sandercock et al.; Antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2008, Issue 3. Jul. 2008. 9000132 226 Schaefer et al.; Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects; Am J Cardiol; 95(9):1025-1032; May 1, 2005. 9000132 227 Shopes; A genetically engineered human IgG mutant with enhanced cytolytic activity; J Immunol; 148(9):2918-2922, May 1, 1992. 9000132 228 Sims et al.; A humanized CD18 antibody can block function without cell destruction; J Immunol; 151(4):2296-2308; Aug. 15, 1993. 9000132 229 Skerra; Bacterial expression of immunoglobulin fragments; Curr Opin Immunol; 5(2):256-62; Apr. 1993. 9000132 230 Stevenson et al.; A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge; Anticancer Drug Des; 3(4):219-30; Mar. 1989. 9000132 231 Strong et al.; Preventing stroke: saving lives around the world; Lancet Neurol.; 6(2):182-7; Feb. 2007. 9000132 232 Suckling et al.; Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque; Expert Opin Ther Targets.; 6(3):309-314; Jun. 2002. 9000132 233 Suresh et al.; Bispecific monoclonal antibodies from hybrid hybridomas; Methods Enzymol; 121:210-228; 1986 (year of pub. sufficiently earlier than effective US filing date and any foreign priority date). 9000132 234 Tutt et al.; Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells; J Immunol; 147(1):60-9; Jul. 1, 1991. 9000132 235 Verhoeyen et al.; Reshaping human antibodies: grafting an antilysozyme activity; Science; 239(4847):1534-6; Mar. 25, 1998. 9000132 236 Wardlaw et al.; Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2009, Issue 4. Oct. 2009. 9000132 237 Witztum; The oxidation hypothesis of atherosclerosis; Lancet.; 344 (8925):793-5; Sep. 17, 1994. 9000132 238 Zapata et al.; Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity; Protein Eng; 8(10):1057-62; Oct. 1995. 9000132 239 Schaal; U.S. Appl. No. 14/279,106 entitled "Value-Assigned Solutions of Lipoprotein-Associated Phospholipase A2 having a long shelf-life," filed May 15, 2014. 9000132 240 Schaal et al.; U.S. Appl. No. 14/279,148 entitled "Long shelf-life kits and methods for standardizing, verifying, calibrating or recalibrating detection of lipoprotein-associated phospholipase A2," filed May 15, 2014. 9000132 241 Shou et al.; U.S. Appl. No. 14/498,980 entitled "Methods for detecting LP-PLA2 activity and inhibition of LP-PLA2 activity," filed Sep. 26, 2014. 9000132 242 Ackermann et al.; Ca(2+))-independent cytosolic phospholipase A2 from macrophage-like P388D1 cells. Isolation and characterization; J. Biol. Chem; 269(12); pp. 9227-9233; Mar. 25, 1994. 9000132 243 Arkin et al.; Inhibition of Protein Interaction: Non-Cellular Assay Formats; Assay Guidance Manual; 26 pages; Mar. 2012. 9000132 244 Atmeh et al.; Albumin Aggregates: Hydrodynamic shape and physico-chemical properties; Jordan Journal of Chemistry; 2(2); pp. 169-182; Jul. 29, 2007. 9000132 245 Attri et al.; Self-association of Zn-insulin at neutral pH: investigation by concentration gradient static and dynamic light scattering; Biophys. Chem.; 148(1-3); pp. 23-27; May 2010. 9000132 246 Bhairi; A guide to the properties and uses of detergents in biology and biochemistry; Calbiochem-Novobio-chem Corporation, San Diego; .COPYRGT. 2001; 43 pgs.; Aug. 13, 2014; retrieved from the internet (http;//wolfson.huji.ac.il/purification/PDF/detergents/calbiochem detergents.pdf). 9000132 247 Burke; Phospholipase A2 biochemistry; Cardiovas. Drugs Ther.; 23(1); pp. 49-59; Feb. 2009. 9000132 248 Cao et al; Lipoprotein-associated phospholipase A2 interacts with phospholipid vesicles via a surface-disposed hydrophobic alpha-helix; Biochemistry; 50(23); pp. 5314-5321; Jun. 14, 2011. 9000132 249 Ferrer et al.; The conformation of serum albumin in solution: a combined phosphorescence deploarization-hydrodynamic modeling; Biophys. J.; 80(5); pp. 2422-2430; May 2001. 9000132 250 Gardner et al.; Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein; J. Biol. Chem.; 283(25); pp. 17099-17106; Jun. 20, 2008. 9000132 251 Heart Protection Study Group; Lipoprotein-associated phoslipase A2 activity and mass in relation to vascular disease and nonvascular mortality; J. Intern. Med.; 268; pp. 348-358; Oct. 2010. 9000132 252 Jaaskelainen et al.; Conformational change in the activation of lipase: an analysis in terms of low-frequency normal modes; Protein Sci.; 7(6); pp. 1359-1367; Jun. 7, 1998. 9000132 253 Karabina et al; Increased activity of plate-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia; Eur. J. Clin. Invest; 27(7); pp. 595-602; Jul. 1997. 9000132 254 Lorber et al.; Purification of octyl-beta-D-glucopyranoside and re-estimation of its micellar size; Biochimica et Biophysica Acta (BBA)- Biomembranes; 1023(2); pp. 254-265; Apr. 13, 1990. 9000132 255 Lund--Katz et al.; High density lipoprotein structure-function and role in reverse cholesterol transport; Subcell Biochem.; 51; pp. 183-227; Nov. 14, 2010. 9000132 256 Mannuzza et al.; Is bovine albumin too complex to be just a commodity? Part One: manufacturing and implications; Bioprocess International; 8(2); pp. 40-42; Feb. 2010. 9000132 257 Mannuzza et al.; Is bovine albumin too complex to be just a commodity? Part two: Manufacturing and implications; Bioprocess International; 8(4); pp. 42-48; Apr. 2010. 9000132 258 Menzies et al.; Stimulation of specific binding of [3H]-progesterone to bovine luteal cell-surface membranes: specificity of digitonin; Mol. Cell Endrocrinol.; 153 (1-2); pp. 57-69; Jul. 20, 1999. 9000132 259 Pande; Membrane lipid composition differentially modulates the function of human plasma platelet activating factor-acetylhydrolase; Biochim. Biophys. Acta.; 1811(1); pp. 46-56; Jan. 2011. 9000132 260 Qin et al.; Concentration-dependent aggregation of CHAPS investigated by NMR spectroscopy; J. Phys. Chem. B; 114(11); pp. 3863-3868; Mar. 25, 2010. 9000132 261 Qin et al.; Proton NMR based investigation of the effects of temperature and NaCL on micellar properties of CHAPS; J. Phys. Chem. B; 115(9); pp. 1991-1998; Mar. 10, 2011. 9000132 262 Samanta et al.; Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and cataysis; J. Biol. Chem.; 283(43); pp. 31617-31624; Nov. 14, 2008. 9000132 263 Samanta et al.; Crystallization and preliminary x-ray crystallographic analysis of human plasma platelet activating factor acetyhydrolase; Protein Pept. Lett.; 16(1); pp. 97-100; Nov. 20, 2011. 9000132 264 SG3; Quality management systems--process validation guidance; The Global Harmonization Task Force; Edition 2; 36 pages; Jan. 2004. 9000132 265 Stafforini et al.; Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor; J. Biol. Chem.; 262(9); pp. 4215-4222; Mar. 25, 1987. 9000132 266 Stafforini et al.; Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma; Proc. Natl. Acad. Sci. USA; 86(7); pp. 2393-2397; Apr. 1989. 9000132 267 Stafforini et al.; Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein; J. Biol. Chem.; 274; 4(11); pp. 7018-7024; Mar. 12, 1999. 9000132 268 Stafforini; Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2); Cardiovasc. Drugs Ther.; 23(1); pp. 73-83; Feb. 2009. 9000132 269 Tjoelker et al.; Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad; J. Bio. Chem.; 270(43); pp. 25481-25487; Oct. 27, 1995. 9000132 270 Tsimihodimos et al.; Altered distribution of platelet-activating factor-acetyhyrolase activity between LDL and HDL as function of the severity of hypercholesterolemia; J. Lipid Res.; 43(2); pp. 256-263; Feb. 2002. 9000132 271 Tsimihodimos et al.; Fenofirate iinduces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins; J. Lipid Res. 44(5); pp. 927-934; May 2003. 9000132 272 Zhang et al.; Interactions between macromolecules and ions: The hofmeister series; Curr. Opin. Chem. Biol.; 10(6); pp. 658-663; Dec. 10, 2006. 9000132 273 Asano et al; Cellular source(s) of platelet-activating-factor acetyhydrolase activity in plasma; Biochem. Biophsys. Res. Commun.; 261(2); pp. 511-514; Aug. 2, 1999. 9000132 274 Ridker et al.; Relationship of lipoprotien-associated phopholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or statin therapy: an analysis form the JUPITER trial; Clinical Chemistry; Clinical Chemistry; 58(5); pp. 877-886; 2012 (year of pub. sufficiently earlier than effective US filing date and any foreign priority date). 9000133 1 Kretz-Rommel, Anke et al., "Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy," The Journal of Immunology, vol. 180:699-705 (2008). 9000133 2 Hart, P.H., "Modulation of Monocyte Effector Functions by Lipopolysacc-haride and Interferon-Y," Dept. of Medicine, University of Melbourne, Royal Melbourne Hospital, Parkville, Vic., 3050 (1987) (Abstract). 9000133 3 Alizadeh et al., "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling," Nature, 403:503-511(2000). 9000133 4 Auchincloss et al. "Strategies to Induce Tolerance," Transplantation Immunology, Bach and Auchincloss, Eds., Wiley-Liss, New York, Chapter 11, pp. 211-218 (1995). 9000133 5 Bach, "Immunosuppressive therapy of autoimmune diseases," Immunology Today, 14(6)322-326(1993). 9000133 6 Banerjee, D., et al., "Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats," Ocular Immunology and Inflammation, 12(2):115-125 (2004). 9000133 7 Barclay and Ward, "Purification and Chemical Characterisation of Membrane Glycoproteins From Rat Thymocytes and Brain, Recognised by Monoclonal Antibody MRC OX2," European J. Biochemistry, 129:447-458(1982). 9000133 8 Barclay et al.,"CD200 and membrane protein interactions in the control of myeloid cells," Trends in Immunology, 23(6): 285-290 (2002). 9000133 9 Barclay, A.N., "Different reticular elements in rat lymphoid tissue identified by localization of la, Thy-1 and MRC OX 2 antigens," Immunology, 44:727-736 (1981). 9000133 10 Barclay, A.N., et al., "Neuronal/Lymphoid Membrane Glycoprotein MRC OX-2 is a Member of the Immunoglobulin Superfamily with a Light-Chain-Like Structure," Biochem. Soc. Symp., 51:149-157 (1985). 9000133 11 Bauvois et al., Constitutive expression of CD26/dipeptidylpepidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. British Journal of Cancer 1999., vol. 79. p. 1042. 9000133 12 Blazer, B.R., et al., "CD28/B7 Interactions Are Required for Sustaining the Graft-VersLeukemia Effect of Delayed Post-Bone Marrow Transplantation Splenocyte Infusion in Murine Recipients of Myeloid or Lymphoid Leukemia Cells," J. Immunol., 159:3460-3473 (1997). 9000133 13 Bodey et al. "Human Cancer Detection and Immunotherapy with Conjugated and Non-Conjugated Monoclonal Antibodies" Anticancer Research 16: 661-674 (1996). 9000133 14 Bohen, S.P., "Variation in gene expression patterns in follicular lymphoma and the response to rituximab," PNAS, 100(4):1926-1930(2003). 9000133 15 Boon, Thierry., "Toward a Genetic Analysis of Tumor Rejection Antigens," Advances in Cancer Res., 58:177-210(1992). 9000133 16 Borriello et al., "MRC OX-2 Defines a Novel T Cell Costimulatory Pathway," J. Immunol., 158:4549-4554(1997). 9000133 17 Borriello, F., et al., "Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX-2 membrane glycoprotein," Mammalian Genome, 9(2):114-118 (1998). 9000133 18 Broderick et al., "Constitutive Retinal CD200 Expression Regulates Resident Microglia and Activin State of Inflammatory Cells During Experimental Autoimmune Uveoretinitis," Am. J. of Pathology, 161(5):1669-1677(2002). 9000133 19 Bruggemann et al., "A Matched Set of Rat/Mouse Chimeric Antibodies: Identification and Biological Properties of Rat H Chain Constant Regions .mu., .gamma.l, .gamma.2a, .gamma.2b, .gamma.2c, .epsilon., and .alpha.1," The Journal of Immunology, vol. 142(9), pp. 3145-3150 (1989). 9000133 20 Bukovsky, A., et al., "Association of lymphoid cell markers with rat ascitic malignant cells," IRCS Med. Sci., 11:866-867 (1983). 9000133 21 Bukovsky, A., et al., "Association of some cell surface antigens of lymphoid cells and cell surface differentiation antigens with early rat pregnancy," Immunology, 52:631-640 (1984). 9000133 22 Bukovsky, A., et al., "The localization of Thy-1.1, MRC OX 2 and la antigens in the rat ovary and follopian tube," Immunology, 48:587-596 (1983). 9000133 23 Bukovsky, A., et al., "The ovarian follicle as a model for the cell-mediated control of tissue growth," Cell Tissue Res., 236:717-724 (1984). 9000133 24 Caldas et al., "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," Mol. Immunol. 39:941-952 (2003). 9000133 25 Chaouat and Clark, FAS/FAS Ligand Interaction at the Placental Interface is not Required for the Success of Allogeneic Pregnancy in Anti-Paternal MHC Preimmunized Mice, Presented at the 6th Congress of the Adria-Alps Soc. of Immunol. of Reprod., (2000) / Amer. J. of Reprod. Immunol., 45:108-115(2001). 9000133 26 Chen, D., et al., "Discrete Monoclonal Antibodies Define Functionally Important Epitopes in the CD200 Molecule Responsible for Immunosupression Function," Transplantation, 79:282-288 (2005). 9000133 27 Chen, D., et al., "Synthetic peptides from the N-terminal regionsl of CD200 and CD200R1 modulate immunosupressive and anti-inflammatory effects of CD200-CD200R1 interaction," International Immunology, 17(3):289-296 (2005). 9000133 28 Chen, Z., et al., "Cloning and characterization of the murine homologue of the rat/human MRC OX-2 gene," Database Medline, Biochemica et Biophysica Acta, 1362(1):6-10 (1997). 9000133 29 Cherwinski, H.M., et al., "The CD200 Receptor Is a Novel and Potent Regulator of Murine and Human Mast Cell Function," J. Immunol., 174:1348-1356 (2005). 9000133 30 Chien et al., "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism," Proc. Natl. Acad. Sci. USA 86:5532-5536 (1989). 9000133 31 Chitnis et al., "The Role of CD200 in Immune-Modulation and Neural Protection in EAE," Abstract, 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal, Jul. 21, 2004. 9000133 32 Chitnis, T., et al., "Elevated Neuronal Expression of CD200 Protects Wlds Mice from Inflammation-Mediated Neurodegeneration," American Journal of Pathology, 170(5):1695-1712 (2007). 9000133 33 Clark et al., "Fg12 prothrombinase expression in mouse trophoblast and decidua triggers abortion but may be countered by OX-2," Mol. Human Reprod., 7:185-194(2001). 9000133 34 Clark et al., "Labile CD200 tolerance signal important in transfusion-related immunomodulation (TRIM) prevention of recurrent miscarriages," Amer. J. Reprod. Immunol., 45:361(2001). 9000133 35 Clark et al., "Procoagulants in fetus rejection: the role of the OX-2 (CD200) tolerance signal," Seminars in Immunol., 13(4)255-263(2001). 9000133 36 Clark et al., "The OX-2 Tolerance Signal Molecule at the Fetomaternal Interface Determines Pregnancy Outcome," Amer. Journal of Reprod Immunol., 43:326(2000). Abstract Only. 9000133 37 Clark et al., Amer. Soc. for Reprod. Medicine, 55th Annual Meeting (1999). Abstract only. 9000133 38 Clark, D.A., "Intralipid as Treatment for Recurrent Unexplained Abortion?", Am. J. of Reprod. Immunol., 32:290-293(1994). 9000133 39 Clark, M.J., et al., "MRC OX-2 antigen: a lymphoid/neuronal membrane glycoprotein with a structure like a single immunoglobulin light chain," EMBO Journal, 4(1):113-118 (1985). 9000133 40 Clarke, M.J., "MRC OX-2 lymphoid brain glycoprotein: S1 mapping suggests higher levels of abnormal RNA in the thymus than in the brain," Biochemical Society Transactions, 14:80-81 (1986). 9000133 41 Cochlovius et al., "Cure of Burkitt's Lymphome in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 .times. CD19 Tandem Diabody, and CD28 Costimulation," Cancer Res. 60:4336-4341 (2000). 9000133 42 Cohen, P.L., "Systemic Autoimmunity," in Fundamental Immunology, Fourth edition, W.E. Paul, Editor, Lippincott-Raven Publishers, Philadelphia, Ch. 33, p. 1067-1088(1999). 9000133 43 Davidson, A., et. al. "Autoimmune Diseases," (editors Mackay and Rosen) New England Journal of Medicine, 345(5):340-350 (2001). 9000133 44 DeNardo et al., "Increased Survival Associated with Radiolabeled Lym-1 Therapy for Non-Hodgkin's Lymphoma and Chronic Lymphocyctic Leukemia." Cancer Supplement (1997) vol. 80, No. 12. pp. 2706-2711. 9000133 45 Dennis, C., "Off by a whisker," Nature, 442,:739-741 (2006). 9000133 46 Dick et al., "Control of Myeloid Activity During Retinal Inflammation," J. of Leukocyte Bio., 74:161-166(2003). 9000133 47 Dorai et al., "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function," Hybridoma, vol. 10(2), pp. 211-217 (1991). 9000133 48 Ebert et al., "Selective Immunosuppressive Action of a Factor Produced by Colon Cancer Cells," Cancer Res. 50:6158-6161 (1990). 9000133 49 Elgert, K. D. "Immunology : Understanding the Immune System," The Genetic Basis of Antibody Diversity, 123 (1996). 9000133 50 Faguet et al., "Blood Kinectics, Tissue Distribution, and Radioimaging of Anti-Common Chronic Lymphatic Leukemia Antigen (cCLLa) Monoclonal Antibody CLL2 in Mice Transplanted With cCLLa-Bearing Human Leukemia Cells." Blood. vol. 75, No. 9 (1990) pp. 1853-1861. 9000133 51 Faisal et al., Cell-surface Associated p43/Endothelial-monocyte-activating-polypeptide-II in Hepatocellular Carcinoma Cells Induces Apoptosis in T-lynphocytes, Asian J. of Surg. 30(1):13-22 (2007). 9000133 52 Fallarino, F., et al., "Murine Plasmacytoid Dendritic Cells Initiate the Immunosupressive Pathway of Tryptophan Catabolism in Response to CD200 Receptor Engagement," J. Immunol., 173:3748-3754 (2004). 9000133 53 Farber, U., et al., "Loss of heterozygosity on chromosome 3, bands q24->qter, in a diploid meningioma," Cytogenet Cell Genet, 57:157-158 (1991). 9000133 54 Feurstein et al., "Induction of Autoimmunity in a Transgenic Model of B Cell Receptor Peripheral Tolerance: Changes in Coreceptors and B Cell Receptor-Induced Tyrosine-Phosphoproteins", J. Immunol., vol. 163:5287-5297 (1999). 9000133 55 Funakoshi et al., "Antitumor Effects of Nonconjugated Murine Lym-2 and Human-Mouse Chimeric CLL-1 Monoclonal Antibodies Against Various Human Lumphoma Cell Lines In Vitro and In Vivo." Blood vol. 90, No. 8 (1997) pp. 3150-3166. 9000133 56 Ginaldi et al., "Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H," Leukemia Res. 22(2):185-191 (1998). 9000133 57 Giusti et al., "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region," Proc. Natl. Acad. Sci. USA 84:2926-2930 (1987). 9000133 58 Gorczynski and Marsden, "Modulation of CD200 receptors as a novel method of immunosuppression," Expert Opin. Ther. Patents, 13(5): 711-715(2003). See also WIPO Patent No. WO02095030 assigned to Transplantation Tech, Inc. 9000133 59 Gorczynski et al., "Anti-CD200R Ameliorates Collagen-Induced Arthritis in Mice," J. of Immunol., 104(3):256-264(2002). 9000133 60 Gorczynski et al., "Does Successful Allopregnancy Mimic Transplantation Tolerance?", Graft, 4:338-345(2001). 9000133 61 Gorczynski et al., "Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice," Clin. Exp. Immunol., 126:220-229(2001). 9000133 62 Gorczynski et al., "Increased expression of the novel molecule OX-2 is involved in prolongation of murine renal allograft survival." Transplantation, 65(8):1106-1114(1998). 9000133 63 Gorczynski, "CD200 and its receptors as targets for immunoregulation," Current Opinion in Investigational Drugs, 6(5):483-488 (2005). 9000133 64 Gorczynski, L., et al., "Evidence That an OX-2-Positive Cell Can Inhibit the Stimulation of Type 1 Cytokine Production by Bone Marrow-Derived B7-1 (and B7-2)-Positive Dendtritic Cells," J. Immunol., 162:774-781 (1999). 9000133 65 Gorczynski, R., et al., "CD200 Is a Ligand for All Members of the CD200R Family of Immunoregulatory Molecules," J. Immunol., 172:7744-7749 (2004). 9000133 66 Gorczynski, R., et al., "Dendritic Cells Expressing TGFBeta/IL-10, and CHO Cells With OX-2, Increase Graft Survival," Transplantation Proceedings, 33:1565-1566 (2001). 9000133 67 Gorczynski, R.M., "Evidence for an Immunoregulatory Role of OX2 with its Counter Ligand (OX2L) in the Regulation of Transplant Rejection, Fetal Loss, Autoimmunity and Tumor Growth", Archivum Immunologiae et Therapiae Experimentalis, Polish Academy of Sciences, vol. 49(4), pp. 303-309 (2001). 9000133 68 Gorczynski, R.M., "Role of Cytokines in Allograft Rejection," Current Pharmaceutical Design, 7:1039-1057 (2001). 9000133 69 Gorczynski, R.M., "Synergy in Induction of Increased Renal Allograft Survival after Portal Vein Infusion of Dendtritic Cells Transduced to Express TGFB and IL-10, along with Administration of CHO Cells Expressing the Regulatory Molecule OX-2," Clinical Immunology, 95(3):182-189 (2000). 9000133 70 Gorczynski, R.M., "Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages," Eur. J. Immunol., 31:2331-2337 (2001). 9000133 71 Gorczynski, R.M., et al., "A CD200FC Immunoadhesin Prolongs Rat Islet Xenograft Survival in Mice," Transplantation, 73(12):1948-1953 (2002). 9000133 72 Gorczynski, R.M., et al., "An Immunoadhesin Incorporating the Molecule OX-2 Is a Potent Immunosuppressant That Prolongs Allo- and Xenograft Survival," J. Immunol., 163:1654-1660(1999). 9000133 73 Gorczynski, R.M., et al., "Anti-Rat OX-2 Blocks Increased Small Intestinal Transplant Survival After Portal Vein Immunization," Transplantation Proceedings, 31:577-578 (1999). 9000133 74 Gorczynski, R.M., et al., "Augmented Induction of CD4+ CD25+ Treg using Monoclonal Antibodies to CD200R," Transplantation, 79(4):488-491 (2005). 9000133 75 Gorczynski, R.M., et al., "Augmented Induction of CD4+ CD25+ Treg using Monoclonal Antibodies to CD200R," Transplantation, 79(9), pp. 1180-1183 (2005). 9000133 76 Gorczynski, R.M., et al., "CD200 Immunoadhesin Supresses Collagen-Induced Arthritis in Mice," Clinical Immunology, 101(3):328-334 (2001). 9000133 77 Gorczynski, R.M., et al., "Evidence for Persistent Expression of OX2 as a Necessary Component of Prolonged Renal Allograft Survival Following Portal Vein Immunization," Clinical Immunol., 97(1):69-78 (2000). 9000133 78 Gorczynski, R.M., et al., "Induction of Tolerance-Inducing Antigen-Presenting Cells in Bone Marrow Cultures in Vitor Using Monoclonal Antibodies to CD200R," Transplantation, 77(8):1138-1144 (2004). 9000133 79 Gorczynski, R.M., et al., "Interleukin-13, in Combination with Anti-Interleukin-12, Increases Graft Prolongation After Portal Venous Immunization with Cultured Allogeneic Bone Marrow-Derived Dentritic Cells," Transplantation, 62(11):1592-1600 (1996). 9000133 80 Gorczynski, R.M., et al., "Persistent expression of OX-2 is necessary for renal allograft survival," FASEB Journal, 14(6):A1069 (2000). 9000133 81 Gorczynski, R.M., et al., "Receptor Engagement on Cells Expressing a Ligand for the Tolerance-Inducing Molecule OX2 Induces an Immunoregulatory Population That Inhibits Alloreactivity In Vitro and In Vivo," J. Immunol., 165:4854-4860 (2000). 9000133 82 Gorczynski, R.M., et al., "Regulation of Gene Expression of Murine MD-1 Regulates Subsequent T Cell Activation and Cytokine Production," J. of Immunology, 165:1925-1932 (2000). 9000133 83 Gorczynski, R.M., et al., "Structural and Functional Heterogeneity in the CD200R Family of Immunoregulatory Molecules and their Expression at the Fetomaternal Interface," AJRI, 52:147-163 (2004). 9000133 84 Gorczynski, R.M., et al., "The Same Immunoregulatory Molecules Contribute to Successful Pregnancy and Transplantation," AJRI, 48:18-26 (2002). 9000133 85 Greenwood, J.D. and Clark, M., "Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man," (ed. Clark, M.) Pub. Academic Titles, UK, pp. 4-5 (1993). 9000133 86 Gura, T., "Systems for Identifying New Drugs Are Often Faulty," Science, 278:1041-1042 (1997). 9000133 87 Gussow and Seemann, "Humanization of Monoclonal Antibodies," Meth. Enzymol. 203:99-121 (1991). 9000133 88 Hardy et al., "A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice," Proc. Natl. Acad. Sci. USA 94:5756-5760 (1997). 9000133 89 Heaney et al., "Severe asthma treatment: need for characterising patients," Lancet, 365:974-976(2005). 9000133 90 Hegen et al., "Utility of animal models for identification of potential therapeutics for rheumatoid arthritis," Ann. Rheum. Dis., vol. 67, pp. 1505-1515 (2008). 9000133 91 Hoek, R.M., et al., "Down-Regulation of the Macrophage Lineage Through Interaction with OX2 (CD200)," Science, 290:1768-1771 (2000). 9000133 92 Hoek, R.M., et al., "Macrophage regulation by the B7.1/2 homologue OX2?", FASB Journal, 14(6):A1232 (2000). 9000133 93 Huang, "Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis," Pharmacol. Therapeutics, 86:201-215(2000). 9000133 94 Hutchings, N.J., et al., "Interactions of Cytoplasmic Region of OX2R Are Consistent with an Inhibitory Function," Annual Congress of the British Society for Immunology, Dec. 5-8, 2000, Harrogate, UK. 9000133 95 Iwanuma et al., "Antitumor Immune Response of Human Peripheral Blood Lymphocytes Coengrafted with Tumor into Severe Combined Immunodeficient Mice," Cancer Res. 57:2937-2942 (1997). 9000133 96 Jain, "The next frontier of molecular medicine: Delivery of therapeutics," Nature Medicine, 4(6):655-657(1998). 9000133 97 Jansky, L., et al., "Dynamics of Cytokine Production in Human Peripheral Blood Mononuclear Cells Stimulated by LPS or Infected by Borrelia," Physiol. Res., 52:593-598 (2003). 9000133 98 Jeurissen, S.H.M., et al., "Characteristics and functional aspects of nonlymphoid cells in rat germinal centers, recognized by two monoclonal antibodies ED5 and ED6," Eur. J. Immunol., 16:562-568 (1986). 9000133 99 Keil et al., "The Tolerance-Promoting Molecule OX-2 is Expressed in Fetal Trophoblast Cells that Cocoon the `Fetal Allograft` and May Prevent Pregnancy Loss Caused by Cytokine-Activation of FGL2 Prothrombinase," Amer. J. Reprod. Immunol., 45:343(2001) (abstract). 9000133 100 Kim et al., "Divergent Effects of 4-1BB Antibodies on Antitumor Immunity and on Tumor-reactive T-Cell Generation," Cancer Res., 61:2031-2037(2001). 9000133 101 Kjaergaard et al., "Therapeutic Efficacy of OX-40 Receptor antibody Depends on Tumor Immunogenicity and Anatomic Site of Tumor Growth," Cancer Res. 60:5514-5521(2000). 9000133 102 Kneitz, C., et al., "Inhibition of Tcell/B cell interaction by B-CLL cells," Leukemia, vol. 13, pp. 98-104 (1999). 9000133 103 Kretz-Rommel et al, "CD200 Expression on Tumor Cells Suppresses Anti-Tumor Immunity: New Approaches to Cancer Immunotherapy" Journal of Immunotherapy; vol. 29(6), Nov. 2006, p. 666, XP009088616 & 21st Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer; Los Angeles, CA, USA; Oct. 26-29, 2006 ISSN: 1524-9557. 9000133 104 Kretz-Rommel, "CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy," J. Immunol. 178:5595-5605 (2007). 9000133 105 Kretz-Rommel, A., et al., "Immune Evasion by CD200: New Approaches to Targeted Therapies for Chronic Lymphocytic Leukemia," XP009088617, J. Immunother., vol. 28(6), p. 650 (2005). 9000133 106 Kretz-Rommel, A., et al., "The Immuno-Regulatory Protein CD200 Is Overexpressed in a Subset of B-Cell Chronic Lymphocytic Leukemias and Plays a Role in Down-Regulating the TH1 Immune Response," J. Immunother., XP009088618, vol. 27(6):S46 (2004). 9000133 107 Kroese, F.G.M., et al., "Germinal centre formation and follicular antigen trapping in the spleen of lethally X-irradiated and reconstituted rats," Immunology, 57:99-104 (1986). 9000133 108 Kroese, F.G.M., et al., "The ontogeny of germinal centre forming capacity of neonatal rat spleen," Immunology, 60:597-602 (1987). 9000133 109 Liu et al., "Effect of combined T- and B-cell depletion of allogenic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients," Clin. Transplant. 18:518-524 (2004). 9000133 110 Mariuzza et al., "The Structural Basis of Antigen-Antibody Recognition," Ann. Rev. Biophys. Biophys. Chem. 16:139-159 (1987). 9000133 111 Marsh, M.N., "Functional and Structural Aspects of the Epithelial Lymphocyte, with Implications for Coeliac Disease and Tropical Sprue," Univ. Dept. of Medicine, University of Manchester School of Medicine at Hope Hospital, Salford, Manchester UK pp. 55-75 (1985). 9000133 112 Matutes et al., "Morphological and Immuniphenotypic Features of Chronic Lymphocytic Leukemia", Rev. Clin. Exp. Hematol., vol. 4.1, p. 8-33 (2000). 9000133 113 McCaughan et al., "Characterization of the Human Homolog of the Rat MRC OX-2 Membrane Glycoprotein," Immunogenetics, 25:329-335(1987). 9000133 114 McCaughan, G.M., et al., "Identification of the human homologue of the rat lymphoid/brain antigen MRC OX-2," Australian and New Zealand Journal of Medicine 17: 142 (Abstract) (1987). 9000133 115 McCaughan, G.W., et al., "The Gene for MRC OX-2 Membrane Glycoprotein Is Localized on Human Chromosome 3," Immunogenetics, 25:133-135 (1987). 9000133 116 McMaster, W.R., et al., "Identification of la glycoproteins in rat thymus and purification from rat spleen," Eur. J. Immunol., 9:426-433 (1979). 9000133 117 McWhirter et al., Supplemental Materials, PNAS, vol. 103, pp. 1041-1046 (2006). 9000133 118 McWhirter, J.R., et al., "Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation," PNAS, 103(4):1041-1046 (2006). 9000133 119 Mjaaland et al., "Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies", Eur. J. Immunol., 20:1457-1461(1990). 9000133 120 Mjaaland, S., et al., "The Localization of Antigen in Lymph Node Follicles of Congenitally Athymic Nude Rats," Scand. J. Immunol., 26:141-147 (1987). 9000133 121 Mohammad, R.M., et al., "Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model," Leukemia, 10:130-137 (1996). 9000133 122 Mori et al., "Establishment of a new anit-cancer drugs-resistant cell line derived from B-chronic lymphocyctic leukemia" Proceedings, Fifty-Ninth Annual Meeting of teh Japanese Cancer Association, p. 583, # 3788 (Sep. 1, 2000). 9000133 123 Morris, R.J., et al., "Sequential Expression of OX2 and Thy-1 Glycoproteins on the Neuronal Surface during Development," Dev. Neurosci., 9:33-44 (1987). 9000133 124 Mueller et al., "Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function," Hybridoma, vol. 10(2), pp. 211-217 (1991) (abstract). 9000133 125 Mueller et al., "Humanized Porcine VCAM-Specific Monoclonal Antibodies With Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," Molecular Immunology, vol. 34(6), pp. 441-452 (1997). 9000133 126 Myers et al., "Characterization of a Peptide Analog of a Determinant of Type II Collagen that Suppresses Collagen-Induced Arthritis," J. of Immunology, 3589-3595(1998). 9000133 127 Nagelkerken L., et al., "Accessory Cell Function of Thoracic Duct Nonlymphoid Cells, Dentritic Cells, and Splenic Adherent Cells in the Brown-Norway Rat," Cellular Immunology, 93:520-531 (1985). 9000133 128 Nathan and Muller, "Putting the Brakes on innate immunity: a regulatory role for CD200?", Nat Immunol., 2(1):17-19(2001). 9000133 129 Ni et al., "An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant which prolongs allograft survival", FASEB Journal 13(5):A983(1999). 9000133 130 Ohno et al., "Antigen-binding specificities of antibodies are primarily determined by seven residues of VH," Proc. Natl. Acad. Sci., vol. 82, pp. 2945-2949 (1985). 9000133 131 Pakula and Sauer, "Genetic analysis of protein stability and function," Annu. Rev. Genet., vol. 23, pp. 289-310 (1989). 9000133 132 Panka et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," Proc, Natl. Acad. Sci. USA, vol. 85:3080-3084 (1988). 9000133 133 Pardoll, Drew., "Therapeutic Vaccination for Cancer," Clin. Immunol., 95(1):S44-S62(2000). 9000133 134 Paterson, D.J., et al., "Antigens of Activated Rat T Lymphocytes Including a Molecule of 50,000 Mr Detected Only on CD4 Positive T Blasts," Molecular Immunology, 24(12):1281-1290 (1987). 9000133 135 Presta, L., "Antibody engineering for therapeutics," Current Opinion in Structural Biology, 13(4):519-525 (2003). 9000133 136 Preston et al., "The leukocyte/neuron cell surface antigen OX2 binds to a ligand on macrophages", European J. of Immunol., 27(8):1911-1918(1997). 9000133 137 Ragheb et al., "Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2", Immunol. Letters, 68(2,3):311-315(1999). 9000133 138 Ragheb, R.F., "Exploration of OX-2 function in tolerance induction and graft acceptance using an anti-mouse OX-2 monoclonal antibody," Masters Abstracts International, 38(4):971-972 (2000). 9000133 139 Richards, S.J., et al., "Reported Sequence Homology Between Alzheimer Amyloid770 and the MCR OX-2 Antigen Does Not Predict Function," Brain Research Bulletin, 38(3):305-306 (1995). 9000133 140 Riley, "Melanoma and the Problem of Malignancy," J. Exp. Med. 204:1-9 (2004). 9000133 141 Rindfleisch et al., "Diagnosis and Management of Rheumatoid Arthritis," American Family Physician, vol. 72(6), pp. 1037-1047 (2005). 9000133 142 Rioux, P., Campath-1H (Cambridge Univeristy), IDrugs, vol. 2(2); pp. 153-167, Database Medline, abstract No. NLM16160950 (Abstract Only) (1999). 9000133 143 Romagnani, Sergio., "Short Analytical Review: TH1 and TH2 in Human Diseases," Clin. Immunol. Immunopath, 80(3):225-235(1996). 9000133 144 Rosenblum, M.D., et al., "CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance," Blood, 103(7):2691-2698 (2004). 9000133 145 Rosenwald et al., "Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia," J. of Exp. Medicine, 194(11):1639-1647(2001). 9000133 146 Rudicoff et al., "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA 79:1979-1983 (1982). 9000133 147 Sahin et al., "New monoclonal antibody specific for a 6.5 kDa glycoprotein which presents mainly on a B cell of chronic lymphocytic leukemia (CLL)" Immunology Letters, 2001, 76, 1-6. 9000133 148 Schlom, Jeffrey, "Monoclonal Antiboides They're More and Less Than You Think," Molecular and Cellular Research for Future Diagnosis and Therapy, pp. 95-134 (1991). 9000133 149 Schultes et al., "Immunotherapy of Human Ovarian Carcinoma with OVAREX.TM. MAb-B43.13 in a Human-PBL-SCID/BG Mouse Model," Hybridoma 18(1):47-55 (1999). 9000133 150 Sebestyen et al., Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas. British Journal of Hematology. vol. 104, 1999, p. 412-419. 9000133 151 Sehgal, et al., "Generation of the Primary Antibody Repertoire in Rabbits: Expression of a Diverse Set of Igk-V Genes May Compensate for Limited Combinatorial Diversity at the Heavy Chain Locus," Immunogenetics, vol. 50, pp. 31-42 (1999). 9000133 152 Shields, R. L., et. al., "High Resolution Mapping of the Binding Site on Human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc gamma R," Journal of Biological Chemistry, 276(9):6591-6604 (2001). 9000133 153 Simelyte et al., "CD200-Fc, a Novel Antiarthritic Biologic Agent That Targets Proinflammatory Cytokine Expression in the Joints of Mice With Collagen-Induced Arthritis," Arthritis & Rheumatism, vol. 58(4), pp. 1038-1043 (2008). 9000133 154 Smith-Gill, Sandra J., "Biology of Antibody-Mediated Responses," Biologic Therapy of Cancer: Principles and Practice, Chapter 2, pp. 39-51 (1995). 9000133 155 Snyder et al., "Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides," Cancer Res. 65(23):10646-10650 (2005). 9000133 156 Srivastava, P.K., "Immunotherapy of human cancer: lessons from mice," Nature Immunology, 1(5):363-366 (2000). 9000133 157 Steinman, Lawrence., "Assessment of Animal Models for MS and Demyelinating Disease in the Design of Rational Therapy," Neuron, 24:511-514(1999). 9000133 158 Stuart et al., "Monkeying Around with Collagen Autoimmunity and Arthritis," Lab. Invest., 54(1):1-3(1986). 9000133 159 Syme, R., et al., "Comparison of CD34 and Monocyte-Derived Dendritic Cells from Mobilized Peripheral Blood from Cancer Patients," Stem Cells, 23:74-81 (2005). 9000133 160 Tanaka et al., "The Anti-Human Tumor Effect and Generation of Human Cytotoxic T Cells in SCID Mice Given Human Peripheral Blood Lymphocytes by the in Vivo Transfer of the Interleukin-6 Gene Using Adenovirus Vector," Cancer Res. 57:1335-1343 (1997). 9000133 161 Tang et al., Pathogenesis of collagen-induced arthritis: modulation of disease by arthritogenic T-Cell epitope location, J. of Immunology, 113: 384-391 (2004). 9000133 162 Tangri and Raghupathy, "Expression of Cytokines in Placentas of Mice Undergoing Immunologically Mediated Spontaneous Fetal Resorptions," Biology of Reprod., 49:850-856(1993). 9000133 163 Tao et al., "Structural Features of Human Immunoglobulin G that Determine Isotype-specific Differences in Complement Activation," J. Exp. Med., vol. 178, pp. 661-667 (1993). 9000133 164 Taylor, N., et al., "Enhanced Tolerance to Autoimmune Uveitis in CD200-Deficient Mice Correlates with a Pronounced Th2 Switch in Response to Antigen Challenge," J. Immunol., 174:143-154 (2005). 9000133 165 Thomsen et al., "Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo," Tissue Antigens 66:73-82 (2005). 9000133 166 Toder et al., "Mouse Model for the Treatment of Immune Pregnancy Loss," Am. J. of Reprod. Immunol., 26:42-46(1991). 9000133 167 Webb, M., et al., "Localisation of the MRC OX-2 Glycoprotein on the Surfaces of Neurones," J. Neurochemistry, 43:1061-1067 (1984). 9000133 168 Wilczynski, J.R., "Immunoligical Analogy Between Allograft Rejection, Recurrent Abortion and Pre-Eclampsia--the Same Basic Mechanism?," Human Ummunology, 67:492-511 (2006). 9000133 169 Wright et al., "The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in himans," Immunology 102:173-179 (2001). 9000133 170 Wright, G.J., et al., "Lymphoid/Neuronal Cell Surface OX2 Glycoprotein Recognizes a Novel Receptor on Macrophages Implicated in the Control of Their Function," Immunity, 13:233-242 (2000). 9000133 171 Wright, G.J., et al., "The lymphoid/neuronal OX-2 glycoprotein interacts with a novel protein expressed by macrophages," Tissue Antigens, 55 (Supplement 1); vol. 1 (2000). 9000133 172 Wright, G.J., et al., "Viral homologues of cell surface proteins OX2 and CD47 have potential to regulate macrophage function," Annual Congress of the British Society for Immunology, vol. 101 (Supplement 1): 50; Dec. 5-8, 2000. 9000133 173 Yamaguchi et al., "Application of monoclonal antibody for drug delivery system--Missile therapy for cancer," Nihon Rinsho, vol. 56(3), pp. 638-643 (1998). 9000133 174 Yamaguchi et al., "Biological Response Modifier and Missile Cancer Chemotherapy," Biotherapy, vol. 10(4), pp. 605-609 (1996). 9000133 175 Yamaguchi et al., "Immunomissile Therapy Using Tumor Markers: Application of tumor marker for immunotargeting therapy of cancer," Nihon Rinsho, vol. 54(6), pp. 1674-1679 (1996). 9000133 176 Yang, C., et al., "Functional maturation and recent thymic emigrants in the periphery: development of alloreactivity correlates with the cyclic expression of CD45RC isoforms," Eur. J. Immunol., 22:2261-2269 (1992). 9000133 177 Yu, X., et al., "The role of B7-CD28 co-stimulation in tumor rejection," International Immunology, 10(6):791-797 (1998). 9000133 178 Zhang, S., et al., "Molecular Mechanisms of CD200 Inhibition of Mast Cell Activation," J. Immunol., 173:6786-6793 (2004). 9000133 179 Zheng, P., et al., "B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge," Proc. Natl. Acad. Sci. USA, 95:6284-6289 (1998). 9000133 180 Zhu et al., "Radioimmunotherapy of Human B-Cell Chronic Lymphocytic Leukemia in Nude Mice." Cancer Research. 54, 5111-5117 (1994). 9000133 181 Zips, D., et al., "New Anticancer Agents: In Vitro and In Vivo Evaluation," in vivo, 19:1-7 (2005). 9000133 182 Zou et al. Human Glioma-Induced Immunosuppression Involves Soluble Factor(s) That Alters Monocyte Cytokine Profile and Surface Markers, vol. 162, pp. 4882-4892 (1999). 9000133 183 US Office Action for U.S. Appl. No. 12/715,303, filed Mar. 1, 2010, First Named Inventor: Katherine S. Bowdish, dated Jul. 11, 2011. 9000133 184 US Office Action for U.S. Appl. No. 12/715,303, filed Mar. 1, 2010, First Named Inventor: Katherine S. Bowdish, dated Nov. 8, 2010. 9000133 185 US Office Action for U.S. Appl. No. 12/715,303, filed Mar. 1, 2010, First Named Inventor: Katherine S. Bowdish, dated Jul. 22, 2010. 9000133 186 US Office Action for U.S. Appl. No. 13/344,195, filed Jan. 5, 2012, First Named Inventor: Katherine S. Bowdish, dated Apr. 9, 2014. 9000133 187 US Office Action for U.S. Appl. No. 13/344,195, filed Jan. 5, 2012, First Named Inventor: Katherine S. Bowdish, dated Dec. 2, 2013. 9000133 188 US Office Action for U.S. Appl. No. 13/344,195, filed Jan. 5, 2012, First Named Inventor: Katherine S. Bowdish, dated Oct. 8, 2013. 9000133 189 US Office Action for U.S. Appl. No. 10/996,316, filed Nov. 23, 2004, First Named Inventor: Katherine S. Bowdish, dated May 28, 2008. 9000133 190 US Office Action for U.S. Appl. No. 10/996,316, filed Nov. 23, 2004, First Named Inventor: Katherine S. Bowdish, dated May 19, 2008. 9000133 191 US Office Action for U.S. Appl. No. 10/996,316, filed Nov. 23, 2004, First Named Inventor: Katherine S. Bowdish, dated May 12, 2008. 9000133 192 US Office Action for U.S. Appl. No. 10/996,316, filed Nov. 23, 2004, First Named Inventor: Katherine S. Bowdish, dated Feb. 8, 2008. 9000133 193 US Office Action for U.S. Appl. No. 10/996,316, filed Nov. 23, 2004, First Named Inventor: Katherine S. Bowdish, dated Nov. 7, 2007. 9000133 194 US Office Action for U.S. Appl. No. 10/996,316, filed Nov. 23, 2004, First Named Inventor: Katherine S. Bowdish, dated May 14, 2007. 9000133 195 US Office Action for U.S. Appl. No. 10/996,316, filed Nov. 23, 2004, First Named Inventor: Katherine S. Bowdish, dated Feb. 21, 2007. 9000133 196 US Office Action for U.S. Appl. No. 11/171,567, filed Jun. 30, 2005, First Named Inventor: Katherine S. Bowdish, dated May 14, 2007. 9000133 197 US Office Action for U.S. Appl. No. 11/171,567, filed Jun. 30, 2005, First Named Inventor: Katherine S. Bowdish, dated Feb. 14, 2007. 9000133 198 US Office Action for U.S. Appl. No. 11/985,322, filed Nov. 13, 2007, First Named Inventor: Katherine S. Bowdish, dated Nov. 30, 2010. 9000133 199 US Office Action for U.S. Appl. No. 11/985,322, filed Nov. 13, 2007, First Named Inventor: Katherine S. Bowdish, dated Jul. 30, 2010. 9000133 200 US Office Action for U.S. Appl. No. 11/985,322, filed Nov. 13, 2007, First Named Inventor: Katherine S. Bowdish, dated Oct. 5, 2009. 9000133 201 US Office Action for U.S. Appl. No. 11/985,322, filed Nov. 13, 2007, First Named Inventor: Katherine S. Bowdish, dated Jun. 11, 2009. 9000133 202 US Office Action for U.S. Appl. No. 12/286,759, filed Sep. 30, 2008, First Named Inventor: Katherine S. Bowdish, dated Feb. 21, 2012. 9000133 203 US Office Action for U.S. Appl. No. 12/286,759, filed Sep. 30, 2008, First Named Inventor: Katherine S. Bowdish, dated Oct. 21, 2011. 9000133 204 US Office Action for U.S. Appl. No. 12/286,759, filed Sep. 30, 2008, First Named Inventor: Katherine S. Bowdish, dated May 10, 2011. 9000133 205 US Office Action for U.S. Appl. No. 13/029,021, filed Feb. 16, 2011, First Named Inventor: Katherine S. Bowdish, dated May 14, 2014. 9000133 206 US Office Action for U.S. Appl. No. 13/029,021, filed Feb. 16, 2011, First Named Inventor: Katherine S. Bowdish, dated Nov. 21, 2013. 9000133 207 US Office Action for U.S. Appl. No. 13/029,021, filed Feb. 16, 2011, First Named Inventor: Katherine S. Bowdish, dated Jul. 20, 2012. 9000133 208 US Office Action for U.S. Appl. No. 13/029,021, filed Feb. 16, 2011, First Named Inventor: Katherine S. Bowdish, dated Feb. 16, 2012. 9000133 209 US Office Action for U.S. Appl. No. 10/433,207, filed May 30, 2003, First Named Inventor: Katherine S. Bowdish, dated Mar. 25, 2008. 9000133 210 US Office Action for U.S. Appl. No. 10/433,207, filed May 30, 2003, First Named Inventor: Katherine S. Bowdish, dated Oct. 31, 2007. 9000133 211 US Office Action for U.S. Appl. No. 10/433,207, filed May 30, 2003, First Named Inventor: Katherine S. Bowdish, dated May 2, 2007. 9000133 212 US Office Action for U.S. Appl. No. 10/433,207, filed May 30, 2003, First Named Inventor: Katherine S. Bowdish, dated Jul. 12, 2006. 9000133 213 US Office Action for U.S. Appl. No. 10/433,207, filed May 30, 2003, First Named Inventor: Katherine S. Bowdish, dated Mar. 29, 2006. 9000133 214 US Office Action for U.S. Appl. No. 13/533,546, filed Jun. 26, 2012, First Named Inventor: Russell P. Rother, dated Sep. 23, 2013. 9000133 215 US Office Action for U.S. Appl. No. 13/533,546, filed Jun. 26, 2012, First Named Inventor: Russell P. Rother, dated May 2, 2013. 9000133 216 US Office Action for U.S. Appl. No. 13/533,546, filed Jun. 26, 2012, First Named Inventor: Russell P. Rother, dated Mar. 14, 2013. 9000133 217 US Office Action for U.S. Appl. No. 12/452,772, filed Apr. 5, 2010, First Named Inventor: Yi Wang, dated Mar. 13, 2014. 9000133 218 US Office Action for U.S. Appl. No. 12/452,772, filed Apr. 5, 2010, First Named Inventor: Yi Wang, dated May 25, 2012. 9000133 219 US Office Action for U.S. Appl. No. 12/452,772, filed Apr. 5, 2010, First Named Inventor: Yi Wang, dated Oct. 13, 2011. 9000133 220 US Office Action for U.S. Appl. No. 12/452,772, filed Apr. 5, 2010, First Named Inventor: Yi Wang, dated Aug. 4, 2011. 9000133 221 US Office Action for U.S. Appl. No. 13/578,367, filed Jan. 18, 2013, First Named Inventor: Russel P. Rother, dated Feb. 20, 2014. 9000133 222 Almasri, Nidal M. et al., "Reduced Expression of CD20 Antigen as a Characteristic Marker for Chronic Lymphocytic Leukemia," American Journal of Hematology, vol. 40:259-263 (1992). 9000133 223 Bello, Celeste et al., "Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond," Hematology, pp. 233-242 (2007). 9000133 224 Burge, Daniel J. et al., "Pharmacokinetic and Pharmacodynamic Properties of TRU-015, a CD20-Directed Small Modular Immunopharmaceutical Protein Therapeutic, in Patients with Rheumatoid Arthritis: A Phase I, Open-Label, Dose-Escalation Clinical Study," Clinical Therapeutics, vol. 30(10):1806-1816 (2008). 9000133 225 Cui, Weiguo et al., "CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts," PNAS, vol. 104(36):14436-14441 (2007). 9000133 226 Ennishi, D. et al., "CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy," Annals of Oncology, vol. 19:1921-1926 (2008). 9000133 227 Friedberg, Jonathan W., "Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy," Hematology, pp. 329-334 (2005). 9000133 228 Hatherley, Deborah et al., "The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains," Eur. J. Immunol., vol. 34:1688-1694 (2004). 9000133 229 Hernandez-Ilizaliturri, F.J. et al., "Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL)," Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings, vol. 27(15S), 1 page, Poster No. 8543 (2009). 9000133 230 Holodick, Nichol E. et al., "Adult BM generates CD5+ B1 cells containing abundant N-region additions," Eur. J. Immunol., vol. 39(9):2383-2394 (2009). 9000133 231 Kausar, Fariha et al., "Ocrelizumab: a step forward in the evolution of B-cell therapy," Expert Opin. Biol. Ther., vol. 9 (7):889-895 (2009). 9000133 232 Levene, Adam P. et al., "Therapeutic monoclonal antibodies in oncology," J.R. Soc. Med., vol. 98:146-152 (2005). 9000133 233 Marti, G.E. et al., "CD20 and CD5 Expression in B-Chronic Lymphocytic Leukemia," Annals of the New York Academy of Sciences, vol. 651:480-483 (1992). 9000133 234 Milani, Cannon et al., "Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura," Current Opinion in Molecular Therapeutics, vol. 11 (2):200-207 (2009). 9000133 235 Morschhauser, Franck et al., "Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results," Journal of Clinical Oncology, vol. 27(20):3346-3353 (2009). 9000133 236 Petermann, Kimberly B. et al., "CD200 is induced by ERK and is a potential therapeutic target in melanoma," The Journal of Clinical Investigation, vol. 117(12):3922-3929 (2007). 9000133 237 Reddy, N.M. et al., "Rituximab resistance and its association with changes in the internal domain of CD20 antigen and down-regulation of pro-apoptotic protein Bax and Bak in both rituximab-resistant cell lines (RRCL) and diffuse large B-cell lymphoma (DLBCL) patient (pt) samples," Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, vol. 24(18S), 1 page, Poster No. 17509 (2006). 9000133 238 Rijkers, Eva S.K. et al., "The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes," Molecular Immunology, vol. 45:1126-1135 (2008). 9000133 239 Tedder, Thomas F. et al., "Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes," Proc. Natl. Acad. Sci. USA, vol. 85:208-212 (1988). 9000133 240 Teeling, Jessica L. et al., "The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20," The Journal of Immunology, vol. 177:362-371 (2006). 9000133 241 US Office Action for U.S. Appl. No. 12/087,683, filed Jan. 14, 2009, First Named Inventor: Katherine S. Bowdish, dated Aug. 5, 2011. 9000133 242 US Office Action for U.S. Appl. No. 12/087,683, filed Jan. 14, 2009, First Named Inventor: Katherine S. Bowdish, dated May 24, 2011. 9000133 243 US Office Action for U.S. Appl. No. 12/087,683, filed Jan. 14, 2009, First Named Inventor: Katherine S. Bowdish, dated Jan. 4, 2011. 9000133 244 US Office Action for U.S. Appl. No. 12/087,683, filed Jan. 14, 2009, First Named Inventor: Katherine S. Bowdish, dated Sep. 23, 2010. 9000133 245 US Office Action for U.S. Appl. No. 13/311,910, filed Dec. 6, 2011, First Named Inventor: Katherine S. Bowdish, dated Dec. 13, 2013. 9000133 246 US Office Action for U.S. Appl. No. 13/311,910, filed Dec. 6, 2011, First Named Inventor: Katherine S. Bowdish, dated Jul. 1, 2013. 9000133 247 US Office Action for U.S. Appl. No. 10/379,151, filed Mar. 4, 2003, First Named Inventor: Katherine S. Bowdish, dated Jun. 4, 2008. 9000133 248 US Office Action for U.S. Appl. No. 10/379,151, filed Mar. 4, 2003, First Named Inventor: Katherine S. Bowdish, dated Mar. 19, 2008. 9000133 249 US Office Action for U.S. Appl. No. 10/379,151, filed Mar. 4, 2003, First Named Inventor: Katherine S. Bowdish, dated Sep. 24, 2007. 9000133 250 US Office Action for U.S. Appl. No. 10/379,151, filed Mar. 4, 2003, First Named Inventor: Katherine S. Bowdish, dated Mar. 28, 2007. 9000133 251 US Office Action for U.S. Appl. No. 10/379,151, filed Mar. 4, 2003, First Named Inventor: Katherine S. Bowdish, dated Jul. 13, 2006. 9000133 252 US Office Action for U.S. Appl. No. 10/379,151, filed Mar. 4, 2003, First Named Inventor: Katherine S. Bowdish, dated Mar. 27, 2006. 9000133 253 US Office Action for U.S. Appl. No. 10/736,188, filed Dec. 15, 2003, First Named Inventor: Katherine S. Bowdish, dated Apr. 3, 2008. 9000133 254 US Office Action for U.S. Appl. No. 10/736,188, filed Dec. 15, 2003, First Named Inventor: Katherine S. Bowdish, dated Jul. 30, 2007. 9000133 255 US Office Action for U.S. Appl. No. 10/736,188, filed Dec. 15, 2003, First Named Inventor: Katherine S. Bowdish, dated Jul. 26, 2006. 9000133 256 US Office Action for U.S. Appl. No. 10/894,672, filed Jul. 20, 2004, First Named Inventor: Katherine S. Bowdish, dated Feb. 24, 2014. 9000133 257 US Office Action for U.S. Appl. No. 10/894,672, filed Jul. 20, 2004, First Named Inventor: Katherine S. Bowdish, dated Dec. 23, 2013. 9000133 258 US Office Action for U.S. Appl. No. 10/894,672, filed Jul. 20, 2004, First Named Inventor: Katherine S. Bowdish, dated Dec. 28, 2009. 9000133 259 US Office Action for U.S. Appl. No. 10/894,672, filed Jul. 20, 2004, First Named Inventor: Katherine S. Bowdish, dated May 12, 2009. 9000133 260 US Office Action for U.S. Appl. No. 10/894,672, filed Jul. 20, 2004, First Named Inventor: Katherine S. Bowdish, dated Oct. 15, 2008. 9000133 261 US Office Action for U.S. Appl. No. 10/894,672, filed Jul. 20, 2004, First Named Inventor: Katherine S. Bowdish, dated Mar. 19, 2008. 9000133 262 US Office Action for U.S. Appl. No. 10/894,672, filed Jul. 20, 2004, First Named Inventor: Katherine S. Bowdish, dated Nov. 7, 2007. 9000133 263 US Office Action for U.S. Appl. No. 10/894,672, filed Jul. 20, 2004, First Named Inventor: Katherine S. Bowdish, dated May 14, 2007. 9000133 264 US Office Action for U.S. Appl. No. 10/894,672, filed Jul. 20, 2004, First Named Inventor: Katherine S. Bowdish, dated Feb. 1, 2007. 9000133 265 US Office Action for U.S. Appl. No. 12/221,134, filed Jul. 30, 2008, First Named Inventor: Katherine S. Bowdish, dated May 29, 2009. 9000133 266 US Office Action for U.S. Appl. No. 12/221,134, filed Jul. 30, 2008, First Named Inventor: Katherine S. Bowdish, dated Feb. 25, 2009. 9000133 267 US Office Action for U.S. Appl. No. 12/221,122, filed Jul. 30, 2008, First Named Inventor: Katherine S. Bowdish, dated Dec. 1, 2009. 9000133 268 US Office Action for U.S. Appl. No. 12/221,122, filed Jul. 30, 2008, First Named Inventor: Katherine S. Bowdish, dated Jul. 24, 2009. 9000133 269 US Office Action for U.S. Appl. No. 12/221,122, filed Jul. 30, 2008, First Named Inventor: Katherine S. Bowdish, dated Apr. 30, 2009. 9000133 270 US Office Action for U.S. Appl. No. 12/221,122, filed Jul. 30, 2008, First Named Inventor: Katherine S. Bowdish, dated Jan. 23, 2009. 9000133 271 US Office Action for U.S. Appl. No. 12/715,303, filed Mar. 1, 2010, First Named Inventor: Katherine S. Bowdish, dated Oct. 26, 2011. 9000134 1 Jain et al., 2005. Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J. Assoc. Phys. India 53: 513-520. 9000134 2 Nakamura et al., 2000. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol. Dial. Transplant. 15: 1379-1383. 9000134 3 Grant, 1959. The proteins of normal urine. II. From the urinary tract. J. Clin. Pathol. 12: 510-517. 9000134 4 Bakker et al. (2005), "Altered activity of plasma hemopexin in patients with minimal change disease in relapse." Pediatr Nephrol. 20(10):1410-5. 9000134 5 Bergsland et al. (2006), "Urine protein markers distinguish stone-forming from non-stone-forming relatives of calcium stone formers." Am J Physiol Renal Physiol. 291(3):F530-6. 9000134 6 Bernard et al. (1989), "Urine protein 1: a sex-dependent marker of tubular or glomerular dysfunction." Clin Chem. 35 (10):2141-2. 9000134 7 Bernard et al. (1994), "Urinary protein 1 or Clara cell protein: a new sensitive marker of proximal tubular dysfunction." Kidney Int Suppl. 47:S34-7. 9000134 8 Burgi et al. (1989), "Unusually high concentrations of Zn alpha 2-glycoprotein and the lack of alpha 2HS-glycoprotein in human ejaculates." Clin. Chem. 35(8): 1649-50. 9000134 9 Flynn et al. (1992), "Urinary excretion of beta 2-glycoprotein-1 (apolipoprotein H) and other markers of tubular malfunction in "non-tubular" renal disease." J Clin Pathol. 45(7):561-7. 9000134 10 Hale et al. (2001), "Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer." Clin. Cancer. Res. 7(4): 846-53. 9000134 11 Hoffmann et al. (1997), "Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal diseases." Glycobiology. 7(4):499-506. 9000134 12 Igarashi et al. (1993), "An enzyme-linked immunosorbent assay for urinary albumin in patients with insulin-dependent diabetes mellitus." J. Ped. Endocrinol. 6(2): 159-64. 9000134 13 International Search Report from International Application No. PCT/US2008/063429, International Publication No. WO/2008/141285, mailed Jan. 27, 2009. 9000134 14 Joh et al. (1990), "Microlamellar structures in lobular glomerulonephritis associated with monoclonal IgG lambda paraproteinemia. A case report and review of the literature." Acta Pathol Jpn. 40(12):913-21. 9000134 15 Kebler et al. (1985), "Rapidly progressive glomerulonephritis and monoclonal gammopathy." Am J Med. 78(1):133-8. 9000134 16 Kitamoto et al. (2004), "Assessment of thrombin in the urine of glomerulonephritic patients by enzyme-linked immunosorbent assay." Ann Clin Biochem. 41(Pt 2):133-7. 9000134 17 Lehto et al. (1995), "Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis." Kidney Int. 47(5):1403-11. 9000134 18 Nakatsuka et al. (2005), "A case of monoclonal immunoglobulin light- and heavy-chain deposition disease exhibiting atypical deposition with fibrillary structures, successfully treated with chemotherapy." Clin Nephrol. 64(3):221-7. 9000134 19 Nakayashiki (1990), "Sweat protein components tested by SDS-polyacrylamide gel electrophoresis followed by immunoblotting." Tohoku Journal of Experimental Medicine 161(1): 25-31. 9000134 20 Qi and Chen (1985), "[Analysis of measured results of urinary pepsin and 17-OHCS in chronic gastritis with splenic and renal insufficiency based on Chinese traditional medicine]" [in Chinese]. Zhong Xi Yi Jie He Za Zhi. 5(1):27-9, 3. [English abstract.]. 9000134 21 Rakov and Betekhitina (2000), "[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension]" [Article in Russian with English abstract]. Klin Lab Diagn. (7):3-7. 9000134 22 Rampino et al. (2007), "Neutralization of macrophage-stimulating protein ameliorates renal injury in anti-thy 1 glomerulonephritis." J Am Soc Nephrol. 18(5):1486-96. 9000134 23 Rao et al. (2007), "Proteomic Identification of Urinary Biomarkers of Diabetic Nephropathy." Diabetes Care 30:629-37. 9000134 24 Simoni et al. (2006), "Role of free hemoglobin in 8-iso prostaglandin F2-alpha synthesis in chronic renal failure and its impact on CD163-Hb scavenger receptor and on coronary artery endothelium." ASAIO J. 52(6):652-61. 9000134 25 Sobajima et al. (1998), "Urinary excretion of pancreatic stone protein in diabetic nephropathy." Intern Med. 37 (6):500-3. 9000134 26 Tashiro et al. (2002), "Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy." J. Clin. Lab. Analysis 16(1): 1-4. 9000134 27 Tomlinson et al. (1997), "Low molecular weight protein excretion in glomerular disease: a comparative analysis." Pediatr Nephrol. 11(3):285-90. 9000134 28 Valleix et al. (2002), "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family." Kidney Int. 61(3):907-12. 9000134 29 Varghese et al. (2007), "Urine biomarkers predict the cause of glomerular disease." J Am Soc Nephrol. 18 (3):913-22. 9000134 30 Weinberg et al. (1985), "The role of urinary kininogen in the regulation of kinin generation." Kidney Int. 28(6):975-81. 9000134 31 Weinberg et al. (1986), "Urinary kininogen: a possible regulator of kinin formation in normal individuals and subjects with essential hypertension, end-stage renal and liver disease." Adv Exp Med Biol. 198 Pt A:119-25. 9000134 32 Written Opinion of the International Searching Authority from International Application No. PCT/US2008/063429, International Publication No. WO/2008/141285, dated Dec. 21, 2008. 9000135 1 Gopin et al., "A Chemical Adaptor System Designed to Link a Tumor-Targeting Device with a Prodrug and an Enzymatic Trigger," Angewandte Chemie International Edition, Jan. 2003, vol. 42, pp. 327-332. 9000135 2 Kolb et al., "The growing impact of click chemistry on drug discovery," Drug Discovery Today, Dec. 2003, vol. 8, No. 24, pp. 1128-1137. 9000135 3 Wu et al., "Reaction of Propargyl Bromide with Aldehydes in the Presence of Metallic Tin. Synthesis of Homopropargylalcohols and Homoallenylalcohols," Synthetic Communications, Jan. 1990, vol. 20, No. 9, pp. 1279-1286. 9000135 4 Matsuda et al., "Structure-activity relationships of 1'S-1'-acetoxychavicol acetate for inhibitory effect on NO production in lipopolysaccharide-activated mouse peritoneal macrophages," Bioorganic & Medicinal Chemistry Letters, Apr. 2005, vol. 15, pp. 1949-1953. 9000135 5 Jeffrey et al., "Minor groove binder antibody conjugates employing a water soluble .beta.-glucuronide linker," Bioorganic & Medicinal Chemistry Letters, Jan. 2007, vol. 17, pp. 2278-2280. 9000135 6 Kolb et al., "Click Chemistry: Diverse Chemical Function from a Few Good Reactions," Angewandte Chemie International Edition, 2001, vol. 40, pp. 2004-2021. 9000135 7 Kratz et al., "Prodrug Strategies in Anticancer Chemotherapy," Chem. Med. Chem., 2008, vol. 3, pp. 20-53. 9000135 8 Tranoy-Opalinski et al., "Design of Self-Immolative Linkers for Tumour-Activated Prodrug Therapy," Anti-Cancer Agents in Medicinal Chemistry, 2008, vol. 8, No. 5, pp. 1-20. 9000135 9 Nov. 18, 2010 Written Opinion issued in French Application No. 1053921 (with translation). 9000135 10 Jul. 21, 2011 Written Opinion of the International Searching Authority issued in International Application No. PCT/IB2011/052184. 9000135 11 Jul. 21, 2011 International Search Report issued in International Application No. PCT/IB2011/052184. 9000136 1 Eisenbach et al., Immune responses agains HCV-NS3 after accidental infection with HCV-NS3 recombinant vaccinia virus Journal of Viral Hepatitis, 2007, 14: pp. 817-819. 9000136 2 Kitabatake et al. SARS-CoV spike protein expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus, Vaccine, 25: pp. 630-637. 9000136 3 Tsukiyama et al., Activation of the CKI-CDK-Rb-E2F Pathway in full genome hepatitis C Virus-expressing Cells, The Journal of Biological Chemistry, 2004, 279(15), pp. 14531-14541. 9000136 4 Rollier et al., Control of Heterologous Hepatitis C Virus Infection in Chimpanzees Is associated with Quality of Vaccine-induced peripheral T-helper immune response, Journal of Virology, 2004. 78(1): pp. 187-196. 9000136 5 Heile et al., Evaluation of Hepatitis C Virus Glycoprotein E2 for vaccine Design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-Based Vaccine candidates, Journal of Virology. 2000. 74(15): pp. 6885-6892. 9000136 6 C. Eisenbach, et al., Immune responses against HCV-NS3 after accidental infection with HCV-NS3 recombinant vaccinia virus, Journal of Viral Hepatitis, 2007, vol. 14, pp. 817-819. 9000136 7 M. Kitabatake, et al., SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus, Vaccine, 2007, vol. 25, pp. 630-637. 9000136 8 K. Shinoda, et al., Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost, Clinical Immunology, 2006, vol. 119, pp. 32-37. 9000136 9 K. Watanabe, et al., Stability of recombinant vaccinia virus LC16m0 or LC16m8: Preserved laboratory attenuation markers and conserved expression of inserted HBsAg gene, Vaccine, vol. 7, Dec. 1989, pp. 499-502. 9000136 10 Database DDBJ/EMBL/GenBank [online], Accession No. AY045702 Sep. 5, 2007 uploaded, Tsukiyama-Kohara, K., et al., Definition: Hepatitis C virus isolate HCR6, complete genome. [retrieved on May 14, 2009]. 9000136 11 S. Funahashi, et al., Increased Expression In Vivo and In Vitro of Foreign Genes Directed by A-Type Inclusion Body Hybrid Promoters in Recombinant Vaccinia Viruses, Journal of Virology, Oct. 1991, vol. 65, No. 10, pp. 5584-5588. 9000136 12 N. Y. Jin, et al., Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5kDa protein, and hemagglutinin gene promoters support high levels of expression, Arch Virol, 1994, vol. 138, pp. 315-330. 9000136 13 T. Wakita, et al., Efficient Conditional Transgene Expression in Hepatitis C Virus cDNA Transgenic Mice Mediated by the Cre/loxP System, The Journal of Biological Chemistry, vol. 273, No. 15, Apr. 10, 1998, pp. 9001-9006. 9000136 14 K. Inoue, et al., Evaluation of a Cyclophilin Inhibitor in Hepatitis C Virus-Infected Chimeric Mice In Vivo, Hepatology, Apr. 2007, vol. 45, No. 4, pp. 921-928. 9000136 15 Q. L. Choo, et al., Vaccination of chimpanzees against infection by the hepatitis C virus, Proc. Natl. Acad. Sci. USA, Feb. 1994, vol. 91, pp. 1294-1298. 9000136 16 M. Puig, et al., Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection, Vaccine, vol. 22, 2004, pp. 991-1000. 9000136 17 J. D. Abraham, et al., Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins, Vaccine, vol. 22, 2004, pp. 3917-3928. 9000136 18 G. A. Elmowalid, et al., Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees, Proc. Natl. Acad. Sci., May 15, 2007, vol. 104, No. 20, pp. 8427-8432. 9000136 19 J. Youn et al., "Polyvalent Immunization Against Hepatitis B and C Viruses With Recombiant Vaccine Virus", The Tenth Annual Conference on Vaccine Research, May 2, 2007, Abstract of Oral Presentation, p. 67. 9000136 20 Susanne El Gogo et al., "Protective vaccination with heptitis C virus NS3 but not core antigen in a novel mouse challenge model", The Journal of Gene Medicine, Feb. 2008, vol. 10, No. 2, pp. 177-186. 9000136 21 Liz Alvarez-Lajonchere, et al, "Generation and characterization of recombinant vaccinia viruses expressing a hepatitis C virus Core protein, genotype 1b, individually or as a polyprotein", Biotecnologia Aplicada, Jul. 2007, vol. 24, No. 3-4, pp. 246-253. 9000136 22 Christoph Eisenbach, et al, "Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse", Vaccine, Jun. 12, 2006, vol. 24, No. 24, pp. 5140-5148. 9000136 23 K. Watanabe, et al, "Improved recombinant LC16m0 or LC16m8 vaccinia virus successfully expressing hepatitis B surfacce antigen", Vaccine, Elsevier Ltd., GB, Feb. 1, 1989, vol. 7, No. 1, pp. 53-59. 9000136 24 A Supplementary European Search Report, which was completed on May 16, 2012, in the prosecution of EP 09717492, which corresponds to the present application. 9000136 25 H. Yu et al., Immunity and protection by adoptive transfer of dendritic cells transfected with hepatitis C NS3/4A mRNA, Vaccine, vol. 25, pp. 1701-1711, 2007. 9000136 26 V. Chung et al., Development of Cell-Based Assays for In Vitro Characterization of Hepatitis C Virus NS3/4A Protease Inhibitors, Antimicrobial Agents and Chemotherapy, vol. 49, No. 4, pp. 1381-1390, Apr. 2005. 9000136 27 R. Ralston et al., Characterization of Hepatitis C Virus Envelope Glycoprotein Complexes Expressed by Recombinant Vaccinia Viruses, Journal of Virology, vol. 67, No. 11, pp. 6753-6761, Nov. 1993. 9000138 1 NCBI database Acc#ACE75511 Baik et al, 2008. Alignment with SEQ ID No. 2. 9000138 2 Chaseley et al., GenBank Accession No. CO058769 (2011). 9000138 3 Lyman et al., J. Biol. Chem., vol. 75, pp. 613-618 (1927). 9000138 4 Ding et al., WPI Accession No. 2008-M16229 (2008). 9000138 5 Ojima, WPI Accession No. 2006-128844 (2006). 9000139 1 Seo et al. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine. Sep. 25, 2009;27(42):5906-12. doi: 10.1016/j.vaccine.2009.07.033. Epub Aug. 3, 2009. 9000139 2 Borysiewicz et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. Jun. 1, 1996;347(9014):1523-7. 9000139 3 FLT3LG protein [Homo sapiens] GenBank: AAI44130.1. Dated Jan. 8, 2009. http://www.ncbi.nlm.nih.gov/protein/219841754?report=genbank& log$=protalign& blast--rank=1& RID=PR3T8RYN014. 9000139 4 Lethal factor domain I [synthetic construct] GenBank: AAR88323.1. Dated Sep. 15, 2004. http://www.ncbi.nlm.nih.gov/protein/40646957?report=genbank& log$=protalign& blast--rank=4& RID=PR48H4KU014. 9000139 5 E6 [Human papillomavirus type 16]. GenBank: AAD33252.1. Dated Jun. 30, 2000. http://www.ncbi.nlm.nih.gov/protein/AAD33252.1. 9000139 6 E7 [Human papillomavirus type 16]. GenBank: AAD33253.1. Dated Jun. 30, 2000. http://www.ncbi.nlm.nih.gov/protein/AAD33253.1. 9000139 7 Human papillomavirus type 18 E6, E7, E1, E2, E4, E5, L1 & L2 genes. GenBank: X05015.1. Dated Apr. 18, 2005. http://www.ncbi.nlm.nih.gov/nuccore/60975. 9000139 8 Dochez et al. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine. Mar. 20, 2014;32(14):1595-601. 9000139 9 Bourgault Villada, I., et al., "Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif," European Journal of Immunology 30(8):2281-2289, Wiley-VCH, Germany (2000). 9000139 10 Chen, H-W., et al., "Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization," Cancer Biology & Therapy 8(21):2025-2032, Taylor & Francis, United States (2009). 9000139 11 Facchinetti, V., et al., "CD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopes," European Journal of Immunology 35(3):806-815, Wiley-VCH, Germany (2005). 9000139 12 Gallagher, K.M.E. and Man, S., "Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women," The Journal of General Virology 88(Pt 5):1470-1478, Society for General Microbiology, England (2007). 9000139 13 Kather, A., et al., "Identification of a Naturally Processed HLA-A 0201 HPV18 E7 T Cell Epitope by Tumor Cell Mediated in Vitro Vaccination," International Journal of Cancer 104(3):345-353, Wiley-Liss, United States (2003). 9000139 14 Morishima, S., et al., "Identification of HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope," International Journal of Cancer 120(3):594-604, Wiley-Liss, United States (2006). 9000139 15 Nakagawa, M., et al., "Different Methods of Identifying New Antigenic Epitopes of Human Papillomavirus Type 16 E6 and E7 Proteins," Clinical and Diagnostic Laboratory Immunology 11(5):889-896, Amercican Society for Microbiology, United States (2004). 9000139 16 Nakagawa, M., et al. "HLA class I Binding Promiscuity of the CD8 T-cell Epitopes of Human Papillomavirus Type 16 E6 Protein," Journal of Virology 81(3):1412-1423, American Society for Microbiology, United States (2007). 9000139 17 Peng, S., et al., "Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6," Journal of Virology 78(16):8468-8476, American Society for Microbiology, United States (2004). 9000139 18 Ressing, M.E., et al., "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through in Vivo and in Vitro Immunogenicity Studies of HLA-A 0201-binding peptides," The Journal of Immunology 154(11)5934-5943, American Association of Immunologists, United States (1995). 9000139 19 Ressing, M.E., et al., "Occasional Memory Cytotoxic T-Cell Responses of Patients with Human Papillomavirus Type 16-Positive Cervical Lesions Against a Human Leukocyte Antigen-A 0201-Restricted E7-Encoded Epitope," Cancer Research 56(3):582-588, American Association for Cancer Research, United States (1996). 9000139 20 Rudolf, M.P., et al., "Human T-Cell Responses to HLA-A-restricted High Binding Affinity Peptides of Human Papillomavirus Type 18 Proteins E6 and E7," Clinical Cancer Research 7(3 Suppl):788s-795s, American Association of Cancer, United States (2001). 9000139 21 Stauss, H.J., et al., "Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of canidate T-cell epitopes in human papilloma virus," Proceedings of the National Academy of Sciences of the United States of America 89(17):7871-7875, National Academy of Sciences, United States (1992). 9000139 22 Yan, J., et al., "Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques," Vaccine 26(40):5210-5215, Elsevier Science, Netherlands (2008). 9000139 23 Cobrinik, D. et al., "The retinoblastoma protein and the regulation of cell cycling," TIBS 17:312-315, Elsevier Science Publishers, England (1992). 9000139 24 Garcia, F., et al., "ZYC101a for Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial," Obstetrics and Gynecology 103(2):317-326, Lippincott Williams & Wilkins, United States (2004). 9000139 25 Ohlschlager P., et al., "An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response," Vaccine 24:2880-2893, Elsevier Ltd., England (2006). 9000139 26 Schiffman, M.H., et al., "Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial Neoplasia," Journal of the National Cancer Institute 85(12):958-964, National institutes of Health, united States (1993). 9000139 27 Von Knebel Doeberitz, M., et al., "Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA," Int. J. Cancer 51:831-834, Wiley-Liss, Inc., United States (1992). 9000139 28 Yan, J., et al., "Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen," Vaccine 27:431-440, Elsevier Ltd., England (2009). 9000139 29 Zur Hausen, H., "Papillomavirus infections--a major cause of human cancers," Biochimica et Biophysica Acta 1288:F55-F78, Elsevier Science B.V., Netherlands (1996). 9000139 30 Acession No. ACI43214.1, NCBI Database, accessed at http://ncbi.nlm.nih.gov/protein/ACI43214.1, accessed on Oct. 7, 2014. 9000139 31 Borysiewicz L.K., et al., "A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer," The Lancet 347:1523-1527, Lancet Pub. Group, England (1996). 9000139 32 Seo, S.H., et al., "Optimal induction of HPV DNA vaccine-induced CD830 T cell responses and therapeutic antitumor effect by antigen engineering and eletroporation," Vaccine 27:5906-5912, Elsevier Ltd., England (Aug. 3, 2009). 9000139 33 English Language Abstract of Chinese Patent Publication No. CN 1679930 A, Chinese Patent Office, espacenet database (2005) (listed as document FP14 on the accompanying form PTO/SB/08A). 9000140 1 Kaneko et al, DNA Research 7 (3), 217 (2000). 9000140 2 U.S. Appl. No. 60/121,700, filed Feb. 25, 1999, Jofuku et al. 9000140 3 Ahn et al., "Homoeologous relationship of rice, wheat and maize chromosomes" Molecular and General Genetics, 241:483-90 (1993). 9000140 4 Albert et al., "Site-specific integration of DNA into wild-type and mutant lox site placed in the plant genome" The Plant Journal, 7:649 (1995). 9000140 5 Alonso-Blanco et al. (Methods in Molecular Biology, vol. 82, "Arabidopsis Protocols", pp. 137-146, J.M. Martinez-Zapater and J. Salinas, eds., c. 1998 by Humana Press, Totowa, NJ). 9000140 6 Ausubel et al. (Current Protocols in Molecular Biology, Greene Publishing, New York (1992), pp. 1-12. 9000140 7 Azpiroz-Leehan et al., "T-DNA insertion mutagenesis in Arabidopsis: going back and forth" Trends in Genetics, 13:152 (1997). 9000140 8 Biswas et al. "Transgenic indica rice (Oryza sativa L.) plants obtained by direct gene transfer to protoplasts" J. Biotechnol., 32:1-10 (1994). 9000140 9 Bonner et al., "Reduction in the Rate of DNA reassociation by Sequence Divergence" J. Mol. Biol., 81:123 (1973) 9000140 10 Bradshaw et al., "A new vector for recombination-based cloning of large DNA fragments from yeast artificial chromosomes" Nucl. Acids. Res., 23:4850-4856 (1995). 9000140 11 Burke et al., "Cloning of large segments of exogenous DNA into yeast by means of artificial chromosome vectors" Science, 236:806-812 (1987). 9000140 12 Burr ("Mapping Genes with Recombinant Inbreds", pp. 249-254. In Freeling, M. and V. Walbot (Ed.), The Maize Handbook, c. 1994 by Springer-Verlag New York, Inc.: New York, NY, USA; Berlin Germany. 9000140 13 Burr et al., "Gene mapping with recombinant inbreds in maize" Genetics, 118:519 (1998). 9000140 14 Carels et al., "Compositional properties of homologous coding sequences from plants" J. Mol. Evol., 46:45 (1998) 9000140 15 Christou, "Strategies for variety-independent genetic transformation of important cereals, legumes and woody species utilizing particle bombardment" Euphytica, 85(1-3):13-27 (1995). 9000140 16 De Martinis et al., "Silencing gene expression of the Ethylene-forming enzyme results in a reversible inhibition of ovule development in transgenic tobacco plants" The Plant Cell, 11:1061 (1999). 9000140 17 deVicente and Tanksley "QTL analysis of transgressive segregation in an interspecific tomato cross" Genetics, 134:585 (1993). 9000140 18 Evans et al., Protoplasts Isolation and Culture in "Handbook of Plant Cell Culture," pp. 124-176, MacMillan Publishing Company, New York, 1983. 9000140 19 Fennoy et al. "Synonymous codon usage in Zea mays L. nuclear genes is varied by levels of C and G-ending codons" Nucleic Acids Research, 21(23):5294 (1993). 9000140 20 Frischauf et al., "Lambda replacement vectors carrying polylinker sequences" J. Mol. Biol., 170:827-842 (1983). 9000140 21 Fromm et al. "Expression of genes transferred into monocot and dicot plant cells by electroporation" Proc. Natl. Acad. Sci. USA, 82:5824 (1985). 9000140 22 Gardiner et al., "Development of a core FRLP map in maize using an immortalized F2 population" Genetics, 134:917 (1993). 9000140 23 Gleave, "A versatile binary vector system with a T-DNA organizational structure conducive to efficient integration of cloned DNA into the plant genome" Plant Mol. Biol., 20:1203 (1992). 9000140 24 Golovkin et al., "An SC35-like protein and a novel serine/arginine-rich protein interact with Arabidopsis U1-70K protein" J. Biol. Chem. 274:36428 (1999). 9000140 25 Gould et al., "Transformation of Zea mays L. Using Agrobacterium tummefaciens and the shoot apex" Plant Physiology, 95:426 (1991). 9000140 26 Graves and Goldman, "The transformation of Zea mays seedling with Agrobacterium tumefaciens" Plant Mol. Biol., 7:43 (1986). 9000140 27 Hamilton et al., "Antisense gene that inhibits synthesis of the hormone ethylene in transgenic plants" Nature, 346:284-287 (1990). 9000140 28 Hamilton et al., "Stable transfer of intact high molecular weight DNA into plant chromosomes" Proc. Natl. Acad. Sci. USA, 93:9975-9979 (1996). 9000140 29 Hamilton, "A binary-BAC system for plant transformation with high-molecular-weight DNA" Gene, 200:107-116 (1997) 9000140 30 Herrera-Estrella et al., "Chimeric genes as dominant selectable markers in plant cells" EMBO J., 2:987 (1983). 9000140 31 Hosoyama et al. "Oryzacystatin exogenously introduced into protoplasts and regeneration of transgenic rice" Biosci. Biotechnol. Biochem., 58:1500 (1994). 9000140 32 Hu et al., "Escherichia coli one- and two-hybrid systems for the analysis and identification of protein-protein interactions" Methods, 20:80 (2000). 9000140 33 Huynh et al., In: Glover NM (ed) DNA Cloning: A practical Approach, (1985) vol. 1 Oxford: IRL Press (1985), pp. 49-78. 9000140 34 Ichimura et al., "Isolation of ATMEKK1 (a MAP Kinase Kinase Kinase)--interacting proteins and analysis of a MAP Kinase cascade in Arabidopsis" Biochem. Biophys. Res. Comm. 253:532 (1998). 9000140 35 Keegstra and Cline, "Protein import and routing systems of chloroplasts" (1999) The Plant Cell, 11:557-570. 9000140 36 Keller and Manak (DNA Probes, 2nd Ed. pp. 1-25, c. 1993 by Stockton Press, New York, NY). 9000140 37 Klee et al. "Agrobacterium-mediated plant transformation and its further applications to plant biology" Ann. Rev. of Plant Phys., 38:467 (1987). 9000140 38 Klein et al. "High-velocity microprojectiles for delivering nucleic acids into living cells" Nature, 327:70-73 (1987). 9000140 39 Kohler and Milstein "Continuous cultures of fused cells secreting antibody of predefined specificity" Nature, 256: 495 (1975). 9000140 40 Komari et al., "Vectors carrying two separate T-DNAs for co-transformation of higher plants mediated by Agrobacterium tumefaciens and segregation of transformants free from selection markers" Plant J., 10:165 (1996). 9000140 41 Liljegren, "Interactions among APETALA1, LEAFY, and TERMINAL FLOWER1 specify meristem fate" Plant Cell, 11:1007 (1999). 9000140 42 Luo et al., "Mapping sequence specific DNA-protein interactions: A versatile, quantitative method and its application to transcription factor XF1" J. Mol. Biol. 266:479 (1997). 9000140 43 Mariani et al., "A chimaeric ribonuclease-inhibitor gene restores fertility to male sterile plants" Nature, 357: 384-387 (1992). 9000140 44 Marra et al., "High throughput fingerprint analysis of large-insert clones" Genomic Research, 7:1072-1084 (1997). 9000140 45 Martinez et al., "Creation of ecdysone receptor chimeras in plants for controlled regulation of gene expression" Mol. Gen. Genet., 261:546 (1999). 9000140 46 Marty, "Plant Vacuoles" The Plant Cell, 11:587-599 (1999). 9000140 47 Matteucci et al. "Synthesis of Deoxyoligonucleotides on a polymer support" J. Am. Chem. Soc., 103:3185 (1981). 9000140 48 Mayer et al., Sequence and Analysis of chromosome 4 of the plant Arabidopsis thaliana, Nature, 402:769-777 (1999). 9000140 49 McAlister-Henn et al., "Application of the yeast two-hybrid system" Methods, 19:330 (1999). 9000140 50 McCormac et al., "A flexible series of binary vectors for agrobacterium-mediated plant transformation" Mol. Biotechnol., 8:199 (1997). 9000140 51 Michaels et al., "Flowering Locus C encodes a novel MADS domain protein that acts as a repressor of flowering" The Plant Cell, 11:949 (1999). 9000140 52 Muller et al., "High meiotic stability of a foreign gene introduced into tobacco by Agrobacterium-mediated transformation" Mol. Gen. Genet., 207:171 (1987). 9000140 53 Napoli et al., "Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans." The Plant Cell, 2:279 (1990). 9000140 54 Needleman and Wunsch "A general method applicable to the search for similarities in the amino acid sequence of two proteins" J. Mol. Biol., 48:443 (1970). 9000140 55 Oeller et al., "Reversible inhibition of tomato fruit senescence by antisense RNA" Science, 254:437-439 (1991). 9000140 56 Panaud et al., "Frequency of microsatellite sequences in rice (Oryza sative L.)" Genome, 38:1170 (1995). 9000140 57 Paszkowski et al. "Direct gene transfer to plants" EMBO J., 3:2717 (1984). 9000140 58 Pearson and Lipman "Improved tools for biological sequence comparison" Proc. Natl. Acad. Sci. USA, 85: 2444 (1988). 9000140 59 Refseth et al., "Hybridization capture of microsatellites directly from genomic DNA" Electrophoresis, 18:1519 (1997). 9000140 60 Salomon et al., "Genetic identification of functions of TR-DNA transcripts in octopine crown galls" EMBO J., 3:141 (1984). 9000140 61 Sambrook et al. (Molecular Cloning, a Laboratory Manual, 2nd ed., c. 1989 by Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). 9000140 62 Schwarz et al., "The basic region of myogenin cooperates with two transcription activation domains to induce muscle-specific transcription" Mol. Cell. Biol., 12:266 (1992). 9000140 63 Senior et al., "Simple sequence repeat markers developed from Maize sequences found in the Genbank database: Map construction" Crop Science, 36:1676 (1996). 9000140 64 Sheehy et al., "Reduction of polygalacturonase activity in tomato fruit by antisense RNA" Proc. Nat. Acad. Sci. USA, 85:8805 (1988). 9000140 65 Shizuya et al., "Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector" Proc. Natl. Acad. Sci. USA, 89:8794-8797 (1992). 9000140 66 Smith and Waterman, "Comparison of Biosequences" Advances in Applied Mathematics., 2:482 (1981). 9000140 67 Sternberg et al., "Bacteriophage P1 cloning system for the isolation, amplification, and recovery of DNA fragments as large as 100 kilobase pairs" Proc. Natl. Acad. Sci. USA, 87(1):103-7 (1990). 9000140 68 Tanksley and McCouch, "Seed banks and molecular maps: Unlocking genetic potential from the wild" Science, 277:1063 (1997). 9000140 69 Taramino et al., "Simple sequence repeats for germplasm analysis and mapping in maize" Genome, 39:277 (1996). 9000140 70 Tijessen, "Hybridization with Nucleic Acid Probes" in Laboratory Techniques in Biochemistry and Molecular Biology, P.C. vand der Vliet, ed., c. 1993 by Elsevier, Amsterdam. 9000140 71 Urdea et al. "Chemical synthesis of a gene for human epidermal growth factor urogastrone and its expression in yeast" Proc. Natl. Acad. Sci. USA, 80:7461 (1983). 9000140 72 van der Krol et al., "Flavonoid genes in petunia: Addition of a limited number of gene copies my lead to a suppresion of gene expression" The Plant Cell, 2:291 (1990). 9000140 73 Vaucheret et al., "Transgene-induced gene silencing in plants" The Plant Journal, 16:651-659 (1998). 9000140 74 Venkateswarlu et al., "Evidence for T-DNA mediated gene targeting to tobacco chloroplasts" Biotechnology, 9:1103 (1991). 9000140 75 Vergunst et al., "Cre/lox-mediated site-specific integration of Agrobacterium T-DNA in Arabidopsis thaliana by transient expression of cre" Plant Mol. Biol., 38:393 (1998). 9000140 76 Vergunst et al., "Site-specific integration of Agrobacterium T-DNA in Arabidopsis thaliana mediated by Cre recombinase" Nucleic Acids Res., 26:2729 (1998). 9000140 77 Vitale and Denecke, "The endoplasmic reticulum-gateway of the secretory pathway" The Plant Cell, 11:615-628 (1999). 9000140 78 Walden et al., "A novel 205-kilodalton testis-specific serine/threonine protein kinase associated with microtubules of the spermatid manchette" Mol. Cell. Biol., 13:7625-7635 (1993). 9000140 79 Weising et al., "Foreign genes in plants: transfer, structure, expression, and applications" Ann. Rev. Genet., 22:421 (1988). 9000140 80 Office Action from U.S. Appl. No. 11/180,418, document dated May 17, 2007, 11 pages; Sep. 17, 2007 Response to Office Action dated May 17, 2007, 8 pages. 9000140 81 Office Action from U.S. Appl. No. 11/357,357, document dated May 17, 2007, 9 pages; Sep. 17, 2007 Response to Office Action dated May 17, 2007, 6 pages. 9000140 82 Office Action from U.S. Appl. No. 11/362,546, document dated Nov. 15, 2006, 6 pages; Feb. 14, 2007 Response to Office Action dated Nov. 15, 2006, 5 pages. 9000140 83 Final Office Action from U.S. Appl. No. 11/362,546, document dated May 2, 2007, 6 pages; Jul. 2, 2007 Response to Final Office Action dated May 2, 2007, 4 pages. 9000140 84 Office Action from U.S. Appl. No. 11/369,193, document dated Nov. 15, 2006, 7 pages; Feb. 14, 2007 Response to Office Action dated Nov. 15, 2006, 5 pages. 9000140 85 Office Action from U.S. Appl. No. 11/369,173, document dated Nov. 15, 2006, 14 pages; Feb. 14, 2007 Response to Office Action dated Nov. 15, 2006, 6 pages. 9000140 86 Office Action from U.S. Appl. No. 11/369,173, document dated May 3, 2007, 10 pages. 9000140 87 Office Action from U.S. Appl. No. 11/370,240, dated Sep. 27, 2007, 8 pages. 9000140 88 Final Office Action from U.S. Appl. No. 11/357,357, dated Nov. 29, 2007, 9 pages. 9000140 89 Final Office Action from U.S. Appl. No. 11/180,418, dated Nov. 30, 2007, 10 pages. 9000140 90 Office Action from U.S. Appl. No. 11/370,253, dated Oct. 30, 2007, 20 pages. 9000140 91 Office Action from U.S. Appl. No. 11/371,356, dated Oct. 30, 2007, 20 pages. 9000140 92 Office Action from U.S. Appl. No. 11/371,624, dated Oct. 31, 2007, 21 pages. 9000140 93 Office Action from U.S. Appl. No. 11/396,357, dated Nov. 7, 2007, 7 pages. 9000140 94 Office Action from U.S. Appl. No. 11/371,623, dated Nov. 16, 2007, 10 pages. 9000140 95 Office Action from U.S. Appl. No. 11/369,168, dated Oct. 30, 2007, 20 pages. 9000140 96 Notice of Allowance from U.S. Appl. No. 11/367,760, dated Oct. 5, 2007, 6 pages. 9000140 97 Notice of Allowance from U.S. Appl. No. 11/153,185, dated Nov. 13, 2007, 7 pages. 9000140 98 Notice of Allowance from U.S. Appl. No. 11/372,369, dated Nov. 13, 2007, 7 pages. 9000140 99 Notice of Allowance from U.S. Appl. No. 11/396,378, dated Nov. 13, 2007, 7 pages. 9000140 100 Notice of Allowance from U.S. Appl. No. 11/358,685, dated Dec. 21, 2007,4 pages. 9000140 101 Notice of Allowance from U.S. Appl. No. 11/357,747, dated Dec. 21, 2007, 4 pages. 9000140 102 Notice of Allowance from U.S. Appl. No. 11/357,909, dated Dec. 21, 2007, 4 pages. 9000140 103 Notice of Allowance from U.S. Appl. No. 11/368,321, dated Dec. 21, 2007, 4 pages. 9000140 104 Notice of Allowance from U.S. Appl. No. 11/362,546, dated Jan. 23, 2008, 6 pages. 9000140 105 Response to Final Office Action from U.S. Appl. No. 11/180,418, filed Jan. 30, 2008, 5 pages. 9000140 106 Response to Office Action from U.S. Appl. No. 11/369,168, filed Jan. 30, 2008, 7 pages. 9000140 107 Response to Office Action from U.S. Appl. No. 11/370,253, filed Jan. 30, 2008, 7 pages. 9000140 108 Response to Office Action from U.S. Appl. No. 11/371,356, filed Jan. 30, 2008, 7 pages. 9000140 109 Response to Office Action from U.S. Appl. No. 11/371,624, filed Jan. 30, 2008, 8 pages. 9000140 110 Response to Office Action from U.S. Appl. No. 11/371,623, filed Feb. 15, 2008, 4 pages. 9000140 111 Notice of Allowance from U.S. Appl. No. 11/180,101, dated Apr. 28, 2008, 7 pages. 9000140 112 Notice of Allowance from U.S. Appl. No. 11/180,418, dated Mar. 28, 2008, 4 pages. 9000140 113 Response to Final Office Action from U.S. Appl. No. 11/357,357, filed Apr. 29, 2008, 5 pages; and Advisory Action, dated May 14, 2008, 3 pages. 9000140 114 Notice of Allowance from U.S. Appl. No. 11/362,437, dated Apr. 28, 2008, 7 pages. 9000140 115 Office Action from U.S. Appl. No. 11/368,323, dated Mar. 24, 2008, 8 pages. 9000140 116 Office Action from U.S. Appl. No. 11/388,215, dated Apr. 3, 2008, 7 pages. 9000140 117 Final Office Action from U.S. Appl. No. 11/369,168, dated Apr. 16, 2008, 9 pages. 9000140 118 Final Office Action from U.S. Appl. No. 11/370,253, dated May 16, 2008, 9 pages. 9000140 119 Final Office Action from U.S. Appl. No. 11/371,356, dated Apr. 17, 2008, 9 pages. 9000140 120 Final Office Action from U.S. Appl. No. 11/371,624, dated Apr. 16, 2008, 9 pages. 9000140 121 Notice of Allowance from U.S. Appl. No. 11/371,623, dated May 29, 2008, 8 pages. 9000140 122 Office Action from U.S. Appl. No. 11/387,751, dated May 23, 2008, 10 pages. 9000140 123 Notice of allowance from U.S. Appl. No. 11/362,546, dated Jun. 5, 2008, 6 pages. 9000140 124 Response to Office Action from U.S. Appl. No. 11/388,215, filed Jul. 3, 2008, 5 pages. 9000140 125 Examiner Interview Summary from U.S. Appl. No. 11/370,253, dated Aug. 12, 2008, 2 pages; and Response to Final Office Action filed Aug. 18, 2008, 13 pages. 9000140 126 Response to Final Office Action from U.S. Appl. No. 11/371,356, filed Jun. 17, 2008, 4 pages; and Advisory Action, dated Aug. 6, 2008, 3 pages. 9000140 127 Response to Final Office Action from U.S. Appl. No. 11/371,624, filed Jun. 16, 2008, 5 pages; Advisory Action, dated Jul. 11, 2008, 4 pages; Examiner Interview Summary, dated Aug. 12, 2008, 2 pages; and Response to Final Office Action filed Aug. 18, 2008, 13 pages. 9000140 128 Response to Final Office Action from U.S. Appl. No. 11/370,253, filed Sep. 16, 2008, 20 pages; Advisory Action, dated Sep. 24, 2008, 3 pages; and Notice of Appeal, filed Nov. 17, 2008, 1 page. 9000140 129 Response to Final Office Action from U.S. Appl. No. 11/371,356, filed Sep. 16, 2008, 20 pages; Notice of Appeal, filed Oct. 16, 2008, 1 page; and Advisory Action, dated Oct. 28, 2008, 3 pages. 9000140 130 Response to Final Office Action from U.S. Appl. No. 11/371,624, filed Sep. 16, 2008, 20 pages; Advisory Action dated Sep. 24, 2008, 3 pages; and Notice of Appeal filed Oct. 16, 2008, 1 page. 9000140 131 Office Action from U.S. Appl. No. 11/371,334, dated Jan. 8, 2009, 8 pages. 9000140 132 Office Action from U.S. Appl. No. 11/761,165, dated Feb. 4, 2009, 5 pages. 9000140 133 Office Action from U.S. Appl. No. 11/362,546, dated Mar. 19, 2009, 6 pages; and Response to Office Action filed May 11, 2009, 4 pages. 9000140 134 Office Action from U.S. Appl. No. 12/045,487, dated Mar. 31, 2009, 10 pages. 9000140 135 Notice of Allowance from U.S. Appl. No. 11/370,253, dated Apr. 17, 2009, 6 pages. 9000140 136 Notice of Allowance from U.S. Appl. No. 11/371,356, dated Apr. 14, 2009, 6 pages. 9000140 137 Notice of Allowance from U.S. Appl. No. 11/371,624, dated Apr. 8, 2009, 6 pages. 9000140 138 Final office action from U.S. Appl. No. 11/362,546, dated Aug. 7, 2009, 8 pages. 9000140 139 Response to Office Action from U.S. Appl. No. 11/362,546, dated Sep. 23, 2009, 11 pages; Notice of Allowance, dated Oct. 21, 2009, 7 pages. 9000140 140 Notice of Allowance from U.S. Appl. No. 12/040,538, dated Sep. 22, 2009, 4 pages. 9000140 141 Office Action from U.S. Appl. No. 11/370,216, dated Sep. 30, 2009, 12 pages. 9000140 142 Office Action from U.S. Appl. No. 11/371,200, dated Sep. 17, 2009, 10 pages. 9000140 143 Office action from U.S. Appl. No. 11/371,632, dated Oct. 16, 2009, 8 pages. 9000140 144 Response to Office Action from U.S. Appl. No. 11/370,216, dated Jan. 15, 2010, 7 pages. 9000140 145 Response to Office Action from U.S. Appl. No. 11/371,200, dated Dec. 17, 2009, 6 pages. 9000140 146 Final Office Action from U.S. Appl. No. 11/370,216, dated Apr. 21, 2010, 15 pages. 9000140 147 Final Office Action from U.S. Appl. No. 11/371,200, dated Mar. 25, 2010, 11 pages. 9000140 148 Notice of Allowance from U.S. Appl. No. 11/357,760, dated Feb. 28, 2008, 4 pages. 9000140 149 Office Action for U.S. Appl. No. 13/953,972, dated Dec. 16, 2013, 12 pages. 9000140 150 Office Action for U.S. Appl. No. 13/608,968, dated Dec. 16, 2013, 16 pages. 9000141 1 Allison et al. "Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E," Journal of Virology 75(9): 4268-4275 (2001). 9000141 2 Bhardwaj et al. "Biophysical Characterization and Vector-Specific Antagonist Activity of Domain III of the Tick-Borne Flavivirus Envelope Protein," Journal of Virology 75(4): 4002-4007 (2001). 9000141 3 Cardosa et al. "Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses," BMC Microbiology 2(1): 9 (2002). 9000141 4 Chang et al. "A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice," Journal of Virology 74(9): 4244-4252 (2000). 9000141 5 Chang et al. "Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus," Virology 306: 170-180 (2003). 9000141 6 Chiou et al., "Enzyme-Linked Immunosorbent Assays Using Novel Japanese Encephalitis Virus Antigen Improve the Accuracy of Clinical Diagnosis of Flavivirus Infection," Clin. Vaccine Immunol. 15(5):825-835 (2008). 9000141 7 Crill et al., "Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens," PLoS One 4(4):34991 (2009), 18 pages. 9000141 8 Crill et al. "A Detailed Mutagenesis Study of Flavivirus Cross-Reactive Epitopes using West Nile Virus-like Particles," Journal of General Virology 88(4): 1169-1174 (2007). 9000141 9 Crill and Chang, "Localization and characterization of flavivrius envelope glycoprotein cross-reactive epitopes," J. Virology 78(34):13975-73986 (2004). 9000141 10 Greenspan et al. "Defining epitopes: It's not as easy as it seems," Nature Biotechnology 17: 936-937 (1999). 9000141 11 Guerois et al., "Predicting Changes in the Stability of Proteins and Protein Complexes: A Study of More Than 1000 Mutations," J. Mol. Biol. 320:369-387 (2002). 9000141 12 Halstead et al. "The future of dengue vaccines," The Lancet 360: 1243-1245 (2002). 9000141 13 Hoshino et al., "Mapping of antigenic sites involved in serotype-cross-reactive neutralization on group A rotovirus outercapsid glycoprotein VP7," Virol. 199:233-237 (1994). 9000141 14 Lescar et al. "The Fusion Glycoprotein Shell of Semliki Forest Virus: An Icosahedral Assembly Primed for Fusogenic Activation at Endosomal pH," Cell 105: 137-148 (2001). 9000141 15 Modis et al., "A ligand-binding pocket in the dengue virus envelope protein," PNAS 100(12):6986-6991 (2003). 9000141 16 Op De Beeck et al. "Role of the Transmembrane Domains of prM and E Proteins in the Formation of Yellow Fever Virus Envelope," Journal of Virology 77(2): 813-820 (2003). 9000141 17 Pappu et al., "Molecular characterization of a structural epitope that is largely conserved among severe isolates of a plant virus," Proc. Natl. Acad. Sci. USA, 90:3641-3644, (Apr. 1993). 9000141 18 Rey et al., "The envelope glycoprotein from the tick-borne encephalitis virus at 2 .ANG. resolution," Nature 375:291-298 (1995). 9000141 19 Rey, "Dengue virus envelope glycoprotein structure: New insight into its interactions during viral entry," PNAS 100:6899 (2003). 9000141 20 Roberson et al., "Differentiation of West Nile and St. Louis Encephalitis Virus Infections by Use of Noninfectious Virus-Like Particles with Reduced Cross-Reactivity," J. Clin. Microbiol., 45:3167-3174, (Oct. 2007). 9000141 21 Roehrig et al., "Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica," Virology 246(2):317-328 (1998). 9000141 22 Taniguchi et al., "Cross-reactive and serotype-specific neutralization epitopes on VP7 of human rotavirus: nucleotide sequence analysis of antigenic mutants selected with monoclonal antibodies," J. Virol. 62(6):1870-1874 (1988). 9000141 23 Trainor et al. "Mutation Analysis of the Fusion Domain Region of St. Louis Encephalitis Virus Envelope," Virology 360(2): 398-406 (2006). 9000141 24 Twiddy et al. "Phylogenetic evidence for adaptive evolution of dengue viruses in nature," Journal of General Virology 83: 1679-1689 (2002). 9000141 25 NCBI Protein Sequence: "Envelope glycoprotein [Dengue virus type 2]," Accession No. AAO26457 (Jun. 24, 2003) (2 pages). 9000141 26 NCBI Protein Sequence: "Genome polyprotein," Accession No. P09866 (Apr. 3, 2007) (10 pages). 9000141 27 NCBI Protein Sequence: "Polyprotein [Dengue virus type 2 (strain 16681)]," Accession No. AAB58782 (Jun. 4, 19997) (4 pages). 9000141 28 NCBI Protein Sequence: "Genome polyprotein," Accession No. P27915 (Apr. 3, 2007) (9 pages). 9000141 29 NCBI Protein Sequence: "Genome polyprotein," Accession No. P09732 (Apr. 3, 2007) (6 pages). 9000141 30 NCBI Protein Sequence: "Genome polyprotein," Accession No. P14335 (Mar. 20, 2007) (8 pages). 9000141 31 NCBI Protein Sequence: "Genome polyprotein," Accession No. P05769 (Mar. 20, 2007) (10 pages). 9000141 32 NCBI Protein Sequence: "Genome polyprotein," Accession No. P03314 (Apr. 3, 2007) (28 pages). 9000141 33 NCBI Protein Sequence: "Genome polyprotein," Accession No. Q04538 (Apr. 3, 2007) (9 pages). 9000142 1 Dmochoski et al., Taking control of gene expression with light-activated oligonucleotides. Biotechniques, 2007. 43(2): p. 161, 163, 165 passim. 9000142 2 Dussy et al., New light-sensitive nucleosides for caged DNA strand breaks. Chembiochem, 2002. 3(1): p. 54-60. 9000142 3 Mikat and Heckel, Light-dependent RNA interference with nucleobase-caged siRNAs. Rna, 2007. 9000142 4 Croock, Progress in Antisense Technology, Ann. Rev. Med. 55:61-95, 2004. 9000142 5 Nguyen et al., Light controllable siRNAs regulate gene suppression and phenotypes in cells. Biochim Biophys Acta, 2006. 1758(3): p. 394-403. 9000142 6 Shah et al. 1, Light-activated RNA interference. Angew Chem Int Ed Engl, 2005. 44(9): p. 1328-32. 9000142 7 Shah et al. 2, Tolerance of RNA Interference Toward Modifications of the 5.quadrature. Antisense Phosphate of Small Interfering RNA , Oligonucleotides, 17:35-43, 2007. 9000142 8 Shestopalov et al., Light-controlled gene silencing in zebrafish embryos. Nat Chem Biol, 2007. 3(10): p. 650-1. 9000142 9 Tang 1, Controlling RNA Digestion by RNase H with a Light-Activated DNA Hairpin. Angew. Chem, 2006. 45:3523-3526. 9000142 10 Tang 2, Regulating gene expression with light-activated oligonucleotides. Mol Biosyst, 2007. 3(2): p. 100-10. 9000142 11 Tang 3 Regulating gene expression in human leukemia cells using light-activated oligodeoxynucleotides Nucleic Acids Res., 2007. 136:559-569. 9000142 12 Tang 4, Phototriggering of Caged Fluorescent Oligodeoxynucleotides Organic Letters 2005 7:279-282. 9000142 13 Tang 5 Photoregulation of DNA polymerase I (Klenow) with caged fluorescent oligodeoxynucleotides Bioorganic Medicinal Chemistry Letters, 2005 15:5503-5506. 9000142 14 Wagner Gene inhibition using antisense oligodeoxynucleotides, Nature 1994 372:333-335. 9000143 1 European Search Report for European Patent Application No. EP 12189641, Mar. 27, 2013, 8 Pages. 9000143 2 Office Action for Canadian Patent Application No. CA 2,653,451, Mar. 25, 2013, 2 Pages. 9000143 3 Reynolds, et al. (2004) "Rational siRNA design for RNA interference," Nature Biotechnology, vol. 22, No. 3, pp. 326-330. 9000143 4 Weil, et al (2002) "Targeting the Kinesin Eg5 to Monitor siRNA Transfection in Mammalian Cells," Biotechniques 33(6):1244-1248. 9000143 5 Zimmerman, et al. (2006) "RNAi-mediated gene silencing in non-human primates," Nature, vol. 441, May 4: 111-114. 9000143 6 Office Action for Canadian Patent Application No. CA 2,653,451, Mar. 19, 2012, 2 pages. 9000143 7 Agrawal, S., et al., "Antisense oligonucleotides: towards clinical trials." Trends in Biotechnology. Oct. 1996, vol. 14, pp. 376-387. 9000143 8 Bass, B., "The short answer," Nature, May 24, 2001, pp. 428-429, vol. 411. 9000143 9 Elbashir, S., et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," Methods, 2002, pp. 199-213, vol. 26. 9000143 10 Elbashir, S., et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture," Nature, May 24, 2001, p. 494-498, vol. 411. 9000143 11 Elbashir, S., et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in Drosophila Melanogaster Embryo Lysate", The EMBO Journal, 2001, pp. 6877-6888, vol. 20, No. 23. 9000143 12 Elbashir, S., et al., "RNA Interference is Mediated by 21-and 22 Nucleotide RNAs," Genes & Development, 2001, pp. 188-200, vol. 15. 9000143 13 Fire, A., "RNA-triggered Gene Silencing," Trends in Genetics, Sep. 1999, pp. 358-363, vol. 15, No. 9. 9000143 14 Fire, A., et al., "Potent and Specific Genetic Interference by Double Stranded RNA in Caenorhabditis elegans," Nature, Feb. 19, 1998, pp. 806-811, vol. 391. 9000143 15 Robbins, M., et al., "Stable expression of shRNAs in human CD34+progenitor cells can avoid induction of interferon responses to siRNAs in vitro," Nature Biotechnology, May 2006, pp. 566-571, vol. 24, No. 5. 9000143 16 Rose, S., et al., "Functional polarity is introduced by Dicer processing of short substrate RNAs," Nucleic Acids Research, 2005, pp. 4140-4156, vol. 33, No. 13. 9000143 17 Tuschl, T., "Functional genomics: RNA sets the standard," Nature, Jan. 16, 2003, vol. 421, No. 6920, pp. 220-221. 9000143 18 Tuschl T., "RNA Interference and Small Interfering RNAs" Chembiochem, 2001, pp. 239-245, vol. 2. 9000143 19 Tuschl, T., et al., "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy," Molecular Interventions, 2002, pp. 158-167, vol. 2, No. 3. 9000143 20 Tuschl, T., "Mammalian RNA Interference," RNAi, a Guide to Gene Silencing, Chapter 13, G.J. Hannon (ed,), 2003, pp. 265-295. 9000143 21 Tuschl, T., et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," Genes & Development, 1999, pp. 3191-3197, vol. 13. 9000143 22 Tuschl, T., "Expanding small RNA interference," Nature Biotechnology, May 2002, pp. 446-448, vol. 20. 9000143 23 Vickers, T., et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," The Journal of Biological Chemistry, Feb. 28, 2003, pp. 7108-7118, vol. 278, No. 9. 9000143 24 Communication pursuant to Article 94(3) EPC, for European Patent Application No. EP 09015949.2, Apr. 8, 2011, 3 pages. 9000143 25 Office Action for Canada Patent Application No. CA 2,653,451, Jan. 18, 2011, 4 pages. 9000143 26 Hornung, V., et al., "Sequence-specific potent induction of Ifn-a by short interfering RNA in plasmacytoid dendritic cells throughTLR7," Nature Medicine, Mar. 2005, pp. 263-270, vol. 11, No. 3. 9000143 27 Judge, a., et al., "Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice," the Journal of Clinical Investigation, 2009, pp. 1-13. 9000144 1 Yi et al.: "A skin microRNA promotes differentiation repressing `stemness`", Nature, vol. 452, No. 7184, pp. 225-230 with supplementary information pp. 1-11, 2008. 9000144 2 Bueno et al.: "Genetic and Epigenetic Silencing of MicroRNA- 203 Enhances ABL1 and BCR- ABL1 Oncogene Expression", Cancer Cell, vol. 13, No. 6, pp. 496-506 with supplemental data pp. 1-10, 2008. 9000144 3 Najafi-Shoushtari et al.: "MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis", Science, vol. 328, No. 5985, pp. 1566-1569, 2010. 9000144 4 Rayner et al.: "rniR-33 contributes to the regulation of cholesterol homeostasis", Science, vol. 328, No. 5985, pp. 1570-1573, 2010. 9000144 5 Schetter et al.: "MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma", JAMA, vol. 299, pp. 425-436,2008. 9000144 6 Slaby et al.: "Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer", Oncology, vol. 72, pp. 397-402, 2007. 9000144 7 Qian et al.: "High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1", Breast Cancer Res Treat, vol. 117, pp. 131-140, 2009. 9000144 8 Yan et al.: "MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis", RNA, vol. 14, pp. 2348-2360, 2008. 9000144 9 Markou et al.: "Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR", Clin Chem, vol. 54, pp. 1696-1704, 2008. 9000144 10 Chan et al.: "miR-21 microRNA expression in human gastric carcinomas and its clinical association", Anticancer Res, vol. 28, pp. 907-911, 2008. 9000144 11 Gabriely et al.: "MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators", Mol Cell Biol, vol. 28, pp. 5369-5380, 2008. 9000144 12 Cordes et al.: "miR-145 and miR- 143 regulate smooth muscle cell fate decisions", Nature, vol. 460, No. 7256, pp. 705-710, 2009. 9000144 13 O'Connell et al.: "microRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development", Immunity, vol. 33, No. 4, pp. 607-619, 2010. 9000144 14 O'Connell et al.: "Sustained expression of microRNA-155 in hematopoietic stem cells causes a myelo proliferative disorder", The Journal of Experimental Medicine, vol. 205, No. 3, pp. 585-594, 2008. 9000144 15 Bhaumik et al.: "Expression of microRNA-146 suppresses NF-KB activity with reduction of metastatic potential in breast cancer cells", Oncogene, vol. 27, No. 42, pp. 5643-5647, 2008. 9000144 16 Labbaye et al.: "The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer", Journal of Hematology & Oncology, vol. 5, No. 13, 2012. 9000144 17 Jopling et al.: "Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA", Science, vol. 309, No. 5740, pp. 1577-1581, 2005. 9000144 18 Krutzfeldt et al.: "Silencing of microRNA in vivo with `antagomirs`", Nature, vol. 438, No. 7068, pp. 685-689, 2005. 9000144 19 Fabian et al.: "Regulation of MRNA Translation and Stability by microRNAs", Annu. Rev. Biochem., vol. 79, pp. 351-379, 2010. 9000144 20 Croce: "Causes and consequences of microRNA dysregulation in cancer", Nature Reviews Genetics, vol. 10, pp. 704-714, 2009. 9000144 21 Kwon et al.: "MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling", Proc. Natl. Acad. Sci., vol. 102, No. 52, pp. 18986-18991, 2005. 9000144 22 Zhao et al.: "Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis", Nature, 03817, doi:10.1038, pp. 1-7, 2005. 9000144 23 Zhao et al.: "Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2", Cell, vol. 129, pp. 303-317, 2007. 9000144 24 Liu et al.: "miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells", FEBS Letters, vol. 585, pp. 2998-3005, 2011. 9000144 25 Bonci.: "MicroRNA-21 as therapeutic target in cancer and cardiovascular disease.", Recent Pat Cardiovasc Drug Discov, vol. 5, No. 3, pp. 156-161, 2010, (Abstract). 9000144 26 van Rooij et al.: "Searching for MiR-acles in Cardiac Fibrosis", Circ. Res., vol. 104, pp. 138-140, 2009. 9000144 27 Bracken et al.: "A Double-Negative Feedback Loop between ZEB1-SIP1 and the microRNA-200 Family Regulates Epithelial┤Mesenchymal Transition", Cancer Research, vol. 68, No. 19, pp. 7846-7854, 2008. 9000144 28 Kong et al.: "miR-200 Regulates PDGF-D-Mediated Epithelial- Mesenchymal Transition, Adhesion, and Invasion of Prostate Cancer Cells", Stem Cells, vol. 27, pp. 1712-1721, 2009. 9000144 29 Hurteau et al.: "Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E-cadherin expression", Cell Cycle, vol. 8, No. 13, pp. 2064-2069, 2009. 9000144 30 Adam et al.: "miR-200 Expression Regulates Epithelial-to- Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy", Clin. Cancer Res., vol. 15, No. 16, pp. 5060-5072, 2009. 9000144 31 Garzon et al.: "MicroRNA 29b functions in acute myeloid leukemia", Blood, vol. 114, No. 26, pp. 5331-5341, 2009. 9000144 32 Mott et al.: "mir-29 Regulates Mcl- 1 Protein Expression and Apoptosis", Oncogene, vol. 26, No. 42, pp. 6133-6140, 2007. 9000144 33 Fabbri et al.: "MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B", PNAS, vol. 104, No. 40, pp. 15805-15810, 2007. 9000144 34 Webster et al: "Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7", Journal of Biological Chemistry, vol. 284, No. 9, pp. 5731-5741, 2009. 9000144 35 Kefas et al.: "microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and is Down-regulated in Glioblastoma", Cancer Res, vol. 68, No. 10, pp. 3566-3572, 2008. 9000144 36 Elia et al.: "The knockout of miR- 143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease", Cell Death Differ., vol. 16, No. 12, pp. 1590-1598, 2009. 9000144 37 Cheng et al.: "MicroRNA-145, a Novel Smooth Muscle Cell Phenotypic Marker and Modulator, Controls Vascular Neointimal Lesion Formation", Circulation Research, No. 105, pp. 158-166 with supplemental material pp. 1-12, 2009. 9000144 38 Rangrez et al.: "miR-143 and miR- 145: Molecular Keys to Switch the Phenotype of Vascular Smooth Muscle Cells", Circ Cardiovasc Genet, vol. 4, pp. 197-205, 2011. 9000144 39 Printout from www.medjournalarticles.com/ dissertation/3172, MiR-188-5p Suppresseses Tumor Cell Proliferation and Metastasis by Directly Targeting AAC11 in Hepatocellular Carcinoma, 2012, 8 pgs. 9000144 40 Bernstein et al., Role for a bidentate ribonuclease in the initiation step of RNA interference, Jan. 18, 2001, Nature, vol. 409, pp. 363-366. (Abstract). 9000144 41 Elbashir et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, May 2001, Nature vol. 411, pp. 494-498. 9000144 42 Grishok, A., et al., "Genes and Mechanisms Related to RNA Interference Regulate Expression of the Small Temporal RNAs that Control elegans Developmental Timing," Cell 106:23-34 (Jul. 13, 2001). (Abstract). 9000144 43 Hammond, et al., "An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells," Nature 404:293-296 (Mar. 16, 2000). 9000144 44 Hammond, et al., "Argonaute2, a Link Between Genetic and Biochemical Analyses of RNAi," Science, 293:1146-1150 (Aug. 10, 2001). (Abstract). 9000144 45 Hamilton et al., A species of small antisense RNA in posttranscriptional gene silencing in plants, Oct. 29, 1999, Science, vol. 286, pp. 950-952. (Abstract). 9000144 46 Hutvagner, et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA," Science, 293:834-838 (Aug. 3, 2001). (Abstract). 9000144 47 Tabara, H., et al., "The rde-1 Gene, RNA Interference, and Transposon Silencing in C. elegans," Cell 99:123-132 (Oct. 15, 1999). 9000144 48 Zamore, P.D., et al., "RNAi Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," Cell, 101(1):25-33, Cell Press, Cambridge, Massachusetts, US (Mar. 31, 2000), XP-002208683. 9000144 49 Ambros et al., "Heterochronic mutants of the nematode Caenorhabditis elegans", Science, vol. 226, No. 409-416, 1984. 9000144 50 Ambros, "Control of developmental timing in Caenorhabditis elegans", Current Opinion in Genetics & Development, vol. 10, 2000, p. 428-433. 9000144 51 Aravin et al., "Double-stranded RNA-mediated silencing of genomic tandem repeats and transposable elements in the D. melanogaster germline", Current Biology, 2001, 11, pp. 1017-1027. 9000144 52 Argaman et al., "Novel small RNA-encoding genes in the intergenic regions of Escherichia coli", Current Biology, 2001, 11: pp. 941-950. 9000144 53 Calin et al., "Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers", PNAS, Mar. 2, 2004, vol. 101, No. 9, pp. 2999-3004. 9000144 54 Chomczynski et al., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction", Analytical Biochemistry, 162, 1987, pp. 156-159. 9000144 55 Chu et al., "Electroporation for the efficient tranfection of mammalian cells with DNA", Nucleic Acids Research, 1987, 15 (3), Abstract. 9000144 56 Ebby, "Noncoding RNA genes", Current Opinion in Genetics & Development, vol. 9, 1999, (Abstract). 9000144 57 Fagard et al., "AG01, QDE-2, and RDE-1 are related proteins required for post-transcriptional gene silencing in plants, quelling in fungi, and RNA interference in animals", PNAS, Oct. 10, 2000, vol. 97, No. 21, pp. 11650-11654. 9000144 58 Feinbaum et al., "The Timing of lin-4 RNA Accumulation Controls the Timing of Postembryonic Developmental Events in Caenorhabditis elegans", Developmental Biology, 210, (1999), pp. 87-95. 9000144 59 Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", Proc. Natl. Acad. Sci., vol. 84, Nov. 1987, pp. 7413-7417. 9000144 60 Fraley et al., "Introduction of Liposome-encapsulated SV40 DNA into Cells", The Journal of Biological Chemistry, vol. 255, No. 21, Nov. 10, 1980, pp. 10431-10435. 9000144 61 Gauwerky et al., "Activation of MYC in a masked t (8;17) translocation results in an aggressive B-cell Leukemia", Proc. Natl. Acad. Sci., vol. 86, Nov. 1989, pp. 8867-8871. 9000144 62 Graham et al., "A new technique for the assay of infectivity of human adenovirus 5 DNA", vol. 52, Virology, Apr. 1973, p. 456 (Abstract). 9000144 63 Hallam et al., "lin-14 regulates the time of synaptic remodelling in Caenorhabditis elegans", Nature, Sep. 3, 1998, 395, pp. 78-82 (Abstract). 9000144 64 Huettenhofer et al., "RNomics: an experimental approach that identifies 201 candidates for novel, small, non-messenger RNAs in mouse", The EMBO Journal, vol. 20, No. 11, 2001, pp. 2943-2953. 9000144 65 Kallioniemi et al., "Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization", Proc. Natl. Acad. Sci., vol. 91, Mar. 1994, pp. 2156-2160. 9000144 66 Ketting et al., "Dicer functions in RNA interfernce and in synthesis of small RNA involved in developmental timing in C. elegans", Genes Dev., 2001, 15; pp. 2654-2659. 9000144 67 Lau et al., "An Abudant Class of Tiny RNAs with Probable Regulatory Roles in Caenorhabditis elegans", Science, Oct. 26, 2001, vol. 294, No. 5543, pp. 858-862. 9000144 68 Lee et al., "Fluorobenzamidrazone thrombin inhibitors: Influence of Fluorine on Enhancing Oral Absorption", Bioorganic & Medicinal Chemistry Letters, 9 (1999), pp. 2483-2486. 9000144 69 Matthews et al., "Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure", 288, 1999, p. 911. 9000144 70 McCutchan et al, Enhancement of the Infectivity of Simian Virus 40 Deoxyribonucleic Acid with Diethylaminoethyl-Dextran2, JNCI J Natl Cancer Inst (1968) 41, (2), pp. 351-357. 9000144 71 Meng et al., "miR-194 is a Marker of Hepatic Epithelial Cells and Suppresses Metastasis of Liver Cancer Cells in Mice", Haptology, vol. 52, No. 6, 2010, pp. 2148-2157. 9000144 72 Monni et al., "Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer", PNAS, May 8, 2001, vol. 98, No. 10, pp. 5711-5716. 9000144 73 Moss, "Non-coding RNAs: Lightning strikes twice", Current Biology, 2000, 10, pp. R436-R439. 9000144 74 Mourelatos et al., "miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs", Genes Dev., 2002, 16: pp. 720-728. 9000144 75 Rougvie, "Control of developmental timing in animals", Nature Reviews Genetics, Sep. 2001, 2, pp. 690-701. 9000144 76 Schneider et al., "Cell lines derived from late embryonic stages of Drosophila melanogaster", J. Embryol. Exp. Morph., 1972, vol. 27, 2, pp. 353-365. 9000144 77 Slack et al., "Temporal Pattern Formation by Heterochromic Genes", Genetics, vol. 1, 1997, Abstract. 9000144 78 Tam, "Identification and characterization of human BIC, a gene on chromosome 21, that encodes a noncoding RNA", Gene, 274, 2001, Abstract. 9000144 79 Wassarman et al., "Identification of novel small RNAs using comparative genomics and microarrays", Genes & Development, 15, 2001, pp. 1637-1651. 9000144 80 Wightman et al., "Posttranscriptional Regulation of the Heterochronic Gene lin-14 by lin-4 Mediates Temporal Pattern Formation in C. elegans", Cell, vol. 75, Dec. 3, 1993, pp. 855-862. 9000144 81 Wu et al., "17q23 Amplifications in Breast Cancer Involve the PAT1, RAD51C, PS6K, and SIGMA1B Genes", Cancer Res., 2000, 60: pp. 5371-5375. 9000144 82 Capecchi et al., "High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells", Cell, vol. 22, Nov. 1980, pp. 479-488. 9000144 83 Catalanotto et al, "Gene Silencing in worms and fungi", Nature, vol. 404, Mar. 16, 2000, p. 245. 9000144 84 Cavaille et al., "Identificaton of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization", PNAS, vol. 97, No. 26, Dec. 19, 2000, pp. 14311-14316. 9000144 85 Wu et al.: ,,Suppression of cell growth and invasion by rniR-205 in breast cancer, Cell Research, vol. 19, 2009, pp. 439-448. 9000144 86 Iorio et al.: ,,MicroRNA Signatures in Human Ovarian Cancer,Cancer Research, vol. 67, No. 18, 2007, pp. 8699-8707. 9000144 87 Calin et al.: "Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia", PNAS, vol. 99, No. 24, Nov. 26, 2002, pp. 15524-15529. 9000144 88 Chan et al.: "MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells", Cancer Research, No. 65, vol. 14, Jul. 15, 2005, pp. 6029-6033. 9000144 89 Kulshreshtha et al.: "A MicroRNA Signature of Hypoxia", Molecular and Cellular Biology, No. 27, 2007, pp. 1859-1867. 9000144 90 Van Rooij et al.: "Dysregulation of rnicroRNAs after myocardial infarction reveals a role of rniR-29 in cardiac fibrosis", PNAS, vol. 105, No. 35, Sep. 2, 2008, pp. 13027-13032. 9000144 91 Database Geneseq [Online] Aug. 8, 1996 S. Mutants antigen I/II (aa1024-1044) DNA., retrieved from EBI accession No. GSN:AAT36119, Database accession No. AAT36119. 9000144 92 Database Geneseq [Online] Aug. 2, 2001 Human cardiovascular system antigen genomic DNA SEQ ID No. 1605., retrieved from EBI accession No. GSN:AAS36105, Database accession No. AAS36105. 9000144 93 Database Geneseq [Online] Apr. 19, 2001 "Tobacco rpL34 promoter region.", retrieved from EBI accession No. GSN:AAH19667, Database accession No. AAH19667. 9000144 94 Database Geneseq [Online] Aug. 9, 2001 "Human immune/haernatopoietic antigen genomic sequence SEQ ID No. 34996.", retrieved from EBI accession No. GSN:AAK80184, Database accession No. AAK80184. 9000144 95 Kusenda et al.: ,,MicroRNA Biogenesis, Functionality and Cancer Relevance, Biorned Pap Med Fac Univ Palacky Olomouc Czech Repub., vol. 150, No. 2, 2006, pp. 205-215. 9000144 96 Cheng et al.: ,,Antisense inhibition of human rniRNAs and indications for an involvement of rniRNA in cell growth and apoptosis, Nucleic Acids 2005 Researc1290-1297h, vol. 33, No. 4 pp. 1290-1297. 9000144 97 Wang et al.: ,,Prostate apoptosis response protein 4 sensitizes human colon cancer cel,s to chemotherapeutic 5-FU through mediation of an NFKB and microRNA network, Molecular Cancer, vol. 9, No. 98, 2010, pp. 1-19. 9000144 98 Wahlestedt et al., "Potent and nontoxic antisense oligonucleotides containing locked nucleic acids", PNAS, 2000, vol. 97, No. 10, pp. 5633-5638. 9000144 99 DATABASE Geneseq [Online] Jul. 15, 2002, "Human spliced transcript detection oligonucleotide SEQ ID No. 7641.", XP002671443, retrieved from EBI accession No. GSN:ABN34893 Database accession No. ABN34893. 9000144 100 DATABASE Geneseq [Online] Jun. 24, 2002, "Human ORFX polynucleotide sequence SEQ ID No. 19021.", XP002671444, retrieved from EBI accession No. GSN:ABN25272 Database accession No. ABN25272. 9000144 101 DATABASE Geneseq [Online] Feb. 13, 2002, "DNA encoding novel human diagnostic protein #421.", XP002671445, retrieved from EBI accession No. GSN:AAS64617 Database accession No. AAS64617. 9000144 102 Ambros V: "microRNAs: Tiny Regulators with Great Potential" Cell, Cell Press, Cambridge, NA, US LNKD DOI:10.1016/S0092-8674(01)00616-X, vol. 107, Dec. 28, 2001, pp. 823-826, XP002978397 ISSN: 0092-8674. 9000144 103 DATABASE EMBL [Online] Oct. 20, 2000, "CM1-HT0877-190900-426-b01 HT0877 Homo sapiens cDNA, mRNA sequence." XP002591547 retrieved from EBI accession No. EMBL:BF088470 Database accession No. BF088470. 9000144 104 DATABASE Geneseq [Online] Jun. 26, 2001, "Human cDNA sequence SEQ ID No. 13278." XP002591548 retrieved from EBI accession No. GSN:AAH15188, Database accession No. AAH15188. 9000144 105 DATABASE Geneseq [Online] Aug. 8, 1996 "S. mutans antigen I/II (aa1024-1044) DNA.", XP002659848, retrieved from EBI accession No. GSN:AAT36119 Database accession No. AAT36119. 9000144 106 DATABASE Geneseq [Online] D, Aug. 2, 2001, "Human cardiovascular system antigen genomic DNA SEQ ID No. 1605.", XP002659849, retrieved from EBI accession No. GSN:AAS36105 Database accession No. AA536105. 9000144 107 DATABASE Geneseq [Online] Aug. 2, 2001,Human reproductive system related antigen DNA SEQ ID No. 5635.11,XP002668053,retrieved from EBI accession No. GSN:AAL02947 Database accession No. AAL02947. 9000144 108 DATABASE Geneseq [Online] Feb. 7, 2002, "Human spliced transcript detection oligonucleotide SEQ ID No. 5959.", XP002668054,retrieved from EBI accession No. GSN:ABN33211 Database accession No. ABN33211. 9000144 109 DATABASE Geneseq [Online] Sep. 13, 2001, "Novel human)diagnostic and therapeutic gene #2158.", XP002668055, retrieved from EBI accession No. GSN:AAS39100 Database accession No. AAS39100. 9000144 110 DATABASE Geneseq [Online] Aug. 9, 2001, "Probe #3307 used to measure gene expression in human breast sample.", XP002668109, retrieved from EBI accession No. GSN:AAI03316 Database accession No. AAI03316. 9000144 111 DATABASE Geneseq [Online] Aug. 9, 2001, "Human brain expressed single exon probe SEQ ID No. 3386.", XP002668176, retrieved from EBI accession No. GSN:AAK03395 Database accession No. AAK03395. 9000144 112 DATABASE Geneseq [Online] Aug. 9, 2001, "Probe #14654 for gene expression analysis in human heart cell sample.", XP002668111, retrieved from EBI accession No. GSN:ABA36188 Database accession No. ABA36188. 9000144 113 DATABASE Geneseq [Online] Aug. 5, 1999, "Human gene expression product cDNA sequence SEQ ID No. 1651.", XP002668167, retrieved from EBI accession No. GSN:AAZ14182 Database accession No. AAZ14182. 9000144 114 DATABASE Geneseq [Online] Aug. 5, 1999, "Human gene expression product cDNA sequence SEQ ID No. 5028.", XP002668168, retrieved from EBI accession No. GSN:AAZ17555 Database accession No. AAZ17555. 9000144 115 DATABASE Geneseq [Online] May 10, 2001, "Gene expression profile sequence #181.", XP002668169, retrieved from EBI accession No. GSN:AASO4681 Database accession No. AASO4681. 9000144 116 DATABASE Geneseq [Online] Aug. 2, 2001, "Human EST-derived coding sequence SEQ ID No. 908.", XP002668164, retrieved from EBI accession No. GSN:AAH99051 Database accession No. AAH99051. 9000144 117 DATABASE Geneseq [Online] Oct. 11, 2001, "DNA encoding novel human diagnostic protein #4753.", XP002668165, retrieved from EBI accession No. GSN:AAS68949 Database accession No. AAS68949. 9000144 118 DATABASE Geneseq [Online] Jul. 28, 1993, "HIV-1 gag gene branched probe strand 2 forms structure 1.", XP002668166, retrieved from EBI accession No. GSN:AAQ54102 Database accession No. AAQ54102. 9000144 119 DATABASE Geneseq [Online] R 4 Sep. 27, 2001, "Drosophila melanogaster genomic polynucleotide SEQ ID No. 10495.", XP002668047, retrieved from EBI accession No. GSN:ABL19674 Database accession No. ABL19674. 9000144 120 DATABASE Geneseq [Online] 2 Sep. 21, 2000, "Human cancer associated gene sequence SEQ ID No. 356.", XP002668268, retrieved from EBI accession No. GSN:AAC77962 Database accession No. AAC77962. 9000144 121 DATABASE Geneseq [Online] R6 Aug. 6, 1998, "LM609 antibody light chain variable region DNA fragment.", XP002668049, retrieved from EBI accession No. GSN:AAV49823 Database accession No. AAV49823. 9000144 122 DATABASE Geneseq [Online] Sep. 27, 2001, "Drosophila melanogaster genomic polynucleotide SEQ ID No. 10495.", XP002668047, retrieved from EBI accession No. GSN:ABL19674 Database accession No. ABL19674. 9000144 123 DATABASE Geneseq [Online] Sep. 21, 2000, "Human cancer associated gene sequence SEQ ID No. 356.", XP002668268, retrieved from EBI accession No. GSN:AAC77962 Database accession No. AAC77962. 9000144 124 DATABASE Geneseq [Online] Aug. 6, 1998, "LM609 antibody light chain variable region DNA fragment.", XP002668049, retrieved from EBI accession No. GSN:AAV49823 Database accession No. AAV49823. 9000144 125 DATABASE.Geneseq [Online] Dec. 15, 1982, "Partial RNA sequence corresponding to cattle pre-somatotropin.", XP002659796, retrieved from EBI accession No. GSN:AAN20038 Database accession No. AAN20038. 9000144 126 DATABASE GENESEQ [Online] Jan. 25, 2001, "Mouse glycosyl sulfotransferase-6 (GST-6) genomic DNA.", XP002659797, retrieved from EBI accession No. GSN:AAD02705 Database accession No. AAD02705. 9000144 127 DATABASE Geneseq [Online] Aug. 2, 2001, "Human cardiovascular system antigen genomic DNA SEQ ID No. 2411.", XP002659798, retrieved from EBI accession No. GSN:AAS36911 Database accession No. AAS36911. 9000144 128 DATABASE Geneseq [Online] Feb. 7, 2002, "Mouse spliced transcript detection oligonucleotide SEQ ID No. 24151.", XP002659630, retrieved from EBI accession No. GSN:ABN51403 Database accession No. ABN51403. 9000144 129 DATABASE Geneseq [Online] Aug. 9, 2001, "Human immune/haematopoietic antigen encoding cDNA SEQ ID No. 9362.", XP002659777, retrieved from EBI accession No. GSN:AAK64302 Database accession No. AAK64302. 9000144 130 DATABASE Geneseq [Online] Oct. 23, 1997, "Streptococcus pneumoniae leucyl tRNA synthetase gene.", ../ XP002659778, retrieved from EBI accession No. GSN:AAT88991 Database accession No. AAT88991. 9000144 131 DATABASE Geneseq [Online] Jul. 5, 2001, "Human SNP oligonucleotide #288.", XP002659790, retrieved from EBI accession No. GSN:AAL27080 Database accession No. AAL27080. 9000144 132 DATABASE Geneseq [Online] Aug. 9, 2001, "Human immune/haematopoietic antigen genomic sequence SEQ ID No. 22901.", XP002659791, retrieved from EBI accession No. GSN:AAK68089 Database accession No. AAK68089. 9000144 133 DATABASE Geneseq [Online] Oct. 28, 1999, "D. pteronyssius 98 kD mite allergen gene nDerp98-1470 complement.", XP002659792, retrieved from EBI accession No. GSN:AAZ38590 Database accession No. AAZ38590. 9000144 134 DATABASE Geneseq [Online] Aug. 16, 2001, "Human 6-finger VEGF3a/1 DNA constructing oligonucleotide.", XP002659780, retrieved from EBI accession No. GSN:AAD15343 Database accession No. AAD15343. 9000144 135 DATABASE Geneseq [Online] Sep. 27, 2001, "Drosophila melanogaster expressed polynucleotide SEQ ID No. 4649.", XP002659781, retrieved from EBI accession No. GSN:ABL03389 Database accession No. ABL03389. 9000144 136 DATABASE Geneseq [Online] Oct. 19, 1995, "Amplification primer BK83.", XP002659793, retrieved from EBI accession No. GSN:AAT08183 Database accession No. AAT08183. 9000144 137 DATABASE Geneseq [Online] Sep. 30, 1999, "Tobacco plant resistance-associated cDNA fragment 81.", XP002659794, retrieved from EBI accession No. GSN:AAZ33756 Database accession No. AAZ33756. 9000144 138 Quintana et al., "Identification of Novel Genes Coding for Small Expressed RNAs", Science, vol. 294, Oct. 26, 2001, pp. 853-858. 9000144 139 Lee et al., "An Extensive Class of Small RNAs in Caenorhabditis elegans", Science, vol. 294, Oct. 26, 2001, pp. 862-864. 9000144 140 Elbashir et al., "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lystae", The EMBO Journal, vol. 20, No. 23, pp. 6877-6888, 2001. 9000144 141 Drosophila melanogaster sequence (P1 DS08416(D52)), complete sequence; retrieved from Database EMBL Accession No. AC 002442 (Mar. 3, 2000). 9000144 142 Krutzfeldt et al, Strategies to determine the biological function of microRNAs, 2006, Nature Genetics, vol. 37, No. 11, pp. 1163-1165. 9000144 143 Cullen, RNAi the natural wayy, 2005, Nature Genetics, vol. 37, No. 11, pp. 1163-1165. 9000144 144 Lee et al., The C. elegans Heterochronic Gene lin-4 Encodes Small RNAs with Antisense Complementarity to lin-14, 1993, Cell, vol. 75, pp. 843-854. 9000144 145 Marra et al., AA209594, EST Feb. 18, 1997, see search results labeled "20090122--121332--US-11-747-409-88.rst", result #3 in SCPOPE (enclosed in office action). 9000144 146 Pasquinelli et al., "Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA", Nature, vol. 408, No. 6808, 2000, pp. 86-89. 9000144 147 Reinhart et al., "The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans", Nature, vol. 403, No. 6772, Feb. 24, 2000, pp. 901-906. 9000144 148 Moss et al., "The cold shock domain protien LIN-28 controls developmental timing in C. elegans is rgulated by the lin-4 RNA", Cell, vol. 88, No. 5, 1997, pp. 637-646. 9000144 149 GenBank accession No. AE014298, Mar. 15, 2004. 9000144 150 GenBank accession No. AC101777, Nov. 23, 2001. 9000144 151 GenBank accession No. AL392165, Sep. 11, 2001. 9000144 152 GenBank accession No. AL35585, Jul. 25, 2001. 9000144 153 Ambros et al.: "A uniform system for microRNA annotation", RNA, vol. 9, 2003, pp. 277-279. 9000144 154 Farazi et al.: "miRNAs in human cancer", Journal of Pathology, vol. 223, 2011, pp. 102-115. 9000144 155 Teng et al.: "Shhh! Silencing by microRNA-155", Phil. Trans. R. Soc. B, vol. 364, 2009, pp. 631-637. 9000144 156 GenBank accession No. AL355858, Jul. 25, 2001. 9000144 157 Elbashir et al., "RNA interference is mediated by 21-and 22-nucleotide RNAs", Genes & Development, 2001, 15: pp. 188-200. 9000144 158 GenBank accession No. AA208709.1, mu64c06.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone IMAGE:64417, 1 page, Jan. 29, 1997. 9000144 159 GenBank accession No. BF018533.1, uy62c07.y1 McCarrey Eddy round spermatid Mus musculus cDNA clone IMAGE:3664140, 1 page, Dec. 29, 2000. 9000144 160 GenBank accession No. BE420487.1, SWOvL2CASO9G08SK Onchocerca volvulus L2 larvae cDNA Onchoc SWOvL2CASO9G08 5-, mRNA sequence, 1 page, Jul. 24, 2000. 9000145 1 Choi et al, Proc. Nat'l. Acad. Sci., vol. 100, No. 17, pp. 9721-9726 (2003). 9000146 1 Parham et al. (Specific Magnetic Bead--Based Capture of Genomic DNA from Clinical Samples: Application to the Detection of Group B Streptococci in Vaginal/Anal Swabs, Clinical Chemistry 53:9 1570-1576 (2007)). 9000146 2 Traverso et al. (Detection of Apc Mutations in Fecal Dna From Patients With Colorectal Tumors, N Engl J Med, vol. 346, No. 5, Jan. 31, 2002). 9000146 3 Whitney et al. (Enhanced Retrieval of DNA from Human Fecal Samples Results in Improved Performance of Colorectal Cancer Screening Test, JMD Nov. 2004, vol. 6, No. 4). 9000146 4 Verweij et al. (Detection and Identification of Entamoeba Species in Stool Samples by a Reverse Line Hybridization Assay, Journal of Clinical Microbiology, Nov. 2003, p. 5041-5045). 9000146 5 PVP in Stool Samples (hereinafter "PVP"; attached, Nov. 20, 2006). 9000146 6 Laboratory for Environmental Pathogens Research Department of Environmental Sciences University of Toledo ("Polyvinylpyrrolidone (PVPP) cleanup of DNA samples," Dec. 2004). 9000146 7 Berthelet et al. (Rapid, direct extraction of DNA from soils for PCR analysis using polyvinylpolypyrrolidone spin columns, FEMS Microbiology Letters 138 (1996) 17-22). 9000146 8 Fotedar et al. (Laboratory Diagnostic Techniques for Entamoeba Species, Clinical Microbiology Reviews, Jul. 2007, p. 511-532). 9000146 9 Morgan et al. (Comparison of PCR and Microscopy for Detection of Cryptosporidium parvum in Human Fecal Specimens: Clinical Trial, Journal of Clinical Microbiology, Apr. 1998, p. 995-998). 9000146 10 PVPP Sigma-Aldrich (hereinafter "PVPP Sigma"; attached, accessed Jun. 26, 2013). 9000146 11 Ahlquist et al., "HemoQuant, a new quantitative assay for fecal hemoglobin. Comparison with Hemoccoult," Ann Intern Med, 1984, 101:297-302. 9000146 12 Ballabio, et al., "Screening for steroid sulfatase (STS) gene deletions by multiplex DNA amplification," Human Genetics, 1990, 84(6): 571-573. 9000146 13 Barnay, "Genetic disease detection and DNA amplification using cloned thermostable ligase," Proc. Natl. Acad. Sci USA, 1991, 88:189-93. 9000146 14 Beaucage et al., "Deoxynucleoside phosphoramidites--A new class of key intermediates for deoxypolynucleotide synthesis," Tetrahedron Lett., 1981, 22: 1859-1862. 9000146 15 Brown et al., "Chemical synthesis and cloning of a tyrosine tRNA gene," Meth Enzymol., 1979, 68:109-151. 9000146 16 Bustin, "Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays," J. Molecular Endocrinology, 2000, 25:169-193. 9000146 17 Chamberlain et al., "Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification," Nucleic Acids Research, 1988, 16(23):11141-11156. 9000146 18 Don et al., "`Touchdown` PCR to circumvent spurious priming during gene amplification," Nucleic Acids Research, 1991, 19(14):4008. 9000146 19 Guilfoyle et al., "Ligation-mediated PCR amplification of specific fragments from a class-II restriction endonuclease total digest," Nucleic Acids Research, 1997, 25:1854-1858. 9000146 20 Haaf et al., "Polymers of N-vinylpyrrolidone: synthesis, characterization, and uses," Polymer J., 1985, 17(1):143-152. 9000146 21 Hall et al., "Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction," PNAS, 2000, 97:8272. 9000146 22 Hayden et al., "Multiplex-Ready PCR: A new method for multiplexed SSR and SNP genotyping," BMC Genomics, 2008, 9:80. 9000146 23 Hecker et al., "High and low annealing temperatures increase both specificity and yield in touchdown and stepdown PCR," Biotechniques, 1996, 20(3):478-485. 9000146 24 Herman et al., "Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands," PNAS, 1996, 93(13):9821-9826. 9000146 25 Higuchi et al., "A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions," Nucleic Acids Research, 1988, 16(15):7351-7367. 9000146 26 Higuchi et al.,"Kinetic PCR analysis: real-time monitoring of DNA amplification reactions," Biotechnology, 1993, 11:1026-1030. 9000146 27 Higuchi et al., "Simultaneous amplification and detection of specific DNA sequences," Biotechnology, 1992, 10:413-417. 9000146 28 Kalinina et al., "Nanoliter scale PCR with TaqMan detection," Nucleic Acids Research, 1997, 25:1999-2004. 9000146 29 Lyamichev et al., "Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes," Nat. Biotech., 1999, 17:292-296. 9000146 30 Matteucci et al., "Synthesis of deoxyoligonucleotides on a polymer support," J Am Chem Soc., 1981, 103:3185-3191. 9000146 31 Morgan et al., "Comparison of PCR and microscopy for detection of Cryptosporidium parvum in human fecal specimens: Clinical trial.," J. Clin. Microbiol., 1998, 36(4):995. 9000146 32 Narang et al., "Improved phosphotriester method for the synthesis of gene fragments," Meth Enzymol., 1979, 68: 90-98. 9000146 33 Rehmanji et al., "A novel stabilization of beer with Polyclar Brewbrite," MBAA TQ, 2002, 39(1):24-28. 9000146 34 Roux, "Using mismatched primer-template pairs in touchdown PCR," Biotechniques, 1994, 16(5):812-814. 9000146 35 Schouten et al., "Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification," Nucleic Acids Research, 2002, 30(12): e57. 9000146 36 Shames et al., "Identification of widespread Heliobacter hepaticus infection in feces in commercial mouse colonies by culture and PCR assay," J. Clin. Mocrobiol, 1995, 33(11):2968-72. 9000146 37 Stone et al., "Detection of rRNA from four respiratory pathogens using an automated Qbeta replicase assay," Mol Cell Probes, 1996, 10:359-370. 9000146 38 Triglia et al., "A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences," Nucleic Acids Res., 1988, 16:8186. 9000146 39 Vogelstein et al., "Digital PCR," PNAS, 1999, 96: 9236-41. 9000146 40 International Search Report and Written Opinion, mailed Apr. 16, 2013, for International Patent Application PCT/US2012/037581, 21 pages. 9000146 41 Ahlquist et al., "Colorectal Cancer Screening by Detection of Altered Human DNA in Stool: Feasibility of a Multitarget Assay Panel," Gastroenterology, 2000, 119: 1219-1227. 9000146 42 Andreadis and Chrisey, "Use of immobilized PCR primers to generate covalently immobilized DNAs for in vitro transcription/translation reactions," Nucleic Acids Res, 2000, 28:e5, 8 pages. 9000146 43 Fotedar et al., "Labratory Diagnostic Techniques for Entamoeba Species," Clinical Microbiology Reviews, 2007, 20 (3):511-53. 9000146 44 Mangiapan et al. "Sequence Capture-PCR Improves Detection of Mycobacterial DNA in Clinical Specimens," Journal of Clinical Microbiology, 1996, 34. p. 1209-1215. 9000146 45 Qiagen, QIAamp DNA Stool Mini Kit Handbook, Aug. 2001, 40 pages. 9000146 46 QIAamp.RTM. genomic DNA Kits, product information, Apr. 2008, 12 pages. 9000146 47 SIGMA-Aldrich Poly(vinylpolypyrrolidone) product information, retrieved Jun. 26, 2013, 2 pages. 9000146 48 St. John et al., "Rapid capture of DNA targets," BioTechniques, 2008, 44:259-264. 9000146 49 Stratagene, Gene Characterization Kits, product information, 1988, 2 pages. 9000146 50 Weiner et al., "Kits and their unique role in molecular biology: a brief retrospective," Biotechniques, 2008, 44:701-704. 9000146 51 Aquamira Technologies, "Some Important Words in Regards to Filter Ratings," retrived Oct. 3, 2014. 9000146 52 Cullen et al., "Simple and rapid method for direct extraction of microbila DNA from soil for PCR", Soil Biology and Biochemistry, vol. 30, No. 8/9, 1998, pp. 983-993. 9000146 53 Doulton USA, "Absolute Vs. Nominal Microns Pore Ratings," Retrieved Oct. 3, 2014, from http;//doultonusa.com/ HTML pages/absolute--vs--nominal--microns--rating--htm. 9000146 54 European Search Report dated Oct. 27, 2014, EP Patent Application No. 12782489.4, 9 pages. 9000146 55 Lenntech B.V., "Absolute rating vs. nominal rating for filters," www.lenntech.com/library/fine/absolute/absolute-nominal-filters.htm, retrieved Oct. 3, 2014, 1 page. 9000146 56 Zhang et al., "An improved method for purifying genomic DNA from forest leaf litters and soil suitable for PCR", Journal of Soils and Sediments, 2009, vol. 9, No. 3, pp. 261-266. 9000147 1 Riemschneider et al. Bochu Kagaku Kekyusho, 1976; 41(3): 99-106. 9000147 2 Testa et al. Hydrolysis in Drug and Prodrug Metabolism, John Wily & Sons, Sep. 2003, Chapter 8, pp. 419-534, and Chapter 4, pp. 81-162. 9000147 3 Atkinson et al. J. Chem. Soc., 1965, 610-615. 9000147 4 Yang, J. Med. Chem. 2007, 50, 6458-646. 9000147 5 Mel'nikova et al. Zhurnal Obshchei Khimii (1967), 37(7), 1507-11. 9000147 6 Plasman et al. J. Nat. Prod.I 2000, 63, 1261-1264. 9000147 7 Jarman et al. J. Chem. Soc. (C), 1960, pp. 199-203. 9000147 8 Friedlos et al. Biochemical Pharmacology, vol. 44, No. 1, pp. 25-31, 1992. 9000147 9 Araki et al., Science, 305: 1010-1013 (Aug. 13, 2004). 9000147 10 Davies et al., Nucleosides and Nucleotides, 14(3-5): 311-312 (1995). 9000147 11 Esmans et al., Biomed. Mass Spectrom., 7 (9): 377-380 (1980). 9000147 12 Franchetti et al., Bioorg. Med. Chem. Lett., 14: 4655-4658 (2004). 9000147 13 Franchetti et al., Bioorg. Med. Chem., 13: 2045-2053 (2005). 9000147 14 Freyne et al., Carbohydr. Res., 78: 235-242 (1980). 9000147 15 Freyne et al., J. Carbohydr. Nucleos. Nucleot., 3 (3): 113-128 (1976). 9000147 16 Greene, Protective Groups in Organic Synthesis, Third Edition (John Wiley & Sons, Inc., 1999), Protection for the Carboxyl Group, pp. 369-394. 9000147 17 Greene, Protective Groups in Organic Synthesis, Third Edition (John Wiley & Sons, Inc., 1999), Protection for the Hydroxyl Group, pp. 150-160. 9000147 18 Han et al., Journal American Chemical Society, 127(28): 10039-10044 (2005). 9000147 19 Huntley, Nucleosides, Nucleotides & Nucleic Acids, 20(4-7): 731-733 (2001). 9000147 20 Tanimori et al., Bioorg. Med. Chem. Lett., 12: 1135-1137 (2002). 9000147 21 Wang et al., J. Cell Biol., 170 (3): 349-355 (Aug. 1, 2005). 9000147 22 Yalowitz et al., Curr. Med. Chem., 9: 749-758 (2002). 9000147 23 U.S. Patent and Trademark Office, International Search Report in International Patent Application No. PCT/US2006/044580 (May 24, 2007). 9000147 24 U.S. Patent and Trademark Office, Written Opinion in International Patent Application No. PCT/US2006/044580 (May 24, 2007). 9000147 25 Bieganowski et al., Cell, 117: 495-502 (May 14, 2004). 9000147 26 European Patent Office, Extended European Search Report for European Patent Application No. 06837837.1 (Mar. 5, 2014). 9000147 27 Lee et al., Chem. Commun., 729-730 (1999). 9000147 28 Lifshits et al., Khimiya Geterotsiklicheskikh Soedinenii, 3: 352-355 (Mar. 1976) (cited by EPO as CA 85:177804). 9000148 1 U.S. Appl. No. 13/734,199, entitled "Flame Retardant Cellulose", filed Jan. 4, 2013. 9000149 1 Tong et al, Carbohydrate Polymers, 2005, 60, 229-33. 9000149 2 Murata et al, Biol. Pharm. Bull. 2004, 27(3), 440-42. 9000150 1 Lawton, Simon. Organic Process Resaerch & Development 13 (2009) 1357-1363. 9000150 2 "Pure." Merriam-Webster.com. Merriam-Webster, n.d. Web. Sep. 9, 2014. . 9000151 1 Albrecht et al., "Synthesis of 1,2,6-Thiadiazine 1,1-Dioxides via Isoxazolylsulfamides," J. Org. Chem. 44:4191-4194 (1979). 9000151 2 Alderman, "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms," Int. J. Pharm. Tech. & Prod. Mfr. 5(3):1-9 (1984). 9000151 3 Bamba et al., "Release mechanisms in Gelforming Sustained Release Preparations," Int. J. Pharm. 2:307-315 (1979). 9000151 4 Bandurco et al., "Synthesis and Cardiotonic Activity of a Series of Substituted 4-Alkyl-2(1H)-quinazolinones," J. Med. Chem. 30:1421-1426 (1987). 9000151 5 Belikov V.G., Farmatsevticheskaya khimiya, M., Visshaya shkola, 1993, pp. 43-47. 9000151 6 Bellur et al., "Synthesis of 4-(3-hydroxyalkyl)pyrimidines by ring transformation reactions of 2-alkylidenetetrahydrofurans with amidines," Tetrahedron 62:5426-5434 (2006). 9000151 7 Berge et al., "Pharmaceutical Salts," J. Pharm. Sci. 66(1):1-19 (1977). 9000151 8 Bhattacharya et al., "Thieno[3',2' :4,5][1]benzothieno[2,3-d] pyrimidine derivatives: synthesis and conformation," J. Chem. Soc. Perkin Trans. 1, 1994, 6: 689-693. 9000151 9 Blackburn et al., "Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHr1 antagonists," Bioorg. & Med. Chem. Lett. 16:2621-2627 (2006). 9000151 10 Boarland et al., "Monosubstituted Pyrimidines, and the Action of Thiourea on Chloropyrimidines," J. Chem. Soc. 1218-1221 (1951). 9000151 11 Brown, et al., "Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure-Activity Relationships of 1,6-Disubstituted Indoles and Indazoles," J. Med. Chem. 33:1771-1781 (1990). 9000151 12 Buck et al., "A Novel Multigene Family May Encode Odorant Receptors: A Molecular Basis for Odor Recognition," Cell 65(1):175-187 (1991). 9000151 13 Campillo et al., "A study of peculiar tautomerism of pyrido[2,3-c][1,2,6]thiadiazine 2,2-dioxide system," J. Mol. Struct. 678:83-89 (2004). 9000151 14 Campillo et al., " A Novel Tetracyclic System Containing the 1,2,6-Thiadiazine Ring: Synthesis, Structural Assignment and Tautomeric Studies," Heterocycles, 1998, 48(3): 1833-1840. 9000151 15 Chandrashekar et al., "T2Rs Function as Bitter Taste Receptors," Cell 100:703-711 (2000). 9000151 16 Cheng et al., "Potential Purine Antagonists. XII. Synthesis of 1-Alkyl(aryl)-4,6-disubstituted Pyrazolo[3,4-d]pyrimidines" Journal of Organic Chemistry, Jun. 1, 1958 23(1):852-861. 9000151 17 Chien et al., "Nucleosides XI. Synthesis and Antiviral Evaluation of 5'-Alkylthio-5'-deoxy Quinazolinone Nucleoside Derivatives as S-Adenosyl-L-homocysteine Analogs," Chem. Pharm. Bull. 52(12):1422-1426 (2004). 9000151 18 Clau.beta. et al., "Cycloadditionen von Halogensulfonylisocyanaten an Acetylene," Tetrahedron Lett. 2:119-122 (1970). 9000151 19 Corbett et al., "Novel 2,2-Dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as Non-Nucleside Reverse Transcriptase Inhibitors," Bioorg. Med. Chem. Lett. 10:193-195 (2000). 9000151 20 Da Settimo et al.,"Naphtho[1,2-d]isothiazole Acetic Acid Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors," J. Med. Chem. 48:6897-6907 (2005). 9000151 21 Dominguez et al., "Efficient synthesis of 4,4-disubstituted-3,4-dihydro-1H-2,1,3-benzothiadiazine 2,2-dioxides," Tetrahedron Lett. 41:9825-9828 (2000). 9000151 22 Dorwald, "Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design," Weinheim: WILEY-VCH Verlag Gmbh & o. KGaA, 2005, ISBN: 3-527-31021-5. 9000151 23 During et al., "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," Ann. Neurol. 25:351-356 (1989). 9000151 24 Elmegeed et al., "Novel synthesizes aminosteroidal heterocycles intervention for inhibiting iron-induced oxidative stress," Eur. J. Med. Chem. 40:1283-1294 (2005). 9000151 25 El-Sherbeny et al., "Novel Pyridothienopyrimidine and Pyridothienothiazine Derivatives as Potential Antiviral and Antitumor Agents," Med. Chem. Res. 10:122-135 (2000). 9000151 26 Etter et al., "An Enolized Sulfonamide Formed by Strong Hydrogen Bonding to Triphenylphosphine Oxide," J. Org. Chem. 51:5405-5408 (1986). 9000151 27 European Search Opinion based on EP Application No. 08770047.2, mailed on Sep. 14, 2009. 9000151 28 European Search Report, EP Appl. No. 12175764.5, 16 pages (Feb. 22, 2013). 9000151 29 Francis et al., "Anxiolytic Properties of Certain Annelated [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-ones," J. Med. Chem. 34:2899-2906 (1991). 9000151 30 Frauli et al., "Amino-Pyrrolidine Tricarboxylic Acids Give New Insight into Group III Metabotropic Glutamate Receptor Activation Mechanism," Mol. Pharmacol. 71:704-712 (2007). 9000151 31 Garcia-Munoz et al., "Synthesis of Purine-Like Ring Systems Derived From 1,2,6-Thiadiazine 1,1-Dioxide," J. Heterocyclic Chem. 13:793-796 (1976). 9000151 32 Goya and Martinez, "Synthesis and Cytostatic Screening of an SO2 Analogue of Doridosine," Arch. Pharm. (Weinheim) 321:99-101 (1988). 9000151 33 Goya and Paez, "Pteridine Analogues; Synthesis and Physico-Chemical Properties of 7-Oxopyrazino [2,3-c][1,2,6] thiadiazine 2,2-Dioxides," Liebigs Ann. Chem., 121-124 (1988). 9000151 34 Goya et al., "Aminopyrido [2,3-c] [1,2,6] Thiadiazine 2,2-Dioxides: Synthesis and Physico-chemical Properties," Chemica Scripta, 26:607-611 (1986). 9000151 35 Goya et al., "Fused 1,2,6-Thiadiazines: Tetrahydrobenzo[b]thieno[2,3-c] [1,2,6]thiadiazine 2,2-Dioxides," Arch. Pharm. (Weinheim) 317:777-781 (1984). 9000151 36 Goya et al., "N-Glucosy1-5-Amino-4-Carbamoyl- and 4-Ethoxycarbonylimidazoles as Potential Precursors of 4-0xoimidazo[4,5-c]-1,2,6-thiadiazine 2,2-Dioxides," Heterocycles 24:3451-3458 (1986). 9000151 37 Goya et al., "Synthesis of 2S-Dioxo Isosteres of Purine and Pyrimidine Nucleosides IV. Selective Glycosylation of 4-Amino-5H-Imidazo [4,5-c] -1,2,6-Thiadiazine 2,2-Dioxide," Nucleosides & Nucleotides, 6(3), 631-642 (1987). 9000151 38 Goya et al., CAPLUS Accession No. 1987:18628, 2 pages, abstract of ES 531159 A1 (1985). 9000151 39 Hauser et al., "Synthesis of 5-Phenyl-4,6-Dimethyl-2-Pyrimidol and Derivatives from the Cyclization of Urea with 3-Phenyl-2,4-Pentanedione," J. Org. Chem. 18:588-593 (1953). 9000151 40 Hirayama et al., "The Discovery of YM-60828: A Potent, Selective and Orally-Bioavailable Factor Xa Inhibito," Bioorg. & Med. Chem. 10:1509-1523 (2002). 9000151 41 Hirohashi et al. "Nuclear magnetic resonance studies of bicyclic thiophene derivatives. I ring current effects of the benzene ring on the H.alpha. and H.beta. signals of the thiophene ring in benzoylthiophene, thienopyrimidine, and thienodiazepine derivatives" Bulletin of The Chemical Society of Japan, 48(1), 147-156 (1975). 9000151 42 Hirota et al., "Synthesis and Biological Evaluation of 2,8-Disubstituted 9-Benzyladenines: Discovery of 8-Mercaptoadenines as Potent Interferon-Inducers," Bioorg. Med. Chem. 11:2715-2722 (2003). 9000151 43 Hoon et al., Putative Mammalian Taste Receptors: A Class of Taste-Specific GPCRs with Distinct Topographic Selectivity. Cell 96:541-551 (1991). 9000151 44 Howard et al., "Intracerebral drug delivery in rats with lesion-induced memory deficits," J. Neurosurg. 71:105-112 (1989). 9000151 45 Hu et al., "Organic Reactions in Ionic Liquids: Gewald Synthesis of 2-Aminothiophenes Catalyzed by Ethylenediammonium Diacetate," Synthetic Communication 34:3801-3806 (2004). 9000151 46 International Search Report, 5 pages, PCT Appl. No. PCT/US2008/065650 (mailed Nov. 20, 2008). 9000151 47 International Search Report, PCT appl. No. PCT/US2013/053666, 4 pages (Dec. 9, 2013). 9000151 48 Jordan, "Tamoxifen: A Most Unlikely Pioneering Medicine," Nature Reviews: Drug Discovery 2003, vol. 2, pp. 205-213. 9000151 49 Jung et al., "Discovery of Novel and Potent thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors," J. Med. Chem. 49:955-970 (2006). 9000151 50 Kamal et al., "Cyclization of 2-(Carbamoyloxy)- and 2-(Sulfamoyloxy)benzoates Mediated by Liver Microsomes," J. Org. Chem. 53:4112-4114 (1988). 9000151 51 Kamal et al., "Enzymatic Cyclization of 2-(Carbamoyloxy)Benzoates, 2-(Sulfamoyloxy)-Benzoates and 2-(Carbamoyloxy)benzopenones with Yeast and Lipase," Heterocycles 29:1391-1397 (1989). 9000151 52 Kanbe et al., "Discovery of thiochroman derivatives bearing a carboxy-containing side chain as orally active pure antiestrogens," Bioorg. & Med. Chem. Lett. 16:4090-4094 (2006). 9000151 53 Kanuma et al., "Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1," Bioorg. & Med. Chem. Lett. 15:3853-3856 (2005). 9000151 54 Keith, "Synthesis and Reduction of some 1H-2,1,3-Benzothiadiazin-4(3H)one 2,2-Dioxides," J. Heterocyclic Chem., 15:1521-1523 (1978). 9000151 55 Khabnadideh et al., "Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase," Bioorg. Med. Chem. 13:2637-2649 (2005). 9000151 56 Klinger et al., "Inhibition of Carbonic Anhydrase-II by Sulfamate and Sulfamide Groups: An Investigation Involving Direct Thermodynamic Binding Measurements," J. Med. Chem. 49:3496-3500 (2006). 9000151 57 Kyte et al., "A Simple Method for Displaying the Hydropathic Character of a Protein," J. Mol. Biol. 157:105-132 (1982). 9000151 58 Langer et al., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," J. Macromol. Sci. Rev. Macromol Chem. 23:61-126 (1983). 9000151 59 Langer, "New Methods of Drug Delivery," Science 249:1527-1533 (1990). 9000151 60 Lee et al., "Acetonitrile-Mediated Synthesis of 2,4-Dichloroquinoline from 2-Ethynyl-aniline and 2,4-Dichloroquinazoline from Anthranilonitrile," Synlett, 2006 No. 1:65-68 (2006). 9000151 61 Leistner et al., "Eine einfache Synthese von 2-Alhylthio-4-amino-thieno[2,3-d]pyrimidinen," Arch. Pharm. (Weinheim) 322:227-230 (1989). 9000151 62 Levy et al , "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," Science 228:190-192 (1985). 9000151 63 Li et al., "Human receptors for sweet and umami taste," Proc. Natl. Acad. Sci. USA 99:4692-4696 (2002). 9000151 64 Linkies et al., "Ein neues Verfahren zur Herstellung von 6-Methyl-1,2,3-oxathiazin-4(3H)-on-2,2-dioxid Kaliumsalz (Acesulfam-K)," Synthesis 405-406 (1990). 9000151 65 Liu et al., "Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies," Bioorg. & Med. Chem. Lett. 17:668-672 (2007). 9000151 66 Martinez et al., "Benzothiadiazine Dioxide Dibenzyl Derivatives as Potent Human Cytomegalovirus Inhibitors: Synthesis and Comparative Molecular Field Analysis," J. Med. Chem., 43:3218-3225 (2000). 9000151 67 Meyer, Jr. and Skibo, "Synthesis of Fused [1,2,6]Thiadiazine 1,1-Dioxides as Potential Transition-State Analogue Inhibitors of Xanthine Oxidase and Guanase," J. Med. Chem. 22(8):944-948 (1979). 9000151 68 Naganawa et al., "Further optimization of sulfonamide analogs as EP1 receptor antagonists: Synthesis and evaluation of bioisosteres for the carboxylic acid group," Bioorg. Med. Chem. 14:7121-7137 (2006). 9000151 69 Nie et al., "Distinct Contributions of T1R2 and T1R3 Taste Receptor Subunits to the Detection of Sweet Stimuli," Curr. Biol. 15(21):1948-1952 (2005). 9000151 70 Office Action, U.S. Appl. No. 11/760,592, 13 pages (mailed Jan. 7, 2010). 9000151 71 Office Action, U.S. Appl. No. 11/760,592, 19 pages (mailed Oct. 7, 2010). 9000151 72 Office Action, U.S. Appl. No. 11/760,592, 26 pages (mailed Jan. 16, 2014). 9000151 73 Office Action, U.S. Appl. No. 11/836,074, 11 pages (mailed Sep. 29, 2009). 9000151 74 Office Action, U.S. Appl. No. 11/836,074, 13 pages (mailed Oct. 30, 2008). 9000151 75 Office Action, U.S. Appl. No. 11/836,074, 18 pages (mailed Jun. 10, 2009). 9000151 76 Office Action, U.S. Appl. No. 11/836,074, 18 pages (mailed Jun. 23, 2008). 9000151 77 Office Action, U.S. Appl. No. 11/836,074, 7 pages (mailed Nov. 8, 2010). 9000151 78 Office Action, U.S. Appl. No. 12/663,634, 9 pages (mailed Feb. 6, 2013). 9000151 79 Office Action, U.S. Appl. No. 12/663,634, 8 pages (mailed Apr. 12, 2013). 9000151 80 Office Action, U.S. Appl. No. 12/663,634, 8 pages (mailed Jun. 14, 2013). 9000151 81 Office Action, U.S. Appl. No. 12/663,634, 7 pages (mailed Jul. 19, 2013). 9000151 82 Office Action for U.S. Appl. No. 13/051,586, mailed Jun. 21, 2012. 9000151 83 Office Action for U.S. Appl. No. 13/051,586, mailed Feb. 27, 2013. 9000151 84 Pal et al., "Synthesis and Cyclooxygenase-2 (COX-2) Inhibiting Properties of 1,5-Diarylpyrazoles Possessing N-Substitution on the Sulfonamide (-SO2NH2) Moiety," Letters in Drug Design & Discovery 2:329-340 (2005). 9000151 85 Partial European Search Report, EP appl. No. 12175761.1, 7 pages (Feb. 27, 2013). 9000151 86 Petersen et al., "Synthesis of Heterocycles Containing Two Cytosine or Two Guanine Base-Pairing Sites. Novel Tectons for Self-Assembly," Bioorg. Med Chem. 4:1107-1112 (1996). 9000151 87 Rad-Moghadam et al., "One-pot Three-component Synthesis of 2-Substituted 4-Aminoquinazolines," J. Heterocyclic Chem. 43:913-916 (2006). 9000151 88 Rasmussen et al., "The Electrophilic Addition of Chlorosulfonyl Isocyanate to Ketones. A Convenient Synthesis of Oxazines, Oxathiazines, and Uracils," J. Org. Chem. 38:2114-2115 (1973). 9000151 89 Reddy et al., "An Efficient Synthesis of 3,4-Dihydro-4-Imino-2(1H)-Quinazolinones," Synthetic Commun. 18:525-530 (1988). 9000151 90 Robinson et al., "Sulfonamide Ligands Attained through Opening of Saccharin Derivatives," Eur. J. Org. Chem. 19:4483-4489 (2006). 9000151 91 Rodriguez-Hahn et al., "A Study of the Thorpe-Ziegler Reaction in Very Mild Conditions," Synthetic Commun. 14:967-972 (1984). 9000151 92 Rosowsky and Modest, "Quinazolines. III. Synthesis of 1,3-Diaminobenzo[f]quinazoline and Related Compounds," J. Org. Chem. 31:2607-2613 (1966). 9000151 93 Roy et al., "Auto-Redox Reaction: Tin(II) Chloride-Mediated One-Step Reductive Cyclization Leading to the Synthesis of Novel Biheterocyclic 5,6-Dihydro-quinazolino[4,3-b]quinazolin-8-ones with Three-Point Diversity," J. Org. Chem. 71:382-385 (2006). 9000151 94 Saudek et al., "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," N. Engl. J Med. 321:574-579 (1989). 9000151 95 Seijas et al., "Microwave enhanced synthesis of 4-aminoquinazolines," Tetrahedron Lett. 41:2215-2217 (2000). 9000151 96 Sharma et al., "Synthesis and QSAR studies on 5-[2-(2-methylprop 1-eny1)-1H benzimidazol-ly1]-4,6-diphenyl-pyrimidin-2-(5H)-thione derivatives as antibacterial agents," Eur. J. Med. Chem. 41:833-840 (2006). 9000151 97 Silve et al., "Delineating a Ca2+ Binding Pocket within the Venus Flytrap Module of the Human Calcium Sensing Receptor," The Journal of Biological Chemistry, Nov. 2005, vol. 280, pp. 37917-37923. 9000151 98 Srivastava et al., "Solid Phase Synthesis of Structurally Diverse Pyrimido[4,5-d] Pyrimidines for the Potential Use in Combinatorial Chemistry," Bioorg. Med. Chem. Lett. 9:965-966 (1999). 9000151 99 Supplementary European Search Report based on EP Application No. 08770047.2, mailed on Sep. 14, 2009. 9000151 100 Tripathi et al., "Reaction of Flavanones with Chlorosulphonyl Isocyanate," Indian J. Chem. Sect. B 26B:1082-1083 (1987). 9000151 101 Uehling et al., "Biarylaniline Phenethanolamines as Potent and Selective .beta.3 Adrenergic Receptor Agonists," J. Med. Chem. 49:2758-2771 (2006). 9000151 102 Verma et al., "Osmotically Controlled Oral Drug Delivery," Drug Dev. Ind. Pharm. 26:695-708 (2000). 9000151 103 Verschoyle et al., "Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," British J. Cancer 80, Suppl. 2:96 Abstract No. P269 (1999). 9000151 104 Vippagunta et al., "Crystalline solids," Adv. Drug Deliv. Rev. 48:3-26 (2001). 9000151 105 Wilson et al., "Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells," Bioorg. & Med. Chem. 15:77-86 (2007). 9000151 106 Wilson, "Traceless Solid-Phase Synthesis of 2,4-Diaminoquinazolines," Org. Lett. 3:585-588 (2000). 9000151 107 Winkler et al., "Synthesis and microbial transformation of .beta.-amino nitriles," Tetrahedron 61:4249-4260 (2005). 9000151 108 Wright, "The Reaction of Sulfamide with .alpha.- and .beta.-Diketones. The Preparation of 1,2,5-thiadiazole 1,1-Dioxides and 1,2,6-Thiadiazine 1,1-Dioxides," J. Org. Chem. 29:1905-1909 (1964). 9000151 109 Wright, "The Synthesis of 2,1,3-Benzothiadiazine 2,2-Dioxides and 1,2,3-Benzoxathiazine 2,2-Dioxides," Journal of Organic Chemistry 30(11):3960-3962 (1965). 9000151 110 Written Opinion of the International Searching Authority,19 pages, PCT Appl. No. PCT/US2008/065650 (mailed Nov. 20, 2008). 9000151 111 Written Opinion of the International Searching Authority, PCT appl. No. PCT/US2013/053666, 6 pages (Dec. 9, 2013). 9000151 112 Xu et al., "Oxidative cyclization of N-alkyl-o-methyl-arenesulfonamides to biologically important saccharin derivatives," Tetrahedron 62:7902-7910 (2006). 9000151 113 Xu et al., "Purine and Pyrididine Nucleotides Inhibit a Noninactivating K1 Current and Depolarize Adrenal Cortical Cells through a G Protein-coupled Receptor," Molecular Pharmacology, 1999, vol. 55, pp. 364-376. 9000151 114 Yamada et al., "Discovery of Novel and Potent Small-Molecule inhibitors of NO and Cytokine Production as Antisepsis Agents: Synthesis and Biological Activity of Alkyl 6-(N-Substituted sulfamoyl)cyclohex-1-ene-1-carboxylate," J. Med. Chem. 48:7457-7467 (2005). 9000151 115 Yoshizawa et al., "Efficient solvent-free Thrope reaction," Green Chem. 4:68-70 (2002). 9000151 116 Zunszain et al., "Search for the pharmacophore in prazosin for Transport-P," Bioorg. & Med. Chem. 13:3681-3689 (2005).